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Summary
This thesis investigates the value of plasma f ib r inopep tide  A 
and beta-thromboglobulin as markers fo r  thrombosis. The ro le  played 
by in travascu lar f i b r in  deposition and p la te le ts  in thrombosis has 
recently  aroused great in te re s t as well as controversy. Recently 
developed tes ts  measuring in  vivo thrombin generation ( f ib r inop ep tide  A) 
and p la te le t  release (beta-thromboglobulin) might therefore be o f value 
as markers fo r  thrombosis.
Because of the h ighly specialised area of th is  research I was 
required by my supervisor to extensively review the d i f fe re n t  mechanisms 
which have been postulated as causes of thrombosis. In order to 
understand the problems surrounding these proposed mechanisms a deta iled 
discussion on the biochemistry of the haemostatic mechanism is  given in 
Chapter 1. The proposed mechanisms surrounding thrombosis are then 
discussed in  de ta il in  Chapter 2. The methods cu rren t ly  available fo r  
the measurement of p la te le t  ac t iva t ion  and release (beta-thromboglobulin) 
are discussed in  Chapter 3.
In travascu lar f i b r in  deposition has recently been suggested to be 
the re su lt  of an imbalance in thrombin or plasmin generation as discussed 
in  Chapter 2. Chapter 4 therefore discusses in de ta il the development 
of techniques fo r  measuring f ib r inopep tide  A and the recently  developed 
assay of plasmin a c t iv i t y  B yS 15-42, as well as th e i r  app lication to 
previous c l in ic a l  studies. Deta ils of the methods used fo r  the studies 
to be described in  th is  thesis are given in  Chapter 5.
XVII
The f i r s t  c l in ic a l  studies undertaken in th is  thesis examined plasma 
levels of BTG and FPA in  patients with pre-eclampsia and pregnancy 
hypertension (Chapter 6). Abnormalities in p la te le t  a c t iv i t y ,  blood 
coagulation and f ib r in o ly s is  may in part be responsible fo r  the increase 
in  f i b r in  deposition seen in the placental bed in pre-eclampsia as well 
as the pathogenesis of th is  disease. In order to assess the resu lts  in  
pre-eclampsia several other obs te tr ic  groups were studied.
Normal values of BTG and FPA levels were obtained- in  normal, non­
pregnant women, normal non-pregnant women taking oral contraceptives 
and pregnant women in the f i r s t  tr im ester of pregnancy suggesting no 
evidence of in travascu lar coagulation occurs in th is  group.
Increased BTG levels but normal FPA levels were observed in  the 
2nd and 3rd tr im es te r of normal pregnant women, suggesting increased 
p la te le t  a c t iv i t y  is  occurring in th is  group. Increased BTG leve ls 
and FPA leve ls were observed in essential hypertension of pregnancy 
suggesting ac tiva t ion  of coagulation in th is  group. Normal BTG 
levels but increased FPA levels were observed in  patients with in tra  
uterine growth re ta rda tion  (lUGR), possibly re f le c t in g  an increase in  
f i b r in  deposition in  the placental bed in lUGR. S im ila r resu lts  
were observed in patients with mild to moderate pre-eclampsia.
Increased plasma BTG and FPA levels were observed in  patients with 
severe pre-eclampsia suggesting activa t ion  of coagulation is  occurring 
in  these pa tien ts . BTG and FPA measurements did not d is t ingu ish  the 
severe pre-eclampsia patients from the essential hypertensive group.
Measurements of plasma levels of BTG, FPA and B yS 15-42 were then 
studied in  patients with venous thrombosis as described in  Chapter 7.
An increase in  plasma f ib r inogen, BTG and FPA leve ls were observed in 
patients with longstanding re t in a l vein occlusion (RVO) when compared
XVIII
to  control subjects. These measurements did not d is t ingu ish  between 
patients with and without RVO or RVO patients with and without 
complications.
Increased plasma BTG levels were observed in patients with the 
nephrotic syndrome when compared to control subjects suggesting an 
increase in  p la te le t  release occurs in th is  syndrome.
An increase in plasma B yS 15-42 levels in normal volunteers a f te r  
the adm inistra tion of stanozolol suggests d irec t evidence of increased 
plasmin a c t iv i t y  occurs fo r  at least seven days a f te r  administration 
o f th is  drug. The next study therefore evaluated a double b lind t r i a l  
of the administration of stanozolol in the prevention of deep venous 
thrombosis a f te r  major gas tro in testina l surgery. An increase in plasma 
BTG leve ls was observed one day postoperatively in each of three sub 
groups of patients ie  (a) those not receiving or those receiving 
stanozolol treatment (b) those patients who did not and who did develop 
a postoperative DVT, and (c) those patients with and without early 
operable malignancy. This observed increase in p la te le t  a c t iv i t y  may 
be the resu lt of tissue damage and trauma during surgery. In patients 
who then developed a postoperative DVT a s ig n if ic a n t  increase in  plasma 
BTG levels was observed suggesting an increase in p la te le t  ac t iva t ion  
occurs before the onset of thrombosis. The increased values did not 
d is t ingu ish  those with and without thrombosis. Plasma FPA levels 
rose on the f i r s t  day a f te r  surgery and were s ig n i f ic a n t ly  elevated on 
day 7 in those patients who develop a DVT, thus suggesting tha t f i b r in  
formation occurs in patients who develop a DVT.
Higher preoperative FPA levels were observed in patients with 
operable malignancy. Plasma B ^  15-42 leve ls did not f a l l  on the f i r s t
XIX
day of surgery however elevated values were observed a f te r  surgery and 
a f te r  stanozolol adm inistra tion. Higher Byûl5-42 leve ls  were also 
observed on the morning of surgery in patients who develop DVT.
The la s t study in  Chapter 7 measured plasma BTG leve ls  in an o lder 
pa tien t group, patients with malignancy and patients with non-vascular 
il lnesses such as chest in fe c t ion  and compared these groups to a young 
control group. Increased BTG levels were observed in  the e lderly  
controls and the patients with chest in fe c t ion  but not in early  
malignancy when compared to the normal control group. P la te le t 
ac t iva tion  therefore occurs with non-vascular i l ln e s s  and hence such 
ac t iva t ion  is  not spec if ic  to 'vascu lar' i l ln e s s  such as venous thrombosis.
Plasma levels o f BTG, FPA and B 15-42 were subsequently measured in  
a r te r ia l  thrombosis as described in Chapter 8. No evidence of increased 
p la te le t release or f i b r in  formation was found in  patients with acute chest 
pain such as myocardial in fa rc t io n ,  unstable angina or non-cardiac chest 
when compared to control pa tients . Hence BTG and FPA levels are of no 
value in  the separation of patients with acute pain in to  those with and 
without myocardial in fa rc t io n .
The next study in  Chapter 8 found l i t t l e  evidence of increased plasma 
levels o f BTG, FPA or Byg  ^15-42 in patients with coronary disease and no 
re la t io n  between these parameters and the extent of the coronary artery  
disease.
The fo llow ing study found no evidence of p la te le t  ac t iva tion  or 
f i b r in  formation in patients with type I I  or IV hyperlipoproteinaemia.
The next study observed ongoing p la te le t  release and f ib r in  formation 
in  d iabetic  patients with retinopathy and th is  appeared to be higher in  
patients with p ro l i fe ra t iv e  retinopathy than in  those without.
XX
The f in a l study in a r te r ia l  thrombosis examined plasma BTG and FPA 
levels in  patients with trans ien t ischaemic attacks (TIA) and control 
pa tients . P la te le t release ra ther than f i b r in  formation appeared to 
occur in  TIA and plasma BTG leve ls appeared to be an index of patients 
having an increased r is k  of fu r th e r  vascular events.
The measurement o f BTG and FPA as tes ts  fo r  in  v i t ro  blood 
com pa tib i l i ty  o f a r t i f i c i a l  surfaces are described in Chapter 9. BTG 
was found to be a marker of blood com pa tib i l i ty  as observed by the 
f ind ing  tha t s i l ico n e  was more thrombogenic than polypropylene, and 
polyvinyl ch loride was more thrombogenic than s i l ic o n e .
As discussed in  Chapter 10 the resu lts  obtained in th is  thesis have 
suggested tha t abnormalities are suggested but not necessarily proved to  
occur in  both venous and a r te r ia l  thrombosis. The measurement of BTG, 
FPA and B ^  15-42 has provided some ins igh t in to  the possible mechanisms 
of thrombosis and are useful too ls in fu r th e r  c l in ic a l  investiga tions.
Chapter %
H is to r ica l In troduction
In the past few decades much in te res t has been expressed 
in the ro le  played by in travascu lar f i b r in  deposition and 
p la te le ts  in thrombosis. Recently developed tests  measuring 
in vivo thrombin generation ( f ib r inopep tide  A) and p la te le t  
release (beta-thromboglobulin) might be of value as markers 
fo r  thrombosis. I t  is  the purpose of th is  thesis to inves tiga te  
the value of these tes ts .
Before discussing the l i te ra tu re  available on these 
a general review w i l l  be given on haemostasis, thrombosis 
and in travascu lar coagulation in order to ou tl ine  the problems 
involved in  in te rp re t in g  resu lts  of these complex in te rac t in g  
systems in  c l in ic a l  studies.
Haemostasis
The function of haemostasis is  to prevent blood loss 
from in ta c t  vessels and to stop excess bleeding when vessels 
are damaged e ith e r  by cu tt ing  or other trauma. This is 
achieved by deposition of p la te le ts  and f i b r in .  A fu r th e r  
function of haemostasis is  to l im i t  the extent of such 
p la te le t  and f ib r in  deposition to ensure maintenance of the 
patency of the vascular tree .
The prevention or arrest of haemorrhage represents 
one of the most basic homeostatic mechanisms of the body; 
p la te le t  function , vessel contraction and blood coagulation 
protect the body by reduction of blood loss and f ib r in o ly s is  
ensures vessel patency. Failure of any component of these 
complex systems resu lts  in excess bleeding which may vary 
from leakage of a few red ce l ls  from c a p i l la r ie s  to the
more dramatic haemorrhage seen in severe haemophilia, thrombo­
cytopenia or consumption coagulopathy in which the patient may 
bleed spontaneously from a multitude qf s ites and eventually 
die of uncontro llab le haemorrhage. While i t  is  convenient 
fo r  descrip tive  purposes to consider them separately, the 
reactions involved are in t im a te ly  in te r l in ke d  and interdependent.
The P la te le t - H is to r ica l aspects 
P la te le ts are the smallest formed elements of the blood 
and are 2-3 jum in  diameter. They were observed only a f te r  
development of the compound microscope in 1830. Bizzozero 
in  1882 defined these "new c e l ls "  as independent of leukocytes 
and erythrocytes and named them "P lattchen". He demonstrated 
in  severed or damaged blood vessels that the "plattchen" 
accumulated to form a mass which became the e f fe c t iv e  haemostatic 
plug. The early  l i te ra tu r e  on p la te le ts  has been summarised in 
de ta il by Tocantins (1949) and Robb-Smith (1967).
_1 P la te le t morphology
In blood normal p la te le ts  are found in the form of discs 
and they are formed in the bone marrow from megakaryocytes. 
P la te le ts  are also found in lungs, kidneys, l i v e r  and in the 
c irc u la t in g  blood (Bessis, 1977). The p la te le t  count ranges
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normally from 15 x 10 / I  to 40 x 10 / I  of blood and they normally 
survive between 8-14 days in the blood. P la te le ts  are enclosed 
by a membrane and contain organelles including mitochondria, 
lysosomes, tubu la r systems and granules. The p la te le t  granules 
contain a va r ie ty  of stored substances which are released from 
the p la te le t  when they are activated (see Tablel.1). P la te le t 
«granule release w i l l  be discussed in de ta il in Chapter 3.
TABLE 1.1
Constituents of Human P la te le t storage Organelles
P la te le ts  contain three types of storage organelles, 
which can be distinguished by density. These are 
dense granules or bodies, «-granules and lysosomal 
enzyme storage organelles.
a) Dense bodies contain:
Adenosine diphosphate (ADP)
Adenosine triphosphate (ATP)
Guanosine triphosphate (GTP)
Serotonin (5HT)
Calcium
Pyrophosphate
b) Alpha granules contain:
Fibrinogen
P la te le t  Factor 4 (PF4)
^-Throm boglobulin  (BTG)
A1bumi n
Factor V l l l - re la te d  antigen (FV IÎI RAg)
c) Lysozomes contain:
^  -N-Acetylglucosaminidase 
^  -Galactosidase 
^  -Glucuronidase 
^  -Glycerophosphatase
42^.^. P Ia te let function
Transection of a vessel resu lts  in adhesion of a monolayer 
of p la te le ts  to the exposed subendothelial collagen, basement 
membrane and e la s t ic  f ib re s .  Adhesion causes the p la te le ts  to 
release constituents of th e i r  granules, in p a r t ic u la r  beta-thrombo- 
g lobulin. (BIG) and p la te le t  fac to r  four (PF;j^) from the agranules and 
amines such as adenosine diphosphate (ADP) adenosine triphosphate 
(ATP) and the vasoactive m ateria l, serotonin (5-hydroxytryptamine, 
5HT) and C a f r o m  the dense granules. These amines are 
l ibera ted  in to  the "plasmatic atmosphere" of the adherent p la te le ts  
and cause other p la te le ts  in the local c irc u la t io n  to change 
shape from disc to spheroid forms with pseudopodia w ith in  a 
second. These a ltered p la te le ts  aggregate together and form a 
mass with the already adherent p la te le ts  which plugs the defect 
in the vessel. This reaction is  rapid and occurs w ith in  a 
few seconds of vessel in ju ry  (see Figure 1.1a).
In addition to the above mechanism, p la te le t  membrane 
phospholipase Aais activated during aggregation and hydrolyses 
an ester bond in p la te le t  phospholipid to produce arachidonic 
acid ( B i l l s ,  Smith and S i lv e r ,  1972) (see Figure 1 .2 ). This 
arachidonic acid is  then acted on by cyclooxygenase which converts 
i t  to unstable prostaglandin endoperoxides (PGG^ and PGH^). The 
prostaglandin endoperoxides are also transformed by other enzymes 
in to  thromboxane A^ (TXA^, ) in  p la te le ts  and p ros tac lyc l in  (PGI^) 
in endothelium. Both TXA^ and PGI^ are chemically unstable, 
breaking down to thromboxane B^ and 6 oxo-PGFl^ (see Figure 1.2).
Thromboxane was discovered by Piper and Vane in  1969 
in  e ff luen ts  of mammalian lung during anaphalaxis i . e .
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s u s c e p t ib i l i ty  and increased s e n s i t iv i ty  to a foreign substance, 
usually a prote in . In a l le rg ic  patients th is  leads to the 
formation and the release of b io lo g ic a l ly  potent substances such as 
histamine and prostaglandins which then mediate the symptoms of 
anaphalaxis. I t  was then named "rabb it aorta contracting 
substance" (RCS), due to i t s  potent action on th is  t issue .
Later i t s  s truc ture  was elucidated and named thromboxane 
(Svensson, Hamberg and Samuelsson, 1975; Needleman, Moncada,
Bunting et a l . ,  1976).
Extensive research studies have shown tha t TXA^^has two 
prominent physiological functions: i t  is  a powerful vaso­
c o n s tr ic to r  and a powerful aggregating agent which enhances 
rapid accumulation of p la te le ts  at the s i te  o f vessel in ju ry  
(Hamberg, Svensson and Samuelsson, 1975; Malmsten, Hamberg and 
Svensson et a l . ,  1975; Moncada and Vane, 1979). Moncada and Vane 
(1977) and others have suggested tha t a balance is  established 
between prostacyclin production by the endothelium (see Chapter 1.2.4) 
and thromboxane A2^by the p la te le ts .  P ros tac lyc lin  in h ib i ts  
p la te le t  aggregation by s tim ula ting adenylate cyclase, leading 
to  an increase in adenosine 3 ' : 5 ‘ -  cyclic-monophosphate 
(c y c l ic  AMP) leve ls in p la te le ts  (Tateson, Moncada and Vane,
1977; Gorman, Bunting and M i l le r ,  1977). Prostglandin endo­
peroxides and TXA% reduce a raised c y c l ic  AMP level in  p la te le ts  
(M i l le r  and Gorman, 1976) (see Figure 1,3). Because of opposing 
e ffec ts  th is  balance regulates the level of c y c l ic  AMP in 
p la te le ts  in vivo and, there fore , the a b i l i t y  of p la te le ts  to 
to aggregate. This proposition has been re inforced by the 
f ind ing tha t prostacyclin  is  a c irc u la t in g  hormone (Gryglewski,
Korbut and Ocetkiewicz, 1978, Moncada, Korbut, Bunting et a l . ,
1978) with a local e ffe c t due to i t s  short h a l f - l i f e  of two 
minutes.
VESSEL WALL
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PROSTACYCLIN
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Fig^ure 1.3.
Regulation of platelet eyelie-AMP levels 
by metabolites of arachidonic acid 
produced locally or present in blood.
AA-denotes arachidonic acid, PG-prostaglandin, 
c.AMP-cyclic AMP, TXA^"*thromboxane A^, and 
PGI^- prostacyclin.
Collagen f ib res  in the subendothelium adsorb plasma 
fa c to r  XII which activates the coagulation pathway by a series 
of ra ther slow reactions resu lt ing  in thrombin and f ib r in  
generation (see FigureI.lb). Thrombin is  a powerful p la te le t  
aggregating agent. Thus at least three separate mechanisms act 
s y n e rg is t ica l ly  to produce p la te le t  aggregation at the s i te  of 
in ju ry ;  amine release (ADP and 5HT) from p la te le ts ,  TXA^ 
generation and thrombin formed by the coagulation mechanism.
Simultaneously with the above events a phospholipid 
becomes available on the p la te le t  surface (p la te le t  fa c to r  3 
(PFg)) and th is  plays a key ro le in promoting the ac tiva tion  
of factors in the blood coagulation pathway as shown in 
Figurel.4. I t  is  not released in to  the plasma but acts as a surface 
onto which coagulation factors bind and subsequently react.
Serotonin ( 5HT) is  also liberated by adherent and 
aggregated p la te le ts  and has a powerful vasoconstrictive func tion , 
a lte r in g  flow and causing cons tr ic t ion  of the vessel at the s i te  
of formation of the p la te le t  aggregate. A s im ila r  action is  
produced by thromboxane A^. At th is  stage the p la te le t  
aggregate is  unstable and may be washed away by the force of 
blood flow . S ta b il isa t io n  occurs as f ib r in  is  formed in and 
around the aggregated p la te le t  mass (see Figuref.lb).
Thus haemostasis is  i n i t i a l l y  dependent on p la te le t  
and vessel function with formation of a p la te le t  plug. At th is  
early  stage, coagulation seems to play l i t t l e  part but i f  
there is  a defic iency of c lo t t in g  factors as in  haemophilia, 
excess bleeding w i l l  occur la te r  due to fa i lu re  of s ta b i l is a t io n  
of the p la te le t  plug, which requires the formation of f i b r in ,  
and is  washed away as the vasoconstrictor e f fe c t  of 5HT 
TXA% declines.
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Vascular s tructure  and function
From c l in ic a l  studies there is  c lear evidence tha t 
normality of the endothelial ce l l  l in in g ,  basement membrane 
and supporting collagen and e la s t ic  f ib res  are essential 
fo r  haemostasis as well as the components in blood.
In ju ry  to an a r te r io le  or venule leads to immediate 
vasoconstriction probably due to contraction of the muscle 
laye r, by the action of serotonin and thromboxanes 
generated from aggregated p la te le ts  as well as by re f lex  
autonomic action. This response is trans ien t and wears 
o f f  over a period of 10-20 minutes. In c a p i l la r ie s  no such 
muscular mechanism exists but flow in to  a c a p i l la ry  bed is  
con tro lled by a "p re -ca p i l la ry  sphincter" which may serve the 
same function . In addition , from experimental work there is  
evidence tha t occlusion of c a p i l la r ie s  may resu lt from endothelial 
adhesion. This period o f vasoconstriction allows time fo r  
p la te le t  and f i b r in  deposition to occur and secure haemostasis.
The normal c a p i l la ry  is  a simple s tructure consisting of a 
tube lined w ith endothelial ce l ls  on a basement membrane 
supported by pericytes and collagen f ib re s .  The endothelia l 
l in in g  of the vascular tree consists of a s ingle layer of these 
deformable c e l ls ,  30 pm by 10 pm, the long axes o f which are 
aligned to the d ire c t ion  of blood flow. The ce l ls  are joined 
together by in t r a c e l lu la r  bridges and are coated by a th in  
layer of mucopolysaccharide which extends in to  the potentia l 
space between c e l ls .  This continuous sheet of c e l ls  re ta ins 
blood w ith in  the vascular tree , stops p la te le ts  and f i b r in  
forming in  excess but s t i l l  allows the passage of gases, 
nutrien ts and f lu id s  in to  the tissues of the body. These 
endothelial ce l ls  produce prostacyclin (PGI^), fa c to r  V I I I  related 
antigen (V I I I :  RAg) and a f ib r in o ly t i c  a c t iva to r .
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In 1976 i t  was discovered tha t a microsomal enzyme obtained 
from blood vessels transforms PGG^  and PGH^into an unstable 
substance (o r ig in a l ly  ca lled PGX) which is  a potent vasodila tor 
and in h ib i to r  of p la te le t  aggregation (Moncada, Gryglewski,
Bunting and Vane, 1976). This substance was subsequently shown 
to be an intermediary between PGH2^and 6-keto-PGF| a (F ig .1.2) 
and was renamed prostacyclin  (PGI^). P G I^ is  formed by vascular 
tissues from a l l  species examined so fa r  and is  the predominant 
metabolite of arachidonic acid in isolated hearts of the ra t ,  
guinea-pig and ra b b it .  I t  also appears to be a major prostaglandin 
product of the gas tr ic  mucosa of several species. I t  is  a powerful 
in h ib i to r  of p la te le t  aggregation and i t s  production may be in h ib ite d  
by cyclo-oxygenase in h ib i to rs  such as asp ir in .  In addition prosta­
cyc lin  causes already formed p la te le t  aggregates to disaggregate and 
th is  may be a fu r th e r  protective function. The h a l f - l i f e  of 
prostacyclin in the blood is  2-3 minutes which implies tha t local 
s t im u la tion  of production has only a local e f fe c t .
Moncada and Vane (1981) have proposed tha t prostacyclin  
protects the vessel wall against deposition of p la te le t  
aggregates, so providing at least a pa rt ia l explanation of the 
long recognised fac t tha t contact with healthy vascular endo­
thelium is  not a stimulus fo r  p la te le t  clumping. Damage to a 
vessel is  followed by p la te le t  adhesion to the affected s i te  with 
the degree of in ju ry  an important determinant. Such observations 
are in  accordance with the d is t r ib u t io n  of prostacyc lin  synthetase, 
fo r  i t  is  abundant in the intima. Indeed, the endothelial ce l l
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i t s e l f  is  the most active in generating prostacyc lin . There is  
then a progressive decrease in concentration of the enzyme from 
the intima to the adventit ia  (Moncada, Herman, Higgs et a l . ,  1977). 
Moreover, the pro-aggregating elements increase from the sub­
endothelium to  the adven tit ia . These trends render the endothelial 
l in in g  anti-aggregatory and the outer layers of the vessel wall 
much more thrombogenic.
Prostacyclin in h ib i ts  aggregation (p la te le t -p la te le t  
in te rac tio n ) at much lower concentrations than those needed fo r  
adhesion (p la te le t-co llag en  in te rac tion) suggesting tha t prosta­
cyc lin  allows p la te le ts  to s t ick  to damaged vascular t issue and 
begin the repa ir process while at the same time preventing or 
l im i t in g  thrombus formation (Higgs, Higgs, Moncada, et a l . ,  1978). 
Thus in  such a s itua t ion  of close physical prox im ity , the p la te le t 
could contribu te  endoperoxide intermediates to the vessel w a ll,  
thereby increasing prostacyclin  generation. Prostacyclin in h ib i ts  
p la te le t  aggregation by increasing cyc l ic  AMP in p la te le ts  
(see Chapter 1 .2 .3 ).
There is  also evidence tha t normal c irc u la t in g  p la te le ts  
are required to maintain the functional in te g r i t y  of the endo­
th e l ia l  layer. Atrophy of the endothelium resu lts  when p la te le ts  
are q u a n t ita t iv e ly  or q u a l i ta t iv e ly  de fic ien t and i t  seems l ik e ly  
tha t they act in a n u tr i t io n a l ro le . The number of normal 
p la te le ts  required to maintain normality of endothelium is  small 
and in  patients with thrombocytopenia an in fusion of fresh normal 
p la te le ts  can correct the abnormality without ra is ing  the count 
in the systemic c irc u la t io n .  The exact mechanism by which these 
p la te le ts  in te ra c t with endothelial ce l ls  is  not c lear but evidence 
is  now emerging of trans fe r of p la te le t  constituents to the 
metabolic pathways of endothelial c e l ls .
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_1 ._3 B1 Qod Coaquiation
Development of knowledge
In 400 B.C. Plato suggested in the Timaeus tha t blood
contained f ib res  which caused i t  to congeal when i t  l e f t  the
warmth o f the body. William Hewson (1772) loca lised the source 
o f the f ib re s  to the "coagulable lymph" and suggested tha t 
s o l id i f ic a t io n  of such lymph was in i t ia te d  by a i r  and th is  view was 
extended by Thackrah (1819) who postulated a " v i ta l  influence" in 
the vessel wall which prevented c lo t t in g .  This was confirmed 
experimentally by Brucke (1857) using tu r t le  blood which c lo tted  
ra p id ly  in a glazed basin but remained f lu id  i f  kept in the isolated 
heart. L is te r  (1863) confirmed the importance o f the type of
surface in  contact w ith blood by allowing blood to  c lo t  in India
rubber and glass tubes. He then extended these observations 
in vivo and was able to  show that in the in ta c t  c irc u la t io n  
exposure to a foreign surface in i t ia te d  a "contact" mechanism which 
ra p id ly  lead to c lo t t in g  on the foreign surface. In 1905 
Morawitz postulated his now c lassica l theory of coagulation; 
thrombin, formed from prothrombin in the presence of thromboplastin 
and calcium ions converts f ibrinogen to insoluble f ib r in .  In the 
intervening years many other c lo t t in g  factors have been demonstrated 
as a resu lt  of discovering patients with gene tica lly  determined 
haemorrhagic defects. The cascade (w a te r fa l l)  concept o f blood
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coagulation was formulated in 1964 to encompass a l l  the known 
c lo t t in g  factors at tha t time. Since then additional factors  
have been found and a current scheme fo r  the cascade is  shown 
in f ig u re  1.4. I t  is  postulated tha t most of the c lo t t in g  factors  
c irc u la te  as in e r t  pro-enzymes (zymogens) which are converted to an 
active form and th is  in turn activates the fo llow ing zymogen.
I t  is  the recommendation of the International Committee on Blood 
C lo tt ing  Factors tha t the factors be given Roman numerals and the 
activated form be indicated by the addition of the s u f f ix  (a)
(see Table 1 .2 ).
l^.^.^. The Coagulation Mechanism
The coagulation mechanism may best be described in  f iv e  phases 
although i t  should be appreciated that important feed-back 
in h ib i t io n  and acceleration mechanisms do e x is t .
(A) The contact phase of blood coagulation
There are at least four separate c lo t t in g  factors in th is  part 
of the scheme, factors XII and XI, Fletcher fa c to r  (p re -k a l l ik re in )  
and F itzgera ld  fa c to r  (high molecular weight k i ni nogen).
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A model of the coagulation cascade based 
on that proposed by Macfarlane (1964),
TABLE 1,2.
FACTORS INVOLVED IN COAGULATION TO ^  READ _IN CONJUNCTION
WITH FIGURE 1
FACTOR NAME FATE OR ROLE IN COAGULATION
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Fibrinogen
I I
IV
Prothrombi n
I I I  Tissue thromboplastin
Calcium ions
Proaccelerin or Labile 
fa c to r  or Accelerator 
g lobu li n
Converted to  f i b r in  monomer ( la )  
and then to f i b r in  polymer ( Ib ) .  
Absent from serum.
Converted to thrombin ( I l a ) ;  an 
enzyme that converts fibrinogen 
( I )  to  f i b r in  ( la ) .  Absent from 
serum.
A l ipop ro te in  complex released by 
tissue damage which acts in 
conjunction with Factor V II to 
ac tiva te  Factor X 
A cofactor fo r  various enzymatic­
a l l y  catalysed reactions in 
coagulation.
A cofactor fo r  prothrombin 
a c t iva to r  (Xa). Absent from 
serum.
VII Proconvertin or 
Stable Factor
A cofactor fo r  t issue thrombo­
p las t in  ( I I I ) .  Present in 
serum.
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TABLE 1.2 (continued)
FACTOR NAME FATE OR ROLE IN COAGULATION
V I I I
IX
XI
XII
X I I I
PF3
Antihaemophilic 
Factor (AHF)
Christmas fac to r  or 
Antihaemophilic fac to r 
B or Plasma thrombo­
p la s t in  component (PTC) 
Stuart-Prower fac to r
Plasma thromboplastin 
anticedent (PTA) or 
Antihaemophilic fac to r  C, 
Hageman fac to r
F ib r in -s ta b i l is in g
fac to r
P la te le t fa c to r  3
Modified to Factor V l l ia ;  by 
thrombin which accelerates the 
reaction. This fa c to r  is 
d e f ic ie n t in c lass ic  haemophilia. 
Converted to Factor IXa; an 
enzyme that complexes with Factor 
V I I I  to activa te Factor X.
Present in serum.
Converted to prothrombin ac tiva to r 
(Xa) an enzyme tha t converts 
prothrombin ( I I )  to  thrombin ( I la ) .  
Present in serum.
Converted to Factor XIa; an 
enzyme that activates Christmas 
fac to r ( IX ). Present in serum. 
Activated by contact w ith foreign 
surfaces (e.g. glass) damaged 
vascular endothelium or low pH. 
Factor X lla  is  an enzyme that 
activates Factor XI. Present in 
serum.
An enzyme which s ta b il ise s  f ib r in  
polymer (Ib) by formation of cross- 
linkages. Absent from serum.
A phospholipid released from 
p la te le ts  which acts as a cofactor 
fo r  several enzymes concerned with 
coagulation
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Human fa c to r  XII is  a single chain polypeptide which migrates 
in theyS -g lobu lin  band. The sedimentation constant of p u r i f ie d  
fa c to r  X II has been variously estimated between 4.5s and 5.5s with 
the is o -e le c t r ic  point between 5.8 and 7.5 (Spragg, Kaplan and 
Austen, 1973). The molecular weight measured by a va r ie ty  of 
techniques is  about 80,000 (Schoenmakers, Matze, Haanen, et a l . ,  
1965; Revak, Cochrane, Johnston, et a l . ,  1974).
Human fa c to r  XI (plasma thromboplastin antecedent) has an 
apparent molecular weight of about 160,000, a sedimentation 
constant of 6 .9 -7 .5s and an is o -e le c t r ic  point o f 8 .0-8.2 .
I t  migrates in  the -g lobu lin  band (Forbes and Ratnoff, 1972; 
Schiffman and Lee, 1974). I t  has been suggested tha t the s truc tu re  
consists of two iden tica l polypeptide chains with s im ila r  properties 
joined by disulphide bridges (Wuepper, 1972).
Fletcher and F itzgera ld factors are extremely rare coagulation 
abnormalties. Their discovery resulted from the investiga tion  of 
patients with a defect in  the i n i t i a l ,  surface mediated reactions 
of blood c lo t t in g .  A coagulation abnormality has been described 
in  the plasma of a fam ily resu lt ing  from a consanguineous union 
(Hathaway, Belhasen and Hathaway, 1965). In affected 
members the p a rt ia l  thromboplastin time was abnormally long 
(with a normal prothrombin time) and prolonged exposure to 
surface ac tiva t ing  agents corrected th is  defect (Hathaway and 
A1sever, 1970). The d e f ic ie n t prote in , Fletcher fac to r  is  iden tica l 
to plasma p re k a l l ik re in  (Wuepper, 1972). I t  may also be called 
Factor XII-dependant plasminogen proactiva tor. The protein has 
a single chain s tructure  of M.W. 85,000 and migrates in th e -b a n d .
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Deficiency of yet another contact fa c to r ,  F itzgera ld fac to r 
(high molecular weight kininogen) was described in  an asymptomatic 
pa tient who was found to have a prolongation of the activated 
pa rt ia l thromboplastin time (APTT), which, unlike Fletcher fa c to r  
de fic iency, was not corrected by prolonged incubation with kao lin . 
Since the o r ig ina l case several patients have been described 
w ith ra ther d i f fe re n t  defic iencies but the common fa c to r  is 
probably an abnormality in the level of H.M.W. kininogen, a s ing le  
chain prote in of M.W. 110,000 which migrates in the oc band.
A ctiva tion  of fac to r  XII may occur a f te r  exposure to a wide 
va r ie ty  of foreign surfaces such as glass, kao lin , bentonite, 
diatomaceous earths, dacron, nylon, and homocystine. Of more 
in te re s t is  the wide range of physiological substances which may 
also cause a c t iva t ion ; these include, collagen, sebum, basement 
membrane, u r ic  acid c rys ta ls ,  endotoxins and the soaps of 
saturated fa t t y  acids.
The mechanism of ac tiva tion  seems to be re lated to the 
negative surface charge of the material and in h ib i t io n  of ac t iva t ion  
follows exposure of the surface to a p o s it ive ly  charged surface such 
as protamine sulphate, hexadimethrine bromide and cytochrome C 
(Nossel, Rubin, D r i l l in g s ,  et a l . ,  1968). I t  has been suggested 
tha t ac t iva t ion  of fac to r XII resu lts  from conformational changes 
in  the molecule fo llow ing i t s  adsorption onto r ig id ly  spaced 
negatively charged s ites  ( G r i f f in ,  1978). Additional evidence of 
th is  comes from studies suggesting that the molecular weight is 
unaltered by ac tiva t ion  (Cochrane, Revak and Wuepper, 1973;
McMillan, Saito, Ratnoff, e t a l . ,  1974). I t  is  probable that 
ac tiva t ion  is  associated with unfolding of the molecule which in  
the process exposes functional s ites .
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The end resu lt of such ac tiva tion  is  the development of 
active s ites  with esterase and p ro teo ly t ic  a c t iv i t y  as shown by 
the a b i l i t y  to hydrolyse synthetic esters. In add it ion , activated 
fac to r XII in i t ia te s  the c lo t t in g ,  f i b r in o ly t i c ,  k a i l ik re in -k in in  
systems and enhances vascular permeability and chemotaxis. In 
the coagulation cascade activated fac to r  XII acts on fac to r  XI 
(plasma thromboplastin antecedent, P .T.A.). I t  is  also possible to 
s p l i t  fac to r XII in to  two fragments with tryps in  or plasma 
k a l l ik re in  to give fragments of MW 52,000 and 28,000, th is  la t t e r  
being associated with functional a c t iv i t y .
Surface ac tiva t ion  of fac to r XII is  associated w ith a pos it ive  
feedback mechanism in  which HMW - kininogen enhances the ac tiva tion  
o f p re k a l l ik re in  to k a l l ik re in .  This in turn activates more 
fac to r X II .  Further degradation of fac to r XIla occurs with 
production of fragments, one of which, fragment E (MW 28,000) 
reta ins e s te ro ly t ic  a c t iv i t y .
The ac tiva t ion  of fac to r XI by fac to r X lla  does not require 
the presence of ionised calcium and the process consists of 
cleaving in terna l peptide bonds in the two chains resu lt ing  in 
two subunits (heavy chains) with a molecular weight of 50,000 each 
and two subunits ( l ig h t  chains) with a molecular weight of 30,000 
each. The active s i te  is  located on the l ig h t  chains. Trypsin, 
but not plasmin, k a l l ik re in  or thrombin, w i l l  also activa te  fac to r 
XI in a s im ila r  fashion (Saito , Ratnoff, Marshall, et a l . ,  1973).
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Plate le ts  treated with collagen or kao lin , may aTso activa te  
fac to r XI in the absence of fa c to r  XII (Walsh, 1972b). Factor XII 
requires the presence of an additional fac to r  to ac tiva te  pu r if ied  
fac to r XI, th is  is  Fitzgera ld fac to r  (Saito, Ratnoff, Waldman, et 
a l . ,  1975). Activated fac to r  XI is  a hyd ro ly t ic  enzyme which 
converts fac to r IX to i t s  activated form. Factor XIa 
is  inh ib ited  by a va r ie ty  of agents including d i- iso p ro p y l- 
fluorophosphonate (DFP), phenylmethyl sulphonyl f lu o r id e  (PMSF) 
heparin, apyrase Cl in a c t iva to r  and a , -a n t i - t ry p s in  (Forbes,
Pensky and Ratnoff, 1970; Heck and Kaplan, 1974).
I t  has been known fo r  many years that the c lo t t in g  time of 
p la te le t  r ich  plasma from patients with fa c to r  XII defic iency 
is  accelerated by any contact procedure (Ratnoff and Rosenblum, 
1959). This is  probably due to the presence of fa c to r  XI 
adsorbed to the p la te le t  membrane (Horowitz and Fujimoto, 1965). I t  
has also been suggested that small amounts of fa c to r  XII are 
adsorbed on the p la te le t  membrane ( la t r id i s  and Ferguson, 1965).
The addition o f ADP to p la te le ts  releases a clot-promoting agent 
in to  the plasma, but only i f  fac to r XII is  present (Walsh,
1972a). The addition of collagen appears to generate a c t iv i t y  
a t t r ib u ta b le  to activated fac to r  XI (Walsh 1972b). While i t  
i t  seems c lear tha t p la te le ts  may produce a c lot-promoting 
contact product, the exact mechanism is  unclear.
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(D  Formation of fa c to r  IXa
Factor IX (Christmas fa c to r  (CF), plasma thrombo­
p las t in  component (P.T.C.) is  a vitamin-K-dependant glyco­
prote in  containing carboxyglutonic acid residues necessary 
fo r  the binding of calcium. A molecular weight of about
55,000 has been suggested. Vitamin K is  necessary fo r
synthesis of the molecule and i t s  absence due e ith e r  to 
malabsorption of vitamin K or anticoagulant therapy, 
resu lts  in the appearance of a c irc u la t in g  competitive 
in h ib i to r  (p ro te in  induced by vitamin K absence antagonism 
(PIVKA) (Hemker, Keltkamp, Hensen et a l . ,  1963)). This 
p rote in  which is  fu n c t io n a l ly  in e r t  may be detected 
immunologically (Reekers, Lindhout, Kopklaasen et a l . ,  
1973). Such PIVKA's also ex is t fo r  factors I I ,  V II and X 
and they may in te r fe re  with the coagulation process by 
competitive in h ib i t io n .  Factor IX is  the fa c to r  
d e f ic ie n t in patients with Christmas disease, a sex linked 
recessive condition Wiich produces l i fe - lo n g  haemostatic 
d i f f i c u l t i e s .
Factor IX is  activated by fac to r XIa in the presence 
of calcium ions in  a reaction which occurs in  two steps.
In the f i r s t  (slow reaction) an argin ine-a lanine 
bond is  cleaved giving r ise  to  a two chain intermediate 
held together by a disulphide bond. This intermediate 
which is  in e r t  is  then cleaved in a second step at an 
arg1nine-valine bond to give r ise  to activated fa c to r  IX 
and a polypeptide residue (fas t reaction ). Activated
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fac to r  IX consists of a heavy chain (MW 38,000) and a 
l ig h t  chain (MW 16.000) held together by disulphide 
bonds. The l ig h t  chain contains th e -c a rb o x y g lu to m ic  
acid residues, necessary fo r  binding calcium, and the 
heavy chain contains the active s i te  which functions as a 
serine esterase. In addition there is  evidence th a t 
fa c to r  IX may be activated by fac to r Xa and by k a l l ik re in
(Kalousek, Koningsberg and Nemerson, 1975), and a protease
in  Russell's v ipe r venom may also cleave the molecule at 
the arg in ine -va line  bond.
(£) Formation o f fa c to r  Xa
There are two separate pathways fo r  the generation of
fac to r Xa. Both are necessary fo r  normal haemostasis.
The in t r in s ic  pathway - slow fac to r Xa generation 
This step involves the in te rac tion  of fa c to r  IXa, 
fa c to r  V I I I ,  phospholipid and ion ic calcium to  form a 
complex which then activates fa c to r  X (Hemker and Kahn, 1967).
Factor X as i t  normally c ircu la tes  in the plasma is  a 
glycoprotein o f molecular weight 55,000 (Jackson and 
Hanahan, 1968, Fujikawa, Legaz and Davie, 1972; Jesty 
and Esnouf, 1973) the heavy polypeptide chain of fa c to r  X 
is  homologous to the prethrombin-2 portion of prothrombin 
(T i ta n i ,  Hermodson, Fujikawa et a l . ,  1972).
Factor V I I I  (antihaemophilic fa c to r ,  AHF) is  thought to 
have a molecular weight of 2 x 10 ^ o r  higher (Ratnoff, Kass 
and Lang, 1969). Factor V I I I  is  usually p u r if ied  from a 
p rec ip ita te  of plasma which is  then chromatographed on 
large pore agarose gels (Kass, Ratnoff and Leon, 1969;
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Bennett, Forman and Ratnoff, 1973). By such means 
p u r i f ic a t io n  up to 10,000 fo ld may be achieved and the 
material is  homogeneous by u lt ra ce n tr i fu g a t io n  and zone 
electrophoresis. Sedimentation analysis of th is  material 
reveals a symmetric peak with a sedimentation c o e f f ic ie n t  
of 27s.
Factor V I I I  is  the prote in Wiich is d e f ic ie n t in i t s  
a c t iv i t y  in patients with c lass ic  haemophilia (haemophilia 
A). In addition to i t s  a c t iv i ty  in the coagulation 
cascade fa c to r  V I I I  is  necessary fo r  aggregation of human 
p la te le ts  by the a n t ib io t ic  r is to c e t in ,  fo r  p la te le t  
adhesion and correction of a prolonged bleeding time in  
patients with von Willebrand's disease. Separation of 
the coagulation a c t iv i t y  (FV III iC ) and the p la te le t  
aggregating a c t iv i t y  (FVIII:vWF) can be achieved w ith high 
ion ic strength solutes or in the presence of calcium 
ions (0.25M) (Rick and Hoyer, 1973; Wagner, Cooper and 
Owen, 1973; Austen, 1974). This revers ib le  d issocia tion  
produces a low molecular weight fragment of approximately
120,000 (Legaz, Schmer, Counts et a l . ,  1973). Recombination 
o f the small fragment with the large c a r r ie r  molecule occurs in 
the absence of calcium ions. I t  is  not c lea r whether in native 
plasma the two molecules are in combination or ex is t separately.
In c lass ic  haemophilia the evidence is tha t fa c to r  V II I  
molecule is  de f ic ie n t at the s i te  of coagulant a c t iv i t y  
(Zimmerman, Ratnoff and Powell, 1971) but the FVIII RAg is  iden tica l 
to normal (Bennett et a l . ,  1973; Hoyer and Breckenbridge, 1970).
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Factor VIII:vWF is  probably synthesised in the 
vascular endothelium as antigenic material has been 
demonstrated in endothelial ce l ls  and p la te le ts  (Bloom, 
Giddings and Wilks, 1973; Howard, Montgomery and 
Hardi s ty ,  1974).
The phospholipid micelles are probably produced by 
p la te le ts  and both factors VI11 and IXa require to  be 
absorbed onto the m icelle  surface fo r  the reaction to 
occur. There is  also evidence of a feedback mechanism 
in  tha t the reaction may be accelerated by a l te ra t io n  of 
the physical s tructure o f the fac to r V I I I  molecule by 
thrombin (Rapaport, Schiffman, Patch et a l . ,  1963) which 
may be due to conformational changes in the molecule 
ra ther than s p l i t t in g  o f i t  (Davie and Fujikawa, 1975).
Factor V I I I  acts as a regulatory protein enhancing the 
rate o f fac to r  X ac tiva t ion  and th is  is s im ila r  to  the 
ro le  of fac to r  V in  the ac tiva t ion  o f prothrombin 
The e x tr in s ic  pathway - rapid Xa generation
This pathway involves the p a rt ic ip a t io n  o f a tissue 
fac to r  (e x tr in s ic  to the blood), fac to r VII and calcium ions.
I t  has been known fo r  many years tha t addition of 
certa in  t issue extracts activa te  and accelerate the c lo t t in g  
o f plasma. Tissue fac to r  has been id e n t i f ie d  as a ce ll 
membrane component in a va r ie ty  of ce l ls  and has been 
found in  the bra in , lung, kidney, l i v e r  and large vessels 
(Astrup, 1965). Attempts have been made to p u r i fy  i t  
and i t  seems to be a l ipop ro te in  complex with a molecular 
weight between 220,000 and 300,000. The apoprotein has 
been p a r t ia l ly  characterised and that from human brain 
has a molecular weight of 52,000. The l ip id -p ro te in
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complex is  required fo r  coagulant a c t iv i t y  and although 
i t  also has peptidase a c t iv i t y  th is  does not appear to be 
associated with i t s  procoagulant a c t iv i t y .
Factor V II is  a single chain glycoprotein of 
MW 45,000. I t  is  produced by the l iv e r  and requires the 
presence of vitamin K fo r  synthesis. The l i v e r  path­
way may be inh ib ited  by oral anticoagulants and th is  
resu lts  in an immunologically identica l but in e r t  
protein (PIVKA).
Tissue fa c to r ,  fac to r  V II and calcium ions form a complex 
during which fa c to r  V II is  activated and in turn activates fac to r  X
Factor V II is  activated by tissue fa c to r ,  by exposure 
o f plasma to cold and by prolonged contact w ith glass, 
c e l i te  or kao lin . Other factors which modify i t s  function 
are fa c to r  Xa, thrombin, fac to r X l la ,  k a l l ik re in ,  
fac to r  IXa and plasmin (Cochrane, Revak and Wuepper, 1973;
Alexander and Landwehr, 1949; Colman, M attle r and Sherry,
1969; Osterud, Berre, Otnaess et a l . ,  1972).
Factor V II as i t  normally c ircu la tes  in plasma has 
weak p ro te o ly t ic  a c t iv i t y .  When activated by thrombin 
or Xa th is  a c t iv i t y  may be increased several hundred fo ld .
The ro le  o f tissue fac to r  appears to be tha t of a 
co -fac to r s im ila r  to  the ro le  of fac to r V I I I ,  fac to r  V 
and high molecular weight kininogen (Rezvan and Howel1 ,1977) . 
Factor X-ac tiva t ion
Factor X may be activated e ith e r by a complex 
formed by fa c to r  V I I I ,  fac to r IXa, phospholipid and 
ionized calcium or by tissue fac to r and fac to r  V I I I ,  or
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in  v i t r o  by Russell's v iper venom or t ryp s in . During 
ac t iva t ion  there is  a cleavage of a single spec if ic  
a rg in y l" is o le u c ine bond in  the heavy chain of fac to r X, 
with release of one or more polypeptide fragments.
This gives r ise  to  the formation of a glycoprotein of 
molecular weight 45,300 (o(Xa) and a peptide chain o f 
MW 10,000 which is  s p l i t  from the amino terminal end of the heavy 
chain. The resu lt  is  the formation of the active enzyme.
A fu r th e r  degradation may occur e ith e r in Factor Xa or in 
the zymogen as a resu lt  of cleavage of a peptide of 
molecular weight 2,700 from the carboxy terminal portion 
o f the heavy chain. For th is  second degradation, 
thrombin is  necessary and the product is  Factor Xa. The
a c t iv i t y  of activated fac to r  X does not depend on th is  reaction.
Formation o f thrombin 
The enzyme thrombin is  formed by ac tiva tion  of the 
in e r t  precursor, prothrombin ( fa c to r  I I )  by a complex 
formed by fac to r  Xa, fac to r V and phospholipid in the 
presence of ion ic  calcium.
Prothrombin is  a single chain glycoprotein of 
MW 70,000 and is  produced l ik e  factors V I I ,  IX and X in 
the l i v e r .  The rate of synthesis is dependent on 
vitamin K and may be inh ib ited  by oral anticoagulants.
A va r ie ty  of abnormal prothrombins have now been 
described in  patients with reduced levels of immuno- 
reactive material (Shapiro, Martinez and Holburn, 1969).
In these pa tients , ac t iva tion  of prothrombin was
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abnormally slow and abnormal products of s p l i t t in g  were 
found in the serum. Several variants of the molecule 
have been found subsequently by immunological means 
(G iro lam i, 1975).
Factor V was postulated to occur in plasma when i t  
was appreciated tha t p a r t ia l ly  pu rif ied  prothrombin 
required an additional fac to r to rap id ly  convert i t  to 
thrombin (N o lf,  1908). I t  was then observed tha t the 
c lo t t in g  time of stored plasma grew increasingly long 
suggesting the presence of a la b i le  fac to r (Quick, 1943).
A patient w ith such a congenital defic iency was then 
described (Owren, 1947) but th is  is  a rare disorder which 
is  associated with only a minor to moderate bleeding tendency. 
There is  evidence tha t fac to r  V is  synthesised in 
the l i v e r .  There is  dispute over the molecular weight 
of the protein and various estimates range from 70,000 
350,000. I t  is  probable tha t the basic active un it is 
of the order o f 60,000-70,000 and the functional protein 
ex is ts  as m ult ip les o f th is  with calcium ions maintaining 
the in te g r i ty  of the polymer (Day and Barton, 1971).
The function o f fac to r V is  to accelerate the 
conversion of prothrombin to  thrombin in the presence of 
fa c to r  Xa, the evidence is  tha t i t  has no other a c t iv i t y .
Activa tion  of prothrombin is  complex and has been 
defined by Magnusson, Peterson, Settrup-Jenson et a l . ,
1975. I t  is  probable tha t ac tiva tion  occurs in 
several steps and the reaction is  fu r th e r  complicated 
by digestion of the molecule by forming thrombin. I t
is  probable tha t in vivo more than one pathway of 
thrombin production ex is ts .
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In the fac to r Xa mediated pathway prothrombin is 
cleaved to  give two products: pre-thrombin 2
(intermediate I I )  and fragment 1:2. Prothrombin 2 is  then 
cleaved at an arg in ine-iso leuc ine bond to give thrombin. 
This is  the pathway when pure systems are used and the 
reaction takes place in the presence of a thrombin 
In h ib i to r .  I f  thrombin is  not inh ib ited  at the time of 
formation i t  acts on the prothrombin molecule i t s e l f  and 
cleaves o f f  fragment 1 to  give prethrombin 1 (intermediate 
1) which is  then slowly converted to  thrombin by the 
fa c to r  Xa complex. In addition thrombin acts on fragment 
1:2 to  give fragment 1 and th is  competitive ly in h ib i ts  
prothrombin conversion (Prowse, Mattock, Esnouf et a l ,
1976). Also the calcium binding s ites of prothrombin 
are in fragment 1:2 and fragment 1 and the removal of 
fragment 1 by thrombin generation does not allow the 
fa c to r  Xa complex to bind properly and resu lts  in 
slow generation o f fu r th e r thrombin. Factor V 
competes with fragment 1 fo r  a common binding s i te  on 
the prothrombin molecule and reduces th is  in h ib i to ry  
action and thus accelerates the reaction. Phospho­
l i p i d  also increases the reaction rate by about ten fo ld  
perhaps by binding the reactants to the l ip id s  surface 
and so ra is ing  the local concentration of the molecules 
or by inducing conformational changes in the prote in .
Thrombin is  the product o f prothrombin ac t iva t ion . 
Thrombin is  a two-chain (A and B) serine protease with 
a molecular weight o f approximately 38,000. The 
la rger B chain has sequence homology with other serine 
proteases p a r t ic u la r ly  those from the pancreas. The
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short A chain re s t r ic ts  the s p e c i f ic i ty  of the enzyme. 
Thrombin has numerous a c t iv i t ie s  in coagulation, the 
two most important functions are to  convert f ibr inogen 
to f i b r in  and to induce p la te le t  aggregation and 
release. Thrombin also activates fac to r  V I I I ,  
digests fragment 1:2 o f prothrombin, a lte rs  the 
s truc tu re  of factors  V and V I I ,  and in v i t r o  i t  also 
digests a va r ie ty  o f synthetic substrates.
E.* Conversion o f f ibr inogen to f ib r in
Fibrinogen is  a glycoprotein synthesised in the 
l i v e r  parenchymal c e l ls .  I t  is  the in e r t  c irc u la t in g  
precursor of f i b r in  and as such i t  plays a key ro le in 
haemostasis.
Fibrinogen is  a ^g-g lobulin  w ith a molecular weight 
o f approximately 340,000 of which 3% is  carbohydrate.
I t  is  thought to  have an elongated form (Shulman, 1953;
Caspary and Kekwick, 1957) but i t s  detailed shape is  
unknown. Hall and S layter, 1959, obtained electron 
micrographs o f ind iv idual molecules, revealing a protein
o
about 475A long consisting o f a l in e a r array o f three 
g lobu lin  domains (see Figure 1.5(A)). Koppel (1970) 
proposed a sphere of 24 nm which he suggested had the 
form of a pentagonal dodecahedron (see f igu re  1. 5 (B ) ) .  
Despite considerable controversy, the ' t r in o d u la r '  
model o f Hall and S layter is  now generally accepted.
o
More recently  a precise length o f 450A has been 
obtained fo r  the t r in o d u la r  model, with a more 
deta iled substructure (see Figure 1.5(C)) (Weisel, P h i l l ip s  
and Cohen, 1981).
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Figure 1.5.
Three proposed slopes for the fibrinogen 
molecule (a) the trinodular representation 
of Hall and Slayter (1959)
(b) the pentagonal dodecahedron of 
Koppel (1970)
(c) the multi-nodular structure proposed 
by Weisel, Philips and Cohen (1981),
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The fibr inogen molecule is  a dimer, each h a lf  
consisting of three d iss im ila r  polypeptide chains 
(A<v, w ith molecular weights of 63,000, 56,000
and 47,000 joined by disulphide bridges (McKee, Mattock 
and H i l l ,  1970; Gaffney, 1977). These chains are 
linked by disulphide bonds near the N-terminal end of 
the oz and } (  chains (see Figure 1.6).
In addition to i t s  function in coagulation 
f ib r inogen , because of i t s  molecular size and shape, 
has important e ffec ts  on red ce ll  aggregation and is  the 
most important prote in determinant of plasma v isco s ity .  
I t ,  the re fo re , plays an important part in determining 
blood flow (Dintenfass 1971, Lowe, Drummond, Forbes 
et a l . ,  1981). There is  also some evidence which 
l in ks  the fibrinogen level as a r isk  association in 
a therosc leros is , immunity, in the inflammatory response, 
in  defence mechanisms against invasion by bacteria  and 
by malignant ce l ls  and i t  is  of importance in  providing 
a scaffo ld  fo r  f ib ro b la s t  growth in wound healing.
The conversion of fibr inogen to f ib r in  involves 
p ro teo lys is , polymerisation and s ta b i l is a t io n  (see Figure 
1 .7). Fibrinogen cleavage is  confined to the 'amino- 
terminal ends of the Aa and B ^  chains. Thrombin f i r s t  
s p l i t s  the arg in ine (Aal6)-g lyc ine (Aal7) bond on the 
Aa chain to provide f ib r inopeptide  A (FPA-16 amino 
acids). This reaction proceeds rap id ly  and leads to  
conformational change with end to end associations of the 
intermediate f i b r in  monomer molecules. Thrombin then
ÇOOH
ALPHA 
COOH '
COOH
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Six Chain structure of FIBRINOGEN 
■ “ -  -  “ -  Interchain disulphide bonds
/  FPA 
/} FPB
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Figure 1.6
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npniNOCcri t h r o m b in ,  f ib r in  + 2 ( f ib r in o p e p t id e  a ")
MONOMER '
+  z ( FIBRINOPEPTIDE b )
FIBRIN
MONOMER ^ pr o to fib r ils
FIBRIN 
PROTOFIBRILS ? ±  FIBRIN ^POLYMERISATION j ---------- 3
FIBRIN
XIII
FIBRIN ( c r o s s  l in k e d ) ------------ 4
Figure 1.7 
The conversion of fibrinogen to fibrin,
(1) Activation by thrombin, removal of FPA and FPB,
monomeric fibrin.
(2) End-end polymerisation, protofibrils.
(3) Lateral association of protofibrils , fibrin fibers,
(4) Covalent cross-linking by Factor Xllla cross- 
linked fibrin.
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cleaves the arginine (By8 14)-glycine ( B ^  15) bond on 
the Byô chain to produce f ib r inopeptide  B (FPB-14 amino 
acids) a f te r  a lag phase.
The subsequent process of polymerisation is  poorly 
understood. I t  would appear to involve the formation of 
weak revers ib le  bonds between the polymerising un its . A 
schematic model o f the i n i t i a l  events involved in the 
polymerisation o f f i b r in  has been proposed by D o o l i t t le  
1981 (see Figure 1.8) and is  consistent with e lectron- 
micrographic and s truc tu ra l data.
The fibr inogen molecule (a) is  converted in to  a 
f i b r in  monomer (b) by the release of f ib r inopeptides A 
and B as described previously. The newly exposed ends 
o f the alpha chains serve as "knobs" tha t in te ra c t with 
"holes" in the terminal domain, l ink ing  f i b r in  monomers 
w ith the observed half-monomer overlap (c ) .  The 
assembly can be extended in to  a long "intermediate 
polymer" two molecules th ick  (d) which is  s ta b il ise d  by 
the formation o f covalent c ross-links  between adjacent 
terminal domains. Intermediate polymers are then 
interwoven la te r a l ly  to form a f u l l y  developed f i b r in  
strand. The i n i t i a l  polymerisation seems to depend 
s p e c i f ic a l ly  on the alpha knobs. The end-to-end 
covalent c ross-l ink ing  is  between two gamma chains. 
Lateral growth may be mediated by the beta knobs 
and then strengthened by alpha-chain c ro ss - l ink ing .
I t  is  important to  keep in mind tha t the raison 
d 'e t re  of the f ib r in o g e n - f ib r in  transformation l ie s  in
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FIBRINOPEPTIDE. A
THROMBIN
I \
FIBRINOPEPTIDE B 
ALPHA KNOB  
BETA KNOB
CROSS LINK
Figure 1.8.
Polymérisation of Fibrin
The fibrinogen molecule (a) is converted into 
fibrin monomer (b) by the removal of fibrino- 
peptides A and B. Fibrin monomers then form 
by half monomer overlaps (c). Long 
intermediate polymers are then formed by 
extension of the monomers (d), stabilisation 
occurs by the formation of covalent cross links 
between terminal domains.
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i t s  a b i l i t y  to produce a gel tha t can prevent blood loss 
from a closed c ircu la to ry  system. F ib r in  c lo ts  are 
gelled and semi-solid masses formed by an all-pervading 
network of f ib re s .  O rd inar ily  the propagating f ib re s  
become entangled in  the formed elements of the blood, 
inc lud ing the red and white c e l ls ,  but especia lly  the 
p la te le ts  with which preferred in te ractions occur.
Factor X I I I  ( f i b r in  s ta b i l is in g  fa c to r )
In the f in a l  stage of blood coagulation f ib r in  
becomes inso lub le  as a re su lt  of the c ross - l ink ing  o f 
f i b r i n  monomer by the action of a transpeptidatlng 
enzyme (F X III)  f i r s t  described by Lorand and Jacobsen (1958).
Plasma fa c to r  X I I I  is  composed of two A chains 
(MW 75,000) and two B chains (MW 88,000); the whole 
molecule has an A B ^  structure with a molecular 
weight of 320,000 (Schwartz, Pizzo, H i l l  et a l . ,  1973).
Factor X I I I  c ircu la tes  as an inactive precursor in 
plasma, and is  activated to  X l l la  by the action of 
thrombin in  the presence of ion ic  calcium. This 
enzyme is  responsible fo r  the strengthening of f i b r in -  
t o - f i b r i n  bonds by in te r-g lu tam y l-e - lys ine  bridges to 
form y  - ^  dimers and more slowly across c< chains 
(Lorand, 1972). Covalently s tab il ised  f i b r in  is  
mechanically stronger than non cross-linked f i b r in  and 
is  more re s is tan t to f ib r in o ly s is .
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Physiologlcal in h ib i to rs  of blood coagulation
I t  is  probable tha t every activated coagulation 
fa c to r  in the cascade has one or more in h ib i to rs  which 
regulate the rate of generation of the active product 
or determines i t s  destruction. The purpose of these 
would seem to be the l im i ta t io n  of ac t iva t ion  o f 
coagulation and protection against inadvertent 
deposition of f i b r in  in the vascular tree .
The most important of such in h ib ito rs  is  antithrombin 
I I I  (A T I I I ) .  The presence of an in h ib i to r  o f thrombin 
has been postulated since Morawitz (1905) showed a 
gradual decline in coagulant a c t iv i t y  of c lo tted  blood.
I t  was i n i t i a l l y  suggested tha t th is  might be due to 
e ith e r  some spec if ic  antithrombin or to adsorption of 
thrombin to f ib r inogen. I t  was soon appreciated tha t 
using heparinised plasma acceleration of th is  in h ib i to ry  
e f fe c t  occurred and i t  was thought to be due to  the 
presence o f a heparin co-facto r in plasma, Clark (1938). 
Deficiency of antithrombin a c t iv i t y  and low heparin 
co-fac to r a c t iv i t y  in plasma was associated with a 
genetic predisposition to  thrombosis (Egeberg, 1965) and 
la te r  the anti thrombin associated with heparin co-facto r 
a c t iv i t y  was prepared (Abilgaard, 1968).
ATIII is  the most important of at least s ix  d if fe re n t  
antithrombins three of which (a^ -a n t i t ry p s in ,  a 2 " 
macroglobulin and ATIII)  play a physiological ro le . I t  
is  estimated tha t 75% of anti thrombin a c t iv i t y  is  due to 
A T II I .
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A TIII is  anot^j-globulin with a molecular weight of 
about 65,000. ATIII reacts with thrombin to produce a 
complex in  which both components are inactiva ted . The 
rate of the reaction depends on the concentrations of thrombin 
and A T II I ,  and there is  some evidence tha t the mechanism 
of antithrombin a c t iv i t y  is  made more e f f ic ie n t  by ac t iva t ion  
o f the system by the early stages of coagulation.
ATIII has in h ib i to ry  actions on fa c to r  Xa (Seegers,
Cole and Harmison, 1964) except when associated with 
p la te le ts ,  fa c to r  V - phospholipid complex or phospholipid 
i t  is  la rge ly  protected. Neutra lisation of fa c to r  Xa 
generated in plasma is  rapid and complete w ith in  15 minutes 
(Odegard, Lie and Abildgaard, 1975). This is  analogous to 
the s itu a t io n  with thrombin and suggests the in h ib i to ry  
system is  primed by the e a r l ie r  stages of the cascade.
There is  also evidence th a t ATIII plays a part in  
ne u tra l isa t ion  of fa c to r  IXa (Rosenberg, McKenna and 
Rosenberg, 1975; Osterud, Miller-Andersson, Abildgaard 
et a l . ,  1976), XIa (Damus, Hicks and Rosenberg, 1973),
XIla (Stead, Kaplan and Rosenberg, 1976) and plasmin and 
the rate of in a c t iva t io n  of a l l  these factors is  accelerated 
by the addition of heparin.
Recently prote in C, a new anticoagulant has been 
discovered. Protein C, a vitamin K dependent fa c to r ,  is  the 
zymogen of a serine protease, previously known fo r  many years 
as auto-prothrombin I I -A  (Mammen, Thomas and Seegers, 1960; 
Seegers, Novoa, Hendry et a l . ,  1976). Isolated protein C 
consists of a two-chain molecule tha t can be converted in to  a
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serine protease by the p ro teo ly t ic  cleavage of a peptide bond 
in the amino-terminal region of the heavy chain (Fernlund and 
S ten flo , 1979). Both thrombin (K is ie l ,  Ericsson and Davie, 
1976; K is ie l , .  1979; K is ie l ,  Canfield, Ericsson et a l . ,
1977) and Russel's v iper venom (K is ie l et a l . ,  1976) have 
been reported to catalyse such a reaction. Thombin ac tiva t ion  
of prote in C has recently been reported to be g reatly  
accelerated by an endothelial ce ll surface fa c to r  (Esmon and 
Owen, 1981).
The potent anticoagulant action of protein C (Mammen 
et a l . ,  1960; Seegers, Marlar and Walz, 1978) is  probably 
re lated to the ina c t iva t ion  of activated fa c to r  V and 
activated fa c to r  V I I I ,  thus l im i t in g  Xa and thrombin 
generation (K is ie l et a l . ,  1976; Marlar, K leiss and G r i f f in ,  
1981). A stim u la tory e ffe c t on f ib r in o ly s is  has also been 
reported but i t  is  not c lear whether th is  is  a d ire c t or 
in d ire c t  e f fe c t .
Recently congenital defic iencies in prote in C have been 
reported with the affected fam ilies  having a thrombotic 
tendency ( G r i f f in ,  Evatt, Zimmerman et a l . ,  1981; Bertina, 
Broekmans, van der Linden et a l . ,  1982).
F ib r in o lys is  
%.^._1 Development of knowledge
I t  has been known fo r  more than a century tha t 
blood c lo ts  slowly l i q u i f y  (Hunter 1794, Denis 1838,
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Dastre 1893). Early investigators concluded tha t a
physiological process occurred, the function of which
was the removal of f i b r in  a f te r  i t  had f u l f i l l e d  i t s
function in haemostasis. As a resu lt  of intense
inves tiga tion  over the past 30 years, f ib r in o ly s is  and
thrombolysis have been shown to be the processes by
which f i b r i n ,  in  the form of e ith e r a c lo t  or a thrombus,forms
degradation products (FDP). The dominant mechanism
is  the plasminogen-plasmin system; in  th is ,  the inactive
protein precursor (plasminogen) is  activated to the enzyme
plasmin by an a c t iva to r  the reaction being contro lled
by the presence of in h ib i to rs .  Such ac tiva to rs
may be of t issue , plasma or synthetic o r ig in  and th is
step may be in h ib ite d  by a va r ie ty  of physiological or
therapeutic in h ib i to rs  (see Figure 1 .9 ). I t  is  known
tha t a lte rna te  mechanisms of f ib r in o ly s is  ex is t but
these seem to be of minor importance (Plow and Edgington, 1975).
I t  is  probable tha t the f ib r in o ly t i c  process 
functions as a major homeostatic mechanism in the 
maintenance of patency in the vascular tree by c o n tro l l in g  
deposition of f i b r in .  However, the physiological control 
of the system remains con trovers ia l. In add it ion , the 
importance of defic ienc ies of part or the whole of the 
system in the production o f vascular occlusion is  not yet 
c lea r. Activa tion  of f ib r in o ly s is  fo r  therapeutic 
purpose is  possible and in selected s itua tions  is  of 
proven value (Forbes, Lowe and Prentice, 1978).
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a c t iv a t o r s
FIBRIN
THROMBUS
PLASM INO G EN
XII a
Endothelium  • 
Tissues  
White cells  
Red cells  
U rokinase  
Streptokinase
THROMBUS
(F IB R IN )
PLASMIN
INHIB ITORS
Activation
Inhibitors
a  2 “  Antiplasmin 
a  2 “ Macrogiobuiin
^  F IBRIN  DEGREDATION  
PRODUCTS ( F D P s )
Figure 1.9
The basic fibrinogenolytic/fibrinolytic pathway 
is shown.
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A va r ie ty  of theories have been proposed to explain 
the se lective d igestion of f i b r in  in travascu la r ly . 
Plasminogen may be bound se le c t ive ly  to f i b r in  
(A lk ja e rs ig ,  Fletcher and Sherry, 1959); plasmin may 
be dissociated from anti-plasmin in contact with f ib r in  
(Ambrus and Markus, 1960); plasminogen a c t iva to r  may 
be bound to  f i b r in  (Chesterman, A ll ing ton  and Sharp, 1972).
The Plasminogen - Plasmin System 
The four components of th is  system are plasminogen, 
plasmin, plasminogen a c t iva to r  and in h ib i to rs .
(a_) Plasminogen
Human plasminogen is  a single-chain beta-g lobulin  
o f approximate molecular weight 90,000. I t  is  present 
in  normal adult plasma in a concentration o f 200 ng/ml 
and in  the in fan t at a lower level and is  present in a l l  
body f lu id s .  Two forms of the molecule have been 
prepared and th e i r  biochemical and physiological a c t iv i t ie s  
in tensely studied. They d i f f e r  in the composition of th e i r  
amino term inals. Native human plasminogen has glutamic 
acid in the N-terminal position (glu-plasminogen) (Wallerr 
and Wiman, 1970), and the other main form has lys ine as 
the N-terminal amino acid (Lys-plasminogen) (Robbins, 
Summaria, Hsieh et a l . ,  1967). The b io log ica l 
importance of th is  biochemical d ifference is  con trovers ia l. 
Both types occur in m u lt ip le  but e lec trop ho re t ica l ly  
d is t in c t  forms (C o l len and de Maeyer, 1975). The 
molecular weights o f glu- and lys-plasminogen have been 
estimated variously as being of the order o f 97,000
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and 84,000 (C o l len. Ong and Johnson 1975) and 85,000 and
82,000 respective ly (Robbins, Summaria and Barlow, 1975). 
I t  seems l i k e ly  tha t the lys-form results  from lim ited  
proteo lys is  o f the glu-form by plasmin formed during 
the p u r i f ic a t io n  procedure (C o l len and de Maeyer, 1975; 
Collen et a l . ,  1975; Markus, Evers and Hobika, 1976)
Lys-plasminogen is  more read ily  absorbed to f i b r in  and 
more read ily  activated than glu-plasminogen (Thorsen,
1975) and fo r  these reasons may be of greater potentia l 
value in thrombolysis (Kakkar, 1978).
(b) Plasmin
Plasmin is  a p ro teo ly t ic  enzyme formed from the 
inac tive  precursor plasminogen by any o f a va r ie ty  of 
ac t iva to rs . The molecule consists of two amino-acid 
chains o f d i f fe re n t  lengths connected by a disulphide 
bond. These two chains re su lt  from s p l i t t in g  of an 
a rg in ine -va line  bond during ac tiva tion  to  produce a 
heavy (A) chain M.W. approximately 68,000 and a l ig h t  
(B) chain, M.W. approximately 25,000. The A-chain 
contains the N-terminal end and the B-chain contains 
the C-terminal end and the active serine centre. The 
action of plasmin is  not re s tr ic ted  to  f ib r in  and i t  
s p l i t s  peptide bonds in p ra c t ic a l ly  a l l  prote in 
substrates and a wide va r ie ty  of esters of argin ine 
and lys ine . I t  is not normally detected in human 
plasma as i t  is  rap id ly  neutralised by in h ib i to rs .
(£) Activa tion  of plasminogen
The princ ipa l a c t iva to r  o f plasminogen in blood is 
presumed to be present in the endothelium of blood
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vessels and is  released 'on demand' by, fo r  example, 
exercise, hypercoagu lab il ity , and drugs (Todd, 1959).
At least two forms of th is  type of a c t iva to r ,  e x tr in s ic  
and in t r in s ic ,  are present and the former is  enhanced 
by exercise while the la t t e r  is  not (Marsh and Gaffney, 
1980). The re la t ionsh ip  of these two activa to rs  to  
each other is  not c lear. Plasminogen ac tiva to rs  have 
been found associated with the endothelial c e l ls  of 
vessels, in  e p ith e l ia l  c e l ls ,  synovium, mésothélium, 
red c e l ls ,  and p la te le ts ,  and in such diverse tissues 
as uterus, ovary, lung, thyro id  and prostate (Plow 
and Edgington, 1975; Semar, Skoza and Johnson, 1969; 
Ekert, Friedlander and Hardi s ty ,  1970). I t  is  of 
in te re s t  tha t a va r ie ty  of tumours may produce 
plasminogen a c t iva to r  which may in te r fe re  with local 
haemostasis (Davidson, McNicol, Frank et a l . ,  1969) 
but may also be implicated in the metastasis of 
malignant c e l ls  (Christman, Acs, S ilag i et a l . ,  1975).
Despite the in te res t in activator-plasminogen 
in te ractions to produce active plasmin, most work on 
the a c t iva t io n  mechanism of plasminogfen has been 
performed using the exogenous activa tors  streptokinase 
(SK) and urokinase (UK).
C ircu la t ing  blood a c t iva to r
The walls of the blood vessels are the source of 
c irc u la t in g  blood plasminogen a c t iva to r  (Todd, 1959; 
Chakrabarti, Birks and Fearnley, 1963). Normally
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the plasminogen a c t iva to r  content of c irc u la t in g  blood 
is  low but i t  is  increased a f te r  physical exercise 
and stress (Biggs, Macfarlane and P i l l in g ,  1947;
Marsh and Gaffney, 1980), by venous occlusion (Bennett, 
Ogston and Ogston, 1968) and in  response to a number 
of diverse s t im u li .
While studies on blood plasminogen activa tors  
have been hampered by i t s  extreme l a b i l i t y  i t  has been 
suggested tha t the isolated form of plasminogen 
a c t iva to r  is  re la t iv e ly  stable (Ogston, Bennett and 
Mackie, 1976). Thus other enzymes in blood may 
contr ibu te  to the destruction of plasminogen a c t iva to r  
in  blood obtained a f te r  occlusion. I t  has been 
recently  suggested that the two forms of plasminogen 
a c t iv a to r ,  in t r in s ic  and e x tr in s ic ,  may be merely 
expressions of such enzymic conversions (Marsh and 
Gaffney, 1980) though the majority  opinion favours 
the view tha t they are two d is t in c t  enzymic systems 
(K lu f t ,  1978). Furthermore, the post-exercise 
(or other forms of stress) e x tr in s ic  plasminogen 
a c t iv a to r  is  a serine protease of M.W 60,000 while 
the in t r in s ic  ( fa c to r  X ll-associated) plasma plasminogen 
a c t iva to r  has been shown not to be a serine protease 
and to be immunologically d is t in c t  from the e x tr in s ic  
form (Mackie, Booth and Bennett, 1979).
Plasminogen ac t iva to r is  made up of two chains 
(M.W 31,000 and 38,000) connected by disulphide bridges, 
while the smallest chain has been shown to contain a 
serine-type active s i te  (R ijken, Wijngaards, Zaal-De-Jong 
et a l . ,  1979). I t  is ,  however, becoming c lea r tha t
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these two chains are formed by a p ro teo ly t ic  cleavage 
o f a s ingle-chain prote in .
Exogenous activa tors  
Bacterial ac tiva tors
Although many bacteria produce plasminogen 
ac tiva to rs  the only one of therapeutic importance is  
tha t produced by B-haemolytic streptococci, s trepto­
kinase (SK). This is  an a2-globulin with a 
molecular weight o f 46,000. For therapeutic 
purposes i t  may be produced re la t iv e ly  free of other 
streptococcal proteins but i t  remains antigenic and 
adm inistra tion may be associated with a l le rg ic  and 
immune reactors. Streptokinase does not possess any 
d ire c t  enzymatic a c t iv i t y  and i t  requires the presence 
o f a p ro -ac tiva to r (see la te r ) .
Urinary ac t iva to r
F ib r in o ly t ic  a c t iv i t y  has been shown to be present 
in  urine fo r  almost a century and crude concentrates of 
human urine have been used in the laboratory and in 
patients with a va r ie ty  o f thrombotic disorders 
(Sob e l ,  Mohler, Jones et a l . ,  1952). Such preparations 
o f urinary ac t iva to r  (urokinase, UK) contain at least two 
components with molecular weights of approximately 31,000 
and 55,000. They are p a r t ia l ly  identica l as shown by 
cross re a c t iv i ty  with spec if ic  anti sera and i t  is 
thought tha t the higher molecular weight material is  
degraded during p u r i f ic a t io n .  Activa to r produced by 
renal ce l l  cu ltures has been shown to have corresponding 
properties and immunological id e n t i ty  (Bern ik and Kwaan, 
1969; Barlow, Rueter and Tribby, 1975).
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Other body flu1d activa tors
E p ithe lia l c e l ls  of other tubu lar systems commonly 
produce activa tors  to dissolve f ib r in  which may be 
p o te n t ia l ly  produced in th e i r  lumens. Plasminogen 
ac tiva to rs  are found in human m ilk , seminal f l u id ,  
cerebo-spinal f l u id ,  sa l iva , tears and b i le .
Activa tion  mechanisms
i . '  Streptokinase (SK)
Human plasminogen (plgn) and SK form an equimolar 
complex which undergoes an a lte ra t io n  leading to  the 
evo lution of an active s i te  in the plasminogen part of 
the SK-plgn complex (C aste ll ino , 1979). This activated 
complex (SK - plgn*) can e ith e r  d i re c t ly  convert 
plasminogen to plasmin or can i t s e l f  be in tram olecu larly  
converted to an SK-plasmin complex (SK-pl). The SK 
moiety o f th is  la t t e r  complex is  degraded but other
tissues contain in h ib i to rs  of plasmin but the function
and importance is  not c lea r.
{ d )  In h ib ito rs  o f piasminogen activa tion
A va r ie ty  of poorly defined in h ib i to rs  o f plasminogen 
ac t iva t ion  have been described in plasma (McNicol, Gale 
and Douglas, 1963; Lauritsen, 1968). At least three 
have been p a r t ia l ly  characterised; they have no a n t i ­
plasmin a c t iv i t y .  They range in M.W from 20,000-
75,000 and in h ib i t  vascular, and tissue activa tors  as well 
as urokinase (Markwardt, 1978; Hedner, 1973; Bennet, 1967; 
Aoki and Moroi, 1974; Beattie , Ogston, Bennett et a l . ,  1976.
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Fibrinogen - plasmin in te ractions
The f i r s t  deta iled examination of the fragments 
obtained from fibr inogen fo llow ing plasmin attack 
was carried out by Nussenzweig, Seligman, Pelmont et a l . ,  
in  1961. They found tha t plasmin-induced f ibrinogen 
digests, when fractionated on DEAE ion-exchange columns, 
separated in to  f iv e  major f ra c t io n s , which they called 
A, B, C, D and E, and they described fragments D and E 
as plasmin res is tan t or terminal-core fragments, having 
molecular weights o f 83,000 and 33,000 respective ly .
These core fragments had been described e a r l ie r  as od 
a n d f i b r i n o g e n  (Seegars, Ni e f t  and Vanderbelt, 1945). 
Fragments D and E were 50% and 20% by weight of the 
o r ig ina l fibr inogen molecule and represented in d iv id u a l ly  
d is t in c t  s truc tu ra l and antigenic regions of f ib r inogen. 
They also observed intermediate p lasm in-lab ile  degradation 
products of f ib r inogen, which were subsequently named by 
other workers as X and Y fragments.
Examination of the subunits of the various fragments 
of f ibr inogen in conjunction with carbohydrate s ta in ing 
and thrombin treatment of the various polypeptide chains 
has produced a var ie ty  of schemes of f i b r in  degradation 
which have a number of common features. These are 
summarised asshown in f ig u re  1.10.
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C mol.wt.344,000 ) Cmol.wt. 3 00 ,000 -400 ,000  D Cmol.wt. 150,000 )
N
A a -
B/3-
7 -
N
N
C
FRAGMENT E 
Cmol. w t. 5 0 ,0 0 0  )
N
Aor
B/3
7
C
N N
C C
FRAGMENT D FRAGMENT D
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Figure 1.10
Schematic diagram of the plasmin-mediated conversion of 
fibrinogen to its core fragments D and E, showing the 
intermediate fragments X and X. (Taken from Gaffney, 1977).
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The conservation of both the NH^ -terminal amino 
acids and the fibr inopeptides A of the Aa chains 
suggests early hydrolysis with s p l i t t in g  of a peptide of 
M.W 40,000 from both carboxyl ends of the Aa chains 
leaving a high molecular weight fragment X (M.W. 250,000) 
which consists of the Aa chain remnants disulphide 
bonded to in ta c t  and ^  chains (Gaffney and Dobos,
1971; Harder and Budzynski, 1975). This high molecular 
weight fragment may s t i l l  c lo t  under the action of 
thrombin. In the next step a peptide of M.W 6,000 is  
s p l i t  from the N-terminal ends of the B/3chains 
(Mosesson, Finlayson and Galanakis, 1973), then a l l  
three chains are cleaved on one side of the p a r t ia l ly  
degraded dimer to  release fragment D, of M.W 94,000 and 
leaving fragment Y (M.W 150,000)(Gaffney, 1977; Furlan, 
Kemp and Beck, 1975; Harder, Shulman and C a rro l l ,  1969). 
Fragment Y is  then rap id ly  cleaved to produce a second 
fragment D and a th i rd  fragment, fragment E (M.W 50,000). 
Fragment E i s a  dimer made up of the N-terminal sections 
o f  the three chains of fibrinogen (Kowalska-Loth,
Garlund, Egberg et a l . ,  1973). Fragments Y, D and E 
do not c lo t  on addition o f thrombin. They in h ib i t  the 
conversion of f ibrinogen to f ib r in  by thrombin. The 
la rge r o f these fragments has a greater e ffe c t on 
in h ib i t io n  o f c lo t t in g  arid p u r if ied  Y is  most ac tive , 
and i t  has been shown tha t they in h ib i t  the enzymatic 
as well as the polymerisation phase of c lo t t in g  
(Latallo-, Budzynski, L ip insk i et a l . ,  1964; L ip in s k i,  
Wegrzynowicz, Budzynski et a l . ,  1967).
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Non- cross 1 inked f i b r in  and piasmin degradation 
From a biochemical viewpoint, i t  seems reasonable to 
regard non-cross linked f ib r in  as being qu ite  s im ila r  to 
f ib r inogen. In th e i r  chemical s tructure only the lack 
of f ib r inopeptides A and B distinguishes non cross- 
linked f i b r in  from f ib r inogen. Thus fibr inogen 
fragments X and Y d i f f e r  from f i b r in  fragments X and Y 
in tha t the la t t e r  fragments lack f ib r in op ep tid e  A. 
Fibrinogen fragments D and E have been shown to be 
d i f fe re n t  from fragments D and E derived from f ib r in  by 
th e i r  d i f fe r in g  a b i l i t y  to bind spec if ic  anti sera. In 
radioimmunoassay assay systems these immunologically 
based differences have been proposed to d is t ingu ish  
between f ib r inogeno lys is  and f ib r in o ly s is  in man 
(Edgington and Plow, 1979).
Cross-1 inked f i b r in  and plasmin degradation 
Degradation of cross-linked f ib r in  proceeds at a 
slower ra te , as the A oc chain c ross-l ink ing  confers 
resistance to the i n i t i a l  steps of plasmin digestion 
(Gaffney and Brasher, 1973). Unique fragments called 
0 dimer and E are formed. The D-dimer fragments 
contain the cross-linked Y-chain remnants of the 
o r ig ina l f i b r in  (Pizzo, Schwartz, H i l l  et a l . ,  1973; 
Kopec, Teisseyre, Dudek-Wejciechowska et a l . ,  1973).
I t  has been suggested tha t detection of D-dimer may 
provide a means o f monitoring thrombolytic treatment 
(Gaffney and Brasher, 1973). The molecular weight 
of the D-dimer is  between 63,000 and 80,000 and there 
is  evidence of D-dimer and fragment-E complexing (Hudry- 
Clergeon, Paturel and Suscillon, 1974; Gaffney, Lane and 
Kakkar, 1975). See f ig u re  1.11.
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1
Figure 1.11.
The stable fragment "D^E" that survives the plasmin 
digestion of cross-linked fibrin.
(Arrows denote plasmin attack points)
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Bio1oqical functions of f l b r i n (ogen) degradation products ( FDP) 
As well as in h ib i t in g  polymerisation of f i b r in  and the 
action of thrombin, FDPs have the fo llow ing actions.
1_. E ffect on p la te le t  function
FDPs in h ib i t  p la te le t  aggregation, adhesion and the release 
reaction, the high M.W products being more active than low M.W 
products (Kowalski, Kopec and Wejrzynowicz, 1964; Jerushalmy 
and Zucker, 1966; Stachurska, La ta llo  and Kopec, 1970).
Their action is  probably due to adsorption of fragments 
onto the p la te le t  membrane (Kopec, Budzynski, Stachurska 
et a l . ,  1966) and is  found whether the production of 
fragments is  due to SK, defibrase or ancrod (Kowalski 
et a l . ,  1964; Olsson and Johnsson, 1972; Prentice,
Turpie, Hassanein et a l . ,  1969).
2 ,  E ffects on heart and blood vessels
These are due to low M.W peptides which potentiate the 
e ffec ts  of bradykin in, angiotensin, adrenaline and sero­
ton in (Buluk and Malofiejew, 1969; Takaki, Yamaguchi and 
Ohsato, 1974). Low M.W fragments also increase the 
permeability of skin c a p i l la r ie s  (Malofiejew, 1971). 
F ib r in o lys is  associated with the c e l lu la r  
compartment o f blood 
The in te rac t io n  of enzymes other than plasmin with 
f i b r in  has recently  been reviewed (L a ta l lo ,  Teissyre,
Arde lt e ta l . ,  1978). The most important progress in 
our knowledge of the ro le  of non-plasmic proteases in
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the pathophysiology of thrombosis should be ascribed to 
the neutral proteases of certa in  blood c e l ls .  The 
p a r t ic ip a t io n  of polymorphonuclear neutrophils has been 
demonstrated in the process of f i b r in  d isso lu t ion  
(Riddle and Barnhart, 1964). I t  has been suggested 
tha t plasmin may play only a minor ro le  in  spontaneous 
f ib r in o ly s is  (Moroz and Gilmore, 1976), while granulocytes 
have been shown to contain the components of an 
a lte rn a t ive  f ib r in o ly t i c  pathway in man (Plow and 
Edginton, 1975). Neutrophil granules have been shown 
to  degrade both fibr inogen and f i b r in  (Kopec et a l . ,  1973). 
P late le ts contain elastase, thus suggesting a possible 
ro le  in  thrombus d isso lu tion  (Legrand, Pegnaud, Caen 
et a l . ,  1975). Lysis of f i b r in  has been achieved by 
l y t i c  agents secreted by eosinphils (Kwaan and Hatem, 1978). 
While c e l lu la r  enzymes have been viewed with some 
scepticism in  f ib r in o ly s is ,  they might explain the 
clearance of thrombi from vessels through which there is  
no measurable blood flow.
Whether the mechanisms and components involved during 
the formation of f i b r in  in  vivo are part of an ongoing systemic 
process is  unknown, but i t  is  probably h ighly un like ly .
That f i b r i n ,  as i t  forms, mediates i t s  own destruction 
seems certa in  and the ro le of a competent f i b r in o ly t i c  
system in th is  destruction seems essentia l. The 
reactions which have been discussed are relevant to 
most n a tu ra l ly  and drug-induced d e f ib r in a t ion  episodes.
The question arises as to th e i r  s ign if icance in the 
destruction of f i b r in  in thrombi and th is  w i l l  be 
discussed in  Chapter 2.
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CHAPTER 2 
INTRAVASCULAR BLOOD COAGULATION
A ’ l '  In troduction
In travascular blood coagulation w i l l  be defined in th is  
thesis as ac tiva t ion  of the coagulation mechanism with the 
formation of thrombin in  the c irc u la t in g  blood and of 
thrombi w ith in  the blood vessels. As a thrombus 
(o r microthrombus) has a d e f in i te  h is to log ica l s tructure 
composed of p la te le ts ,  red blood c e l ls ,  leukocytes as 
well as inso luble f i b r in ,  i t  is  appreciated tha t many 
in te r - re la te d  fac to rs , besides coagulation, are involved 
in  i t s  development.
In travascu lar coagulation may be c la ss if ie d  in to  
several types:
1- Pre-thrombotic state (Synonyms: hypercoagulable
s ta te , hypercoagu lab il i ty , thrombotic tendency)
This term describes a c l in ic a l  state in  which the patient 
is  at increased r is k  o f developing thrombosis or in t r a ­
vascular coagulation in which insoluble f i b r in  deposition 
occurs although actual thrombi or microthrombi are not 
present at th is  stage. I t  may be associated with an 
increased level of coagulation factors in  the blood or 
w ith  the presence of activated coagulation factors or p la te le ts .
2.  Local thrombosis
This term describes the development of a macroscopic, 
inso luble f ib r in - p la te le t  thrombus in a segment of an a r te ry  
or vein. This often occurs secondary to local vascular disease.
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! •  In travascular coagulation - local and disseminated 
Local in travascu lar coagulation is  the development 
o f microthrombi or insoluble f i b r in  deposits in the small 
blood vessels of a sing le organ.
Disseminated in travascu lar coagulation 
(Synonyms: D IG ,de fib r ina tion , consumption coagulopathy, 
in travascu la r w ith f ib r in o ly s is  or abnormal p ro te o ly t ic  a c t iv i t y ) .
DIG has been defined as a pathological process which 
resu lts  in the development of micro-thrombi or insoluble 
f i b r in  deposits in the blood vessels of several organs 
and those areas of the vasculature not involved in primary 
disease. DIG is  not a separate e n t i ty  but is  a condition th a t 
may occur in association with any disease or c l in ic a l  s tate.
Atherosclerosis 
Atherosclerosis is  the most frequent d isorder of blood 
vessels. I t  occurs as a re su lt  of atheromatous plaques 
in  the endothelium of the blood vessel. Such atheromatous 
lesions are found only in the a r te r ia l  c i rc u la t io n ,  
gradually developing from a previously normal a r te r ia l  w a ll .
The l ip id  i n f i l t r a t i o n  theory explains atheroma on the basis 
o f the progressive accumulation of l ip id s  o r ig ina t in g  in  the 
blood (Anitachow and Ghalatow, 1913). Another view is  tha t 
the atheromatous plaque is  the end resu lt of the 
incorporation o f microthrombi formed on the endothelium 
(Duguid, 1976) or of the stimulation of smooth muscle 
c e l ls  by adherent p la te le ts  (Ross and Glomset, 1976).
Whatever the explanation, the plaque may then be the focus
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fo r  rapid thrombin generation, possibly as a resu lt  of 
haemorrhage in to  or near the plaque. P la te le t aggregation 
and f i b r in  formation occurs. P la te le t aggregation 
probably depends on the balance between the TXA^ and PGI% 
leve ls in the p la te le t  i t s e l f  and the vessel wall 
(Moncada and Vane, 1978). I f  the resu lt ing  thrombus is  
large enough, blood flow to the myocardium is  impaired 
and in fa rc t io n  or sudden death may ensue.
2 , 2 .  Development o f knowledge
That blood can coagulate w ith in  the vascular system 
during l i f e  has been known fo r  two thousand years 
(Anning, 1957). During the seventeenth century 
pathologists were fa m i l ia r  with the presence of c lo tte d  
blood w ith in  the heart, aneurysms and blood vessels 
(Wiseman, 1686; Malpighi, 1686; P e t i t ,  1731;
Beniv ien i, 1928), but at f i r s t  they did not d is t ingu ish  
between thrombosis, the process by which l iq u id ,  f low ing 
blood turns in to  a so lid  mass in the l iv in g  blood 
vessels (Poole and French, 1961) and embolism, the 
process through which thrombi break o f f  and are carried 
in the blood stream to obstruct the flow of blood at a 
point fa r  removed from the thrombosis. Wiseman (1686) 
and Hunter (1817) f i r s t  suggested such c lo t t in g  w ith in  
the vessels might be as a resu lt of the slowing of blood flow. 
Richardson (1858) also suggested abnormal coagulation 
was involved. Virchow (1863) proposed tha t three possible 
factors determine the s i te  and extent of a thrombus.
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1. Damage to the vessel wall
2. A lte ra t ions  in the flow of the blood
3. Changes in the c irc u la t in g  blood
These three factors s t i l l  form the central theme of 
modern views on the mechanism of thrombosis. Despite 
the discovery of p la te le ts  by Bizzozero (1882) w ith th e i r  
accumulation on exposed subendothelial structures 
fo llow ing in ju ry  to the vessel wall and the gradual 
e luc idation  o f the coagulation mechanism over the la s t  
century, i t  has only been in the la s t two decades that 
our knowledge o f thrombosis has begun to  develop.
^._3. The Prethrombotic State
A great d iv e rs i ty  in the manifestations o f human 
thrombotic disease occurs throughout the human body.
The mechanism of occlusion o f a peripheral a r te ry  with 
atheroma probably has l i t t l e  s im i la r i t y  to the process 
o f thrombus deposition in the deep c a l f  veins o f an 
immobile leg. The structure o f such thrombi is  
d i f fe re n t  as is  the natural h is to ry  of the disease 
process and the recognised p rec ip ita t ing  fac to rs .
I t  is  improbable tha t s im ila r  changes would appear in 
blood as a prelude to two such d iss im ila r  c l in ic a l  
events. Thus the successful prediction o f the onset 
o f thrombosis is  associated with controversy and 
f ru s t ra t io n .  Among the many d i f f i c u l t i e s  in the
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predic tion of the onset of thrombosis is  in deciding 
which changes in haemostatic function ind icate hyper­
co a g u la b il i ty .  Reduction in the concentration of 
coagulation factors may be a re f le c t io n  of active 
consumption of coagulant prote in , as occurs in severe 
in travascu lar coagulation (Denson, 1977). However, 
low levels may arise due to fa i lu re  of synthesis 
e.g. in l i v e r  fa i lu re  (Bloom, 1975), a condition in 
which a lte ra t ions  in coagulant protein concentrations 
is  eas ily  m isinterpreted. Only a minute proportion 
of zymogen need be activated fo r  f ib r in  generation 
to  ensue (Wessler and Yin, 1968) and i t  therefore 
seems l i k e ly  tha t in most instances of hypercoagulability  
the fra c t io n  o f coagulant protein consumed w i l l  be too small 
fo r  re l ia b le  measurement. The thrombogenic potentia l 
resu lt ing  from increase in the concentration of coagulation 
factors  is equally open to  argument. Fibrinogen, factors V 
and V I I I  and fibr in -degradation  products, may behave as 
acute-phase reactants and r ise  non-spec if ica lly  in disease 
(Isacson and Nilsson, 1972),
Measurements fo r  the ac tiva tion  of thrombin in 
the c irc u la t io n  may be of value in predicting 
patients susceptible to  thrombosis. The assay of 
soluble f i b r in  monomer complexes (Bang and Chang, 1974) 
and f ib r inopeptide  A (Nossel, Yudelman, Canfield et a l . ,  
1974) have indicated tha t these derivatives of fibrinogen 
are present in the blood of normal ind iv idua ls . Whilst 
the d is t r ib u t io n  of values in patients prone to thrombosis 
overlaps tha t found in the healthy population, th is  has
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s t i l l  to be ascertained fo r  several c l in ic a l  conditions 
associated with or resu lt ing  in fu ture thrombotic events.
Measurements of the ac tiva t ion  of p la te le ts  may also 
be of value in predicting thrombosis. P la te le ts  might 
be more reactive than normal, a property tha t could be 
id e n t i f ie d  as a lowered threshold fo r  aggregation or 
adhesion. P la te le ts  which have taken part in the formation 
o f a p la te le t  thrombus might show a measurable increase in the 
release of p la te le t  spec if ic  proteins eg BTG, which should be 
increased in the plasma and decreased in the p la te le t  a f te r  
p la te le t  adherence and aggregation have occurred. The 
measurement of p la te le t  release as an index of a prethrombotic 
state in several c l in ic a l  conditions has s t i l l  to  be determined. 
2 A ,  Thrombosis
One of the fundamental problems in e luc idating the 
mechanism of thrombosis is  tha t events occurring in 
thrombosis are s im ila r  to those which occur in the 
formation of a haemostatic c lo t .  However a c lo t  formed 
in  v i t r o  d i f fe rs  from a thrombus. A c lo t  is a s tructure 
with the f i b r in  network uniformly mixed with the p la te le ts  
and red c e l ls  evenly d is tr ib u te d  w ith in  the f i b r in  network.
An a r te r ia l  thrombus consists of two parts, the white 
head (p la te le t  thrombus) and the red t a i l  (composed of red 
blood ce l ls  and f i b r in ) .  A venous thrombus is  formed by 
an extensive f ib r in  network in which red blood ce l ls  are 
enmeshed. Thrombi may form anywhere in the c i rc u la t io n ,  
in  the a r te r ie s ,  veins, c a p i l la r ie s  or chambers and valves 
o f the heart. An occlusive thrombus occupies the whole 
lumen o f the vessel and obstructs flow , whereas a mural
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thrombus adheres to a loca lised area of the wall (usually  of 
the heart) and blood continues to flow past the thrombus with 
microthrombi being released in to  the bloodstream. Occlusive 
thrombi do not often form in the aorta but are found more 
commonly in medium arte r ies  and smaller vesels.
2 A  A ,  Mechanisms o f Thrombosi s 
1* Damage to  the vessel wal1 
Vasoactive substances 
Tissue trauma, by exposing the blood to various 
extravascular s truc tu res, and by the release o f active 
substances, may have an important ro le in thrombosis.
In general, accumulated metabolic products and material 
released from damaged c e l ls  (e.g. la c ta te , potassium, 
hydrogen ion, adenosine) produce re laxation o f vascular 
tone, res to ra tion  of flow to anoxic areas being paramount.
A number of vasoactive substances a t t ra c t  p a r t ic u la r  
in te re s t because o f th e i r  presence in p la te le ts  
(prostaglandins, serotonin (5HT) and adenosine diphosphate 
(ADP). TXA ^ , an unstable intermediate of p la te le t  
prostaglandin biosynthesis is  a possible thrombogenic 
agent, being both a powerful p la te le t  aggregating agent 
and also a potent vasoconstrictor (Needleman et a l . ,  1976;
Moncada and Vane, 1978). Serotonin released during the 
p la te le t  release reaction, promotes fu r th e r p la te le t  aggregation 
and is  a potent co n s tr ic to r  of peripheral vessels when released 
in to  the a r te r ia l  c irc u la t io n  (Roddie, Shepherd and Whelan, 1955) 
ADP can promote vasoconstriction and p la te le t  microthrombus 
formation in  a r te r ie s  (Begent and Born, 1970).
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In h ib i to r  Systems
Loss of physiological defence mechanisms in the vessel 
wall may con tr ibu te  to thrombosis. At least two in h ib i to r  
systems are known which protect the endothelium from 
platelet-aggregate formation. Vascular ce l ls  show strong 
ADPase a c t iv i t y  (Lieberman, Lewis and Peters, 1977) which 
would tend to disperse p la te le t  aggregates. However, a 
much more important defence mechanism is  provided by 
prostacyclin  (PGI% ) ,  a prostaglandin synthesised in the 
vessel wall (see chapter 1 .2 .4 . ) .  PGI% is a vasodila tor 
and powerfully in h ib i ts  both p la te le t  aggregation and 
adhesion to the subendothelium and also promotes p la te le t  
disaggregation (Cazenave, Dejana, Kinlough-Rathbone et a l . ,  
1979). In the l ig h t  of current knowledge 261% is the 
most active of the agents which confer on the vascular 
endothelium a uniquely non-thrombogenic surface.
A marked reduction in  PGI% production by the heart 
and vessel wall is  found in rabbits made a therosc le ro tic  
(Dembinska-Kiec, Gryglewska, Zmuda et a l . ,  1977).
S im ila r ly  human a therosc lero tic  t issue does not produce 
PGI% , whereas tissue obtained from an adjacent vessel 
does (Angelo, V i l l a ,  Mysliwiec et a l . ,  1978). Production 
of prostacyclin seems to be the important a r te r ia l  mechanism. 
Small f i b r in  thrombi formed on the vessel wall are 
probably normally cleared by f ib r in o ly t i c  mechanisms. 
Plasminogen a c t iva to r  is  produced by endothelial ce l ls  
and released continuously in to  the bloodstream (Pandolfi, 
Nilsson, Robertson et a l . ,  1967). In patients with 
venous thrombosis, f i b r in o ly t i c  a c t iv i t y  of the vessel
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walls is  impaired even at s ites  not ac t ive ly  involved 
in  the thrombotic process (Randolph!, Isacson and 
Nilsson, 1969). Failure of these normally protective 
functions of the vessel wall may promote thrombosis. 
F ib r in o lys is  seems to be the most important mechanism 
on the venous s i te .
Response to in ju ry
Some ind ica tion  of a possible ro le of the vessel wall 
in  thrombogenesis comes from observations of the e ffects  
o f in ju ry .  Endothelial ce l ls  may be damaged during 
in te rcu rren t i l ln e s s  by c irc u la t in g  substances such as 
thrombin, bacteria l endotoxin, and neuraminidase, a l l  of 
which have been shown experimentally to in ju re  endothelial 
ce l ls  and promote p la te le t  and f ib r in  deposition (Barnhart 
and Chen, 1978). When the in ju ry  is  minor, p la te le t  
thrombi form and parts break o f f  to be washed away by the 
c i rc u la t io n .  The degree of in ju ry  is  an important 
determinant of the size of the thrombus: fo r  the
development of a large thrombus, severe damage or physical 
detachment o f the endothelium must occur. This is  in 
accord with the d is t r ib u t io n  of prostacyclin synthetase 
(see chapter 1 .2 .4 .)  from the intima to  the ad ven tit ia , 
re su lt ing  in the vessel wall being thrombogenic. 
Homocystine, the amino acid present to excess in homo- 
cys t in u r ia ,  has been shown to promote atherosclerosis­
l i k e  lesions and thrombosis as a resu lt of primary damage 
to the endothelium (Harker, Ross, S lich te r et al 1976).
In patients with c l in ic a l  thrombosis uncerta inty arises 
as to whether vascular damage has preceded or followed
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the thrombotic process. However, endothelial damage has 
been observed both in the a r te r ies  and veins of women dying 
from pulmonary embolism, possibly induced by administration 
of oestrogen-containing contraceptive p i l l s  ( I ra y ,  Manion 
and Taylor, 1970) and in the coronary a rte r ies  of healthy 
young men who were the victims of v io len t death (Enos,
Beyer and Holmes, 1955); evidence suggesting tha t 
endothelial damage precedes thrombosis.
2.4Z A lte ra tions in the Flow of Blood
In normal haemostasis, reduction in blood flow 
allows the haemostatic plug to withstand the d isrupting 
e f fe c t  o f blood flow , thus, sealing the damaged vessel wall 
u n t i l  f ib ro b la s t  growth ensures a permanent repa ir system. 
In thrombosis, disturbances in blood flow are believed to 
enhance the formation of a thrombus. Experiments using 
branched extracorporeal shunts have i l lu s t ra te d  the 
importance of blood flow in thrombogenesis. Branched 
p la s t ic  tubes inserted between the carotid  a rte ry  and 
jug u la r vein in pigs, resulted in the formation of 
p la te le t  microthrombi downstream of flow d iv ide rs  on the 
walls o f the tube (Mustard, Murphy, Rowsell et a l . ,  1962). 
P la te le ts  were deposited p re fe re n t ia l ly  at these s ites  of 
tu rbu len t flow and did not attach elsewhere to the tube 
surface. There appears to be a notable s im i la r i t y  
between the d is t r ib u t io n  of thrombi in th is  model and 
the s i t in g  of human thrombo-atherosclerotic deposits.
Shear rate and the presence of red ce lls  are c r i t i c a l l y  
important haemodynamic factors in thrombogenesis, at 
least in re la t io n  to p la te le t  deposition. P la te le t
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deposition and p la te le t  microthrombus formation have 
been shown to increase l in e a r ly  with increasing shear 
ra te (Begent and Born, 1970; Friedman, Liem, Grabowski 
et a l . ,  1970; T u r i t to ,  Muggli and Baumgartner, 1977).
Glass models of branched and curved a rte r ies  have 
shown tha t p la te le t  microthrombus formation occurs 
se le c t ive ly  where turbulence and vortex formation can 
lead to stagnation point flow (Baldauf, Wurzinger and 
Kinder, 1978). Thrombosis may also be promoted by the 
e f fe c t  of shear stress in sens it is ing  blood p la te le ts  
(Brown, Leverett, Lewis et a l . ,  1975).
Experiments on p la te le t  thrombus formation have 
also emphasised the importance of red c e l ls .  Red 
c e l ls  provide a major force con tr ibu ting  to the movement 
o f p la te le ts  from the axial stream towards the vessel 
wall (Grabowski, Friedman and Leonard, 1972; Goldsmith, 
1971). The presence of red ce lls  increases d if fu s io n  of 
p la te le ts  to the vessel surface and increases p la te le t -  
surface c o l l is io n  energy (Brash, Brophy and Feuerstein,
1976), re su lt ing  in  an increased rate of p la te le t  
microthrombus formation at the vessel surface (T u r i t to  and 
Baumgartner, 1975; Cazenave, Packham, Davies et a l . ,  1978).
Evidence which re lates experimental obsevations 
d ire c t ly  to human disease is  d i f f i c u l t  to obtain. There 
is  be tte r evidence fo r  the relevance of factors which by 
reducing blood flow may contribu te to thrombogenesis as a
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resu lt  of s tasis in the vessel lumen. Patients with 
d iabetic  vascular disease (McMillan, 1976; Barnes, Locke, 
Scudder et a l . ,  1977; Lowe, Morrice, Forbes et a l . ,  1979) 
and severe peripheral vascular disease (Dormandy, Hoare,
Colley et a l . ,  1973) have increased blood v iscos ity  
compared to normal subjects. Thrombotic episodes in  
patients with polycythaemia are more frequent in those 
patients with the highest haemotocrits (Pearson and Weatherley- 
Mein, 1978), an e ffec t probably mediated by slowing of 
flow since small changes in haematocrit lead to proportion­
a l ly  much la rger changes in blood flow (Thomas, Du Boulay, 
Marshall et a l . ,  1977). I t  seems a l l  the more l i k e ly  
th a t reduction in  blood flow may contribute to thrombosis, 
since i t  has been shown in v i t ro  tha t fo llow ing contact 
a c t iv a t io n ,  thrombi form only in  s ta t ic  blood (B o tt i  and 
Ratnoff, 1964). Stasis may p a r t ic u la r ly  encourage 
thrombosis on the venous side of the c irc u la t io n .
Pathological studies have shown tha t deep venous thrombi 
form p re fe re n t ia l ly  at s ites  where ligaments or tendons 
may compress the vein, or valve cusps in te rru p t laminar 
flow (S e v it t  and Gallagher, 1961).
Evidence fo r  a lte ra t ions  in the flow of blood as a 
component in the formation of a thrombus remains 
c ircum stan tia l, u n t i l  be tte r methods become ava ilab le fo r  
studying flow in the in ta c t c irc u la t io n .  I t  is  reasonable 
to in fe r  tha t turbulence contributes to thrombosis in  the 
a r te r ia l  c i rc u la t io n ,  while stasis may be a more potent 
fac to r  in the genesis of venous thrombi.
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2 A 3 .Changes in the c irc u la t in g  blood
(A) P la te le ts
There is  substantial evidence that blood p la te le ts  
are involved in the development of thrombosis, p a r t ic u la r ly  
in  the a r te r ia l  c irc u la t io n  (Mustard, Kinlough-Rathbone and 
Packham, 1974; Paton and Douglas, 1976; White and 
and H e p t in s ta l l ,  1978; Mustard, Packham and Kinlough- 
Rathbone, 1978).
While p la te le ts  do not adhere to normal endothelial 
c e l ls  (Stemerman, 1974), they have been shown to adhere 
to  exposed subendothelium (see Chapter 1 .2 .4 .) .  Following 
attachment of the i n i t i a l  p la te le t  monolayer, there is  
accretion of fu r th e r  p la te le ts ,  a process probably 
con tro lled through the release o f ADP (Cazenave, Packham,
Gucci one et a l . ,  1975; Tschopp and Baumgartner, 1976).
TXA2  ^ probably strongly augments th is  process by inducing 
fu r th e r  p la te le t  aggregation and vasoconstriction (Moncada 
and Vane, 1978). Under certa in  circumstances a p la te le t  
microthrombus may form. A lte rn a t ive ly  white ce l ls  and 
f ib r in  may add to the p la te le t  mass bu ild ing up a 
s tab il ise d  mature thrombus (Mustard et a l . ,  1978).
Whether p la te le t  aggregates can be present in  the 
in ta c t c irc u la t io n  is  not known, although there are 
observations to suggest tha t they do occur (Begent and Born, 1970) 
and tha t such aggregates are found more frequently  in patients 
with thromboembolic disorders (Dougherty, Levy and Weksler, 1977).
Adhesion or aggregation leading to secretion of 
p la te le t  granule contents in the immediate v ic in i t y  of 
the blood vessel wall may produce vascular e ffe c ts .
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P la te le ts  can release acid hydrolases (see TableU) 
and also a ca tion ic  protein capable of a lte r in g  vascular 
permeability (Nachman, Weksler and F e rr is , 1972). Such 
substances have p o te n t ia l ly  destructive e ffec ts  on the 
intima which may augment minor localised thrombotic 
a c t iv i t y .
Changes in  the PGI% /TXA^ balance (see chapter 1.2.3) 
might predispose towards thrombosis. Increased production 
o f TXA2 in vivo by p la te le ts  has been found in patients 
with a r te r ia l  thrombosis and in recurrent venous 
thrombosis (Lagarde and Dechavanne, 1977). In add it ion , 
increased s e n s i t iv i t y  to aggregating agents and increased 
release of TXA% - l ik e  a c t iv i t y  has been described in 
patients who have survived myocardial in fa rc t io n  
(Szczeklik, Gryglewski, Musial et a l . ,  1978). Increased 
levels o f TXB^ (a stable end product o f TXA2  ) have also 
been observed in patients during attacks of angina (.Lewy,
Smith, S i lve r  et a l . ,  1979). Moreover, p la te le ts  from 
rats made d iabe tic , release more TXA% and th e i r  vessel 
walls produce less prostacyclin (Harrison, Reece and 
Johnson, 1978) and there are reports of s im ila r  resu lts  in man 
Johnson, Harrison, Raftery et a l . ,  1979). A lowered prostacyclin 
production by cultured endothelial ce l ls  in the presence 
o f ^  -thromboglobulin has been observed (Hope, Martin 
and Chesterman et a l . ,  1979). This might occur in localised 
vascular segments during the p la te le t  release in  v ivo, suggesting 
th a t the in h ib i to ry  e ffec t of a p la te le t  release product on PGI^ 
synthesis might be a possible mechanism fo r  promoting thrombosis, 
however th is  was not shown in a la te r  study (Poggi, Niewiarowski, 
Holt et a l . ,  1981).
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An increased prostacyclin production has been 
reported in uraemia (Remuzzi, Cavenaghi, Mecca et a l . ,
1977) and in the blood vessels of the spontaneously 
hypertensive ra t (MacIntyre, Iferson and Gordon, 1978).
Thus i t  seems tha t diseases which favour the development 
o f thrombosis are associated with an increase in  TXA^and a 
decrease in prostacyclin  formation, whereas an increased 
prostacyc lin  plus decreased TXA2  is  present in some 
conditions associated with an increased bleeding tendency.
In te rac tion  of p la te le ts  with blood coagulation may 
provide an add it ina l pathway by which s l ig h t  vascular in ju ry  
resu lts  in thrombosis. P la te le ts  can in i t i a t e  both the 
in t r in s ic  pathway (Walsh, 1972a)and by stim ula tion of the 
e x tr in s ic  pathway accelerate the local rate o f thrombin 
formation about one thousand-fold (M ile t ich ,  Jackson and 
Majerus, 1977). This combination of pro-thrombotic 
properties makes the p la te le t  micro-environment an ideal 
nidus fo r  i n i t i a t io n  of thrombosis (Walsh, 1973).
(^) Coagulation
I t  seems inev itab le  tha t since f ib r in  deposition occurs 
in  the formation of a thrombus, disturbance o f the blood- 
coagulation mechanism should be a prime element in thrombogenesis 
A c tiva tion  of the in t r in s ic  system has been shown 
by the formation of f i b r in  in s ta t ic  blood exposed to 
ac tiva to rs  o f fac to r  XII (B o tt i  and Ratnoff, 1964).
Flow normally helps to prevent th is  by dispersal o f the 
stimulus and m obilisa tion of plasma in h ib i to rs .  Most 
recognised activa to rs  of fac to r XII are charged
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pa rt ic les  (Ratnoff, 1977) which ra re ly  occur in the 
c irc u la t io n .  However, th is  may be part of the 
mechanism fo r  in travascu lar thrombosis which fo llows 
amniotic f lu id  or fa t  embolism (Sharp, 1977). Contact 
ac t iva t ion  may also re su lt  from exposure o f the blood 
to  free fa t ty  acids (Nossel, 1976) and collagen (Wilner, 
Nossel and Leroy, 1968), bacteria l endotoxin (Morrison 
and Cochrane, 1974), p ro te o ly t ic  enzymes (Kaplan and 
Austen, 1972), isoimmune IgG (Lopas,B irndorf, Bell 
e t a l . ,  1973) and homocystine (Nossel, 1976). The 
c irc u la t io n  might be exposed to such compounds during 
i l ln e s s  or fo llow ing trauma, leading to thrombus 
formation in stagnant flow. P urif ied  preparations o f 
fa c to r  XII and XI do not generate coagulant a c t iv i t y  
when exposed to  kaolin  (Schiffman and Lee, 1974) and i t  
seems probable tha t contact ac t iva t ion  of fa c to r  XII has 
a l im ited  ro le  both in haemostasis and in thrombosis 
because a lte rna t ive  pathways adequately compensate fo r  
de fic iency o f fa c to r  X I I .  Hageman ( fa c to r  X II)  
de fic iency is usually asymptomatic (Ratnoff, 1977) and 
John Hageman died of a pulmonary embolism. Most of 
those s tim u li which might induce activa t ion  o f fac to r 
X II in vivo also stimulate blood p la te le ts  and possibly 
generate in t r in s ic  coagulation a c t iv i t y  through the 
inherent pro-coagulant function of p la te le ts  (Walsh, 1974).
Involvement o f the coagulation mechanism in thrombosis 
might more feas ib ly  arise via the e x tr in s ic  pathway.
This might occur by the ac tiva t ion  of fac to r  V I I .  Addition 
o f t issue fa c to r  causes rapid generation o f fac to r  Xa 
which autocatalyses the reaction by conversion of native
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fac to r  VII to  a more potent two-chain form (R adc lif fe  
and Nemerson, 1975). Tissue fa c to r ,  present in the 
plasma membrane o f endothelial c e l ls  is  l i k e ly  to  be 
released in to  the c irc u la t io n  not only by trauma but by 
sup e rf ic ia l damage to  the endothelium. A d d it io n a lly  
fa c to r  V II may be activated by factors IXa and X I la ,  
plasmin and k a l l ik re in  (Laake and Osterud, 1974) which 
may prime the system fo r  rapid generation o f fa c to r  Xa 
a f te r  s l ig h t  vascular in ju ry .
I t  seems feas ib le  tha t as f i b r in  deposition occurs in the 
formation of thrombi, thrombin generation might be involved in 
the e a r l ie s t  stages o f thrombogenesis. Recent technical 
advances have resulted in sensitive assays fo r  the demonstration 
o f thrombin a c t iv i t y  in the c irc u la t io n  eg fib r inopep tide  A.
The app lica tion  o f such assays to thrombosis w i l l  be discussed 
in  greater de ta il in Chapter 4.
Thrombotic episodes have been reported to  occur in 
patients with congenital de fic ienc ies o f c lo t t in g  
fac to rs . Venous thrombosis occurred in patients with 
defic iency o f fac to r VII (Godal, Madsen and Nissen - 
Meyer, 1962), and, as previously noted, fac to r XII 
(Ratnoff, Busse and Sheon, 1968). Also recent reports of 
acute myocardial in fa rc t io n  in severely affected haemophilic 
patients (Small, Jack, Lowe et a l . ,  1983) ra ise the 
question of a central ro le  fo r  coagulation disturbance 
in  the pathogenesis of thrombosis. Congenital defic iencies 
in the f i b r in o ly t i c  system or in ’in h ib i to rs  such as a n t i ­
thrombin I I I  may be associated with an increased 
s u s c e p t ib i l i ty  to thrombosis (Egeberg, 1965; Mackie,
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Bennett, Ogston et a l . ,  1978; B arrow c lif fe , Johnson and Thomas,
1978). More recently  a congenital defic iency of prote in C 
has been discovered in fam ilies  susceptible to  thrombosis 
( G r i f f in ,  et a l . ,  1981, Bertina et a l . ,  1982). Protein C is  
thought to l im i t  Xa and thrombin formation. In addition to a 
potent s tim u la tory  e f fe c t  on f ib r in o ly s is  i t  is  possible tha t 
prote in  C is  involved in the regulation of thrombus growth.
Congenital dysfibrinogenaemia has been associated with thrombotic 
episodes as described in  fibrinogens Baltimore (Beck, Charache and 
Jackson, 1963), New York (Mondiry, B ilez ik ian  and Nossel, 1975),
Marburg (Fuchs, Egbring and Havenmann, 1977) and Copenhagen 
(Sandbjerg-Hansen and Clemmensen, 1980), but i t  is  not known, except 
in  the case of f ibr inogen New York, i f  the dysfibrinogenaemia is  
responsible fo r  the thrombosis. In fib r inogen . New York, decreased 
binding of thrombin by the c lo t  was observed and i t  was assumed that 
i t  might be the cause of the thrombotic disorder (L iu , Nossel and 
Kaplan, 1979).
I t  has been postulated tha t f i b r in  deposition and subsequent 
thrombosis might re su lt  from the fa i lu re  of f i b r in  to absorb onto 
i t s  surface the required plasminogen and a c t iva to r  needed to mediate 
i t s  own destruction (Gaffney 1981). Recently a new type of congenital 
dysfibrinogenaemia with defective f ib r in o ly s is  -Dusard syndrome - 
has been found in a fam ily  with recurrent thrombosis (Soria, Soria 
and Caen, 1983). The thrombosis was a ttr ibu ted  to the abnormal 
polymerisation of f i b r in  which did not allow the exposure of binding 
s ites  fo r  plasminogen on the f i b r in  surface, resu lt ing  in in e ffe c t ive  
thrombolysis. O
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Astrup (1956) postulated tha t the patency of the vascular 
system depended on a dynamic equilibrium between constantly active 
coagulation and f ib r in o ly t i c  systems. Reviews of th is  hypothesis 
concluded tha t ne ither thrombin nor plasmin proteo lys is  makes a 
major con tr ibu tion  to f ibrinogen turnover in normal ind iv idua ls  
and that the hypothesis of a dynamic equilibrium between c lo t t in g  
and ly s is  remains unproven (McNicol and Douglas, 1976). Nossel (1981) 
proposed an a lte rna t ive  view tha t the re la t iv e  rates of proteo lys is 
of the B |B chain of f ibr inogen by thrombin and plasmin determine the 
occurrence of thrombosis (see f ig u re  2 . 1 ).
I f  a single f ibr inogen molecule is  considered, in  reaction (1 ), 
thrombin cleaves fibr inogen to  y ie ld  free FPA and f i b r in  I monomer which 
polymerises in reaction (2 ). Thrombin and plasmin then compete fo r  
the NH^ -terminal end of the B jg  chain. I f  thrombin cleaves the B^ 
chain before plasmin the products are FPB and f i b r in  I I .  I f  plasmin 
cleavage precedes tha t of thrombin the products are B 1-42 and fragment X 
The balance between the rates of f i b r in  I I  and fragment X formation 
would then determine the pathophysiological consequences of f i b r in  I 
generation. Predominant f i b r in  I I  formation resu lts  in thrombosis 
whereas predominant fragment X does not.
Problems associated with the thrombotic mechanism
The find ings of an association between an abnormal blood 
te s t  and thrombosis does not imply tha t the former abnormality
promoted the la t t e r  event. Thrombosis may equally well give r ise  to
the blood changes: while such changes may find c l in ic a l  use as
'markers' of thrombosis, they may not re f le c t  the thrombus per se, 
but some other fa c to r  associated w ith thrombosis. The
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<  __________
Fibrinogen
© I  T H R O M B IN
1 .16 t
Fibrin I  M O N O M E R
©i
T T
1 T
Fibrin I  POLYMER
THROMBIN PLASMIN
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1 4 2 I- 4
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Fibrin H  Fragment X
1 1
THRO MBOSIS D I G
Figure 2.1.
Postulated scheme of fibrinogen proteolysis 
in vivo, Half fibrinogen molecules are 
depicted, (Taken from Nossel, 1981).
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re la t ionsh ip  between a blood te s t  and thrombosis may 
therefore be causal (abnormal blood mechanisms promotes 
thrombosis), consequential (thrombosis promotes change 
in  blood), or coincidental (thrombosis and blood tes t 
are each associated with another fac to r or fac to rs , 
known or unknown). Epidemiological d iffe rences, as 
well as h is to log ica l differences (p la te le ts  predominate 
in  a r te r ia l  thrombi, f i b r in  in venous thrombi) and 
differences in therapeutic response (eg anticoagulants), 
demand tha t we consider a r te r ia l  thrombosis and venous 
thrombosis ra ther d i f fe re n t ly .  C lin ica l studies 
should, involve matching control subjects and 
thrombotic subjects fo r  such basic factors as age, sex 
and smoking. As w i l l  be discussed throughout th is  
thesis i t  is only by taking such essential factors 
in to  account tha t appropriate conclusions can be made 
about the resu lts  obtained in c l in ic a l  studies.
77
2 . 5 .  Disseminated Intravascular Coagulation (£*X*£)
As previously described (2.1) D.I.C. resu lts  
in  the formation o f microthrombi and insoluble f i b r in  
deposits throughout the vasculature. The severe 
disturbance of haemostasis resu lts  in abnormal bleeding, 
small vessel obstruction by f ib r in  and sometimes by p la te le ts ,  
in  tissue necrosis, and in m u lt ip le  organ dysfunction.
Mechanism of £.X.C^.
The i n i t i a l  event in D .I.C . is  the ac tiva t ion  of 
the coagulation sequence. This ac t iva t ion  causes 
consumption of coagulation factors and p la te le ts ,  with 
f i b r in  deposition in the m icroc ircu la t ion . F ib r in  
deposition provokes secondary f ib r in o ly s is ;  the 
combination o f f ib r in o ly s is  with the lack of p la te le ts  
and coagulation factors leads to a bleeding tendency.
At the same time, f ib r in  deposits occlude small blood 
vessels and cause ischaemic damage to various organs 
and may lead to a microangiopathic haemolytic anaemia.
This sequence o f events is  shown in Figure 2.2 and 
w i l l  be discussed below.
Intravascular Blood Coagulation
Three major mechanisms in the ac tiva tion  of 
coagulation leading to  D .I.C . have been suggested by 
Muller-Berghaus (1977).
1. D irect ac tiva t ion  of prothrombin or fac to r  X 
by a p ro teo ly t ic  enzyme or enzymes.
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INTRAVASCULAR
' A C TIVA T IO N  
OF C O A G U L A T IO N
C O N SU M PTIO N  O F COAGULATION  
AND PLATELETS
s e c o n d a r y
FIB R IN OLYSIS
BLEEDING
t e n d e n c y
FIB R IN  DEPOSITION  
IN THE MICROCIRCULATION
ISCHAEM IC  M ICROANGIOPATHIC  
ORGAN HAEM O LYTIC  A N A E M IA  
d a m a g e
Figure 2.2
Sequence of events In disseminated intravascular 
coagulation (taken from Brozovic, 1981).
79
2. Activa tion  via the e x tr in s ic  system by the 
release of tissue thromboplastin.
3, Activa tion  through Hageman fac to r ( fa c to r  X II) 
and the in t r in s ic  system.
Activa tion  of the coagulation system is  believed to be 
in i t ia te d  by several ' t r ig g e r '  mechanisms as outlined below. 
Erythrocytes
Red ce ll  stroma carries potent thromboplastic 
a c t iv i t y  and in mechanical haemolysis may activa te  
coagulation through the e x tr in s ic  pathway (M ulle r- 
Berghaus, 1977). Immunologically induced haemolysis 
probably induces D.I.C. through antlgen-antibody complexes. 
Platel ets
A ll  the tr igge rs  of in travascu lar coagulation can 
induce p la te le t  aggregation and release. Thrombin 
generated during the ac tiva tion  w i l l  enhance p la te le t  
reactions and cause a fu r th e r  f a l l  in the p la te le t  count. 
However, p la te le ts  are not essential fo r  the development 
o f D . I .C . , as i t  can be induced in profoundly thrombo­
cytopenic animals (Muller-Berghaus, 1977).
Leukocytes
Leukocytes are the princ ipal target ce l ls  fo r  
endotoxin in the c irc u la t in g  blood, both in man and in  
experimental animals. Administration of endotoxin 
causes a f a l l  in the white ce ll count, a ffec t ing  the 
neutrophils in p a r t ic u la r  (C line, Melmon, Davis et a l . , 1968).
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The damaged ce lls  release procoagulant t issue-thromboplastin­
l ik e  m ateria l. Monocytes can also release procoagulant 
a c t iv i t y  a f te r  exposure to endotoxin. Blast ce l ls  in 
acute leukaemia have a high content of procoagulants 
and D.I.C . commonly occurs in th is  condition (Gralnick 
and A b re l l , 1973).
Vessel Wal1
As previously described, endothelial damage and the 
exposure of subendothelial structures is associated with 
the ac t iva t ion  of Hageman fa c to r ,  release of t issue 
thromboplastin and in i t i a t io n  of p la te le t  reactions, each 
of which can t r ig g e r  or accelerate D.I.C . Minimal 
endothelial damage may in te r fe re  with prostacyclin formation 
and enhance p la te le t  reactions leading to low grade D.I.C. 
Complement
The complement system is  activated in vivo and in  
v i t r o  by the same t r ig g e rs ,  but a d ire c t functional 
re la t ion sh ip  between the two systems is  not c le a r ly  
established (Brown, 1975; Muller-Berghaus, 1977).
Complement ac t iva tion  a ffec ts  the c l in ic a l  course of 
D.I.C . by changing the re a c t iv i ty  and permeability 
o f the vessel w a l l ,  neutrophil chemotaxis and p la te le t  
aggregation (P fue lle r  and Luscher, 1972).
Anti gen-anti body complexes
Immune complexes are able to activa te  coaguation in 
several ways. They may activa te fac to r  XII d i re c t ly  
(McKay, 1972) or damage the endothelial ce l ls  with
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subsequent in d ire c t  ac t iva t ion  of the in t r in s ic  pathway. 
They may also activa te  the complement system resu lt ing  
in release of procoagulants which may induce D.I.C 
(Gotze and Mill 1er-Eberhard, 1971). Immune complexes 
can cause p la te le t  aggregation and the release 
reaction, thus accelerating D.I.C.
The ro le  o f modifying factors
A number of factors have been suggested as determining 
the severity  and spread of D .I.C . as discussed below. 
Blockade o f the re t icu lo -endo the lia l system (RES)
Normally the RES protects the ind iv idua l from D .I.C . 
by removing activated c lo t t in g  factors and f i b r in  monomer 
complexes as well as the t r ig g e r  i t s e l f .  Experimental 
blockage of the RES leads to fulminant D .I .C .,  as in the 
Schwartzman reaction (Bel 1er, 1969). Blockage also 
resu lts  in increased frequency of D.I.C. in  l i v e r  
disease and pregnancy (Evensen and H jo r t ,  1970).
In h ib i t io n  o f f ib r in o ly s is
The fa i lu re  to lyse f ib r in  deposited in the 
m icroc ircu la t ion  leads to severe organ damage and to  
fu r th e r  acceleration of D.I.C . A n t i f ib r in o ly t ic  
agents enhance D.I.C. in man (McKay and Muller-Berghaus, 
1967) and when given in combination with thrombin cause 
D .I.C . in experimental animals (Margarettan, Zunker and 
McKay, 1964).
Stimulation o f the adrenergic system
Many experiments point to the importance o f 
catecholamines in D.I.C. (Muller-Berghaus, 1977). For 
example, s tim ula tion o f  oc receptors a ffec ts  the 
peripheral blood flow and plays an important ro le in the 
p rec ip ita t ion  of f i b r in  in the skin and the kidney._______
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Elevated piasma 1ip ids
The combination of l ip id  infusion and endotoxin 
in je c t io n  provokes severe D.I.C . in experimental animals 
(Huth, Schoenborn and Knorpp,1967). This may resu lt from blockade 
of the RES, in h ib i t io n  of f ib r in o ly s is  or as a re su lt  
o f the procoagulant e ffec t of l ip id s  (Evensen and H jo r t ,  1970). 
Reduced plasma inhb ito rs
Reduced plasma levels of antithrombin I I I  are found 
in  l i v e r  disease, acute phase reactions, a f te r  in ju ry  
and in congenital defic iency. In a l l  these conditions 
there is  an increased frequency of thrombosis and D.I.C . 
Consumption of in h ib ito rs  at a la te r  stage of D .I.C . 
perpetuates the process.
Pregnancy
I t  is  known tha t pregnancy predisposes to D.I.C .
Endotoxin administered to pregnant animals may re su lt  
in  the Shwartzman reaction. A marked reduction in 
f ib r in o ly t i c  a c t iv i t y  has been found in pregnancy 
(Astedt, Isacson, Nilsson et a l . ,  1970).
L iver disease
Inadequate clearance mechanisms, poor synthesis of 
coagulation factors and a generalised metabolic disturbance 
con tr ibu te  to a high frequency of D.I.C, in  l i v e r  disease. 
Consumption of Coagulation Factors
A ctiva t ion  of the coagulation sequence leads to the 
consumption of c irc u la t in g  coagulation factors  and p la te le ts .
The factors involved are those consumed during normal 
coagulation: fa c to r  V, V I I I ,  prothrombin, f ib r inogen.
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fa c to r  X I I I  and to a lesser extent, fac to r X. In acute 
D.I.C . low levels or to ta l absence of factors  V and V I I I ,  
reduced prothrombin levels and an almost to ta l absence 
of c lo t ta b le  fibrinogen are commonly found. In sub­
acute D.I.C . factors V and V I I I  are decreased, with 
prothrombin remaining almost normal and plasma 
fibr inogen varying from to ta l absence to near normal 
values. In chronic or low grade D.I.C. the consumption 
may be minimal, and the in travascular ac t iva t ion  may give 
r ise  to fa l la c io u s ly  high values fo r  the c lo t t in g  fa c to r  
assays. Fibrinogen, fac to r  V I I I  and V may also be 
ra ised, a resu lt  of the compensation process (Cooper, Bowie and 
Owen, 1974) where increased synthesis of coagulation factors in 
response to low grade D.I.C . leads to true high plasma leve ls . 
F ib r in  deposition
The end resu lt  of the coagulation sequence ac tiva t ion  
is  the formation of in travascu lar f i b r in .  The s i te  and 
extent of f i b r in  deposition depend on the re la tionsh ip  
between thrombin-fibrinogen and p lasm in -f ib r in  in te r ­
actions, on the stage of D .I .C .,  and on various factors 
tha t e f fe c t  lo ca lisa t io n  of f i b r in  deposits.
Thrombin- fibrinogen reaction
Thrombin cleaves f i r s t  f ib r inopep tide  A, then
fib r inopep t
polymerisat
de B from fibrinogen (see 1.3, 2e) 
on begins before a s ig n if ic a n t amount of
fib r inopep tide  B is  released (D o o l i t t le ,  1977). Soluble 
f ib r in - f ib r in o g e n  complexes lacking only one of the four 
f ib r inopeptides may be formed. These complexes can be 
precip ita ted by ethanol or protamine sulphate in v i t ro  
and th e i r  presence in plasma denotes that the c irc u la t in g
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f ib r inogen is  p a r t ly  degraded. The complexes are removed 
by the RES, but p re c ip ita t io n  of f i b r in  may occur as the 
next step i f  the ac tiva t ion  process accelerates or i f  
lo ca lis in g  fac to rs , such as stasis favour i t .
PIasmin- f i b r i n (ogen) reactions
Plasmin cleaves many d i f fe re n t  fragments from 
f ib r in  and fib r inogen. The largest of those (X and 
la rger) are c lo t ta b le  and can, therefore , polymerise 
with f i b r in  monomers in to  soluble complexes or can be 
prec ip ita ted  with them. The extent of f i b r in  
deposition and organ damage depends mainly on the 
e ff icacy  of the f ib r in o ly t i c  system.
Morphology and lo ca lisa t io n  o f f ib r in  deposition
In the early  stages of D .I .C .,  spherical f i b r in  structures 
can be shown by the electron microscope on the surface of 
RES c e l ls  in the spleen and the l i v e r  (Stewart, 1971).
In the la te r  stages micro and macrothrombi are found 
in  the m a jority  of patients dying with D.I.C, (Minna,
Robboy and Colman, 1974).
F ib r in  thrombi are observed more frequently in the 
kidney than in the other organs. McKay (1970) 
suggested tha t most thrombi form in systemic c irc u la t io n  
as f i b r in  aggregates, and tha t by a sieving e ffe c t they 
are eventually caught in smaller vessels. Because of i t s  
r ich  microvasculature, the kidney acts as an excellent sieve.
A va r ie ty  o f skin lesions are associated with D.I.C. 
eg gangrene. F ib r in  thrombi are inva riab ly  demonstrated
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in  the c a p i l la r ie s  and venules of the p a p il la ry  dermis and 
occasionally of the re t ic u la r  dermis and subcutaneous 
tissues (Minnaet a l . ,  1974).
The pathogenesis of lung lesions in D.I.C. is  complex.
At the early  stages p la te le t - r ic h  micro-thrombi are 
commonly observed (B ley l,  1977) owing to the sieving 
e f fe c t  of the lungs; the lungs have a s im ila r  ro le  in 
the venous c irc u la t io n  to tha t of the kidney on the a r te r ia l  
side. The p la te le t  r ich  microthrombi may convert to 
f ib r in - r i c h  thrombi a f te r  the destruction of p la te le ts .
At a la te r  stage of D .I.C . cha rac te r is t ic  lung lesions 
consist of f i b r in  deposits both in travascu la r ly  and 
extravascularly in the a lv e o l i .  Although the formation 
o f in travascu lar f i b r in  deposits is  eas ily  explained in 
the presence o f D .I .C .,  the o r ig in  of extravascular 
f i b r in  is  more d i f f i c u l t  to in te rp re t.  I t  is  possible 
tha t i t  arises as the resu lt  o f extravasation of 
soluble f i b r in  monomer complexes that la te r  p rec ip ita tes . 
Secondary f ib r in o ly s is
D if fe ren t mechanisms may account fo r  the generalised 
ac t iva t ion  o f f ib r in o ly s is  in D.I.C. eg (A) the t r ig g e r  
tha t in i t ia te s  in travascu lar coagulation may also activate 
the f ib r in o ly t i c  sequence, (B) the activated form of 
Hageman fac to r  induces f ib r in o ly s is  simultaneously with 
the ac tiva tion  of the in t r in s ic  pathway and the 
k a l l ik re in -k in in  system (Ogston and Bennett, 1977),
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(C) proteases other than plasmin, derived from damaged 
c e l ls  may also pa rt ic ipa te  in the f ib r in o ly t i c  process 
(L a ta l lo  et a l . ,  1978) and (D) the lack of in h ib i to rs ,  
which are ra p id ly  consumed in the early stages of D .I.C . 
enhances generalised f ib r in o ly s is .
Z . 6 .  Atherosclerosis
Recently endothelial ce l ls  have been found to 
generate part of the recognised properties of the fa c to r  
V I I I  molecule. Endothelial ce l ls  synthesise von 
Willebrand fa c to r  (VIII:vWF) and also the moiety 
recognised by anti sera to fac to r V I I I  raised in  rabbits 
(FVIII R:Ag), but the coagulant property (FVIII:C ) is  
not produced there. The physiological ro le  of th is  
s i te  of synthesis is  unknown, as yet. Factor V I I I  has 
no accurately defined vascular function . However, 
there is  increasing circumstantia l evidence to suggest 
th a t von Willebrand fac to r  may be involved in  p la te le t -  
vessel-wall in te rac tions ; in the absence o f von 
Willebrand fa c to r ,  p la te le t  adhesion to subendothelium 
is  reduced (Weiss, Baumgartner, Tschopp et a l . ,  1978) and 
in  subjects with von Willebrand's disease, p la te le t  plug 
formation at s ites  of in ju ry  is  defective (Jorgensen 
and Borchgrevink, 1964). Pigs with von Willebrand's 
disease appear to be res is tan t to the development of 
atherosclerosis (Fuster and Bowie, 1978; Fuster, Bowie, 
Lewis et a l . ,  1979); implying tha t p la te le t  adhesion to 
the vessel wall mediated by von Willebrand fa c to r  may
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play a part in atherogenesis. Further evidence of a 
vascular ro le  in the development of atheroma comes 
from the find ing  tha t the smooth muscle ce l ls  
p ro l i fe ra t in g  in the fibro-muscular lesions are monoclonal 
in  o r ig in  (Benditt and Benditt, 1973), a property 
conventionally associated with tumour c e l ls .  Atheromatous 
plaques may, there fore , be analogous to benign tumours, 
smooth muscle ce l ls  continuing to p ro l i fe ra te  
spontaneously fo llow ing an in i t ia t in g  stimulus at the 
time o f vascular in ju ry .  P la te le ts  may also con tr ibu te 
to  atherogenesis by the provision of a ce ll mitogen 
which stimulates smooth muscle ce l l  p ro l i fe ra t io n  (Ross, 
Glomset and Marker, 1977). Further evidence to support 
th is  hypothesis comes from observations tha t p la te le t  
material can be demonstrated in h is to log ica l sections 
from human atheromatous plaques (Woolf, 1978) and tha t 
the induction of thrombocytopenia can protect against 
experimental atherosclerosis in animals (Moore, Friedman,
Singal et a l . ,  1976).
There are strong ind ications that disturbances in the 
PGI^ /TXA^ balance are involved in atherogenesis.
L ip id peroxides are potent in h ib ito rs  of prostcyc lin  
synthetase (Moncada et a l . ,  1976) and se lective 
in h ib i t io n  of prostacyclin formation by these substances 
could lead to increased p la te le t aggregation, 
which in turn could play a ro le in the atherogenesis. 
Indeed, l i p id  peroxidation takes place in plasma as a 
non-enzymic reaction and atherosc lero tic  plaques contain
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l i p id  peroxides (S la te r, 1972; Glavind, Hartmann, 
Clemmesen et a l . ,  1952). Thus, l i p id  peroxides could be 
s h i f t in g  the balance of the system in favour of TXA2 » 
and may predispose to thrombus formation. As described 
previously, reduced prostacyclin formation occurs in the 
hearts at vessel walls of rabbits made a theros le ro tic  
and also in human a therosc lero tic  t issue. In addition , 
increased release of TXA2 - l i k e  has been described in 
rabbits  made a therosc lero tic  by d ie t (Shimanoto, 
Kobayashi, Takahashi et a l . ,  1978).
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CHAPTER 3
- THRQMBQGLOBULIN: m  INDEX OF IH VIVO PLATELET RELEASE
3. ]^ .  Introduction
The adhesion of p la te le ts  to the in jured vessel wall 
with release of granule constituents and the resu lt ing  
formation of p la te le t  aggregates are important in i t ia t in g  
mechanisms in thrombosis, as discussed in the previous 
chapter. The occurrence o f a r te r ia l  thrombi on 
atheromatous plaques and the predominance o f p la te le ts  in 
a r te r ia l  thrombi suggest tha t p la te le t  ac t iva t ion  and 
release might be especia lly relevant to  thrombosis in the 
a r te r ia l  c irc u la t io n .
_3._2. _In V itro  Tests of P Ia te let Activation
Within the la s t  few decades, several in v i t r o  tests 
have been developed as markers o f p la te le t  ac t iva tion  v iz : 
_1. B1 eeding time
The skin bleeding time is thought to assess p la te le t  
in te rac tion  with the vessel wall to form the primary 
haemostatic plug. Micropuncture of an a r te r io le  or 
venule causes bleeding and the time taken to arrest the 
bleeding is  measured.
A shortened bleeding time has been described in 
patients with myocardial in fa rc t io n  and atherosclerosis 
(O'Brien, Etherington, Jamieson et a l . ,  1974; O'Brien, 
Etherington, Jamieson et a l . ,  1975) as well as in 
subjects at r is k  of a r te r ia l  disease due to diabetes or 
type I I  hyperlipoproteinaemia (J o is t ,  Baker and Smith, 
1978; J o is t ,  Baker and Schoenfeld, 1979).
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2. P la te le t survival
The lifespan of p la te le ts  can be assessed using 
radio labelled p la te le ts . Sodium chromate ( Cr) is  
the most re l ia b le  label although i t  has the technical 
problem tha t i t  binds to plasma prote ins, erythrocytes, 
leukocytes and p la te le ts , hence the p la te le ts  require to 
be isolated and labelled in v i t r o .  Once the rad io­
labelled p la te le ts  are reinfused, approximately 50-70% 
remain in the c irc u la t io n .  The pattern of survival of 
Cr-labelled p la te le ts  is  l in e a r  in normal subjects 
(Marker, 1978) but where p la te le ts  are subject to  
abnormal destructive process or in te rac tion  with damaged 
vascular endothelium, an exponential disappearance pattern 
is  seen (Murphy, Francis and Mustard, 1972). A large 
number of studies have now associated decreased p la te le t  
survival w ith the l ike lihood  of a r te r ia l  thrombosis (Murphy 
and Mustard, 1962; Steele, Battock and Genton, 1975) although 
others have not (Abrahamsen, 1968; Marker and S l ic h te r ,  1974).
Decreased p la te le t survival has also been found in  
venous thrombosis in the acute stage (Abrahamsen, 1968;
Marker and S l ic h te r ,  1974), in patients with recurrent 
thrombosis in the non-acute phase (Steele, Weil y and 
Genton, 1973), and in patients with r is k  associations fo r
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venous thrombosis such as advancing age, surgery and 
malignancy (Abrahamsen, 1968).
Thromboembolism from abnormal heart valves also 
resu lts  in a decreased p la te le t  survival (Steele, Weily,
Davies et a l . ,  1974; Weily, Steele, Davies et a l . ,  1974).
3^ . P la te le t production 
An a lte rn a t ive  approach to assessment of p la te le t  
survival is  measurement of p la te le t production time using 
p la te le t  formation of malondialdehyde (MDA) which is 
blocked fo r  the lifespan of the p la te le t  by a s ing le dose 
of a sp ir in .  The time taken fo r  MDA formation to return to 
baseline values is  measured, and has been found to 
co rre la te  well w ith survival of radio labelled p la te le ts  
(S tuart, Murphy and Oski, 1975). Shortened p la te le t  
production time has been reported in subjects with 
peripheral a r te r ia l  disease (Celia , Zahavi, de Haas et a l . ,  1979) 
P la te le t count
The c irc u la t in g  p la te le t  count re f le c ts  a balance 
between production and surv iva l.  High p la te le t  counts 
are associated w ith increased rates of aggregation as 
well as with spontaneous aggregation in v i t r o ,  increased 
'c i r c u la t in g '  p la te le t  aggregates, and response to 
treatment with asp ir in  in vivo.
Increased p la te le t  counts have been associated with 
a r te r ia l  or venous thrombosis. In a r te r ia l  diseases and 
in  patients with r is k  associations fo r  a r te r ia l  disease
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studies have generally found p la te le t  counts to  be 
lower, not higher and i t  has been suggested tha t these 
lower p la te le t  counts re f le c t  shortened p la te le t  
survival (O'Brien, 1977).
_5. P la te le t volume
This is  the c irc u la t in g  p la te le t  ce ll mass per volume 
o f blood. Since younger p la te le ts  are la rge r, increased 
mean p la te le t  volume may re f le c t  increased p la te le t  
turnover and hence decreased mean p la te le t  age (Karpatkin,
1978). However, p la te le t  size is  effected by p la te le t  
is o la t io n  methods, hereditary fac to rs , and disturbance of 
megakaryocyte growth and release. An increased p la te le t  
ce l l  volume has been reported in patients a f te r  myocardial 
in fa rc t io n  and with chronic a r te r ia l  diseases or diabetes 
(Enticknap, Gooding, L a n s l^  et a l . ,  1969). However, 
since these patients also have lower p la te le t  counts, 
th e i r  c irc u la t in g  p la te le t  ce ll mass per volume of 
blood remains normal (O'Brien, 1977).
P la te le t adhesion
P la te le t adhesion ex vivo has usually been measured 
by exposure o f freshly-drawn blood to glass or collagen- 
coated surfaces. The most widely used methods are those 
in  which fresh or anticoagulated blood is  drawn through 
p la s t ic  tubes containing glass beads: the f a l l  in p la te le t
count due to  p la te le t  re tention in the column is  measured. 
Such tes ts  in fac t measure p la te le t  adhesion as well as 
aggregation. Results are influenced by many factors 
including flow ra te , haematocrit and von Willebrand fac to r.
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P la te le t re tention may be increased in acute 
venous thrombosis but is  normal in recurrent venous 
thrombosis (Isacson and Nilsson, 1972; O'Brien, et a l . ,  1975) 
and in a r te r ia l  diseases.
Z* P la te le t aggregation
P la te le t  aggregation in v i t r o  has usually been 
measured in  c i t ra te d  p la te le t - r ic h  plasma using the 
photometric technique of Born (1962). A pa ra l le l beam 
of l ig h t  from a tungsten source is  shone through a 
cuvette containing a sample of p la te le t  rich plasma.
Maximal in terference of l ig h t  transmission occurs when 
the p la te le ts  are evenly d is tr ibu ted  throughout the 
plasma. Upon addition of an aggregation stimulus such 
as ADP, adrenaline, collagen and thrombin, an i n i t i a l  
increase in optical density occurs as the p la te le ts  
change shape. This is  quickly followed by a rapid 
decrease in optical density as the p la te le ts  clump 
together, allowing more l ig h t  through the cuvette.
C ircu la t ing  p la te le t aggregates can also be 
measured. In the method of Wu and Hoak (1974) 
blood is drawn in to  a syringe containing EDTA (which 
has been shown to disperse p la te le t  aggregates, at 
least those induced by ADP) or EDTA plus formalin 
(which f ixes aggregates). The ra t io  of p la te le t
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counts in the two samples, a f te r  cen tr ifuga tion  to obtain 
p la te le t  r ich plasma, gives a measure of f ixed p la te le t  
aggregates which are spun down with the red c e l ls .
In the method of Hornstra (1978), blood is  drawn 
through a m ic ro f i l te r  at a constant ra te : p la te le t  aggregates
obstruct the f i l t e r  and cause an increased pressure gradient 
across the f i l t e r  which is  continuously recorded.
Increased aggregation has been found in d iabetics 
and in type I I  hyperlipoproteinaemia by some workers 
(Carvalho, Colman and Lees, 1974; Tremoli, Maderna,
S ir to r i  et a l . ,  1979) but not by others (Jo is t  et a l . ,
1979; Lowe, Drummond, Third et a l . ,  1979).
Increased p la te le t  aggregates have been reported in  
a r te r ia l  diseases such as acute myocardial in fa rc t io n ,  
stroke or trans ien t cerebral ischaemia (Wu and Hoak, 1974; 
Dougherty, Levy and Webster, 1977; Lowe, Reavey and 
Johnston et a l . ,  1979; Schwartz, Hawiger, Timmons et a l . ,
1980); others have not confirmed th is  (Prazich, Rapaport, 
Samples et a l . ,  1977). There are also c o n f l ic t in g  reports 
in  chronic a r te r ia l  disease (Wu and Hoak, 1974; Lowe et 
a l . ,  1979; Jonker and den Ottolander, 1979). Increased 
aggregates have been reported in diabetes (Preston, Ward,
Marcola et a l . ,  1978; Gensini, Abbate, F av il la  et a l . ,
1979) and hyperlipidaemia (Wu, Armstrong, Hoak et a l . ,
1975; Lowe, Johnston, Drummond et a l . ,  1979., Lowe,
Drummond, Third et a l . ,  1979). Increased p la te le t  aggregates 
are not spec if ic  fo r  vascular disease as they have been reported 
in  patients with in fe c t ion  or malignancy (Lowe et a l . ,  1979d).
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Z* P Ia te let shape change
P la te le t shape change fo llow ing stim ulation with 
aggregating agents is  re flected in the photo-aggregometer 
as a f a l l  in  l ig h t  transmission p r io r  to the increased 
transmission which occurs on aggregation. Shape change 
appears also to  influence changes in p la te le t  e lec tro ­
phoretic m o b il i ty  in response to low doses o f aggregating 
agents. Increased s e n s i t iv i ty  to  such m o b il i ty  changes 
has been described in  women taking oral contraceptives 
aa well as patients with a r te r ia l  disease or hyper- 
lip idaemia: plasma fac to rs , possibly l ip id s ,  appear
to  be responsible (Hampton and M itch e ll ,  1974).
2 '  P la te let coagulant a c t iv i t y
Increased p la te le t  fa c to r  3 (PF3  ) a c t iv i t y  has been 
found in patients with type I I  hyperlipoproteinaemia 
(Nordoy and Rodset, 1971). Collagen induced coagulant 
a c t iv i t y  has been reported to  be increased in patients 
with trans ien t cerebral ischaemia (Walsh, Pareti and 
Corbett, 1976), acute re t in a l vein occlusion (Walsh, 
Goldberg, Tax et a l . ,  1977) and in  patients fo llow ing hip 
surgery who subsequently developed venous thrombosis 
(Walsh, Rogers, Harder et a l . ,  1976).
Although some of the tests  discussed are re la t iv e ly  
simple and involve l i t t l e  interference with c ircu la t in g  
p la te le ts :  the information they reveal is  probably
relevant to p la te le t  behaviour in vivo but with l i t t l e  
ins igh t in to  underlying mechanisms. Other tests 
involve more d ras tic  interference with the p la te le t
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environment, such as anticoagulation, separation from 
other c e l ls ,  and exposure to foreign surfaces: they
allow study of se lective phenomena in re la t iv e  iso la t io n  
at the cost o f removing other influences normally present 
as well as the possible in troduction of a r te fac ts . The 
is o la t io n  of p la te le ts  from whole blood involves r is k  of 
a c t iva t io n ,  deactivation and se lec tion , due to a n t i -  
coagulation, mechanical factors (traumatic venepuncture, 
shaking, haemolysis, cen tr ifuga tion  and changes in  pH or 
temperature ( fo r  review see Sixma, 1978). Thus, most 
o f these tes ts  have not proven to  be e f fe c t ive  in 
detecting thrombosis or a "pred isposition" towards thrombosis 
with c o n f l ic t in g  resu lts  often being obtained as discussed.
^  -Thromboglobulin 
In troduction
P la te le ts  contain a number of granules in which a 
va r ie ty  of substances are stored and which are subsequently 
released from the p la te le t  when they are activated (see 
Table 1 .1 ). Proteins are localised in p a r t ic u la r  in the 
a-granules. ^  -thromboglobulin (BTG) was one o f the 
f i r s t  proteins to  be iso lated and characterised. Sensitive 
radioimmunoassays of BTG have been developed allowing i t s  
measurement in p la t le t  free plasma. While i t  is  recognised 
tha t such assays are also subject to the experimental 
a r te fac ts  discussed previously, plasma concentrations of 
BTG should provide, in  theory, a more sensitive and 
spe c if ic  index of in -v ivo  p la te le t  ac t iva tion  and release.
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The present knowledge about BTG with regard to i t s  
chemistry, measurement, release and the measurement of 
BTG levels in c l in ic a l  studies as an ind ica to r of in 
vivo p la te le t release in various disorders w i l l  be reviewed. 
Iso la t ion  and characterisation o f BTG and 
related proteins 
Almost 20 years ago, Salmon and Bonameaux (1958) 
f i r s t  reported the presence of beta-globulins in 
p la te le ts .  Subsequently, Grette (1962) demonstrated 
proteins in the soluble material released by p la te le ts  
during thrombin induced aggregation and i t  was shown 
la te r  tha t th is  material contained p la te le t  spe c if ic  
alpha and beta globulins (Davey and Luscher, 1968). I t  
was f i r s t  isolated by Moore, Pepper and Cash (1975a), 
and by Moore and Pepper (1976). Because of i t s  
-g lobu lin  m o b il i ty  on ce llu lose acetate e le c tro ­
phoresis and i t s  lo ca lisa t io n  in p la te le ts ,  i t  was 
called yS -thromboglobulin.
BTG was found to have a molecular weight of 
36,000 by sucrose density cen tr ifuga tion . Amino 
acid sequencing studies demonstrated the molecule to 
be composed of four subunits o f 81 ami noacids each 
w ith a molecular weight of 8851 (Begg, Pepper,
Chesterman et a l . ,  1978). When the amino acid sequence 
of BTG is  aligned with tha t of p la te le t fa c to r  4 (Pl^) 
(another alpha granule protein tha t is  chemically and 
immunologically d is t in c t  from BTG) 42 of the 81 residues 
are identica l w ith PF^ residues (Begg et a l . ,  1978).
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Recently i t  has been shown that BTG has an iso­
e le c t r ic  point of pH 7.0, with another c lose ly related 
p ro te in , " lo w -a f f in i ty  p la te le t  fac to r 4" (LA-PF^ ) 
having an is o -e le c t r ic  point of pH 8.0 (Rucinski, 
Niewiarowski, James et a l . ,  1979).
LA-PF^ appears to  d i f f e r  from BTG only in i t s  
four amino terminal amino acids, which are Asn - Leu - 
Ala - Lys. Residues 5-12 of LA-PF^ have been shown 
to  be identica l to  residues 1-8 of BTG (R uc insk i et a l . ,
1979). Experimental studies seem to ind ica te  tha t 
LA-PF^ is  o r ig in a l ly  secreted by the p la te le ts  and then 
converted to  BTG by a p la te le t  secretory protease 
(Niewiarowski, Walz, James et a l . ,  1980). The available 
anti-BTG and anti-LA-PF^ antibodies do not d i f fe re n t ia te  
between both proteins (Rucinski et a l . ,  1979). I t  
appears tha t BTG is  a p ro teo ly t ic  product o f LA-PF^ , 
whether the p ro te o ly t ic  conversion occurs in vivo is  not 
c lear (Holt and Niewiarowski, 1979).
Content and lo ca lisa t io n  of BTG
BTG, LA-PF^ and PF4  appear to be p la te le t  spec if ic  
(Moore, Pepper and Cash, 1975a; Moore, Pepper and Cash, 
1975b; Niewiarowski, 1977). The concentration of BTG 
in  various washed organ samples was measured by radio­
immunoassay and only trace amounts were detected. I t  
is  o f in te res t to  note tha t the highest concentration of 
BTG was found in the spleen and th is  may re f le c t  th e i r  
s i te  of destruction (Ludlam, 1979)(see Table 3 .1 . ) .
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TABLE 3.1.
BTG CONTENT OF VARIOUS TISSUES
ng/gm 
net weight t issue
Brain 3.8
Kidney 5.6
Skeletal muscle ' 4.0
Stomach 4.2
Lung ve n tr ic le  9.0
Lung 30.4
L iver 40.0
Spleen 92.0
P la te le ts  1,240,000
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In addition Kaplan found tha t PF^ and BTG antibodies 
did not crossreact with haemolysate, leucocyte ex trac t, 
human albumin or fibrinogen (Kaplan, Nossel, D r i l l in g s  
et a l . ,  1978). - BTG has been estimated to  represent 
at least 0.5% and probably 2.5% of the to ta l p la te le t  
dry weight, and at least 10% by weight of the granule 
content (Moore and Pepper, 1976). LA-PF^ and PI^ 
cons titu te  1 . 6% and 0 . 8% respective ly of secreted 
proteins (Rucinski et a l . ,  1979). The normal 
p la te le t  content o f BTG is 18 ug/10 p la te le ts  
(Weiss, W itte, Kaplan et a l . ,  1979) while tha t of 
LA-PF^ is  24 ug/10 ^ p la te le ts  (Rucinski et a l . ,  1979).
BTG, LA-PF^ and PF^ are localised in the alpha 
granules o f the p la te le ts ,  together with p la te le t  derived 
growth fac to r  and fibrinogen. This has been demonstrated 
by subce llu la r fra c t iona t ion  with sucrose density gradient 
cen tr ifuga tion  followed by assay of the frac tions  obtained 
(Kaplan, Broekman, Chernoff et a l . ,  1979; Fukami, 
Niewiarowski, Rucinski et a l . ,  1979) or morphological 
study with electron microscopy (Ryo, P r o f f i t t  and 
Devel, 1980). Additional evidence comes from studies of 
in  v i t r o  release of BTG and PF^ in comparison to  the 
release of substances from dense bodies (serotonin, ATP o r  
ADf)and the acid hydrolase containing granules (Kaplan et a l . ,  
1979; Ryo et a l . ,  1980; W itte , Kaplan, Nossel et a l . ,  1978). 
i n  v i t r o  release o f BTG 
In v i t r o  release of BTG only becomes s ig n if ic a n t  
a f te r  seven minutes as reported by Ludlam and Cash (1976),
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with BTG and PF^ appearing in the serum 
simultaneously in s im ila r  concentrations (Dawes, Smith 
and Pepper, 1978). BTG and PF^ can be released from 
blood anticoagulated with e ith e r  EDTA, c i t ra te  or 
heparin, with the release being temperature and pH 
dependent (Ryo et a l . ,  1980; Witte et a l . ,  1978).
In v i t r o  release of BTG and PF^ induced by 
various pro-aggregating agents l ik e  ADP, collagen and 
thrombin has also been studied.
ADP or epinephrine do not induce release of BTG 
and PF^ with primary aggregation, but during biphasic 
aggregation both p la te le t  proteins are released in a 
s im i la r  manner (Kaplan et a l . ,  1978; Ryo e ta l . ,  1980).
ADP induced release of BTG and PF  ^ is  s im ila r  to  tha t 
of l^C -se ro ton in  but beta-glucuronidase, a lysosomal 
is not released by ADP (Ryo et a l . ,  1980).
Collagen induces release of BTG, PF^, ^^C- 
serotonin, p la te le t  derived growth fac to r  (PDGF) and 
fibr inogen although such release is  dose dependent 
(Kaplan et a l . ,  1978; Witte et a l . ,  1978).
Thrombin also induces release of BTG, PF4  ,
C-serotonin, PDGF and f ib r inogen, however, higher 
thrombin concentrations are required fo r  the release of 
the dense granule components, serotonin and ADP, and even 
higher doses are required fo r  acid hydrolase release 
(Witte et a l . ,  1978).
BTG and PF4  release is  also induced by arachidonic 
acid and by the endoperoxide analogue U46619 (Kaplan et a l . ,  
1979) with a somewhat smaller release of 1 ^ -s e ro to n in .
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These studies ind icate tha t the release mechanism 
fo r dense granule release, alpha-granule release and 
lysosomal enzyme release are d if fe re n t  (Kaplan et a l . ,  
1979; Ryo et a l . ,  1980).
^.3^._5. B io logic a c t iv i t y  of BTG
The exact b io log ica l functions of BTG remain unclear 
but some b io log ica l a c t iv i t ie s  have been recognised.
While i t  was o r ig in a l ly  thought tha t BTG had antiplasmin 
a c t iv i t y  (Moore et a l . ,  1975) th is  a c t iv i t y  was la te r  
shown to be separable from BTG (J o is t ,  Niewiarowski,
Nath et a l . ,  1976). Because of i t s  abundance in 
p la te le ts ,  i t  has been suggested BTG might be a matrix 
or packing prote in v^ich helps to s ta b i l is e  the active 
constituents and is  re ad ily  released by b io log ica l 
s t im u li (Moore and Pepper, 1976).
BTG has a weak heparin-neutra lis ing a c t iv i t y  
(Moore and Pepper, 1976). The spec if ic  antiheparin 
a c t iv i t y  of BTG, LA-PF^ is  1.9, 2.6 and 17 heparin 
units/mg prote in respective ly (Rucinski et a l . ,  1979).
I t  has been suggested tha t BTG inh ib ited  
production of PGI^ by cultured endothelial c e l ls ,  
suggesting a ro le  fo r  BTG in  the process of thrombosis 
(see Chapter 2.4.3) but th is  observation was not 
confirmed in a la te r  study (Poggi et a l . ,  1981).
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As recently  discussed by Kaplan (1980) whether BTG has 
cel 1 -growth s tim u la ting  properties remains to be established.
3.3 .6 . Metabolism and clearance of BTG 
The clearance of BTG and PF4  was f i r s t  studied with 
the in fus ion of serum or p la te le t  concentrate in to  normal 
ind iv idua ls  (Dawes et a l . ,  1978). The h a l f - l i f e  o f BTG 
clearance was estimated to be about 100  minutes, with 
PF^ being cleared too rap id ly  to allow determination 
of the h a l f - l i f e .  The rapid clearance of PF ^  may be 
re lated to i t s  binding to endothelial c e l ls  (Busch,
Dawes, Pepper et a l . ,  1979; Pumphrey, Pepper and Dawes,
1979). BTG is  catabolised by the kidney, with such 
catabolism by the kidney being more important than 
renal excretion (Bastl, Musial, Kloczewiak et a l . ,
1981). Because of the short h a l f - l i f e  of PF^ , the 
measurement of BTG in plasma and urine might give a more 
spec if ic  index of p la te le t  ac t iva t ion  and release.
Radioimmunoassay o f BTG 
The is o la t io n  and p u r i f ic a t io n  of BTG enabled spec if ic  
antibodies to be raised against BTG with the subsequent 
development of radioimmunoassays fo r  the detection of 
BTG in  plasma or urine as described by several labora tories 
(Ludlam, Moore and Bolton, et a l . ,  1975; Kaplan et a l . ,  1978; 
Bolton, Ludlam, Moore et a l . ,  1976; Han, Butt, Turpie 
et a l . ,  1980). Purif ied BTG can be labelled w ith
Iodine by the method o f Hunter and Greenwood (1962) 
and a rabb it antiserum raised against p u r if ied  BTG.
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Bolton et a l , ,  1976, developed a method where they 
incubated anti serum, sample or standard and rad io ­
labelled tra ce r fo r  a specified time. In th e i r  
standard assay, incubation was fo r  24 hours, with 
antibody bound BTG being separated from free antigen 
with a second antibody over another 24 hours. To 
increase fu r th e r  the s e n s i t iv i ty  of the assay, more 
d i lu te  anti serum and tracer was used with tracer being 
added 24 hours a f te r  samples had been incubated with 
anti serum. A more rapid method was developed by the 
use of an anti serum covalently linked to Sepharose - 4B. 
A fte r a one hour incubation, bound and free BTG were 
separated by cen tr i fuga tion . A commercial k i t  has 
been developed along the princ ip les of the rapid assay 
w ith bound and free BTG being separated by cen tr ifuga tion  
with ammonium sulphate. The detection l im i ts  of the 
methods ( in  ng/ml) were 0.7 fo r  the standard assay,
0.04 fo r  the sensitive assay and 0.6 fo r  the rapid assay. 
S im ila r radioimmunoassays have been developed 
fo r  LA-PF^ and PF^ with detection l im i ts  of 0 . 1  ng/ml 
(Rucinski et a l . ,  1979) and 0.2 ng/ml (Rucinski et a l . ,  
1979; Levine and Krentz, 1977; Handin, McDonough and 
Lesch, 1978) respective ly.
105
Preparation o f p la te le t  poor plasma fo r  assay
o f plasma BTG
Plasma levels of BTG can only adequately re f le c t
in  vivo p la te le t  ac t iva t ion  and release when in v i t r o
release is  eliminated or minimised. Four steps seem
c r i t i c a l  in the preparation of p la te le t  poor plasma
( 1 ) proper venepuncture, (2 ) rapid cooling of the blood,
(3) ice (0-4 ° C ) ,  (4) cen tr ifuga tion  at 4*^0.
Anticoagulation with a n t ip la te le t  agents is  also c r i t i c a l .
I t  is  recommended that blood is  added promptly to a
mixture of EDTA, PGEj, and theophyll ine, maintained at a
o
temperature between 0 and 4 C, and centrifuged fo r  
60 minutes at l , 0 0 0 g, in  order to obtain low leve ls of 
BTG (Ludlam, 1976).
Because of the potentia l d i f f i c u l t i e s  in blood 
co lle c t io n  and processing, i t  has been suggested tha t 
the measurement of BTG in  urine might provide a more 
re l ia b le  index of in vivo p la te le t  ac t iva t ion  in patients 
w ith normal renal function (Dawes et a l . ,  1978). They 
found a mean urinary BTG level o f 0.14 ng/ml in normal 
subjects, i . e .  0.5% of the plasma level (Dawes et a l . ,
1978; Dawes, Smith, Borsey et a l . ,  1979). Such a low 
ra te  of excretion might lower the s e n s i t iv i ty  of the assay.
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BTG leve ls in c l in ic a l  disorders
_A. Deep venous thrombosis
A prelim inary study of plasma BTG levels in six 
patients revealed that a l l  patients had raised BTG 
levels (Ludlam, Bolton, Moore et a l . ,  1975a). While 
th is  suggested th a t BTG leve ls might be of c l in ic a l  
value in patients with suspected venous thrombosis, 
a la te r ,  more extensive study did not confirm these 
resu lts  (Smith, Duncanson, Ruckley et a l . ,  1978).
Elevated plasma BTG levels had a s e n s i t iv i ty  of only 
50% although the mean BTG concentration was s ig n i f ic a n t ly  
increased in the patients with thrombosis compared with 
normal subjects. Patients who had a pulmonary embolism 
in  addition to DVT had BTG levels s ig n i f ic a n t ly  higher 
than those with DVT alone. They also measured BTG 
s e r ia l ly  in 46 patients screened a f te r  major surgery. 
Thirteen patients developed venous thrombosis as 
detected by I fibrinogen scanning. There was no 
s ig n if ic a n t  d ifference in mean BTG levels between 
patients with or without thrombosis. Increased BTG 
leve ls have been reported in patients with recent 
venous thrombosis (abnormal in  46%) but normal leve ls 
were found in patients with chronic venous thrombosis 
(abnormal in  6 %) (Celia , et a l . ,  1979). A la te r  
study demonstrated that both plasma and urine BTG 
were s ig n i f ic a n t ly  elevated in patients with DVT compared
107
to symptomatic patients with a negative venogram.
S e n s it iv i ty  (37%) and s p e c i f ic i ty  (80%) of the plasma
BTG assay fo r  the diagnosis of DVT were low. The urine
BTG assay had a s e n s i t iv i t y  o f 37% but a s p e c i f ic i t y  of
100%. Serial BTG measurements were made in plasma and
urine post-operative ly in neurosurgical cases. BTG
was elevated post-operative ly and returned to normal
w ith in two or three days, but rose again in ten patients
in association with the development of DVT. The rise
t2^
preceded the uptake of I- f ib r inogen  and lasted fo r  
only a few days (de Boer, Han, Turpie et a l . ,  1981).
S im ilar resu lts  have been obtained by other workers 
(Bolton, Cooke, Lekhwani et a l . ,  1980; Owen, Kvam,
Kaplan et a l . ,  1980).
Such studies c le a r ly  suggest that p la te le t  
ac tiva tion  occurs in venous thrombosis but is  maximal 
or l im ited  to the i n i t i a l  phase of thrombosis development. 
Coronary a rte ry  di sease
Elevated levels of BTG and PF^ _ were f i r s t  reported by 
several workers (Denham, Fisher, James et a l . ,  1977; O'Brien, 
Etherington and Shuttleworth, 1977; Handin et a l . ,  1978).
A number of resu lt ing  studies have shown an elevation in plasma
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BTG levels in acute myocardial in fa rc t io n  (Rasi, T o r t i la  and 
Ikkala , 1980), in both acute myocardial in fa rc t io n  and acute 
angina but normal levels in stable angina (Smitherman,
Milam, Woo et a l . ,  1981). A small but s ig n if ic a n t  
increase in BTG and PF^ has been reported in patients 
with stable angina and coronary a r te ry  disease and in  
patients with myocardial in fa rc t io n  (F i le s , Mai pass,
Yee et a l . ,  1981). Another study has reported 
s ig n i f ic a n t ly  increased BTG levels in acute myocardial 
in fa rc t io n ;  stable and unstable angina when compared 
to  normal groups (Serneri, Gousini, Abbate et a l . ,  1981).
Almost a l l  the patients in the abnormal groups had BTG 
levels above the upper l im i t  of the normal range, thus 
ra is ing  the question of whether the data are not 
p a rt ly  the resu lt of in v i t r o  release due to technical 
problems. A study using seria l measurement of plasma 
and urine BTG found levels in normal patients and those 
with non-cardiac chest pain were s im ila r .  Mean plasma 
BTG was increased in patients with myocardial in fa rc t io n  
or angina, however, 61% of the patients with coronary 
disease had normal leve ls . In the patients with 
myocardial in fa rc t io n ,  the highest values were observed 
at the time of admission and w ith in  four hours of the 
chest-pain episode. Urine BTG levels were not 
d i f fe re n t  from controls in the patients with in fa rc t io n  
and angina (de Boer, Turpie, Butt et a l . ,  1981).
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A s ig n if ic a n t  d ifference in plasma PF^ levels has 
been reported between patients with and without a confirmed 
myocardial in fa rc t io n  (White and Marouf, 1981) but th is  has 
not been confirmed (Levine, L in d e n fe ld ,  E l l is  et a l . ,  1981).
Despite the varying levels of BTG reported in the various 
studies which may in  part be the resu lt of in v i t r o  release, 
p la te le t  ac t iva t ion  and release occur in patients with 
coronary a r te ry  disease, in p a rt icu la r  in acute ischaemic 
events such as myocardial in fa rc t io n  or angina. Such 
p la te le t release is  an intermediate process in coronary 
atheroma, and only of a measurable magnitude in certa in  
patients. Whether a causal re la tionsh ip  occurs between 
p la te le t  release and the c l in ic a l  complications of 
coronary atheroma remains to be established.
£ . Cerebrovascular disease
Elevated plasma BTG levels have been reported in 
patients with stroke or trans ien t cerebral ischaemic 
attacks (TIA) (Hoogendijk, Jenkins, van Wijk et a l . ,
1979). PF^was also found to be increased in these 
patients (Matsuda, Seki, Ogawara et a l . ,  1979). In contrast, 
another study reported normal levels of plasma BTG in patients 
a few months a f te r  a cerebrovascular accident (CVA)
(Celia et a l . ,  1979). Increased levels of BTG have been 
reported in a group of young patients (mean age 35 years) 
with TIA and stroke, blood sampling being carried out 
in the non-acute phase, days or weeks a f te r  the acute 
ischaemic event. In another study plasma BTG leve ls 
were not s ig n i f ic a n t ly  d i f fe re n t  in patients with acute 
p a rt ia l stroke when compared to normal pa tients.
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Subsequent measurements a few weeks la te r  gave s im ila r  
resu lts  (de Boer et a l . ,  1981).
Studies of BTG levels in patients with cerebro­
vascular disease have produced inconsistent resu lts  
and more studies are required.
£. Peripheral vascular di sease
BTG and PF^ levels were elevated in patients with 
peripheral vascular disease. A fte r treadm ill exercising 
only BTG showed a s ig n if ic a n t  increase in levels (Baele, 
Bogaerts, Clement et a l . ,  1981). In contrast normal 
plasma BTG levels were observed before and a f te r  exercise 
tes t in g  in another study (Baker, Fareed, Messmore et a l . ,  
1981). Normal plasma and urine BTG levels have been 
observed in patients with peripheral a r te r io sc le ro s is  
(Johnston, de Boer and Turpie, 1981).
Studies of BTG and PF ^  appear to be inconclusive 
in  patients with peripheral vascular disease and fu r th e r  
studies are required to elucidate the association 
between p la te le t  ac t iva t ion  and peripheral a r te r ia l  disease. 
£ ,  Cardiac valve disease
Plasma levels of BTG are increased in patients with 
rheumatic heart disease and cardiac valve prosthesis.
Most of the studies reported no corre la t ion  between 
levels of BTG or P F w i t h  the number o f valves involved, 
the type of valve inserted (mechanical or bioprosthesis) 
or a h is to ry  of thromboembolism. In a recent sudy 
higher BTG levels were found in patients with double
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valve replacements when compared to patients with single 
mechanical replacements who had s ig n i f ic a n t ly  higher BTG 
values than patients with porcine valves. Patients who 
had s ing le mechanical valves and who developed emboli 
had s ig n i f ic a n t ly  higher BTG levels than those without 
embolic episodes (Pumphrey and Dawes, 1981), Another 
study reported increased ufine BTG levels in patients with 
prosthetic valves (Turpie, de Boer, Genton et a l . ,  1981).
I t  appears tha t p la te le t  ac t iva t ion  is  a more continuous 
process in patients with a r t i f i c i a l  heart valves compared 
to  patients with coronary artery  disease.
£ . Diabetes mel1itu s
P la te le t abnormalities have been described in patients with 
diabetes mel1 i tu s  and are thought to contribute to the vascular 
complications of the disease, hence plasma BTG concentration has 
been studied extensively in patients with diabetes mel1 i tu s .  
Normal plasma levels of BTG were found in the f i r s t  
study reported in  patients su ffe r ing  from diabetes with 
known complications of the disease including neuropathy, 
retinopathy and ischaemic skin lesions (Campbell, Dawes,
Fraser et a l . ,  1977). Two la te r  studies reported 
increased plasma BTG levels in patients with diabetes.
One study found the BTG in  the d iabetic patient was 
increased compared to normal subjects and the highest 
values were observed in patients with vascular complications 
(Burrows, Chavin and Hockaday, 1978). In the second study 
elevated BTG levels were found in d iabetic  patients both 
with and without vascular complications
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(Prèston, Ward, Marcola et a l . ,  1978). I t  has been 
suggested tha t the studies by Preston and Burrows may 
re f le c t  in v i t ro  release, as th e i r  anticoagulant did 
not contain prostaglandin Ej, (E d i to r ia l ,  Lancet, 1978).
Many recent studies have reported elevated BTG levels in  
patients with diabetes. While most of these studies 
used an anticoagulant containing prostaglandin E,, 
there is  a wide overlap with the control groups and a 
wide va r ia t ion  in ind iv idual patient re su lts .
A s ig n if ic a n t  drop in BTG has been reported in patients 
having th e i r  diabetes con tro lled by d ie t (Burrows, 1981;
Preston et a l . ,  1978; Vois in, Rouselle, Guimont et a l . ,  1981). 
Another study, however, reported no co rre la t ion  between BTG and 
the actual fasting blood glucose concentration, the amount of 
24 hours glucosuria or the values of haemoglobin A,
(Schernthaner, Sinzinger, Silberbauer et a l . ,  1981).
No co rre la t ion  between BTG and HbA levels has been reported by 
other laboratories (Matthews, O'Connor, Hearnshaw et a l . ,  1979; 
van Cost, 1981). I t  has been suggested tha t BTG levels are 
highest in patients with vascular complications such as 
retinopathy (Burrows et a l , ,  1978; Zahavi, Jones, Betteridge 
1979; Janka, Standi and Mehmert, 1981, Schernthaner et a l . ,  1981) 
although th is  was not observed in another study (van Cost, 1981).
An in te res ting  study has reported BTG and PF levels 
were normal in patients with diabetes alone. In 
patients with diabetes and peripheral a r te r ia l  disease, 
increased BTG were observed while PF. levels were not
T
d if fe re n t  from normal, suggesting that in  v i t r o  release
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was l im ite d . Increased BTG levels were reported in a group 
of patients with peripheral a r te r ia l  disease, but without 
diabetes. This study supports the active ro le  of p la te le ts  
in thrombotic occlusive a r te r ia l  disease, but not in diabetes.
Although the m ajority  of studies suggest in vivo 
p la te le t  ac t iva t ion  occurs in patients with diabetes, no 
d e f in i t iv e  conclusions can be drawn. The elevated 
levels reported are probably the resu lt of in  v i t r o  
release. There is  evidence tha t p la te le ts  are activated 
in vivo in patients with diabetes when peripheral 
vascular disease is  also present. However, no causal 
re la tionships should be drawn.
£ . Miscellaneous conditions
Both BTG and PF^ levels in plasma were reported to 
be elevated in hyperlipidemia (Zahavi et a l . ,  1981;
F iles et a l . ,  1981). Elevated urine BTG leve ls have been 
reported in  hypertension (Anderton. Fananapazir and Dawes, 1980) 
but these resu lts  are probably due to abnormal clearance of BTG 
in  hypertensive nephropathy than in vivo release since the 
m a jority  of the abnormal values occurred in patients with renal 
in su ff ic ie n cy . Increased BTG levels have been reported 
in  m yopro life rative disorders (Boughton, A ll in g to n  and 
King, 1978; Ire land , Lane, Wolff et a l . ,  1982) and in 
thrombocytosis (Boughton et a l . ,  1978; Han, Turpie 
and Genton, 1979). Increased BTG levels have been 
observed in malignancy (F a r re l l ,  Duffy, Duffy et a l . ,
1979; B idet, Fe rr ie re , Besse et a l . ,  1980; Murakoshi,
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Takei, Seya et a l . ,  1981). The study by Murakoshi et a l . ,  
1991also observed elevated plasma FPA levels suggesting 
in  vivo p la te le t  release in cancer patients is associated 
with low-grade DIG.
BTG leve ls have also been studied in various diseases 
associated with DIG. Elevated BTG levels have been 
reported in patients with established pre-eclampsia 
{Redman, A ll in g to n , Bolton et a l . ,  1977; in the acute 
phase of haemolytic uraemic syndrome (Cossu, Tantalo, 
Paracchini et a l . ,  1981) and in cancer (Muraskoshi et a l . ,  
1981). BTG, PF^ , and FPA levels were a l l  increased 
a f te r  in tra u te r in e  infusion of hypertonic saline to 
terminate pregnancy (Nossel , Wasser, Kaplan et a l . ,  1979) 
suggesting in vivo p la te le t release occurs in association 
with in vivo thrombin generation. Increased BTG levels 
have also been reported in patients with septicaemia, 
complicated w ith DIG (Han et a l . ,  1979). Elevated 
p la te le t  BTG levels have been observed in congenital 
p la te le t  disorders eg. in  May-Hegglin anomaly which is 
characterised by normal or low p la te le t count, giant 
p la te le ts  and leukocyte inclusions (Fabris, Casonato,
Randi et a l . ,  1980). P la te le t release de fic ienc ies 
have been observed in storage pool disease, which is  a 
bleeding disorder characterised by a decrease in  the 
number and contents of p la te le t  dense granules (Weiss et 
a l . ,  1979, P a re ti,  Dawes, Franchi et a l . ,  1979). Increased 
BTG levels have been reported in pulmonary disease
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(Nenci, Berretine, Todisco et a l . ,  1981); a f te r  anaesthesia 
(Zahavi, Price and Kakkar, 1980); and In Raynaud's 
phenomenon (Zahavi, Hamilton, O 'R e il ly  et a l . ,  1979).
Concl usions
Despite the problems associated with in v i t r o  release, 
te n ta t ive  conclusions can be drawn from the various 
c l in ic a l  studies published previously. P la te le t 
ac t iva tion  and release occurs in patients with coronary 
arte ry  disease, in  p a r t ic u la r ,  in  association with 
myocardial in fa rc t io n  or angina. This release does not 
occur in  a l l  patients. P la te le t ac tiva tion  and release 
also occurs in patients with cardiac valve prosthesis and 
in  association with the development of venous thrombosis.
The measurement of BTG does not appear to have a ro le  
in  the c l in ic a l  management of a r te r ia l  and venous thrombo­
embolism as no anti p la te le t  drug has been shown to lower 
plasma or urine levels in various c l in ic a l  disorders.
A ro le  does ex is t fo r  the measurement of BTG in 
e luc idating  the ro le of in vivo p la te le t ac t iva t ion  and 
release in the pathogenesis of a r te r ia l  and venous 
thromboembolic disease.
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CHAPTER 4
FIBRINOPEPTIDE A: AN INDEX OF _IN VIVO THROMBIN
GENERATION AND FIBRIN( OGEN) FRAGMENT, B ^ - 4 2 :  
AN INDEX OF PLASMIN GENERATION
Introduction
In normal haemostasis the formation of f i b r in  from 
fibr inogen is  required to s ta b i l is e  the p la te le t  plug 
formed a f te r  vessel wall in ju ry  as previously discussed 
(see Figure 1 .1 (b )) .  F ib rin  is  a major constituent of 
thrombi, p a r t ic u la r ly  those which form in  veins and on the 
myocardial w a ll.  In addition , f ib r in  and also fibrinogen 
have been demonstrated as key constituents of a r te r ia l  wall 
lesions. The persistence of in travascu lar f i b r in  is  
thought to resu lt from increased f ib r in  formation or 
decreased f ib r in o ly s is .  F ib rin  formation and d isso lu tion  
is  believed to be p r im ari ly  associated with the a c t iv i t y  of 
thrombin and plasmin as discussed in Chapter 1. The action 
o f thrombin on fibr inogen and plasmin on f ib r in (ogen) resu lts  
in the release of spec if ic  soluble fragments whose quan tita t ion , 
in  theory, may be an index of enzymic a c t iv i t y  in vivo. Such 
measurements of f ib r in (ogen) degradation products seem 
relevant to the study of thrombosis associated with 
ac tiva t ion  of e ith e r blood coagulation or f ib r in o ly s is .
jjn V it ro  Tests o f Thrombin Derived Fibrinogen Fragments 
A. Soluble f ib r in - f ib r in o g e n  complexes
Soluble intermediate products are produced during the 
conversion of f ibr inogen to f ib r in  by thrombin (Blomback
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and Laurent, 1957; Blomback, Hogg, Garlund et a l . ,  1976) 
(see Chapter 1.3.E). The potential physiological 
s ign if icance of soluble intermediate f ib r in - f ib r in o g e n  
complexes were demonstrated in the blood of rabbits  
treated with endotoxin (Shainoff and Page, 1960). Such 
complexes consisted of fibrinogen with f i b r in  lacking 
only f ib r inopep tide  A (FPA) and were also cold precipi tab le 
(c ry o f ib r in ) .  When the level of c ry o f ib r in  in  the rabbits  
c irc u la t io n  exceeded 26% of the plasma fib r inogen, the 
c ry o f ib r in  dissociated in to  fibrinogen and f i b r in  in  
equimolar proportions, the f ib r in  then p re c ip ita t in g  from 
solu tion (Shainoff and Page, 1962). Several assays have 
been proposted to detect and quantita te these complexes.
1_, Paracoagulation assays
Fibrinogen is  a large protein of l im ited  s o lu b i l i t y  in 
aqueous medium. A lte ra t ion  of s o lu b i l i t y  by varying s a l t  
concentration (Blomback, 1967), e i th e r  through the addition 
of organic solvents such as ethanol (Blomback and Blomback, 
1956) and dimethylformamide (Blomback and Blomback, 1966) 
or the addition of charged substances such as protamine 
sulphate has been used to p rec ip ita te  fibr inogen and 
certa in  of i t s  derivatives (L ip inski and Worowski, 1968). 
Macromolecular complexes formed between f ib r inogen, 
soluble f i b r in  and various degradation products w i l l  be 
less soluble than fibrinogen i t s e l f  and may be quantitated 
by d i f fe re n t ia l  p rec ip ita t ion  techniques. The term 
"paracoagulation" was f i r s t  used by Derechin (1955) who 
demonstrated tha t when human plasma in which plasminogen 
had been activated by streptokinase was c lo tte d  with
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thrombin, and the resu lt ing  c lo t  dissolved, add ition  of 
quantit ies  of protamine sulphate in s u f f ic ie n t  to p rec ip ita te  
fib r inogen from so lu tion led to re c lo t t in g  of the mixture. 
Protamine sulphate te s t
This te s t  is  thought to be sensitive to the presence 
of early  f i b r in  X m ateria l, as well as f i b r in  monomer.
A good co rre la t io n  has been found between the resu lts  of 
the seria l d i lu t io n  protamine sulphate te s t  and the soluble 
complex concentration using agarose gel f i l t r a t i o n  
(Gurewich and L ip in s k i,  1976). The study examined plasma 
samples from thrombin and endotoxin treated rabb its , as 
well as samples from patients with in travascu lar coagulation.
In c l in ic a l  studies, most series report a high 
incidence of pos it ive  tes ts  in patients with DIG (Seamen, 
1970; Miewarowski and Gurewich, 1971; Gurewich and 
Hutchinson, 1971). The incidence of pos it ive  tes ts  in  
deep venous thrombosis varies in d i f fe re n t  series. In one 
study, an incidence of 8 % pos it ive  tests in symptomatic deep 
venous thrombosis patients with posit ive venograms 
(Gurewich, Hume and Pa tr ick , 1973). Seamen (1970) detected 
only two posit ive  tests  in 16 deep venous thrombosis patients 
while another study found one positive te s t  in  38 deep 
venous thrombosis patients.
A s ig n if ic a n t  incidence of pos it ive  tes ts  has also 
been found in pulmonary thromboembolism, in acute a r te r ia l  
thromboembolism, in  disseminated malignant disease, in  
renal disease (Gurewich and Hutchinson, 1971; Gurewich 
et a l . ,  1973; Palester-Chlebowczyk, Strzyzewska,
Sitkowski et a l . ,  1971) and in systemic hypertension
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(Zola-Sleczek and Szczepaniec, 1974). In contrast another 
study only found one pos it ive  tes t out of 305 samples 
tested. This was a case of DIG but 15 other s im ila r  
cases gave negative tests  (Hedner and Nilsson, 1972).
I t  is  probable tha t variables such as incubation 
time, f ibrinogen le v e l,  anticoagulant used to co l le c t  the 
blood sample and brand of protamine sulphate are important 
in th is  technique.
Ethanol ge lation te s t
The ethanol ge lation tes t is reportedly insens it ive  
to early  f i b r in  degradation products (Gurewich, 1973;
Breen and T u l l is ,  1968) and is  said to respond p r im arily  
to soluble f i b r in  (Godal and Abildgaard, 1966; Breen and 
T u l l i s ,  1968). I t  appears to be less sensitive  than the 
protamine sulphate te s t in p re c ip ita t in g  f i b r in  
(Yudelman, Spanondis and Nossel, 1974).
G onfl ic t ing  resu lts  have also been obtained by the 
use of the ethanol gelation te s t in c l in ic a l  studies.
In one study, only 11.4% of a large number of unselected 
patients with malignant disease, pneumonia, pulmonary 
embolism, a r te r ia l  and venous thrombosis showed a pos it ive  
te s t  (K ie ru l f  and Godal, 1971). In another study o f an 
unselected group of patients with s im ila r  c l in ic a l  
diseases, 10% pos it ive  tes ts  were found, but only f ive  
out o f 17 patients with DIG had positive  te s ts .
Thus th is  is  unre liab le  and is  not recommended fo r  
c l in ic a l  use.
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2 . exclusion chromatography
In addition to d i f fe re n t ia l  p re c ip ita t io n ,  gel sieving 
methods may be used fo r  the id e n t i f ic a t io n  o f macromolecular 
complexes of f ibr inogen in c ircu la t in g  blood. Agarose gel 
chromatography was applied to the id e n t i f ic a t io n  of 
complexes of higher molecular weight than native fibrinogen 
formed in v i t r o  {Sasaki, Page and Shainoff, 1966), then to 
c l in ic a l  studies (F letcher, A lk jaers ig , O'Brien et a l . ,  1970). 
The technique used by Fletcher et a l . ,  1970, employs re la t iv e ly  
short (15-30 cm) Biogel A-5M columns; e lu t ion  conditions 
are ca re fu l ly  con tro l le d , and the fibrinogen in eluates is  
determined immunologically by an automated system. The 
proportion of f ib r inogen-re la ted antigen e lu t ing  before and 
a f te r  a fibrinogen standard is  analysed using a computer 
programme. Use of longer gel columns increased the time 
required fo r  analysis but provides subs tan tia l ly  greater 
reso lu tion  (Vermylen, Donati and Verstraete, 1971;
Donati, Verhaeghe, Culasso et a l . ,  1976; McKillop,
Edgar, Forbes et a l . ,  1975).
In studies related to the detection of deep venous 
thrombosis (DVT) the chromatographic method gave 41 
abnormal resu lts  out of 72 patients. In 22 of these 
abnormal pa tients , f ibrinogen scans were normal. In 
15 of the patients abnormal results  were present pre- 
op e rta t ive ly . In another study 12 out of 38 patients showed 
abnormal chromatography resu lts  which were v e r i f ie d  by veno­
graphy (Bang and Chang, 1974). Abnormal resu lts  have been
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reported in women taking oral contraceptives and in some 
normal control women (A lk jae rs ig , Fletcher and Burstein,
1975). Another study reported increased complexes in normal 
pregnant women and highly elevated levels in  women with 
pre-eclampsia (McKillop, Howie, Forbes et a l . ,  1976).
Increased soluble complexes have also been reported in  
cerebral vascular accidents (A lk jae rs ig , Laursen and 
Fletcher, 1972), in  myocardial in fa rc t io n  (F letcher and 
A lk ja e rs ig , 1973), acute glomerulonephritis (F letcher and 
A lk jae rs ig , 1973), type I I  hyperlipoproteinaemia 
(Carvalho et a l . ,  1974) and DIC (Kazama and Abe, 1976).
A c r i t i c a l  problem with the chromatographic analysis 
in  c l in ic a l  samples has been s p e c i f ic i t y ,  since the 
complexes are l i k e ly  to represent products of in ta c t  and 
plasmin degraded f ib r in ,  fibrinogen and other proteins 
(Mosher, 1975). In v i t ro  data suggests tha t fragment X 
derived from f i b r in  polymerises to form soluble macro­
molecular complexes. In add it ion , components of early  
p lasm in -f ib r in  digest mixtures copolymerise with fibrinogen 
in the absence of thrombin to y ie ld  soluble complexes.
These early  f i b r in  digests also copolymerise with f i b r in .
Such copolymerisation also occurs in vivo (Chang and Bang, 1977). 
£ .  A f f in i t y  chromatography methods
Stab ilised insoluble fibrinogen derivatives of human 
f ibr inogen were prepared by immobilisation of the protein 
onto CNBr-activated Sepharose 6 B by Matthias and co-workers, 1977 
When thrombin-treated plasma is  passed through columns 
containing immobilised fibr inogen, the f ib r in  was absorbed
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and could be eluted with buffers containing IM NaCl or 
2M Na Br. Plasma samples from a patient with DIC gave 
s im ila r  resu lts  (Matthias, Reinicke and Heene, 1977).
However, in view of the studies by Chang and Bang (1977) 
on complex formation between early f i b r in  degradation 
products and f ib r inogen , i t  is  un like ly  tha t the a f f i n i t y  
method can d is tingu ish  between soluble f ib r in  and early 
p lasm in-f ib r in  digestion product complexes in  plasma samples.
Although the gel exclusion chromatography method is  
re la t iv e ly  spec if ic  in the detection of soluble f i b r i n -  
f ib r inogen complexes when compared to the protamine 
sulphate and ethanol gelation tes ts  i t  is rather time 
consuming as is  the a f f in i t y  chromatography of f ib r inogen.
The gel exclusion and a f f in i t y  chromatography 
methods cannot be spec if ic  e ith e r fo r  thrombin or fo r  
plasmin action in  vivo and may actua lly  re f le c t  the 
action of e i th e r or both of these enzymes.
£ .£ . Fibrinopeptide £
£._3._1. In troduction
Thrombin action on fibrinogen results in cleavage of 
a rg iny l-g lyc ine  bonds to release two molecules of 
f ib r inopep tide  A (FPA) from the NH^ -terminal segment of 
the Aa chain and two molecules of f ib r inopep tide  B (FPB) 
from the NH^  - terminal segment of the B chain (see 
Chapter 1, 3 .2 .c ) .  Thrombin susceptible bonds are not 
cleaved by plasmin (Blomback, 1967), thus measurements 
of the fib r inopeptides should d istingu ish the action of 
thrombin from plasmin. Since thrombin cleaves the A 
peptide before the B peptide (Blomback, 1967) e f fo r ts
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have been focussed on the measurement of FPA as an index 
of thrombin generation.
Iso la t ion  and characterisation of FPA
The release of f ib r inopep tide  A and B a f te r  thrombin 
cleavage of f ibr inogen was f i r s t  reported over 20  years 
ago (Bettelheim and Bailey, 1952) and subsequently 
confirmed by other workers (Blomback and Vestermark, 1958; 
Blomback, 1958; Nossel et a l . ,  1974).
The most frequently used method fo r  iso la t in g  the 
f ib r inopep tide  has been cation-exchange chromatography 
of f i b r in  c lo t  supertnatant (Blomback and Vestermark,
1958; Blomback, Blomback, Edman et a l . ,  1966). Modifications 
o f th is  method have been described (Murtaugh and Gladner, 1974).
Fibrinopeptide A is  composed of 16 amino acids with 
a molecular weight of 1535 (see Figure 4 .1 . ) .  Because of 
t h e i r  small size solid-phase peptide synthesis has become 
an important a lte rna tive  method fo r  th e i r  preparation 
(Erickson and M e rr i f ie ld ,  1976). This method is  of 
p a r t ic u la r  importance fo r  immunologic and physiologic 
studies in which re la t iv e ly  large quantit ies of f ib r in o -  
peptides are required as tyrosyl analogs of f ib r in o ­
peptides are needed tha t may be conveniently rad io­
labe lled . Synthesis of human fibrinopeptides A and B 
have been carried out by several workers (Blomback,
Blomback, Olsson et a l . ,  1969; Johnson and May, 1969;
Budzynski and Marder, 1973; Wilner, Nossel, Canfield 
et a l . ,  1976). Canine fib r inopeptide  A, i t s  amino 
tyrosyl analog (Wilner and Birken, 1975) and guinea pig 
f ib r inopep tide  A (Wilner, 1980) have also been
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Fibrinopeptide A 
1
H,N -  Ala -  Asp -  Ser -  Gly -  Glu -  Gly
7
Asp-Phe-Leu-Ala -G lu  -  Gly -  Gly -  Gly 
15
Val -Arg
Fibrinopeptide B 
1
Pyr -G ly-V a l -  Asn -Asp - Asn -  Glu 
8 10
Glu —Gly “ Phe~Phe -S e t — Ala — Arg
Figure 4.1
Amino acid sequences of fibrinopeptides A and B
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synthesised. A synthetic analog of f ib r inopeptide  A,
N-benzoyl-L-phenyl-a lanyl-L-valy l-L-arg i ni ne -P -n itro - 
an il id e  hydrochloride appears to be useful as a 
chromogenic sub s tra te 'fo r  quantita ting  the amidolytic a c t iv i t y  
o f several enzymes {Svendsen, Blomback, Blomback et a l . ,  1972).
Variants of f ib r inopeptide  structure are normally 
present w ith in  ind iv idua ls  of certa in species. A 
m inority  of human A peptide molecules lack amino-terminal 
alanine (AY), and the serine residues in others are 
phosphorylated (AP)(Blomback et a l . ,  1966).
£.3_._3. jjn v i t r o  Release of FPA
In v i t ro  release of FPA occurs a f te r  seven minutes
in  a syringe containing non-anticoagulated blood (Nossel et a l . ,  
1974; Prowse, Vigano, Borsey et a l . ,  1980). S im ilar in v i t r o  
release was found in agitated blood at 37 C with ag ita t ion  
markedly accelerating the in v i t ro  release (Kaplan, D r i l l in g s  and 
Lesznik, 1981). As previously discussed, thrombin cleaves 
fibrinogen to release FPA and FPB sequentia lly . The generation 
o f thrombin on the p la te le t  surface has been suggested by 
several workers who demonstrated tha t FPA formation and 
a -granule prote in release followed s im ila r  time courses 
(Prowse et a l . ,  1980; Kaplan et a l . ,  1981). Such
resu lts  are in contrast to a previous report (Kaplan et a l . ,  1978)
which showed FPA release at thrombin concentrations at least one 
hundred fo ld  lower than those which caused BTG and PF , release.
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The e a r l ie r  resu lts  of Prowse et a l . ,  and Kaplan et a l . ,  
suggest tha t thrombin generated in the blood has equal 
access to plasma fibrinogen fo r  f i b r in  formation and to 
p la te le ts  fo r  induction of the release reaction in 
contrast to added thrombin which p re fe re n t ia l ly  cleaves 
fib r inogen. P la te le t release in the undisturbed system 
is  e n t i re ly  dependent on thrombin action since blocking 
thrombin action with h irudin completely prevents p la te le t  
release (Kaplan et a l . ,  1981).
Collagen markedly increased in  v i t ro  release of FPA, 
with p la te le t  release occurring e a r l ie r  than FPA release 
(Kaplan et a l . ,  1981). Such release by collagen may be 
as a resu lt  of collagen ac tiva tion  of the contact 
ac t iva t ion  system (Wilner et a l . ,  1968) and release of 
p la te le t  fa c to r  V by collagen (Chesney, P ife r  and Col man, 1978; 
V id e ,  Lages and Weiss, 1980) with resu lting  thrombin formation.
ADP does not release s ig n if ic a n t  amounts o f FPA 
in v i t r o  although i n i t i a l  rapid release of BTG and PF^  
does occur (Kaplan et a l . ,  1981), although cons is ten t ly  
small elevations of FPA release are present. This data 
supports the hypothesis tha t increased p la te le t  release 
contributes to increased thrombin formation although the 
increment contributed by p la te le t  release is  c le a r ly  small.
FPA in  v i t r o  release does not occur in the presence 
of prostaglandin E^(PGE^ ) and theophylline (Kaplan et a l . ,  1981) 
suggesting tha t the re la t iv e ly  small amount of FPA 
present in control samples is  unimportant in determining 
the ro le of thrombin generation.
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Some snake venoms release FPA in v i t r o .  Ancrod 
(A rv in ) , and Reptilase are p a r t ia l ly  pu r if ied  frac t ions  
containing coagulant enzymes which can be isolated from 
the crude venoms of the Malayan (Agkistrodon rhodostoma) 
and South American (Bothrops atrox) p i t  vipers respective ly 
(Esnouf and Tunnah, 1967 Klobusitzky and Konig, 1936).
Ancrod contains both a thrombin-like coagulant enzyme, 
which cleaves only FPA from fib r inogen, and a less 
spec if ic  protease f ra c t io n ,  capable of degrading FPA 
as well as other proteins in v i t r o  (Ewart, Hatton,
Basford et a l . ,  1979; Pizzo, Martin, Schwartz et a l . ,  1972). 
Unlike thrombin ancrod does not activate fa c to r  X I I I  
(Barlow, Holleman and Lorand, 1970). Reptilase also 
contains a throm bin-like coagulant enzyme which cleaves 
only FPA from fibr inogen in v i t r o .  Unlike ancrod, rep ti lase  
does activa te fa c to r  X I I I  (Pizzo, Martin, Schwartz et a l . ,  1972). 
i n  vivo release o f FPA 
Plasma FPA levels r ise  immediately in patients 
receiving in trau te r ine  in jec t io n  of hypertonic saline 
(Nossel, Wasser, Kaplan et a l . ,  1979) to terminate 
pregnancy and has been shown to be associated with in vivo 
coagulation ac tiva tion  as re flected by reduction in 
f ib r inogen , c lo t t in g  fac to r  leve ls , and p la te le t  counts, 
and by elevated FDP leve ls (Stander, Fleossa, Glueck et a l . ,  
1971; Weiss, Easterling, Odomn et a l . ,  1972; Schwartz, Greston 
and K le iner, 1972; Van Royen, Treffers and ten Cate, 1974).
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As discussed previously the FPA level rises gradually 
in blood co llected in a p la s t ic  syringe and added at regular 
in te rva ls  to tubes that contain anticoagulant. Whereas 
FPA generation increases non-linearly  when exogenous 
thrombin is  mixed with normal blood in the syringe, 
generation is  usually  l in e a r in c l in ic a l  samples, and the 
ra te can be calcu lated. Slow rates were found in normal 
blood and in blood from patients with venous thrombosis 
or a o r t ic  aneurysm and greatly  elevated FPA leve ls .
These resu lts  suggest tha t thrombin action might be 
predominantly loca lised in these conditions. Generation 
rates were four to  140 times fas te r  than normal in blood 
from patients infused with prothrombin-complex concentrates 
and in patients with DIC, acute pulmonary embolism, active 
systemic lupus erythematosis or renal transplant re je c t ion . 
These f ind ings suggest tha t thrombin a c t iv i t y  is  g rea tly  
increased in the peripheral blood of patients w ith such 
diseases (Nossel, T i ,  Kaplan et a l . ,  1976).
Acute inflammation increases the absorption of FPA 
from extravascular s i te s ,  but the peak FPA levels achieved 
fo llow ing intravenous in je c t io n  are s t i l l  13 times greater 
than the peak levels obtained fo llowing in je c t io n  of an 
equivalent dose of peptide in to  an acutely inflamed 
muscle. These f ind ings suggest tha t in travascu lar 
thrombin action is  fa r  more e ffe c t ive  in e levating plasma 
FPA leve ls than is  extravascular thrombin.
£ .£ .£ .  B io log ic A c t iv i ty  o f FPA
The princ ipa l function of FPA appears to be to mask a 
spec if ic  polymerisation s i te  w ith in  the E domain of the 
fib r inogen molecule (Blomback, Hessel, Hogg et a l . ,  1978).
T hA  A x a c t  loca tion of such a d o I vmerisation s i te  has not been
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completely resolved. The id e n t i f ic a t io n  of an Act 19 
Arg+Ser amino acid exchange in the mutated fibr inogen 
D e tro it  (Blomback, Blomback, Mammen et a l . ,  1968) associated 
with a polymerisation defect (see Chapter 4 .1 Blomback,
Hessel, Hogg et a l . ,  1978) and the study of the k ine tics  
of f ib r inopep tide  release from Aa chain fragments (Hogg and 
Blomback, 1978) have both demonstrated the importance of 
spec if ic  sequences in the N-terminal section of the Aa chain 
fo r  the in te rac tion  with thrombin and subsequent polymerisation,
The recent use of high performance l iq u id  chromatography 
(HPLC) analysis of f ib r inopeptide  release with subsequent 
amino acid analysis of the fib r inopeptides has id e n t i f ie d  
other amino acid exchanges in th is  region with resu ltan t 
polymerisation defects (see Table 4 .1 ).
Human FPA appears to cause po ten tia tion of bradykin in- 
induced smooth contraction (Bayley, Clements and Osbahr,
1967) and vasoconstric tion, presumably due to  the d irec t 
s t im u la tion of vascular smooth muscle c e l ls  (Osbahr, 1975).
Fibrinopeptides in re la t iv e ly  high concentrations are 
capable of com petitive ly in h ib i t in g  the reaction of thrombin 
and fibr inogen as observed by the prolongation of the 
re c a lc i f ic a t io n  time of human plasma fo llow ing addition of 
a mixture of FPA and FPB (Bettelheim, 1956). Studies 
with synthetic peptide analogues (Blomback et a l . ,  1969) 
demonstrated tha t the s i te  on FPA recognised by thrombin 
involves the carboxy-terminal arginine (arg) and a 
phenylalanine (phe) residue located eight residues 
from the amino-terminal. The spacing between Phe and
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Arg is  apparently c r i t i c a l  fo r  thrombin in h ib i to ry  
a c t iv i t y .  This FPA s ite  makes only a minor con tr ibu tion  
to  the s p e c i f ic i ty  of thrombin action on f ibr inogen.
The c r i t i c a l  thrombin recognition s i te  on human fibr inogen 
Aa chains appears to be located in the region Aa 17-51.
_4.3^.^. Metabolism and clearance o f FPA
A study on both the heparin induced reduction of 
plasma FPA in patients and the clearance of infused FPA 
from normal volunteers has determined a h a l f - l i f e  fo r  
removal o f FPA from the c ircu la t io n  of about three minutes 
(Nossel et a l . ,  1974). Because only about 1% of plasma 
FPA is  present in the urine (Tegger-Nilsson and Grondahl, 1974; 
A lk jaers ig  and F letcher, 1982), i t  has been suggested that the 
kidney may play a d irec t ro le  in the degradation of the peptide 
as i t  is  cleared from the c ircu la t io n  (Nossel, 1976).
A recent study examined the clearance of I
desaminotyrosyl human FPA from the ra t c irc u la t io n .  The
results  obtained in th is  study suggest tha t FPA clearance
from the c irc u la t io n  can be described by a biphasic
exponential curve. An i n i t i a l  rapid clearance had a
h a l f - l i f e  of less than 2 minutes and th is  was followed
by a slower component with a h a l f - l i f e  of approximately 
iK*one hour when I FPA was injected in to  control ra ts . 
B ila te ra l nephrectomy of the rats s ig n i f ic a n t ly  elevated 
the plasma concentration and also prolonged the slow 
component h a l f - l i f e  to  73 minutes. In ra ts with 
ureteral l ig a t io n  identica l clearance curves to the
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nephrectomised rats were obtained, strongly suggesting 
tha t the labelled peptide was being d ire c t ly  f i l t e r e d  at 
the glomerulus and excreted by the kidney. The fas t 
component was probably caused by eq u il ib ra t io n  o f the 
peptide throughout in tra  and extravascular spaces and 
the slow component re flected the action o f catabolic 
processes once e q u i l ib ra t io n  was obtained. Blood 
samples withdrawn from control or nephrectomised rats 
at the completion o f the experiments contained in ta c t  
FPA and a major degradation fragment demonstrable by 
gel f i l t r a t i o n  on GIO Sephadex. A s im ila r  degradation 
could be e l ic i te d  by in v i t r o  incubation o f 125i_pp/\ 
w ith fresh c it ra te d  blood. Urine also degraded 
125 i - fpA in v i t r o  or in  vivo to fragments, one o f which 
was o f s im ila r  molecular size to tha t produced in blood.
This suggests tha t degradation o f FPA occurs in plasma 
and urine rather than the kidney i t s e l f .
Immunochemistry o f FPA
Fibrinogen and fragments of the fibrinogen molecule 
containing FPA react to  variable degrees with anti-FPA 
anti sera, and thus require processing procedures fo r  
removal o f fibr inogen and FPA-containing fibrinogen 
fragments from plasma samples p r io r  to assay ( fo r  a more 
deta iled discussion see Chapter 5).
The immunoreactivity o f 14 anti sera to human FPA, 
prepared by immunising rabbits  with th is  peptide 
conjugated to albumin c a r r ie r  protein were studied (Canfie ld, 
Dean, Nossel et a l . ,  1966; Nossel, B u tle r, Wilner et a l . ,
1976). A ll  the anti sera tested showed comparable
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r e a c t iv i ty  to free human FPA in so lu tion but disparate 
re a c t iv i t ie s  were observed when fibrinogen and fibrinogen 
fragments containing FPA were tested. The anti sera 
could be divided in to  three groups: Group I could read ily  
d is t ingu ish  free f ib r inopep tide  A from fragments of 
fib r inogen containing the FPA sequence, whereas groups I I  
and I I I  could d is tingu ish  the free peptide from i t s  
parent molecule less well or not at a l l .  Group I 
antiserum could d is t ingu ish  free FPA (Act 1-16) from the 
smallest plasmin derived fragment (A 0 6 1-23) tha t might 
be present by an order o f one hundred fo ld  d iffe rence 
in  immunoreactivity (Canfield et a l . ,  1966). This 
suggests tha t in  the group I ,  but not in the groups I I  
and I I I  an tisera , antigenic determinants were hidden in the 
la rger FPA-containing fragments o f the fibrinogen molecule, 
suggesting tha t the immunoreactive s ites on the f ib r inopeptide  
molecule detectable by these groups of anti sera d i f f e r  as w e ll.
The re a c t iv i t ie s  of a Group I anti serum (R2) and a 
Group I I  anti serum (R33) were studied with synthetic 
COOH-terminal homologous o f human FPA. The antigenic 
determinants o f R2 anti serum s p e c i f ic i ty  resided w ith in  
the COOH-terminal ten residues o f the FPA molecule, and 
the Phe 8 , Asp 7 and Arg 16 contributed to  R2 immuno­
re a c t iv i ty .  The antigenic determinants required fo r  
R33 s p e c i f ic i t y  were c le a r ly  d i f fe re n t  and seemed to  
include residues in the more hydrophilic  NH^ terminal 
h a lf  of the FPA molecule as w e ll .  By the use of 
spec if ic  immunologic reagents and techniques, there fore , 
assays could be developed tha t are both sensitive  and
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spec if ic  and are c le a r ly  capable of d is tingu ish ing the 
products of thrombin proteolysis from those of plasmin 
proteo lys is  in c l in ic a l  blood samples 
Radioimmunoassay of FPA 
The development of radioimmunossays fo r  FPA has 
allowed more sensitive  measurements of the peptide to be 
carried out in  plasma (Nossel, Younger, Wilner et a l . ,  1971; 
Nossel et a l . ,  1974; Budzynski, Harder and Sherry, 1975; 
G e rr its ,  F l ie r  and van der Meer, 1974; Kockum, 1976;
Hofman and Straub, 1977). lodinated tracers can be 
prepared by the radio iod ination of desaminotyrosyl 
FPA with Iodine. The tyrosyl analogue of the 
f ib r inopep tide  is  used because a l l  mammalian FPA and 
certa in  FPB do not contain tyrosine in th e i r  primary 
s truc tu re . Nossel et a l . ,  1971, developed a method where 
they incubated anti serum and sample or standard overnight, 
radio labelled trace r was added fo r  one hour. Bound and 
free FPA were separated by the addition of charcoal, 
followed by cen tr i fug a tio n . The detection l im i t  o f the 
assay is  0.013 p moles. A commercial k i t  has now been 
developed according to th is  method. Normal values are 
around 1 pmole per ml.
FPA in c l in ic a l  disorders 
A. Deep venous thrombosis
Several studies have investigated f ib r inopeptide  A 
levels in patients with deep venous thrombosis (DVT). In 
one study FPA levels were measured in the plasma of 81 
patients with deep venous thrombosis with and without
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associated pulmonary embolism (Yudelman, Nossel, Kaplan 
et a l . ,  1978). Of 47 patients with pos it ive  venography 
and/or lung scan, 42 had elevated FPA levels >1.3 pmol/ml 
(mean 7.4) and f iv e  had levels <1.3 pmol/ml. Of 34 
patients with negative venography and/or lung scan, 29 had 
FPA levels of >1.3 pmol/ml and f iv e  had levels <1.3 pmol/ml.
In another study elevated levels of FPA were found in 
patients with DVT and in patients with pulmonary embolism 
(Peuscher, van Aken, F l ie r  et a l . ,  1980). The FPA level 
in  patients with DVT confined to the c a l f  veins was not 
elevated and was s ig n i f ic a n t ly  lower in  patients with 
proximal DVT.
A recent study assessed the pred ic tive values of 
FPA and BTG in patients suspected of having acute DVT or 
pulmonary embolism (PE). Raised FPA and BTG levels were 
found in patients in whom DVT or PE was confirmed when 
compared to patients in whom these disorders were excluded. 
Raised FPA and BTG concentrations were also found in 
patients with inflammatory disorders and malignancy.
Thus despite a s p e c i f ic i t y  of 96% in symptomatic patients 
suspected of having a DVT or PE, raised levels of FPA and 
BTG are not spec if ic  fo r  thrombosis.
The reduction in  FPA concentrations in venous thrombo­
embolism by the administration of heparin is  evidence tha t 
elevated leve ls are caused by in travascular thrombin action 
(Nossel et a l . ,  1976; Peuscher et a l . ,  1980; van H u ls te ijn ,  
B r ie t ,  Koch et a l . ,  1982; Yudelman and Greenberg, 1982). 
However FPA leve ls remained elevated during continuous
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treatment with heparin in patients with pulmonary in fa rc t io n ;  
and/or pleural exudate; bronchopneumonia (Peuscher et a l . ,  1980; 
van H u ls te ijn ,  Fibbe, Bertina et a l . ,  1982) or in patients with 
DVT or PE with concurrent sepsis or malignancy (Yudelman and 
Greenberg, 1982). This persistent elevation may be the resu lt of 
extravascular formation o f FPA which is not blocked by the action 
of heparin. Heparin has also been shown to reduce the elevation 
in  FPA a f te r  surgery (Torngren, Noren and Savidge, 1979).
S im ila r resu lts  were obtained a f te r  surgery in dogs 
(Meden-Britth and Radegran, 1980).
Myocardial in fa rc t io n
As discussed in  Chapter 1, Figure 1 (b ) ,  f i b r in  produced 
by the generation of thrombin, consolidates p la te le t  thrombi 
and hence thrombin generation is  suggested in the develop­
ment of atherosclerosis. Plasma concentrations of FPA 
have, the re fo re , been measured in several studies in 
patients with myocardial in fa rc t io n .
In one study, FPA levels were s ig n if ic a n t ly  increased 
in  29 patients admitted to hospital with myocardial 
in fa rc t io n .  The increase in  FPA was more pronounced in 
patients with proven myocardial in fa rc t io n  and corresponded 
to  the size of the in fa rc t io n  (Johnsson, Orinius and Paul, 1979).
In another study greatly  elevated levels of plasma FPA 
were reported in patients with acute myocardial in fa rc t io n  
as well as in spontaneous angina and e f fo r t  angina.
However, the reported mean values of FPA fo r  each group 
had large standard deviations suggesting tha t the elevated 
levels may be the resu lt of in v i t ro  release in blood
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sampling (Serneri et a l . ,  1981).
In a recent study elevated levels of FPA were reported 
in  patients admitted to hospital with a h is to ry  and/or 
c l in ic a l  symptoms of acute myocardial in fa rc t io n .  Within 
one week levels had returned to normal but th is  may be the 
resu lt of in h ib i t io n  of in travascu lar FPA formation by the 
use of anticoagulant therapy or the exhaustion of extra- 
vascular FPA generation in the in farc ted tissue  (van 
H u ls te ijn ,  K o l f f ,  B r ië t et a l . ,  1982,
£. Coronary a rte ry  disease
In a recent study plasma FPA levels were measured in 
patients in whom myocardial in fa rc t io n  had occurred more than 
six months previously and in patients with abnormal coronary 
arteriograms without previous myocardial in fa rc t io n .
FPA levels were normal in each group. PF^ and BTG were 
s ig n i f ic a n t ly  elevated in the group with a previous 
myocardial in fa rc t io n  (Nichols, Owen, Kaplan et a l . ,  1982). 
S im ilar resu lts  were reported in another study (van H u ls te ijn  
et a l . ,  1982c).
_D. Mai iqnancy
Elevated levels of plasma FPA were found pre-operative ly 
in  patients with malignancy (Torngren et a l . ,  1979).
In another study, 124 patients with various types of 
malignancy were studied. Elevated FPA leve ls were found in  
a l l  patients with one th i rd  also having an acceleratedaFPA 
Eight of the 45 patients with accelerated^FPA had signs o f 
low grade DIC. While^FPA normalised in patients given heparin, 
FPA leve ls did not decrease. The results  of th is  study
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indicated tha t 30% of the selected patients with malignancy 
had evidence of in travascu lar thrombin a c t iv i t y  and in  70% of 
these patients FPA is  generated, at least in part, at a s i te  
accessible to thrombin. Elevated FPA levels appeared 
to  be spec if ic  fo r  active metastatic disease as patients 
without metastasis had normal FPA levels (Peuscher,
Cleton, Armstrong et a l . ,  1980). In another study in 
patients with disseminated neoplasia, an intravenous heparin 
bolus lowered the FPA level in  11/11 cases, while continuous 
heparin treatment led to suppression or normalisation o f 
the FPA levels in 5/6 cases (Mombelli, Roux, Haeberli et a l . ,  
1982). The slow or incomplete decrease in FPA observed 
in  some cases supports the find ings of Peuscher et a l . ,  1980. 
Elevated plasma leve ls o f FPA have also been reported in  
another study on malignant disease (Yoda and Abe, 1981).
Several studies have reported increased FPA leve ls 
e ith e r  pre, during or a f te r  surgery (Torngren et a l . ,  1979; 
Davies, Sobel and Salzman, 1980; Lane, Ire land, Wolff 
et a l . ,  1982; Owen, Kvam, Nossel et a l . ,  1983). An 
experimental study in  dogs has suggested tha t th is  
operative increase is  caused by tissue damage during the 
operation and th a t FPA concentrations normalise w ith in  24 
hours (Meden-Britth and Radegran, 1980).
Increased plasma levels o f FPA have also been reported 
in  acute leukaemia (Myers, Pickles, Barb et a l . ,  1981); 
l i v e r  c ir rh o s is  (Coccheri, Mannucci, Palareti et a l . ,  1982) 
and in major bacteria l in fections (van H u ls te ijn  et a l . ,  1982).
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Normal levels of FPA have been reported in type I I  
hyperlipoprotelnaemia (Nossel, Smith, Seplowitz et a l . ,  
1979; K i l ln e r  and Lees, 1981) and in m ye lopro life ra tive  
disorders (Ire land et a l . ,  1982). 
ây® 15-42 Peptide 
Introduction 
Following the i n i t i a l  release of FPA and f i b r in  
monomer formation, fu r th e r thrombin action releases 
f ib r inopep tide  B (FPB; By6  1 £PyrJ - 14 [A rg J  ) by 
cleaving B ^  14 Arg-15 Gly (Blomback et a l . ,  1978; 
B i le z ik ia n , Nossel, Butler et a l . ,  1975). A lte rn a t ive ly  
fo llowing the i n i t i a l  release of FPA i f  plasmin intervenes 
before fu r th e r  thrombin action the B ^  1 [J y 0  - 42 QArgJ 
(B^21-42) fragment is  released from fibrinogen and the 
B^15 £G lyJ -42 [ArgJ (B 15-42) fragment is  released 
from f i b r i n ,  cleavage at B jg42 j [A rg ^ -43 /Â laJ producing 
'X - l ik e '  fragments (see Figure 2 .1 ). These, i t  has 
been suggested can be read ily  removed from the c irc u la t io n  
by the f ib r in o ly t i c  system. Plasmin can be seen to 
act in a regula tory ro le ,  co n tro l l in g  the amount o f 
pathological f i b r in  tha t is  formed. Limited thrombin 
action can, therefore , take place in the c i rc u la t io n ,  
increasing the concentration of FPA and soluble f i b r in ,  
without there being f ib r in  deposition.
Unfortunately the d irec t assay fo r  FPB has been 
d i f f i c u l t  in c l in ic a l  s itua t ions . To date, two causes 
fo r  the d i f f i c u l t y  in spec if ic  FPB quantita tion  have 
been id e n t i f ie d .  F i r s t ,  la rger FPB containing peptides
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(eg B^  1-42) cross-react with anti FPB serum, thereby 
con tr ibu ting  to  immunoreactive plasma FPB concentrations 
(Nossel et a l . ,  1979). Second, i t  has been established 
tha t carboxypeptidase-B in human plasma cleaves the 
COOH-terminal arginine from FPB in v i t r o ,  the resu lt ing  
Bj8 l  [ P y r J  - 13 fA laJ peptide, desarginyl-FPB, shows 
markedly decreased a c t iv i t y  with some anti-FPB sera 
(La Gamma and Nossel, 1978), and hence, immunoreactive 
plasma FPB concentrations may be lowered by carboxy- 
peptidase-B in vivo and during the plasma processing procedcure. 
Recently a study which investigated the immunologic 
s p e c i f ic i t ie s  o f seven anti-FPB sera showed tha t certa in 
antisera d iscrim inate between the c ro ss -re a c t iv i t ie s  of 
large peptide fragments containing the FPB sequence 
(eg f ib r inogen, the NH  ^ -terminal disulphide.knot o f fibrinogen 
(N-DSK) and BjSl [P y rJ  -118 fWetJ ) and smaller fragments 
containing the FPB sequence (eg BjSl-42 and desarginyl-FPB).
An assay spec if ic  fo r  B^31-42 is  not available 
however the slope o f the in h ib i t io n  curve fo r  Bjgl-42 
with the FPB anti serum is d i f fe re n t  from tha t o f FPB and 
the immunoreactivity o f B ^ 1-42 increases te n -fo ld  or 
more a f te r  treatment with thrombin, whereas tha t o f FPB 
is  unaltered. Hence B ^ l-4 2  can be distinguished from 
FPB by an increase in  FPB immunoreactivity on treatment 
w ith thrombin (TIFPB). In v i t r o  generation o f Byôl-42 
occurs a f te r  treatment o f plasma with streptokinase 
and is  much more rapid in rep ti lase  treated plasma in 
which f i b r in  I ra ther than fibrinogen is  the substrate
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(Nossel et a l . ,  1979bî?. This increase in B^1 -42  has 
also been demonstrated in  vivo a f te r  streptokinase 
in fus ion  in  healthy volunteers (Prowse, Dawes, Lane 
et a l . ,  1982). Increases in  B jgl-42 have also been 
observed to occur in  vivo a few days a f te r  surgery 
(Lane et a l . ,  1982a; Owen et a l . ,  1983).
A problem associated w ith TIFPB immunoreactivity is  tha t i t  
probably includes the measurement o f B jg l - 2 1  along with B^ g 1-42 
as B ^ 1-21 also shows a marked increase in Immunoreactivity 
a f te r  treatment with thrombin (Nossel et a l . ,  1979b).
Radioimmunoassays have also been developed fo r  the 
la te  plasmin cleavage products, fragment D and E (Gordon,
Martin , Landon et a l . ,  1975). Unfortunately, these 
methods have not yet been vigorously applied to the 
quan tita t ion  of deriva tives in c l in ic a l  plasma samples, 
la rge ly  because of the problems of production of 
s u f f ic ie n t  quantit ies  of h ighly spec if ic  antisera.
Serum fragment E concentrations have been reported to be 
elevated in patients with DVT (Gordon, Cooke, Bowcock et a l . ,  
1977; Zi el insky, Hirsh, Straumanis et a l . ,  1982) and in  
patients with acute pa rt ia l stroke (De Boer et a l . ,  1982).
Butt et a l . ,  1982).
Recently a new radioimmunoassay has been described 
fo r  the detection of fragments containing the B|8l5-42 
sequence (Kudryk, Robinson, Netre et a l . ,  1982). Since 
th is  peptide sequence is  part of a BjS-chain fragment 
released during the e a r l ie s t  stage of plasmin p ro teo lys is .
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th is  assay should be of value in c l in ic a l  investigations 
on a l l  disease states associated with fibrino(geno) ly s is .
Iso la t ion  and characterisation o f Byg 15-42 
Batroxobin d igestion o f N-DSK (Aocl-51, B ^  1-118, 
y  1-78) derived from fibrinogen allows the p a rt ia l 
release o f the B^31-42 peptide. The la t t e r ,  a f te r  
p a rt ia l p u r i f ic a t io n ,  can be fu r th e r digested with 
thrombin. This resu lts  in the cleavage of the 8^14 Arg- 
15 Gly bond, and y ie lds  B ^15-42 and free FPB. Separation 
o f B ^ 15-42 is  achieved by fra c t iona tion  on Sephadex G50 and GIO 
B ^ 15-42 is  composed o f 28 amino acids with a molecular 
weight o f 3040 (see f igu re  4 .2 ) .  Since ByS 15-42 contains 
a tyros ine  residue at posit ion B ^  41, i t  can be d i re c t ly  
labe lled with Iodine.
± • ± • 3 ,  Immunoreactivity o f ^  ^  15-42 anti serum
Pure fibrinogen cross-reacts with B p  15-42 antisera, 
a s im ila r  c ro ss -re a c t iv i ty  is  observed in plasma. FPB, 
fragments D and E do not show any c ro ss -re a c t iv i ty  with 
B j 3  15-42 antiserum. B 15-42 and B 1-42 react with 
near id e n t i ty  in the assay system (Kudryk et a l . ,  1982). 
j . .£ .£ . Metabolism and clearance o f ^ ^  15-42
The in v i t r o  s t a b i l i t y  of B yS 15-42 standard was 
measured in serum at 4°C and at 37°C. The h a l f - l i f e  at 
4°C was found to  be 18-20 hours. At 37^C the h a lf -  
l i f e  was 30 minutes. The addition of 1,10 phenanthroline 
prevented decay o f B yô 15-42 at both 4 °C  and 37^0 
(Kudryk et a l . ,  1982).
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B ^ 15 -42 Peptide 
15 20
Gly -  His-A rg -Pro-Leu -  Asp -  Lys -  Lys -  Arg-Glu 
25 30
Gly -  Ala -  Pro- Ser -  Leu -  Arg - Pro -Ala -  Pro -  Pro
35 40
Pro - 1 le -  Ser -  Gly -  Gly -  Gly -Tyr -  Arg
Figure 4.2 
Amino acid sequence of ByS 15-42 peptide
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The clearance o f 125 i b jS 15-42 has been examined in 
the ra t c i rc u la t io n .  The B yS 15-42 clearance from the ra t 
c irc u la t io n  is  s im ila r  to tha t o f FPA. An i n i t i a l  rapid 
clearance had a h a l f - l i f e  o f less than two minutes and 
th is  was followed by a slower component with a h a l f - l i f e  
o f 228 minutes when 125j g ^  15-42 was in jected in to  
control ra ts . B i la te ra l nephrectomy prolonged the slow 
component to  420 seconds and s ig n if ic a n t ly  elevated the 
plasma concentration. In contrast to FPA, the clearance 
o f 125i B yS 15-42 in  ra ts with ureteral l ig a t io n  was 
s ta t i s t i c a l l y  ind is tingu ishab le  from that o f the control 
group. These resu lts  strongly suggest tha t 125% B ^  15-42 
was being catabolised by the kidney (Lane, Marwick and 
Thomson, 1982).
Radioimmunoassay of, 3 ^  15-42 
Recently a sensitive  radioimmunoassay has been 
described fo r  the measurement o f fragments containing the 
ByS15-42 sequence derived from f ib r in (ogen) in  c l in ic a l  
blood samples (Kudryk et a l . ,  1982). lodinated tracers 
were prepared by the rad io iod ination  o f B ^  15-42 with 
125iodine. In the assay, plasma samples were treated 
w ith  ethanol in order to  p rec ip ita te  fib r inogen, which 
otherwise would cross-react w ith the anti serum. The 
supernatant or standard in appropriate d i lu t io n s  was 
incubated with anti-B yS 15-42 serum and a constant amount 
o f 125% By6  15-42 overnight. The antigen-antibody 
complex was then absorbed onto rabb it inso lu b il ised  a n t i ­
rabb it IgG. The la t t e r  complex was spun down and i t s
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ra d io a c t iv i ty  determined,the detection l im i t  fo r  the assay 
is  0.008 p mole. Normal values were less than 3 p mole 
per ml. A radioimmunoassay k i t  has now been developed 
fo r  th is  assay.
4 .4 .6 . B #15-42 in c l in ic a l  conditions
Plasma levels o f BjS15-42 have been reported to  be 
s ig n if ic a n t ly  higher in uraemic patients undergoing 
haemodialysis (Kudryk et a l . ,  1982). This increase was 
suggested to occur as a resu lt  of decreased heparin 
concentrations in the blood. However, an a lte rna t ive  
explanation o f these resu lts  has been suggested: the
elevated leve ls of ByBl5-42 are, at least in pa rt,  the 
re su lt  of impaired renal catabolism (Sherman, 1982) as 
shown in the ra t c irc u la t io n  model (Lane et a l . ,  1982b).
In conclusion, while i t  has been shown that 
increased levels o f FPA are not spec if ic  fo r  thrombosis, 
measurements o f FPA and B ^  15-42 are o f great 
importance in  determining the in vivo action of thrombin 
and plasmin on fib r in (ogen) in the pre-thrombotic, 
thrombotic and post-thrombotic s i tu a t io n , as well as in 
non-thrombotic c l in ic a l  conditions. The measurement 
o f plasma levels o f FPA and B ^  15-42 should, therefore , 
provide fu r th e r  ins igh t in to  the molecular mechanisms 
involved in in travascular f i b r in  deposition.
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CHAPTER V 
MATERIALS and METHODS
Introduction
In th is  chapter the application o f the technique of 
radioimmunoassay as a measurement of the p la te le t  release 
reaction and thrombin and plasmin generation w i l l  be 
discussed. Radioimmunoassay w i l l ,  therefore, be 
discussed f i r s t  and then i t s  application to the measurement 
o f BTG, FPA and Bjgl5-42.
S . 2 .  Radioimmunoassay - H is to r ica l and Theoretical Aspects
The in troduction o f radibimmunoassay occurred two 
decades ago (Ya low and Berson, 1960). Radioimmunoassays 
have allowed a greater s e n s i t iv i t y ,  s p e c i f ic i t y ,  ease of 
performance and smaller sampling volumes than previously 
used b io log ica l assays.
The basic p r in c ip le  o f a radioimmunoassay is  
i l lu s t ra te d  in f igu re  5.1. I f  a given amount o f antigen 
and antibody are allowed to  react together, then at 
equ il ib rium  they w i l l  form an antigen-antibody complex 
(the overlapping area B) together with a proportion of 
both the antibody and the antigen (F) which remain free.
Figure 5.1. shows binding o f antigen to antibody in  the 
presence o f d i f fe re n t  to ta l masses o f antigen. The
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Antibody
+
Antigen
Antibody
+
Antigen
Figure 5,1
The basic principle of a binding assay, 
using immunoassay as an example. In a 
radioimmunoassay radiolabelled and 
unlabelled antigen compete for a fixed 
number of sites on the antibody, the 
higher the concentration of unlabelled 
antigen the lower the amount of radio­
labelled antigen bound.
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d is t r ib u t io n  o f the antigen between the bound and free 
phases is  d i re c t ly  re lated to  the to ta l amount o f antigen 
present and thus provides a means fo r  quantita ting  the 
1 a t te r .
The amount o f antibody used in a radioimmunoassay is  
determined from the antibody d i lu t io n  curve. This 
involves the incubation o f a f ixed amount o f rad io labelled 
antigen ( tracer) w ith d i f fe re n t  concentrations o f the 
an ti serum. A fte r  the appropriate incubation and separation 
o f free and bound f ra c t io n s , an antiserum d i lu t io n  curve is 
obtained by p lo t t in g  the percentage o f tracer bound against 
d i lu t io n  o f the antiserum (see Figures 5.5 and 5 .9 ). The 
concentration o f antiserum chosen fo r  use in a radioimmuno­
assay is  usually tha t which is  s u f f ic ie n t  to bind approxim­
a te ly  50% o f the trace r.
A standard curve is  then obtained by the incubation 
o f the predetermined amount of anti serum and radio­
labe lled tra ce r with d i f fe re n t  known concentrations of 
p u r i f ie d  unlabelled antigen. Labelled and unlabelled 
antigen compete fo r a fixed number o f binding s ites  on 
the antibody: the higher the concentration of unlabelled
antigen the lower the percentage o f tracer bound (see 
Figures 5.6 and 5.10). When a sample is  substituted fo r  a 
standard, the value obtained fo r  the percentage bound is 
simply extrapolated by reading down from the curve to  the 
the horizontal axis.
^._3• Radioimmunoassay o f BTG
The radioimmunoassay method depends on competition 
between BTG and 125 i- la b e l le d  BTG fo r  a l im ited  number
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o f binding s ites  on a BTG spec if ic  antibody. The amount 
o f 125 I - la b e l le d  BTG bound by the antibody w i l l  be 
Inversely proportional to the concentration of unlabelled 
BTG present in p la te le t-poo r plasma samples. The 
antibody-bound 12^ I - la b e l le d  BTG is  separated by a 
p re c ip ita t io n  technique. A fte r  cen tr i fug a t io n , the 
p rec ip ita ted  ra d io a c t iv i ty  is  measured in a gamma counter.
By measuring the proportion o f 125 i_ iabelled BTG bound in 
the presence o f a se r ie s 'o f  BTG standards the concentration of 
BTG in  unknown samples can be in terpo lated from a standard curve. 
Method o f Ludlam's Group
With the iso la t io n  o f BTG and production of an a n t i ­
serum in a rabb it (Moore, Pepper and Cash, 1975a), a radio­
immunoassay was developed using these reagents (Ludlam, Moore, 
Bolton et a l . ,  1975). BTG was radio labelled with 125% by 
the chloramine T method (Hunter and Greenwood, 1962). The 
antiserum was used at a f in a l  concentration (1:50,000) which 
bound approximately 60% of the tracer ( f in a l  concentration 
o f 1 ng m l). Anti serum, sample (or standard BTG) and 
tra ce r were incubated at 4 °  C fo r  three days before antibody 
bound BTG was separated from the free antigen by a double 
antibody method. The p rec ip ita te  containing the bound 
antigen was counted fo r  125; -jp g gamma counter. The 
working range o f the radioimmunoassay as described was 
2.5-150 ng/ml o f plasma. However, by incubating the 
sample (or standard) fo r  three days with antiserum at a 
f in a l  concentration o f 1:300,000 p r io r  to the addition 
o f tracer ( f in a l  concentration 100  pg/ml) and then
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incubating fo r  a fu r th e r three days before separation of 
antibody bound pro te in , the detection l im i t  could be 
decreased to 500 pg/ml o f plasma.
_ 5 Modi f i cat i ons by other workers 
(A) Bolton, Ludlam, Moore et a l . ,  1976
This group described three d if fe re n t  radioimmunoassays 
fo r  BTG:
Standard radioimmunoassay
This modified the method o f Ludlam et a l . ,  1975 from 
s ix  days to two days. Anti serum, sample and tra ce r were 
incubated at 4 °  C fo r  24 hours. Antibody bound was 
separated from free 125] g-j-Q as fo llows: a f te r  the 
addition o f non-immune rabbit serum (to act as c a r r ie r  fo r  
the p rec ip ita te  of anti-BTG anti serum) and donkey a n t i ­
rabb it serum the tubes were incubated fo r  18 hours at 
4®C and the p rec ip ita te  containing the antibody bound BTG 
fra c t io n  collected by cen tr ifuga tion  at 1700 g fo r  45 
minutes. The 125% -jn the p rec ip ita te  was measured in a 
gamma counter. The detection l im i t  fo r  th is  assay was 500 pg/ml. 
Sensitive radioimmunoassay
To increase the s e n s i t iv i ty  fu r th e r ,  a tra ce r 
concentration o f 20 0  pg/ml was used with a correspondingly 
greater d i lu t io n  of anti sera to  bind about 50% o f the 
tra ce r.  Tracer was added a f te r  samples had been incubated 
with anti serum fo r  24 hours at 4^0 as th is  has been shown to 
improve the s e n s i t iv i ty  o f the radioimmunoassay (Hales and
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Randle, 1963). A fte r  a fu r th e r 24 hours, antibody-bound 
1 2 5 1 BTG was separated from free BTG as before.
The s e n s i t iv i t y  o f th is  assay was 40 pg/ml.
Rapid radioimmunoassay method
This modified method used antiserum covalently 
coupled to Sepharose-4B by the method o f Cuatmcasas (1 9 7 0 ) .  
Plasma samples or standards were d ilu ted  in bu ffe r and 
125i BTG was added. A suspension of solid-coupled a n t i ­
serum, d ilu ted  to bind about 50% o f  the tracer was added.
The tubes were mixed gently fo r  one hour at room 
temperature, and the antibody bound separated from the 
free 125[  BTG by cen tr ifuga tion  (1700 g fo r  ten minutes 
at room temperature) a f te r  the addition of d iluen t 
containing 15 Tween 80 as a wash. A fte r discarding the 
supernatants, the residues were washed with fu r th e r 
d i lue n t and fo llow ing cen tr i fug a tio n , the I in  the 
residue was counted. The s e n s i t iv i ty  o f th is  assay was 
500 pg/ml.
(1) Kaplan, Nossel , D r i l l in g s  et a l . ,  1978
In th is  modified assay 125i BTG trace r was used at a 
d i lu t io n  which gives about 1 0 ,0 0 0  counts per minute (cpm) 
per tube ( ie  19 pg BTG). Antiserum was used at a d i lu t io n  
o f 1:160,000 to  1:320,000. These concentrations bound 
0-50% of the tra ce r.  A fte r adding sample or standards, 
the assays were incubated overnight at 4^0, then antibody 
bound separated from the free BTG by the addition of
0.5 ml cold saturated (NH^)2 S0 ^ at 40C. Tubes were 
centrifuged fo r  15 minutes at 3000g at 4^0. The ^25 j
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in the p re c ip ita te  was counted in a gamma counter. The 
s e n s i t iv i t y  o f th is  assay was 14 pg ml 
(£) Han, B u t t , Turpie et a l . ,  1980 
(j_) Routine assay
In th is  assay BTG anti serum was d ilu ted  with bu ffe r 
(1:300,000) to  bind 50% of tracer and incubated with sample 
or standard at 4°C fo r  24 hours. Antibody bound and free 
125% BTG was separated by the addition o f goat a n t i ­
rabb it IgG and polyethylene glycol (PEG). A fte r  mixing the
tubes were l e f t  at room temperature fo r  f iv e  minutes, 
centrifuged at 1500 g fo r  20 minutes. The 125% the 
p re c ip ita te  was counted in a gamma counter. The s e n s i t iv i ty  
■of th is  assay was 4 ng/ml.
( i i ) One hour non-equilibrium assay 
In th is  assay BTG antiserum was d i lu ted  (1: 50,000) 
to  bind 50% o f tra ce r .  Incubation of antiserum, tracer 
and sample or standard was carried out at room temperature 
fo r  one hour. Separation of antibody bound and free BTG 
was as described in the routine assay.
^.3^.^. Method fo r  radioimmunoassay o f BTG used in th is  thesis 
(A) Preparation of patient piasma 
Blood samples were collected by a flawless clean 
venepuncture without trauma. Immediately a f te r  insertion  
o f the needle, the tourniquet was released and 2.7 ml o f 
blood was collected through a 21G Abbott b u t te r f ly  in a 
s te r i le  3 ml p la s t ic  syringe and immediately transferred 
in to  a precooled polystyrene tube containing EDTA and 
theophyll ine as supplied in the BTG radioimmunoassay k i t
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supplied by the Radiochemical Centre (Amersham, England). 
The polystyrene tube was inverted three times and placed 
in  an ice-water s lu rry  at 4 °  C fo r  a minimum of 30 minutes 
and a maximum of 120 minutes before cen tr ifuga tion  at 
3000 g fo r  30 minutes. 0.5 ml of the middle layer of 
p la te le t  poor plasma was assayed e ith e r immediately or 
stored in p la s t ic  tubes at -70oC u n t i l  assayed.
(^) Radioimmunoassay o f BTG
This assay was carried out using a commercial k i t  
supplied by the Radiochemical Centre. The k i t  contained:
1 v ia l containing up to 2 pCi 1 2 5 1 BTG, freeze-dried. 
5 reference standards o f human BTG in  bu ffe r ,  
nominally 10,20,50,100 and 225 ng/ml , freeze-dried. 
1 v ia l ammonium sulphate so lu tion.
24 sampling tubes containing EDTA and theophyll ine . 
Method
1. Immediately before u s e , 125 %  ^ anti-BTG serum and the 
reference standards were dissolved in d is t i l l e d  water.
2. 50 ul a liquots o f the standards or p la te le t-poo r plasma
unknowns were pipetted in to  the assay tubes.
3 . 2 0 0  ul o f 125% BTG was then added.
4. 200 ul o f anti-BTG serum was aliquoted in to  the tubes.
5. A ll tubes were vortexed and incubated fo r  one hour at 
room temperature.
6 . 500 ul a liquots o f the ammonium sulphate so lu tion
were pipetted in to  a l l  tubes.
7. A ll tubes were vortexed and centrifuged immediately at 
1500 g fo r  ten minutes at room temperature.
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8 . The supernatant was decanted and the tubes were 
allowed to  drain in racks and excess l iq u id
removed from the rims of the tubes with paper t issues.
9. The 1 25i -jn the p rec ip ita te  was counted.
The tubes were then counted in a PRIAS programmable
gamma counter, programmed to calcu la te the percentage of 
tra ce r bound in the tubes containing the set o f standards. 
A standard curve was then printed out as shown in 
Figure 5.2. The percentage bound of tracer in  the 
unknown samples was compared to  th is  curve and the BTG
values read o f f  the horizontal axis.
_ 5 . _ 3 Methodological variables in the BTG assay 
(A) R eproducib il ity  and accuracy of the BTG assay
The re p ro d u c ib i l i ty  of the BTG assay was tested as
fo llows: in four d i f fe re n t  plasmas the BTG concentration
was measured on four occasions (mean BTG leve ls ranging 
from 10-40 ng/ml) ;  the mean in te r  assay c o e f f ic ie n t  of 
va r ia t ion  was 4.6%. The accuracy of the BTG assay was 
tested by examining four d i f fe re n t  plasmas four times 
w ith in  the same assay; the mean intra-assay co e f f ic ie n t  
o f variance was 5.4%.
(1) S ta b i l i t y  o f BTG in frozen plasma
BTG leve ls determined in plasma samples immediately
a f te r  venepuncture did not d i f f e r  from BTG levels stored 
up to f iv e  months at -7CPC (see Table 5 .1 ).
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Figure 5.2
A programmed "print-out” of a standard curve for the 
radioimmunoassay of BTG, calculated from the 
percentage bound ^^5j b tG. The percentage of the 
tracer bound (vertical axis) is progressively 
reduced with increasing concentrations of standard
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TABLE 5.1
REPRODUCIBILITY AND ACCURACY OF BTG, FPA M  MEASUREMENTS
INTRA 
ASSAY PRECISION
INTER 
ASSAY PRECISION
BTG
FPA
*CV%
CV%
Bjgl5-42 CV%
5.4
4.4 
9.7
4.6
3.2
10.2
*CV% = COEFFICIENT OF VARIATION
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TABLE 5.2.
STABILITY OF BTG IN FROZEN PLASMA
PLASMA BTG ( n£/ml)
PATIENT
GB
BEFORE
STORAGE
37
AFTER
STORAGE
39
STORAGE
TIME
(MONTHS)
1
CP 36 29
AT 53 47
AB 46 51
OS 39 44
MEAN 42.2 42
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(_Ç) E ffect o f antiocoagulant mixtures on BTG concentrations 
The tubes fo r  blood sampling in the Amersham radio­
immunoassay k i t  contain EDTA and theophylline in the 
anticoagulant. However, the o r ig ina l method (Ludlam et a l . ,  
1975) recommended the use of an anticoagulant mixture 
containing EDTA and two anti p la te le t  agents (theophylline 
and prostaglandin E PGEi)as th is  mixture has been shown 
to  reduce in  v i t r o  release of BTG (Ludlam and Cash, 1976) 
during plasma preparation. To te s t th is  hypothesis, 
blood samples were obtained with a single venepuncture 
from 33 healthy male and female subjects (mean age 27.9 +
1.3 (SEM) years, range 20-46 years) and equal volumes 
were immediately added to tubes containing e ith e r EDTA 
and theophylline or the "complete" mixture including PGE .^ 
Table 5.3 shows the results  obtained a f te r  the assay of BTG 
in  the samples. While the mean level obtained in samples 
collected without PGE, was higher than the mean level o f 
samples collected with PGE,, the d ifference was not 
s ta t is t i c a l l y  s ig n if ic a n t .  In order to minise in v i t r o  
release o f BTG during plasma processing 0.1 ml o f 1 ug/ml PGE^  
was normally added to  a l l  BTG tubes unless otherwise stated.
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TABLE 5 .3
BTG CONCENTRATIONS (n^/ml) l ü  HEALTHY SUBJECTS WITH TWO 
DIFFERENT ANTICOAGULANT MIXTURES (n = 23)
ANTICOAGULANT MEAN + SEM RANGE
MIXTURE
With PGE, 21.3 ± 2.3 10-51
Without PGE, 24.1 + 2.1 11-49
SIGNIFICANCE OF 
ANTICOAGULANT WITH
AND WITHOUT PGE^: p NS
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Effect o f physiological variables on the BTG assay 
(A) A£6 and Sex
Blood samples were obtained from volunteers who 
comprised hospital s ta f f ,  known to be healthy and on 
no drug treatment. These included two groups: a group of 
young volunteers, 47 females (mean age 23 ± 0.6 years, 
range 18-40 years) and 19 males (mean age 26.7 + 0.7 years, 
range 18-40 years); a group o f middle aged volunteers,
6 females (mean age 54.0 + 2.2 years, range 41-60 years) 
and 4 males (mean age 50.8 ± 3.3 years, range 45-60 years). 
Blood samples were also obtained from a group of e lde r ly  
contro ls who attended a Day Centre fo r the e lde r ly  in  the 
c i t y .  An attempt was made to select only those who were 
apparently pe rfec t ly  healthy and were not on drug treatment 
and did not have a past h is to ry  of a vascular event.
These included 20 females (mean age 74.6 + 2.2 years, range
61-91 years) and 15 males (mean age 77.1 + 1.9 years, range
62-89 years). The resu lts  obtained are shown in  Table 5.4.
In the female group there is  a s ta t is t i c a l l y
s ig n if ic a n t  increase in  BTG levels with age between the 
young age group compared to the middle aged and the 
e lde r ly  group. In the males, BTG shows an increase in  
the e lde r ly  group when compared to the young group but 
there appears to be a decrease in  BTG in the middle aged 
group possibly as a resu lt of the small sampling size.
Plasma BTG in the males is  higher than in the female 
groups, except in the middle aged group, a s ta t i s t i c a l l y  
s ig n if ic a n t  increase being shown between males and females 
in  the young age group. When a l l  the groups were 
examined together, a pos it ive  co rre la t ion  was found 
between age and BTG ( r  = 0.39, p <0.01).
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TABLE 5.4.
COMPARISON OF SEX AND AGE ON PLASMA BTG LEVELS (n£/ml) 
jN  VOLUNTEERS (MEAN + SEM)
*p < 0 .0 5 , **p<  0.001, NS (not s ig n if ic a n t)
FEMALES
Y0UNG(n=47) MIDDLE AGED(n=6) ELDERLY(n=20)
Age (years) 23.0 + 0.5 54.0 + 2.2 74.6 ±  2.2
BTG (ng/ml) 15.9 ± 1.2 20.5 + 1.4* 27.2 + 2.4**
MALES
Y0UNG(n=19) MIDDLE AGED(n=4) ELDERLY(n=15)
Age (years) 26.7 + 0.7 50.8 + 3.3 77.1 + 1.9
BTG (ng/ml) 25.4 + 2 .8** 16.5 + 4.3 28.3 + 4.4
SIGNIFICANCE OF
SEX DIFFERENCE: p < 0.001 NS NS
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{ B)  Acute smoking
The e ffe c t of acute smoking on plasma BTG leve ls  was 
studied on ten volunteers who included males and females 
(mean age 28.3 + 1.8 years, range 21-47) not taking any 
anti p la te le t  drugs, who were habitual smokers. They 
abstained from smoking nine hours p r io r  to sampling. A 
blood sample was obtained from each volunteer p r io r  to the 
smoking o f three c iga re ttes , which were smoked w ith in  
20 minutes then ten minutes a f te r  the la s t  c iga re tte  had 
been smoked. The resu lts  obtained are shown in tab le  5.5. 
No s ig n if ic a n t  d iffe rence was found in plasma BTG leve ls  
before and a f te r  acute smoking.
(£.) Exercise
The e ffe c t o f maximal exercise on plasma BTG leve ls 
was measured on nine male volunteers (mean age 27.6 + 2.1 
years, range 23-32 years) not taking any a n t i -p la te le t  
drugs. A blood sample was obtained p r io r  to  exercise.
The subjects then performed erect b icycle ergometry using 
a graded exercise protocol with an i n i t i a l  work-1 oad o f 
300 k.p.m's (50 w a tts ), increasing by 300 k.p.m. at 
3 minute in te rva ls  u n t i l  exhaustion. During the la s t  
30 seconds o f peak exercise a second venepuncture was 
performed and a blood sample fo r  BTG estimation was 
removed. The resu lts  obtained are shown in  Table 5.6.
No s ig n if ic a n t  d iffe rence was found in plasma BTG 
leve ls a f te r  maximal exercise.
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TABLE 5._5
EFFECT OF ACUTE SMOKING ON PLASMA BTG LEVELS
M  volunteers (mean + s m )  ( j i= io)
PRE POST
BTG (ng/ml) 27.4 + 3.6 24.4 + 3.7
SIGNIFICANCE OF
ACUTE SMOKING p NS
TABLE 5.6.
e f fe c t  ^  MAXIMAL EXERCISE OH PLASMA BTG LEVELS Ing/ml) 
IN VOLUNTEERS (MEAN t  SEM (n=9)
PRE POST
BTG (ng/ml) 18.1 + 1.4 20.1 + 2.4
SIGNIFICANCE OF
MAXIMAL EXERCISE p NS
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Radioimmunoassay of FPA
The radioimmunoassay of FPA depends on the competition
between unlabelled and I labelled FPA fo r  a l im ited
number of binding s ites on a FPA spec if ic  antibody. The
amount of I FPA bound to the antibody is  inverse ly
proportional to the concentration of unlabelled FPA in
p la te le t  poor plasma from which fibrinogen has been removed.
A f te r  p re c ip ita t io n  and cen tr ifuga tion  the antibody bound 
I I FPA is  measured in a gamma counter. By measuring 
the amount of FPA bound in a series of standards the 
concentration of FPA in  unknown samples is  in terpo la ted 
from a standard curve.
Method o f Nossel' s group
With the iso la t io n  of human FPA from plasma and 
production of an anti serum in  a ra b b it ,  a radioimmunoassay 
was developed using these reagents (Nossel et a l . ,  1971).
FPA lacks an amino acid which can be iodinated (see Figure 4 .1 ) ,  
hence tyros ine was coupled to the amino terminal alanine of 
synthetic or native FPA by the use of the ONP (p-hydroxy- 
phenylpropionic acid p-nitrophenyl ester) ester method 
(Goodfriend and B a l l ,  1969). FPA was rad io labe lled  with
I by the chloramine T method (Hunter and Greenwood,
1962): 30 ul o f 0.3M phosphate bu ffe r (pH. 7.4) and 20 ul
of c a r r ie r - f re e  I (6 mCi) were mixed, and 15 ul of 
tyrosyla ted FPA (5 ug) was added. 25 ul of chloramine T 
(100 ug) and, a f te r  30 seconds, 50 ul of sodium metabi­
su lph ite  (120 ug) were added, and a f te r  a fu r th e r  30 
seconds, 50 ul of ovalbumin (2 mg) was added as a c a r r ie r .
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The mixture was passed over a Sephadex G-10 column 
(1.2 X 10 cm) equ il ib ra ted with 0.05M T r is ,  O.IM sa line 
(ph 7 .5 ). 0.5 ml frac tions  were collected and
ra d io a c t iv i ty  was counted. The early peak of rad io ­
a c t iv i t y  was used as the radio labelled antigen, being 
d ilu ted to give about 12,000 cpm per 50 u l . Radio­
immunoassay was performed as fo llows: the assay tubes
contained, in 0.5 ml f in a l volume, 250 ul b u ffe r ,  50 ul 
'*^1 FPA, 100 ul of the standard or sample to be assayed, 
and 100 ul of antiserum d ilu ted  1:1000 (a d i lu t io n  tha t 
binds about 30% of the to ta l counts). Tubes were 
incubated fo r  one hour at room temperature. Antibody 
bound I FPA was separated from free FPA by 
p rec ip ita t ion  of the bound peptide by the addition o f 
2 ml of dioxane-water 9:1 and immediate cen tr ifuga tion
1'L‘SI in the p rec ip ita te  was counted in a gamma counter. 
T r is -sa l in e  bu ffe r (0.15M, pH 8.5) with 1 ng/ml ovalbumin, 
was used as a d i lu e n t , fo r  a l l  reagents. The s e n s i t iv i t y  
of th is  assay was 0.1 ng FPA (2 ng FPA/ml plasma).
Modifications by other workers 
(A) Nossel, Yudelman, Canfield et a l . ,  1974 
In th is  modified method the rad io labe ll ing  technique 
was improved: the fo llowing reagents were added sequentia lly
in to  a conical tube - 10 ul solution containing 2-5 mCi 
* ^ I ;  30 ul 0.5M phosphate bu ffe r pH 7.5; 10 ug FPA in 
15 ul d is t i l l e d  water, and 15 ul chloramine T (50 ug) in
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0.5 M phosphate bu ffe r , pH 7.5. T h ir ty  seconds la te r  
20 ul sodium metabisulphite (96 ug) in 0.5M phosphate 
bu ffe r ,  pH 7.5, 20 ul heparinised normal plasma and 
200 ul 0.5M phosphate bu ffe r ,  pH 7.5 were added. The 
iodinated peptide was separated on a Sephadex GIO column 
as described previously (Nossel et a l . ,  1971).
The radioimmunoassay technique was modified by a 
preincubation and an increase in the amount o f plasma 
tested: the assay tubes contained 100 ul of anti serum,
500 ul o f te s t plasma or FPA standards made up to 500 ul 
with tris-ovalbumin bu ffe r . A fte r a 24 hour incubation 
at 4 0 c, 50 ul o f tracer was added. A one hour 
incubation at 4^0 took place before the separation of 
500 ul of cold ( 4 0 C) charcoal suspension. A fte r  mixing 
the tubes were immediately centrifuged, the supernatant 
decanted and counted in a gamma counter. This modification 
resulted in an increase in s p e c i f ic i ty  from 2 ng/ml in the 
o r ig ina l assay to 0.15 ng/ml.
Fibrinogen cross-reacts with the FPA antiserum and 
while extraction  through an XM50 u l t r a f i l t r a t i o n  membrane 
(a membrane tha t reta ins molecules o f molecular weight 
34,000 and above) gave reproducible results  with bu ffe r 
so lu tions, variable resu lts  were obtained when plasma 
samples were tested (Nossel et a l . ,  1971). In th is  
method the plasma was separated, 2.5 ml o f ethanol was 
added to 2.5 plasma in a 12 ml conical centrifuge tube 
in  an ice bath. A fte r  30 minutes incubation, the tube 
was centrifuged at 1,500 g at 4*^ C fo r  20 minutes; 4 ml 
o f the supernatant was pipetted in to  a fresh conical
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centrifuge tube, which was recentrifuged at 1,500 g at 
4 0 c fo r  20 minutes to e lim inate any remaining p re c ip ita te ,  
and the top 2 ml was pipetted in to  a segment o f d ia lys is  
tubing and dialysed fo r  at least 24 hours at 4 0 C. Manual 
inversion occurred once an hour when possible. Reproducible 
recovery of 75-100% o f FPA added to plasma was obtained.
The lowest FPA levels in plasma, thus re f le c t in g  the 
least in v i t r o  generation o f FPA were obtained with an 
anticoagulant mixture of heparin, 1000 U, and T rasy lo l,
1000 U, in 0.15M Na c l ;  9 mls of blood being added to 
1 ml anticoagulant.
{ B)  Harenberg, Hepp and Schmidt - Gayk, 1979 
Three steps o f the radioimmunoassay were modified:
Plasma d ia lys is  was omitted. 200 ul o f the 
supernatant of the ethanol precip ita ted plasma extract 
was added to  m ic ro l i t re  cups. The extract was evaporated 
w ith nitrogen, then anti serum was added fo r  24 hours, then 
tra ce r fo r  one hour. Bound and free 125 i  FPA were 
separated by the addition o f charcoal.
By the use of a second m odification the bound 125% ppA 
was separated by the use of a second antibody: normal
rabb it serum, anti serum and sample or standard were incubated 
fo r  one hour. Rabbit-immunoglobulin antiserum from goat and
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tracer were added, and incubated overnight at 4 C. The 
m ic ro t i t re  plates were then centrifuged, the p re c ip ita te  
washed with bu ffe r , recentrifuged and counted in  a gamma 
counter. The s e n s i t iv i t y  of th is  assay was 0.16 ng/ml.
(^) Kockum and Frebe lius, 1980
In th is  modified method bentonite was used fo r  the 
rapid removal of cross-reacting fibrinogen from plasma: 
bentonite was mixed with t r is - s a l in e  bu ffer containing 
ovalbumin to a concentration of usually 100 ng/ml. The 
bentonite was mixed on a magnetic s t i r r e r .  While s t i l l  
s t i r r in g  0.5 ml of the bentonite suspension was pipetted 
in to  tubes followed by 1 ml of plasma. The tubes were
capped and t i l t e d  fo r  ten minutes on a reciprocal mixer
at room temperature, then centrifuged (4°C, 5000g fo r  
10 minutes). The supernatant was pipetted o f f  and 
assayed d ire c t ly  or frozen at -65°C u n t i l  analysis. 
Radioimmunoassay was performed as described by Nossel et a l . ,  
1974. The detection l im i t  fo r  th is  assay was 0.019 ng/ml. 
^._4.^. Method fo r  radioimmunoassay of FPA used in th is  thesis 
(A) Preparation of patient piasma 
Blood samples were collected by clean flawless vene­
puncture without trauma as described in  5.3 .2. The f i r s t  
2.7 ml of blood was removed and usually used fo r  BTG 
estimation. Using a new syringe 9 ml of blood was removed 
in to  1 ml of anticoagulant containing 1000 lU heparin 
(Heparin sodium, Weddel Pharmacueticals L td . ,  West Sm ith fie ld , 
London); 1000 KIU tra sy lo l (T rasy lo l, Bayer Pharmaceuticals 
Ltd. Haywards Heath, Sussex, England) in  sodium ch lo r ide ,
0.15M. A fte r gentle inversion three times, the sample was
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placed on ice or centrifuged immediately at 2000g fo r  20 
minutes at 4°C. Plasma was assayed immediately or snap 
frozen and stored at -70^0 u n t i l  assayed.
( B.) Radioimmunoassay of FPA 
lod ination o f desaminotyrosyl FPA 
(j_) Material s
Standard FPA, desaminotyrosyl FPA and rabb it anti-human 
FPA serum were purchased from IMCO Corporation Ltd (Stockholm, 
Sweden); Sodium (c a r r ie r  free) was supplied by the 
Radiochemical Centre (Amersham, England). Ovalbumin,
Grade V, and t r i s  (Trizma(&)Base) were obtained from Sigma 
Chemicals L td . ,  London. Sephadex GIO (Pharmacia (Great 
B r i ta in )  Ltd. Hounslow, Middlesex, England); sodium 
ch lo ride  (s a l in e ) ,  sodium phosphate (phosphate); Chloramine 
T, sodium metabisulphite and sodium barbitone which were a l l  
"Analar" grade were purchased from BDH Chemicals L td . ,
Poole, Dorset, England. Heparinised normal plasma was 
obtained by adding 9 ml o f blood to  0.2 ml heparin, 5000 
lU/ml and 0.8 ml saline 0.15M. A fte r mixing the blood 
was centrifuged, plasma separated and stored frozen in 
a liquots  at -70°C.
( i i ) Radiolabel l in g  of desaminotyrosyl FPA
1. To a conical reaction tube containing 10 ug
desaminotyrosyl FPA in ammonium bicarbonate O.IM, 
which was stored frozen at -7QoC, add 30 ul phosphate 
bu ffe r 0.5M, pH 7.5.
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2. In rapid succession add 15 ul chloramine T (23.5 ug) 
and 10 ul Na 125; (approximately 1 mCi). Mix fo r  
30 seconds.
3. Add 20 ul sodium metabisulphite (48 ug), mix fo r  
30 seconds.
4. Add 20 ul heparinised normal plasma
5. Add 200 ul phosphate bu ffe r.
6. Apply reaction mixture to  a 15 ml p la s t ic  p ipe tte  
which contains 10 ml Sephadex GIO equ il ib ra ted  with 
t r i s  0.05M - saline O.IM, pH 7.5.
7. Collect 30 0.5 ml f ra c t io n s .
8. Count each fra c t io n  in a W ilj single well gamma
counter fo r  10 seconds.
The separation obtained on Sephadex GIO between 
125j pp/\ and free ^25% -js i l lu s t ra te d  in f igu re  5.3 (a ). 
The fra c t io n  containing the highest 125i pPA a c t iv i t y  is 
d i lu ted  with 4.5 ml T r is -sa l in e  bu ffer containing 80 mg 
ovalbumin. A liquots containing 100 ul 125[ pp/\ are 
stored frozen at - 7CPC. *^^ I FPA is  usually stable fo r  
three weeks at -70oC a f te r  which the non spec if ic  binding 
is  usually greater than 10% and thus the tra ce r should not 
be used a f te r  three weeks.
Specific a c t iv i t y  of FPA
To obtain the spec if ic  a c t iv i t y  of 12% pp/\ i q  
was removed from the iod ination mixture before i t  was 
applied to  Sephadex GIO. 90 ul phosphate bu ffe r was 
added, then 10 ul was applied to two presoaked 3MM 
chromatography s t r ip s ,  3 cm wide (Whatman, UK, Maidstone, 
Kent). The s tr ip s  were presoaked in 0.05M Barbitone
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Figure 5.3 (a)
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Separation of I-labelled FPA from ( I) iodide
on Sephadex G-10. The separation was carried out
by gel-filtration of an iodination reaction mixture
containing ppA (10 ug) of specific radioactivity
51 uCi/ug, chloramine-T (23.5ug), sodium metabisulphite
(48 ug) and phosphate buffer 230 ul and approximately
1 mCi of iodide in a total volume of 305 ul.
The column (5g) of Sephadex G-10 was equilibrated
with 0.05 M tris, 0,1 M NaCl buffer, pH 7.5.
Unretarded iodinated protein was eluted first,
followed by a smaller (^^^l) iodide peak.
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bu ffe r pH 8.6. Electrophoresis was carried out using a 
current of 10 m amps, 500 vo lts  in barbitone bu ffe r .
The s tr ip s  were dried then divided in to  0.6 cm and 
counted in a gamma counter. The separation of protein 
associated counts and free 125i is  shown in f igu re  5 .3(b). 
The spec if ic  a c t iv i t y  is  consequently calculated:
Analysis of chromatography s tr ip s  -
Av of both s tr ip s  
Total counts: 338350
Protein associated counts: 206294
% incorporation: 61
Specific  a c t iv i t y :
10 ug = 1000 u C i l2 5 i
For 100% incorporation. Specific a c t iv i t y  = 100 uCi/ug 
For 6% incorporation. Specific a c t iv i t y  = 61 uCi/ug
Preparation o f samples from patients
This was carried out according to the IMCO protocol: 
frozen pa t ien t 's  plasma was thawed at 37oC. When ju s t  
thawed, i t  was kept at O^C. 2.5 ml of thawed or fresh 
plasma was put in  a glass centrifuge tube at OPC. 2.5 ml 
absolute ethanol (Burrough L td . ,  London) (0°C) was added, 
the tube vortexed and kept at 0^0 fo r  30 minutes. A fte r  
cen tr ifuga tion  at 2000g fo r  20 minutes at 4^0, 4 ml of the 
supernatant was transferred to a new centrifuge tube and
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Figure 5.3 (b)
Electrophoresis separation of 10 ul (a 1:10 dilution 
of the iodination reaction mixture in 5.3 (a) 
on 3MM chromatography strips. Electrophoresis was 
carried out using a current of 10 m amps in 0.05M 
barbitone buffer, pH 8.6 for one hour.
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kept at 0°C fo r  30 minutes. A fte r cen tr ifuga tion  at 2000g 
fo r  20  minutes at 4^C, 2 ml o f the supernatant was placed 
in a segment o f 1-8 32" d ia lys is  tubing (Medicell In ternational 
L td . ,  London) and dialysed against 8 m1 t r i s  0.05M, saline
0 .1 . ,  ovalbumin 0.1%, pH 8.5 on a rocking shaker at 4°C 
overnight. The d ia lysate was assayed immediately. Due to 
the cross-reaction o f plasma fibrinogen with FPA antiserum (see 
Figure 5.4) i t  was necessary to remove the fibrinogen from plasma 
Assay procedure
This was set up according to  the IMCO protocol:
1. Add ethanol and bu ffe r according to Table 5.7. The 
bu ffe r  used was T r is  0.05M, saline O.IM, ovalbumin
0.1%, pH 8.5.
2. Add 100 ul o f FPA A(20 ng/ml) to  tubes 7 and 8 .
D ilu te  200 ul o f FPA (20 ng/ml) with 200 ul bu ffe r.
Add 100 ul o f th is  to tubes 9 and 10. D ilu te  the 
remaining 20 0  ul with 2 0 0  ul bu ffer and add 100  ul 
o f  th is  to tubes 11 and 12 etc.
3. Add 500 ul pa t ie n t 's  d ia lysate to duplicate tubes.
4. Add 100 ul anti serum o f adequate d i lu t io n  to  a l l  tubes
except 1-4.
In the assay protocol i t  is recommended tha t an a n t i -  
serum concentration is  used which resu lts  in 30-50% 
binding o f the antiserum to  the tra ce r.  The protocol 
recommends a 1 :1 0 0 0  d i lu t io n  of anti serum which, when an 
anti serum curve is  set up, does resu lt in a binding of 
40-50% as shown in Figure 5.5.
5. Mix and cap tubes, incubate overnight at 4oC.
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Figure 5.4
Inhibition of binding of FPA tracer by- 
standard amounts of "cold" FPA ( m— » )
and pure fibrinogen ( o— a). A 1:1000 
dilution of FPA antiserum was used and 
this bound about 40% of tracer in 
absence of either competitor.
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Figure 5.5
Antiserum dilution curve for FPA antiserum, 50% binding 
of the FPA tracer occurs at the 1:1000 dilution.
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6 . 125 I desaminotyrosyl FPA tracer is  d i lu ted  with 
b u ffe r to give about 10,000 cpm/50 u l.  50 ul is 
added to each tube.
7. Mix, cap and incubate fo r  one hour at 4°C.
8 . Add 500 ul charcoal suspension (200 ml b u ffe r ,  0.6 gram 
ovalbumin, 5 gram charcoal (activated untreated powder 
supplied by Sigma Chemicals L td . ,  London) to  a l l  tubes 
except 1 and 2 and mix.
9. Centrifuge immediately (w ith in  5 minutes a f te r  addition
o f charcoal) at 3000 g fo r  10 minutes at 4°C.
10. Decant the supernatant in to  new tubes, cap and count
I ra d io a c t iv i ty  in a PRIAS Auto-Gamma counter.
Determination o f resu lts  
,1. Calculate average o f duplicates.
2. The charcoal control is  the blank and is  subtracted
from a l l  other f igu res .
3. Anti serum control x 100 = anti serum binding %
bu ffe r control
4. Standard FPA or pa t ie n t 's  sample x 100 = binding % of
anti serum control anti serum binding
5. Subtract % binding from 100% to obtain % in h ib i t io n  o f binding.
6 . Draw the standard curve (see Figure 5.6 ) and ca lcu la te 
from the curve the amount o f FPA in pa tients ' samples.
7. Correct pa tien ts ' FPA value to  obtain ng/ml plasma 
(correction  fac to r  o f 2 0 ).
Within the la s t  year FPA concentrations in  s c ie n t i f ic  
journa ls has been expressed in picamoles per ml (pmol/ml).
1 pmole is  equivalent to  1.535 ng/ml. Therefore the 
value of FPA obtained in p a t ie n t 's  sample expressed in 
ng/ml is  divided by 1.535.
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%  inh ib ition  
of b in d in g
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FPA ng
Figure 5.6
Standard curve for radioimmunoassay of human FPA. 
Values (average of doubles) represent the means 
of five experiments, standard deviation indicated 
by vertical bars. Separation of bound 125x FPA 
by the double antibody technique.
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S A , 3,  Methodological variables in the FPA assay
(A) Reproducib il ity  and accuracy of the FPA assay 
The re p ro d u c ib i l i ty  of the FPA assay was tested as 
fo llows: in four d i f fe re n t plasmas the FPA concentration
was measured on four occasions (mean FPA levels ranging 
from 1 .2 -6 .8  pmole/ml); the mean In te r  assay c o e f f ic ie n t  
of variance was 3.2%. The accuracy of the FPA assay was 
tested by examining four d if fe re n t  plasmas four times 
w ith in  the same assay; the mean intra-assay co e f f ic ie n t  
o f variance was 4.4% (see Table 5.1).
{ B)  Stab11I t y  o f FPA 1n frozen piasma 
FPA levels determined in plasma samples immediately a f te r  
venepuncture did not d i f f e r  from FPA levels stored up to 
f iv e  months at -70*C (see Table 5.8).
(C.) Comparison o f ethanol extraction and bentonite 
extraction on FPA recovery
Recovery was assessed by the addition to normal plasma 
of 1.5, 5 and 6.25 pmol/ml FPA before (a) ethanol 
p re c ip ita t io n  and d ia lys is  and (b) bentonite ex trac tion . 
Ethanol p re c ip ita t io n  was carried out as described in
5.4.2 (b ). Bentonite extraction was carried out as fo llows: 
Bentonite (Sigma Chemicals Ltd. London) was mixed with TSO 
bu ffe r to a concentration of usually 100  mg/ml.
The solu tion was s t i r re d  with a wooden app lica to r 
s t ick  and then placedon a magnetic s t i r r e r .  While s t i l l  
s t i r r in g  0.5 ml of the bentonite suspension (50 mg of 
bentonite)was pipetted into tubes containing 1 ml fresh
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TABLE 5.8
STABILITY OF FPA IN FROZEN PLASMA
PLASMA FPA ( pmol/ml)
Patient
JT
AMcK
JD
SM
Before
Storage
4.7
6.8 
2.5 
1.2
A fte r
Storage
5.1 
6.8
2.1 
1.2
Storage 
Time (Months) 
5 
3 
2 
1
Mean 3.8 3.8
TABLE 5.9.
EFFECT OF ETHANOL OR BENTONITE EXTRACTION ON FPA RECOVERY
Amount o f FPA 
added to plasma
Recovery a f te r  extraction  
Ethanol then d ia lys is  Bentonite
2.5 pmol/ml 89 100
5 pmol/ml 106 112
6.25 pmol/ml 99 107
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or thawed plasma. The tubes were capped, vortexed then 
t i l t e d  fo r  10 minutes on a reciprocal mixer at room 
temperature and centrifuged (4*C, 3000g fo r  10 minutes),
1 ml of plasma supernatant was removed in to  a clean tube 
and another 0.5 ml of bentonite suspension was added.
A fte r t i l t i n g  on the mixer fo r  another 10 minutes, c e n t r i ­
fugation was again carried out. The supernatant was 
assayed immediately. The resu lts  obtained in Table 5.9 
show tha t adequate recovery was obtained by both methods,
(ID) Effectiveness of ethanol and bentonite in 
separating FPA from fibrinogen in piasma 
To determine the actual amount of fibr inogen l e f t  in  
the ethanol and bentonite supernatants a f te r  ex trac t ion , 
f ibr inogen concentrations were measured before and a f te r  
extractions in the plasma of two normal con tro ls .
Fibrinogen was estimated according to the method of 
C la u s s , 1957. The lowest detection l im i t  of
the fibr inogen assay was 0.04 mg/ml which is  equivalent to  200 
pmoles. From Table 5.10 i t  is evident tha t both methods 
are adequate in removing fibrinogen from plasma.
(I.) A comparison o f charcoal and sol id phase double 
antibody in the separation o f bound I FPA 
The use of powdered charcoal fo r  the removal of free 
I antigen, thus leaving the bound fra c t ion  in the 
supernatant, has been used fo r  many years (Herbert, Leu, 
Gottl ieb et a l . ,  1965). Unfortunately charcoal also
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TABLE 5.10
EFFECTIVENESS OF ETHANOL AND BENTONITE IN SEPARATING FPA 
FROM FIBRINOGEN IN PLASMA
F ib r i nogen 
in  plasma 
( pmoles/ ml)
Fibrinogen 
concentration 
a f te r  ethanol 
extraction 
(pmoles/ml)
Fibrinogen 
concentration 
a f te r  bentonite 
extraction 
( pmoles/ml)
1. 14,417
2. 8,529
235
235
235
235
TABLE 5.11
COMPARISON OF CHARCOAL AND SAC-CEL IN SEPARATING BOUND I FPA
Plasma FPA ( pmol/ml + SEM)
n = 24
Charcoal
Suspension
3.7 + 0.8
Sac-cel
Suspension
3.6 + 0.8
(range 0.4-13 pmol/ml) (range 0.4-13 pmol/ml)
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"competes" with the antiserum and thus s tr ip s  labelled 
antigen from the bound complex i f  s t r i c t  adherence is 
not kept to immediate cen tr ifuga tion  once the charcoal 
suspension has been added. The use of a 'double* or 
'second* antibody should circumvent any non spec if ic  
binding to  charcoal. The 'second* antibody is  sp e c if ic ,  
th e ^ f-g lo b u lin  of the species in which the f i r s t  antibody 
was raised - eg since FPA anti serum was raised in  rabb its , 
the second antibody would be raised against a ra bb it .
More recently  so lid  phase double antibodies in which the 
second antibody is  coupled to  an insoluble matrix such as 
ce llu lose  have been developed (den Hollander and Schuurs, 
1971). In 1982 a commercial so lid  phase double antibody - 
Sac-cel (Wellcome Diagnostics) became ava ilab le . Sac-cel is  
a ce llu lose coupled a n t i - ra b b it  so lid  phase double antibody.
To determine the effectiveness o f Sac-cel in separating 
the bound ^ I  FPA, FPA estimations were carried out in 24 
duplicate samples. In one sample the FPA estimation was 
carried out using the IMCO protocol w ith charcoal separation 
o f bound and free 125j FPA. In the second sample 
0.1 ml o f Sac-cel suspension was added to each tube a fte r  
incubation with tra ce r.  The tubes were vortexed then 
l e f t  fo r  one hour at room temperature during which vortexing 
was repeated at 20 and 40 minutes. A fte r one hour, 1 ml 
o f d is t i l l e d  water was ca re fu l ly  layered in to  each tube, 
with minimum disturbance o f the Sac-cel p e l le t ,  to reduce 
the non-specific binding to the sides of the tubes. The 
tubes were centrifuged at 2 0 0 0  g fo r  two minutes at room
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temperature. The supernatant was removed by suction 
and the p re c ip ita te  counted in a gamma counter. As 
shown in tab le  5.11 no d iffe rence was found in the values 
o f FPA determined by the use of e ith e r charcoal or the 
double antibody body. In order to minimise any possible 
non-specific binding due to charcoal s tr ip p in g , the double 
antibody method was used in the la t t e r  studies reported in 
th is  thes is .
^ .4 .4 .  E ffect o f physiological variables on the FPA assay 
(A) _and ^ex
Using the same protocol as described in 5.4.2 (A) blood 
samples were obtained from three groups; a group o f young 
volunteers, 40 females (mean age 22.9 + 0.7 years, range 
18-40 years) and 19 males (mean age 26.7 ± 0.7, range 18- 
40 years); a group of middle aged volunteers; 4 females 
(mean age 53.5 t  3.9 years, range 42-59 years) and 4 males 
(mean age 50.2 + 3.7 years, range 42-59 years); an e ld e r ly  
volunteer group, 14 females (mean age 78.7 + 2.3 years, 
range 64-91 years) and 12 males (mean age 76.8 + 2 .3  years, 
range 62-89 years). The resu lts  obtained are shown in 
Table 5.12.
In the female group there is  a s t a t is t ic a l l y  s ig n if ic a n t  
increase in age from the young age group to the e lde r ly  group. 
Although the FPA level is  increased in the middle aged group 
th is  d ifference is  not s ig n if ic a n t  due to the small sampling
TABLE 5 .1 2
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COMPARISON OF SEX AND AGE ON PLASMA FPA LEVELS 
r in o l / i ï iT r IN VOLUNTEERS (MEAN + SÊM)
*£<0.05, * *  £<£.02, •k'kie p<0 .0 0 1
FEMALES
Young (n=40) Middle aged (n=4) E lderly  (n=14) 
Age (years) 22.9 + 0-7 53.5 + 3.9
FPA (pmol/ml) 0.76 + O ./ l  1.7 + 0.4
78. 7 + 2.3 
1.75 + 0.4*
Age (years) 26.7 + 0.7 
FPA (pmol/ml) 0.4 + 0
MALES
Young (n=19) Middle aged (n=4) E lderly  (n=12)
50.2 t  3.7 
0.7 + 0.3
76. 8 + 2.3 
2. 3 + 0 .5***
SIGNIFICANCE OF
SEX DIFFERENCE p<0.01 NS NS
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TABLE 5 .1 3
EFFECT ^  ACUTE SMOKING ON PLASMA FPA LEVELS ( pmol/ml) 
JN VOLUNTEERS (MEAN + S m )  (N=_10)
PRE POST
FPA (pmol/ml) 0.4 + 0 0.4 t  0
SIGNIFICANCE OF
ACUTE SMOKING p NS
TABLE 5.14
EFFECT OF MAXIMAL EXERCISE ON PLASMA FPA LEVELS ( pmol/ml) 
m  VOLUNTEERS (MEAN ± SEM) (n=9)
PRE POST
FPA (pmol/ml) 0.4 + 0 0.4 + 0
SIGNIFICANCE OF
MAXIMAL EXERCISE p NS
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size. S im ilar resu lts  were obtained in the male groups 
with FPA being s ig n i f ic a n t ly  increased in the older group. 
Plasma FPA appears to be increased in the female groups 
when compared to the male groups except fo r  the older male 
group, a s ta t is t i c a l l y  s ig n if ic a n t  increase being shown 
between males and females in the young age group. When a l l  
the groups were examined together, a corre la t ion  was found 
being age and FPA (r=0.51, p< 0 .0 0 1 )  .
(A) Acute smoking
The e f fe c t  o f acute smoking on plasma FPA leve ls was 
studied on the same ten volunteers as described in the 
protocol in 5.3.4 (B). The resu lts  obtained are shown in 
Table 5.13. No d ifference was found in plasma FPA levels 
before and a f te r  acute smoking.
{Ç)  Exercise
The e ffe c t  of maximal exercise on plasma FPA leve ls 
was studied on the same nine volunteers as described in 
the protocol in 5.3.4 (C). The resu lts  obtained are 
shown in Table 5.14. No d ifference was found in  plasma 
FPA levels before and a f te r  maximal exercise.
I ' l .  Radioimmunoassay o f Bpl5-42 Peptide
The radioimmunoassay of Bgl5-42 depends on the 
competition between unlabelled and 125% labelled Bpl5-42 
fo r  a l im ited  number of binding s ites on a Bpl5-42 
spec if ic  antibody. The amount o f l 2 5 i  B^5-42 bound to  
the antibody is  inversely proportional to the concentration
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of unlabelled Bpl5-42 in p la te le t  poor plasma from which 
fibrinogen has been removed. A fte r p rec ip ita t ion  and 
cen tr ifuga tion  the antibody bound 125j is
measured in a gamma counter. By measuring the amount o f 
125% b^ 15-42 in  a series o f standards the concentration o f 6)515 
-42 in unknown samples is  in terpolated from a standard curve. 
Method of Kudryk' s Group
This group described the iso la t io n  of human B^15-42 
from human plasma and production o f an anti serum in a 
ra bb it .  A subsequent radioimmunoassay was developed using 
these reagents (Kudryk et a l . ,  1982). The peptide contains 
a tyrosine residue at posit ion B^41 (see Figure 4.2) and, 
therefore , can be labelled with 12%. B^15-42 was radio­
labelled with 125% by the chloramine T method (Hunter and 
Greenwood, 1962): 25 u l ; of sodium phosphate bu ffe r ,
pH 7.5 containing 10 ug B^15-42 peptide was mixed with 
5-10 ul o f c a r r ie r  free Na 125% (% mCi), 10 ul of 
chloramine T (50 ug) is  added and a f te r  mixing (30 seconds) 
the reaction was terminated with 100  ul sodium metabisulphite 
(100 ug). The mixture was passed over a Sephadex G-10 
column (0.38 x 30 cm) equ ilib ra ted with 0.05 M Tris  -
O.IM Na Cl (pH 7 .5 ). To minimise adsorption loss of the 
tra ce r,  the reaction mixture was d ilu ted  with 1 mg/ml 
bovine serum albumen to  act as c a r r ie r .  The early peak 
o f ra d io a c t iv i ty  was used as the radiolabelled antigen, 
being d i lu ted  to give 25,000 cpm per 50 u l . Radio­
immunoassay was performed as fo llows: the assay tubes
contained 0.25 ml f in a l  volume, 50 ul l ^ I ^ B  15-42,
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100  ul o f the standard or sample to be assayed ( th is
was d ilu ted  1 :2 ) ,  and 100  ul of anti serum d ilu ted
1:1500 (a d i lu t io n  tha t binds about 30% of the to ta l
counts). Tubes were incubated fo r  18 hours at 4^C.
12,^Antibody bound I 8j815-42 was separated from free
8)^15-42 by the addition o f an appropriate d i lu t io n  
o f a second antibody. A fte r  end-over-end mixing fo r  
two hours at room temperature, then the tubes were 
centrifuged at 4000 g fo r  20 minutes at room temperature. 
The resu lt ing  p e l le t  was washed three times and then the 
I was counted in a gamma counter. The s e n s i t iv i t y  of 
th is  assay was 0.16 pmol/ml. Fibrinogen was removed 
from plasma by extraction  with ethanol. Recently a 
commercial k i t  has become available fo r  the measurement 
o f 8^15-42.
Method fo r  radioimmunoassay o f Bjgl5-42 used 
in th is  thesis 
(A) Preparation o f pa tient plasma
This was as described fo r  the preparation of pa tient 
plasma in the FPA assay (see 5 .4 .2 ) ,  plasma being assayed 
immediately or snap frozen and stored at -70*0 u n t i l  
assayed.
(1) Radioimmunoassay o f  Bjgl5-42 
lod ination o f BjS15-42 
(J_) Materials
Standard B/215-42 and rabb it anti-human 8^15-42 were 
purchased from IMCO Corporation Ltd (Stockholm, Sweden).
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A ll other reagents were as described in the iod ination of FPA. 
( i i )  Radiolabelling o f 8^15-42
1 . To a conical reaction tube containing 10 ug ByÔ15-42 
peptide in 25 ul sodium phosphate (0.5M) pH 7.5, which 
is  stored at -70°C, add in rapid succession 10 ul 
chloramine T (50 ug) and 10 ul Na 125% (approximately 
1 mCi). Mix fo r  30 seconds.
2. Add 100 ul sodium metabisulphite (100 ug). Mix fo r  
30 seconds.
3. Apply the reaction mixture to a 15 ml p la s t ic  p ipette  
which contains 10 ml sephadex GIO equilib ra ted with 
t r i s  O.OSM-saline O.IM, pH 7.5. Wash the reaction 
mixture with 1 0 0  ul t r is - s a l in e  bu ffe r containing
1 mg/ml bovine serum albumin (BSA).
4. Repeat step 3.
5. Collect t h i r t y  0.5 ml fra c t ions .
6 . Count each f ra c t io n  in a W ilj s ingle well gamma 
counter fo r  ten seconds.
The separation obtained on Sephadex G-10 between 
125% b^ 15-42 and free 125% -js i l lu s t ra te d  in f igu re  5 .7 (a), 
The frac tions  containing the to ta l 125% B)315-42 a c t iv i t y  
are pooled then an equal volume o f buffer containing BSA is 
added. A liquots containing 50 ul 125% Bpl5-42 are stored 
frozen at -70°C. The trace r is  stable fo r  two months at 
-70°C and is  only used when the non spec if ic  binding is  
lower than 5%.
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Figure 5.7(a)
• 1 9 S 1 9 S
Separation of I-labelled 15-42 from ( I)
iodide on Sephadex G-10, The separation was
carried out by gel-filtration of an iodination
mixture containing 125% B ^  15-42 (10 ug) of
specific radioactivity 65 uCi/ug, chloramine-T
(50 ug), sodium metabisulphite (100 ug), and
phosphate buffer (25 ul) and approximately
1 mCi of ) iodide in total volume of 145 ul.
The column (5g) of Sephadex G-10 was equilibrated
with 0.05 M tris, 0.1 M NaCl buffer, pH 7.5.
Unretarded iodinated protein was eluted first,
followed by a smaller (^^^l) iodide peak.
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Specif ie  a c t iv i t y  o f B^15~42
The spec if ic  a c t iv i t y  of 125i B^15-42 was measured
as described fo r  125% pp/\ (see 5.4.2 (B )). The separation 
o f protein associated counts and free 125% is shown In 
Figure 5.7 (b ). The spec if ic  a c t iv i t y  Is consequently 
calculated:
Analysis o f chromatography s tr ip s :
Average of both s tr ip s  
Total counts: 484621
Protein associated counts: 322046
% Incorporation: 66
Specific a c t iv i t y :  10 ug - uCI I
For 100% Incorporation, Specific a c t iv i t y  = 100 uCi/ug
For 6 6% Incorporation, Specific a c t iv i t y  = 66  uCi/ug
Preparation o f samples from patients
Due to the cross-reaction o f plasma fibrinogen with 
Bpi5-42 anti serum (see Figure 5.8) I t  was necessary to 
remove the f ibr inogen from plasma samples. This was 
carried out according to the.method In the IMCO protocol: 
frozen plasma was thawed at 37°C. When ju s t  thawed. I t  
was kept at 0°C. 1 ml o f thawed or fresh plasma was put
in  a p la s t ic  centrifuge tube at 4^0. 1 ml o f absolute
ethanol was added, the tube vortexed and kept at 0°C fo r  
30 minutes. A fte r  cen tr ifuga tion  at 2000g fo r  20 minutes 
at 4^0 the supernatant was removed Into a new centrifuge 
tube and kept at fo r  a fu r the r 30 minutes. Centrifuga­
t io n  was repeated and an a liquo t removed from the supernatant 
fo r  Immediate assay.
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Protein
[b]
associated
counts
125,
§5p00-
■o
Distance from origin (cm.)
Figure 5.7(b)
Electrophoresis separation of 10 ul (a 1:10 
dilution of the iodination mixture in 5,7 (a) 
on 3 MM chromatography strips. 
Electrophoresis was carried out using a current 
of 10 m amps in 0.05M barbitone buffer, pH 8.6 
for one hour.
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Figure 5.8
Inhibition of binding of B 15-42 tracer 
by standard amounts of "cold" 15-42
( a — ^ ) and pure fibrinogen ( ),
A 1:1500 dilution of ByÔ 15-42 antiserum 
was used and this bound about 30% of the 
tracer in absence of either competitor.
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Assay procedure
This was set up according to  the IMCO protocol.
1. Add bu ffe r according to Table 5.15. The bu ffe r
used was T r is  0.04M, Saline O.llM , EDTA O.OIM,
Na N^  0.02%, Trasylol (20 KlU/ml), ovalbumin
1 ng/ml, pH 7.4.
2. Add 100 ul o f 8^15-42 standard (15 ng/ml) to  tubes
7 and 8 . Prepare doubling d i lu t io n s  as shown in  Table 5.15.
3. D ilu te  0.5 ml o f a l l  pa tien ts ' plasma extracts with
0.5 ml bu ffe r .  A liquot 100 ul to  the appropriate tubes.
4. 125 j 3^5-42  is  d ilu ted  with bu ffe r to give about
25,000 cpm/50 u l . 50 ul is  added to each tube.
5. Add 100 ul anti serum of adequate d i lu t io n  to  a l l  tubes 
except 1-4.
In the assay protocol i t  is  recommended tha t an 
antiserum concentration is  used which resu lts  in 25-35% 
binding o f the antiserum to the tracer. The protocol 
recommends a 1:1500 d i lu t io n  of anti serum which, when an 
antiserum d i lu t io n  curve is set up, does resu lt in  a 
binding of 25-35% as shown in Figure 5.9.
6 . Mix and cap the tubes, incubate fo r  18 hours at 4*C.
7. Add 100 ul Sac-cel suspension. Mix, leave fo r  one 
hour at room temperature, vortex at 20 and 40 minutes,
8 . Add 1 ml o f d is t i l l e d  water without d is turb ing p e l le t ,  
centrifuge 2000g fo r  two minutes. Aspirate supernatant.
9. Count ^25 j ra d io a c t iv i ty  in a PRIAS Auto Gamma Counter.
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lOOH
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1:10 1:10^
ANTI SERUM DILUTION
1:10
Figure 5.9
Antiserum dilution curve for ByS 15-42 antiserum. 50% 
binding of the 15-42 tracer occurs at the 1:1500 
dilution.
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Determination o f resu lts
1. Calculate average of cpm doubles. Subtract the 
value of the Sac-cel control (tubes 3 and 4) from 
a l l  averages, except in the non spec if ic  binding 
estimation.
2. Sac-cel control x 100 = % non-specific binding of
bu ffe r control
trace r (NSB). NSB Is usually 2-4% o f bu ffe r con tro l.
Antiserum control *100
Buffer control
The value should be 25-30%.
4. Subtract % binding from 100% to  obtain % In h ib i t io n  
o f binding.
5. Construct the standard curve (see Figure 5.10) and
calcu la te  from the curve the amount of B^5-42 In
pa tien ts ' samples.
6 . Correct patients BjSl5-42 value to  obtain pmol/ml 
plasma (correction fac to r  = 2 0 ).
Methodological variables in the B^5-42 assay
(A) Reproducib il ity  and accuracy of the B^15-42 assay
The re p ro d u c ib i l i ty  o f the Bjgl5-42 assay was tested as 
fo llows: In four d i f fe re n t  plasmas the B^5-42 concentratl
was measured on four occasions (mean B^15-42 levels ranging
0 .8 -4 . 8  pmol/ml); the mean in te r  assay c o e ff ic ie n t of 
variance was 10.2%. The accuracy of the B^5-42 assay was
on
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% inhibition  
of b in d in g
100 1
80 -
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20 -
0.050.01 0.2 0.5
pm ole BjS15-42
0.1
Figure 5.10
Standard curve for radioimmunoassay of 
human Byg15-42. Values (average of doubles) 
represent the means of four experiments, the 
standard deviation indicated by vertical bars.
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tested by examining four d i f fe re n t  plasmas four times 
w ith in  the same assay, the mean intra-assay c o e f f ic ie n t  of 
va r ia t ion  was 9.7% (see Table 5 .1).
(_B) S ta b i l i t y  o f B^15-42 in frozen pi asma
B^15-42 levels determined in plasma samples 
immediately a f te r  venepuncture did not d i f f e r  from B^15-42 
levels in samples stored up to f iv e  months at -70°C 
(see Table 5.16).
1*1*1 Physiological variables in the B^15-42 assay 
Effect o f sex
Blood samples were obtained from a group of young 
volunteers, f iv e  females (mean age 25.2 ± 1 .9  years, 
range 21-32 years) and twelve males (mean age 26.3 ± 1 .2  
years, range 18-33 years). The resu lts  obtained are shown 
in  f igu re  5.17. S im ila r levels o f plasma B^15-42 were 
found in males and females in the young age group.
TABLE 5.16
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STABILITY Of B jÇ^-42 fN  FROZEN PLASMA
P a t ie n t
JT
AMcK
JD
SM
MEAN
B efo re
S torage
10
4
0 . 8
1
A f t e r
S to rage
10
3 .4
0.7
1.3
S to rage  t im e  
( M o n ths )
5
3
2
1
TABLE 5.17
EFFECT Of SfX ON PLASMA B jg lf-4 2  LEVELS ( pmol/m l ) 
fN  YOUNG VOLUNTEERS ( mean ± SEM)
AGE
(YEARS)
B|gl5-42 
( p m o l/m l)
FEMALES 
( n = 5)
MALES
(n = 1 2 )
25 .2  ± 1 .9  0 .9  ± 0 .1
26.3  ± 1 .2  0 .8  ± 0 .1
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CHAPTER 6
Plasma Fibrinopeptlde A and Betathrombogiobul1n 
in Pre-eclampsia and Pregnancy Hypertension
The aim of the studies undertaken in th is  chapter 
was to determine whether plasma levels of f ib r inopeptide  A 
(FPA) and betathrombogiobulin (BTG) were abnormal in  
pregnant women with pre-eclampsia or essential hypertension when 
compared to pregnant women during normal pregnancy. Changes 
in  platelet a c t iv i t y ,  blood coagulation and f ib r in o ly s is  in 
pre-eclampsia may be p a r t ly  responsible fo r  the increase in 
f i b r in  deposition seen in the placental bed in pre-eclampsia 
as well as the pathogenesis o f th is  disease. A b r ie f  
h is to r ic a l review on pre-eclampsia w i l l  be given in the 
f i r s t  part o f th is  chapter (6 .1 ). In the second part (6.2) 
an i n i t i a l  study on pre-eclampsia and pregnancy hypertension 
w i l l  be described. In th is  study plasma samples from 
pregnant women with pre-eclampsia were compared to  pregnant 
women with hypertension, healthy pregnant women in the 
th i r d ,  second and f i r s t  tr im ester o f pregnancy, healthy 
non-pregnant women taking oral contraceptives and 
healthy non-pregnant women not taking oral contraceptives.
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In the next part of th is  chapter (6.3) a second study on the 
administration of oral lab e ta lo l,a  mixed a and ^  b locker,in  the 
management o f mild or moderate pre-eclampsia w i l l  be described. 
In th is  study plasma samples from pregnant women with m ild or 
moderate pre-eclampsia taking oral labeta lo l are compared 
to  the fo llow ing not taking la b e ta lo l:  pregnant women
with mild or moderate pre-eclampsia, pregnant women with 
in trau te r ine  growth re tardation (lUGR) and normal healthy 
pregnant women. The conclusions from both studies w i l l  
be discussed together in 6.4.
_6.1_. Introduction
In the f i f t h  century B.C. Hippocrates noted that 
"drowsiness, f i t s  and coma" were of serious prognostic 
importance in a pregnant woman, but the actual term 
"eclampsia" was f i r s t  introduced by Verandeus in 1619.
I t  is  derived from the Greek word fo r  a " f lash" because 
many such patients complain o f seeing "f lash ing" l ig h ts  
before the onset of a seizure. Lever in 1843 reported 
tha t pro te inuria  was present in patients with eclampsia 
and th is  led to the recognition o f a "pre-eelamptic s ta te " .
I t  was believed fo r  many years tha t the placenta 
manufactured a spec if ic  to x in ,  which was responsible fo r  
both pre-eclampsia and eclampsia (Holland, 1909) and th is  
concept led to the use of the terms "toxaemia o f pregnancy" 
or pre-eelamptic toxaemia (P.E.T). A toxin has never 
been discovered, so i t  is preferable to use the term "pre­
eclampsia" to  describe a c l in ic a l  state which can p o te n t ia l ly
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progress to eclampsia. A number o f hypotheses have been 
produced to explain the cause of pre-eclampsia, becoming so 
numerous, tha t as long ago as 1916 Zweifel termed i t  the 
"disease of theories" (Chesley, 1978).
A precise, generally acceptable d e f in i t io n  o f pre- 
eclampsia has not yet been reached and d if fe re n t  c l in ic a l  
c r i t e r ia  have been used. The main features o f th is  syndrome 
are systemic hypertension, pro te inuria  and oedema. The 
d ifferences in d e f in i t io n  l i e  in the degree o f abnormality 
required to  make a diagnosis. Oedema is d i f f i c u l t  to 
quantita te and is ,  in  any case, present in 40% o f normal 
pregnant women (Thomson, Hytten and B illew icz , 1967). 
Prote inuria appears to ind ica te  a much more severe form 
o f the disease (M a c G illvray, 1961). The diagnosis of 
pre-eclampsia is  usually made, therefore , on the basis of 
sustained hypertension and prote inuria  developing during 
the second h a lf  o f pregnancy (Page, 1972). The use of 
the term "hypertensive disease of pregnancy" was 
suggested in the Lancet (1975) to avoid the problem of 
o f whether a patient is  "toxaemic" or not. Such a 
group, which would include patients with pre-ex is ting 
hypertension and chronic renal disease, would be even 
more heterogeneous than tha t included under the term 
"pre-eclampsia".
The primary fac to r (or factors) responsible fo r  the 
syndrome have not yet been id e n t i f ie d  despite many biochemical 
and other abnormalities being demonstrated along with pre­
eclampsia.
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Page (1972) suggested "an inner vicious c i rc le "  
which tended to be s e l f  perpetuating in a cascade of events 
which is  only broken by the termination of the pregnancy.
Thus a reduction in uteroplacental c ircu la t io n  associated 
with vasoconstriction resu lts  in damage to the placenta, the 
release o f trophoblast in to  the c ircu la t io n  p rec ip ita t ing  
Die, f i b r in  deposition, glomerular endothelial lesions, 
reduced glomerular f i l t r a t i o n  ra te , sodium re tention , 
plasma volume with fu r th e r  reduction in placental perfusion.
He also described an outer c i r c le  of predisposing factors 
such as excess sodium load, chronic renal and hypertensive 
diseases and posture. Recently pre-eclampsia has been 
likened to  a disease of cascades (MacGillvray, 1981) such as 
the calcium transport system, the renin-angiotensin- 
aldosterone system, the k in in  system, the prostaglandins, 
as well as the haemostatic system. D ie t, genetic 
factors and immunologic factors are also involved. These 
factors may break in to  the chain at various points, thus 
p rec ip ita t ing  a sequence o f events which affects  every 
system in the body.
Within the la s t  few years, abnormalities in the 
prostaglandin system in pre-eclampsia, as suggested by 
a defic iency o f prostacyclin have been reported. This defic iency 
may be the re su lt  of reduced prostacyclin synthetase (Lewis, 1981). 
This suggests an imbalance in the TXA^/PGI^^ration in pre-eclampsia 
s im ila r  to tha t suggested in Chapter 2 as a mechanism in thrombosis.
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Changes in the haemostatic mechanism, suggestive of 
in travascular coagulation, have been observed .in pre­
eclampsia. These changes which are s ig n if ic a n t ly  greater 
than those occurring in normal pregnancy, include an 
increased rate of coagulation activa t ion  as suggested by 
an increased fac to r  V I I I  re lated an tigen /fac to r V I I I  
c lo t t in g  ra t io  ( fa c to r  V I I I  ra t io )  (Boneu, Bierme, Fournie 
et a l . ,  1977; Thornton and Bonnar, 1980; Fournie,
Monrozies, Pontonnier et a l . ,  1981) and increased soluble 
f i b r in  monomer complexes (McKillop e t  a l . , ,  1 9 7 6 ) .
Changes in the f ib r in o ly t i c  system, which are 
d i f fe re n t  from those in normal pregnancy, have also been 
found in pre-eclampsia. In pre-eclampsia lower leve ls of 
plasma plasminogen are present than in normal pregnancy 
(Bonnar, McNicol and Douglas, 1971, Howie, Prentice and 
McNicol, 1971). There is  also an increase in the level 
o f in h ib i to r  to urokinase in plasma from patients with 
pre-eclampsia (Bonnar et a l . ,  1971, Howie et a l . ,  1971).
Serum FDP levels are higher in pre-eelamptic women than 
in  normal pregnant controls (Bonnar et a l . ,  1971; Howie 
et a l . ,  1971; Condie 1976) although sequential studies 
suggest tha t cons is tently  raised levels are not always 
present in pre-eclampsia (Gordon, Ratky, S o la e t  a l . ,  1976). 
These resu lts  suggest tha t although there may be increased 
in h ib i t io n  o f f ib r in o ly s is  in pre-eclampsia, th is  is  not 
complete and some ly s is  of insoluble f ib r in  is  occurring.
The resu lts  are, therefore , compatible with a degree o f 
Intravascular coagulation being present in pre-eclampsia.
Changes in p la te le t  a c t iv i ty  have also been 
found in pre-eclampsia. There is  a reduction in p la te le t  
count (Bonnar et a l . ,  1971) leading to thrombocytopenia 
(Pritchard, Weisman, Ratnoff et a l . ,  1954; Howie et a l . ,  1971). 
The lowered p la te le t  count has been assumed to be due to the 
sequestration of p la te le ts  in the m icroc ircu la t ion  of 
organs such as the placenta, kidney and l i v e r  as a resu lt 
of increased p la te le t  aggregation with a concurrent release 
of pi a t ! et granules. While lowered 5HT levels were found 
in severe pre-eclampsia when compared to normal pregnancy 
This may or may not be raised according to another study 
(Jelen, Fananapazier and Crawford, 1979). Another 
ind ica tion  of increased p la te le t  aggregation has been the 
report of increased BTG levels in pre-eclampsia (Redman, 
A ll in g to n , Bolton et a l . ,  1977). Increased levels of 
BTG have also been reported in women taking oral 
contraceptives (Arandi, Saez, Abril et a l . ,  1979; Duncan, 1979).
The estimation of plasma levels of BTG and FPA, 
markers of p la te le t  release and thrombin generation 
respective ly should provide more d irec t evidence of 
p la te le t  and coagulation activa tion  in pre-eclampsia.
PIasma BTG and FPA in Pre- eclampsia and 
Pregnancy Hypertension 
Z._l. Design o f study
Six groups of patients were studied:
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Group 1. Severe pre-eclampsia (n = 13): c r i t e r ia
(1) Hypertension of 150/100mmHg or over before de livery
(2) Prote inuria ranging from 1.5-lOg/day
(3) Generalised oedema
(4) Normal BP and no prote inuria  at postnatal v i s i t .  
Group 2. Pregnancy hypertension (n = 11): c r i t e r ia
(1) Persistent hypertension o f more than 140/90mmHg in 
the f i r s t  tr im ester o f pregnancy
(2) No pro te inuria  or oedema
(3) Lowered BP at post natal v i s i t .
Group 3. Normal pregnancy: c r i t e r ia
(1) Uncomplicated pregnancy free from hypertension, 
oedema and prote inuria
(2) Should d e live r  in fan t o f normal weight.
This group includes:
(A) 20 women in the 3rd tr im ester of pregnancy
(B) 15 women in the 2nd tr im ester of pregnancy
(C) 22 women in the 1st tr im ester of pregnancy
Group 4. This includes 14 healthy non-pregnancy women on
on oral contraception with 30 ug oestrogen p i l l s .  
Group 5. This includes 20 healthy non-pregnant women not 
on oral contraception.
The pregnant groups were matched fo r  age, pa r ity  
and gestation. The non-pregnant women were matched fo r  age 
w ith the pregnant groups, and sampled in mid-menstrual cycle.
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Results
Betathrombogiobuli n 
The plasma BTG levels (measured by the Amersham RIA k i t )  
are shown in f igu re  6.1. No prostaglandin Ej was added to 
the BTG blood sample tubes. No s ig n if ic a n t differences were 
found between the non-pregnant women not taking oral 
contraceptives and the women taking oral contraceptives; nor 
between non-pregnant women and healthy women in the f i r s t  
tr im es te r o f pregnancy. Elevated levels of BTG were found 
in  the second tr im este r (p <0 .0 1 ) and th i rd  tr im este r (p < 0 . 0 1 ) 
o f pregnancy, compared to  the non-pregnant group and the f i r s t  
t r im ester o f pregnancy Group,A fu r the r increase in BTG levels 
was found in pre-eclampsia (p < 0 .0 1 ) and pregnancy hypertension 
(p < 0 .0 2 ) when compared to healthy women in the th i rd  tr im ester 
o f pregnancy. Despite higher levels being obtained in pre­
eclampsia than in pregnancy hypertension, th is  d iffe rence was not 
s t a t is t ic a l l y  s ig n if ic a n t .
Fibrinopeptide A
The plasma FPA levels (measured by the IMCO k i t )  are shown 
in  f igu re  6.2. No s ig n if ic a n t  differences were found between 
the plasma FPA leve ls in the non-pregnant women not taking oral 
contraceptives and the women taking oral contraceptives; nor 
between non-pregnant women and any o f the healthy pregnant groups. 
S ig n i f ic a n t ly  elevated FPA levels were found in  pre-eclampsia 
(p <0 .0 1 ) and pregnancy hypertension (p < 0 ,0 1 ) compared to 
healthy women in the th i rd  tr im ester o f pregnancy. Despite 
higher FPA leve ls being obtained in pre-eclampsia than in  pregnancy 
hypertension, th is  d ifference was not s ta t is t i c a l l y  s ig n if ic a n t .
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Figure 6.1
BTG levels in groups studied. N = normal non­
pregnant. 0/C = non-pregnant taking oral 
contraceptives. PI = normal 1st trimester 
pregnant. P2 = normal 2nd trimester pregnant. 
P3 = normal 3rd trimester pregnant. HT = 
pregnancy hypertension. PE = pre-eclampsia.
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FPA levels in groups studied.
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Labetalo1 in the Management of Mild or Moderate Pre- eciampsia 
6 .2 J .  In troduction
Labetalol is  a unique antihypertensive agent which acts as a 
competitive in h ib i to r  of alpha and beta adrenoreceptors, the 
beta blocking effec ts  having been shown to be non-selective. 
a-adrenergic p la te le t s tim ula tion is  associated with the in h ib i t io n  
o f adenyl-cyclase (Salzman and Levine, 1971), the decrease of 
cyc l ic  AMP (Salzman, 1972a) and the induction o f p la te le t  aggregation, 
a-adrenergic blocking agents prevent th is  chain of reactions and 
s p e c if ic a l ly  in h ib i t  adrenaline-induced p la te le t aggregations 
(Praga and Poglian i, 1971). Oral labeta lo l undergoes considerable 
f i r s t  pass metabolism in  the l i v e r ,  and is  ra p id ly  cleared via the 
b i le  and kidneys. Labetalol is  less l ip o p h i l ic  than propranolol 
or oxprenolol and, the re fo re , may cross the placenta to a 
lesser extent.
The anti hypertensive properties of labeta lo l in non-pregnant 
patients have been well documented. The acute and chronic 
haemodynamic e ffec ts  of labeta lo l in hypertensive patients are 
qu ite d i f fe re n t  from those obtained with propranolol. Thus 
la b e ta lo l 's  anti hypertensive action is  la rge ly  due to a reduction 
in  to ta l peripheral resistance with only small changes in  heart 
rate and cardiac output, whereas ^ -adrenorecep tor blocking drugs 
tend to cause a decrease in cardiac output with an i n i t i a l  r ise  in  
peripheral resistance. To date over 100 pregnant women with 
hypertension o f varying aetio logy have been studied (Michael, 1979; 
Lamming, Broughton and Symonds, 1980) and two possible advantages 
of labeta lo l over anti hypertensive drugs used in  the management of 
high blood pressure in pregnancy have been suggested. F irs t  i t  
has been suggested that labeta lo l may encourage maturation of the
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fe ta l lung (Michael, 1980; Nicholas, 1978) and secondly, labetalo l 
may diminish the p ro te inuria  of patients who have developed 
pro te inuric  pre-eclampsia before commencement o f drug therapy 
(Michael, 1979). Recently work by Lunell (1982) suggests tha t 
labeta lo l has l i t t l e ,  i f  any, e ffec t on uterine blood flow.
I f  fu r th e r  studies confirm the e ff ica cy , apparent safety 
and good tolerance of labeta lo l in pregnancy, i t  may well become 
the drug o f choice fo r  the control o f hypertension in pregnancy.
The study undertaken assessed the use of oral labeta lo l in 
the management of mild to moderate pre-eclampsia. The aim was to 
reduce d ia s to l ic  blood pressure to less than 90 mmHg and to 
determine the e f fe c t  of a reduction in blood pressure on p la te le t
release and thrombin generation by the measurement o f plasma
leve ls  o f BTG and FPA. Plasma levels of BTG and FPA were also
determined in normal prenant women and pregnant women with in tra
uterine growth re tardation . Recently i t  has been suggested that 
a l l  hypertension in pregnancy and in tra  uterine growth re tardation 
should be considered to  have some ''superimposition o f pre-eclampsia" 
(Lewis, 1982).
6.3&. Design o f study
Four groups of patients were studied.
Group 1. Mild to  moderate pre-eclampsia (n = 9) c r i t e r ia :
(1) Hypertension consisting o f a % pro te inuria
<0.5g/day
Blood pressure >95 mmHg <110 mmHg in the th i rd  
tr im es te r o f pregnancy
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This group received drug administration according 
to  the fo llow ing protocol.
Labetalol tab le ts  (Glaxo Group Research L td . ,
Greenford, England) were administred at a s ta r t in g  dose 
o f 100 mg b.d. Dose was increased d a i ly  according to 
the schedule below u n t i l  a d ia s to l ic  blood pressure 
<90 mmHg or the maximum d a i ly  dose of 1200 mg is  reached.
Dose Schedule
Dose level 1 100 mg b.d.
Dose level 2 200 mg b.d.
Dose level 3 300 mg b.d.
Dose level 4 400 mg b.d.
Dose level 5 400 mg t . i . d .
Patients remained in hospital fo r  the duration o f the study. 
Group 2
As fo r  group 1 but no drug administration was given (n = 13). 
Blood samples were obtained pre, 1 week, post la s t 
treatment and a f te r  de live ry .
Group 3 .
In t ra  uterine growth re tardation (n = 8 ) .
Group £ .
Normal pregnancy (n = 21): c r i t e r ia
(1) Uncomplicated pregnancy free from hypertension, 
oedema and proteinurea in the th i rd  tr im es te r of 
pregnancy.
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Should d e live r  in fan t of normal weight.
A l l  groups were matched fo r  age, p a r i ty ,  and gestation.
6 .2 .3 . Results
B1ood pressure
The blood pressure values obtained are shown in Table 6.4,
Blood pressures were taken from the l e f t  arm by the same operator 
on each occasion. S ig n if ic a n t ly  higher differences were in 
pregnant women with pre-eclampsia when compared to normal pregnant 
women and pregnant women with I.U.G.R. D ias to lic  blood pressures 
were lowered with labeta lo l adm inistra tion.
Betathrombogiobuli n
Plasma BTG leve ls are shown in Figure 6.3. No s ig n if ic a n t  
d ifferences were found between the normal pregnant women with
I.U.G.R. or pregnant women with pre-eclampsia e ith e r before or 
a f te r  drug treatment, or without drug treatment.
Fibrinopeptide A
Plasma FPA leve ls are shown in Figure 6.4. Elevated plasma 
levels of FPA were found in pregnant women with I.U.G.R. and 
pre-eclampsia when compared to  normal pregnant women. This
elevation was s t a t is t i c a l l y  s ig n if ic a n t  in the pregnant women with
I.U.G.R. In the group treated with la b e ta lo l,  higher FPA levels 
were obtained a f te r  treatment and s t a t is t ic a l l y  elevated levels 
were obtained a f te r  de live ry .
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TABLE 6 .1 .
BLOOD PRESSURE VALUES (mmHg) IN GROUPS STUDIED
(MEAN VALUES)
Group
Studied
Pre Post  (7 days 
t r e a t m e n t )
Post
D e l i v e r y
S y s t o l i  c /  
D i a s t o l i  c
S y s t o l i  c /
Di a s t o l i  c
S y s t o l i  c /  
Di ast o l i c
P r e - e c l a m p s i a  
L a b e t a l o l  
t r e a t m e n t
P re - ee la mp s i a  
n o n - t r e a t m e n t
I . U . G . R .
Normal
pregnancy
14 0 / 9 4* *
135 /93*
125/81
115/71
133/89
133/91
128/83
130/86
* * p <0 . 0 2 * p <0.05
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60*
5 0 -
BTG
(ng/m\)
40
3 0 -
r i r *
10l I (0(2 I CO£ I
Pre-eclam psia  
Treatm ent group
Pre-eclampsia  
N o n-trea tm en t 
group
lUGR NP
Figure 6.3
Betathromboglobulin levels in each of the 
four groups studied. P/delivery denotes 
post delivery, lUGR-intra uterine growth 
retardation, NP-normal pregnancy.
219
p<  0*02
10-
8 -
FPA 
(ng^l)
6 -
i
“î l
4 -
2 - I .-S i I i
Pre-eclam psia  
Treatment group
Pre-eclam psia  
Non- treatment 
group
iU G  R N P
Figure 6.4.
Fibrinopeptide A levels in each of the 
four pregnancy groups studied.
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6_A, Discusslon
In the i n i t i a l  study no increase in plasma levels of BTG was 
found in  women taking oral contraceptives, in  contrast to two 
previous reports {Arandi et a l . ,  1979; Duncan, 1979).
Neither was there any increase in  plasma leve ls o f FPA. During 
normal pregnancy s ig n if ic a n t  increases in BTG leve ls were observed 
in  the second and th i r d  tr im es te r of pregnancy. This suggests 
p la te le t  ac t iva t ion  is  occurring in  normal pregnancy which is  in 
agreement with a report of a s l ig h t  decrease in  p la te le t  surviva l 
in  normal pregnancy (Rakoczi, T a l l ia n ,  Bagdany et a l . ,  1979). No 
increase in  FPA leve ls was observed, suggesting no detectable 
increase in  thrombin generation in normal pregnancy. This 
f ind ing  suggests tha t the increased soluble f i b r in  monomer 
complexes in normal pregnancy (McKillop et a l . ,  1976) 
may be due e ith e r  to increased thrombin generation which 
cannot be detected by the FPA assay, or to other mechanisms 
which may promote f ib r in  complex formation such as increased 
fibr inogen levels (Kanaide and Shainoff, 1975).
Pregnant women with pre-eclampsia had s ig n if ic a n t  increases 
in  plasma BTG, when compared to normal pregnant women, as 
previously reported (Redman et a l . ,  1977). These f ind ings 
are consistent w ith previously reported p la te le t  ac t iva t ion  
(Whigham, Howie, Drummond et a l . ,  1978) and decreased 
p la te le t  survival in  pre-eclampsia (Rakoczi et a l . ,  1979).
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S ig n if ica n t increases in plasma levels of FPA were shown, 
consistent with previous suggestions of increased thrombin 
generation in  pre-eclampsia (Bonnar et a l . ,  1971;
McKillop et a l . ,  1976). S im ilar but less marked changes were 
found in pregnant women with hypertension without p ro te inuria  
suggesting re la tionsh ips between ac tiva tion  of coagulation and 
p la te le ts  and pregnancy hypertension.
In the second study no increase in  plasma leve ls o f BTG 
was found in pregnancy hypertension or mild pre-eclampsia, 
despite s im ila r  mean values being found fo r  the normal pregnant 
women in  the th i r d  tr im es te r of pregnancy in both studies.
Although s im ila r  elevated levels of plasma FPA were found in  
pregnant women with hypertension in both studies, in  the labeta lo l 
study these differences were not s ig n if ic a n t  as higher FPA levels 
were found in  the normal pregnant women in the th i r d  tr im es te r of 
pregnancy. This f ind ing  would be consistent with increased 
soluble f i b r in  complexes reported in  normal pregnancy (McKillop 
et a l . ,  1976). A s t a t i s t i c a l l y  s ig n if ic a n t  increase in  FPA 
levels in women with in trau te r ine  growth re tardation  when 
compared to normal pregnant women was found. This suggests an 
increased thrombin generation Wiich may resu lt in f i b r in  
deposition in the placental bed with retarded growth of the 
fetus as a re s u lt .
In summary these resu lts  suggest that from the haemostatic 
aspect, elevated FPA leve ls in the I.U.G.R. pregnancy hypertension 
or mild pre-eclampsia and severe pre-eclampsia and elevated BTG 
in severe pre-eclampsia may re f le c t  a continuous spectrum o f 
disease ra ther than separate disorders, as has been suggested
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recently  (Lewis, 1982). The i n i t i a l  study suggested a 
re la t ion sh ip  between hypercoagulability  and hypertension, and that 
possibly increasing blood pressure per se may lead to secondary 
ac t iva t ion  of the coagulation system. A recent study measured 
plasma BTG levels in mild to severe a r te r ia l  hypertension and 
reported tha t disturbances of p la te le t  function were correlated 
with the stage of hypertension (P e tra l i to ,  Fiore, Mangiafico 
et a l . ,  1982). As shown in  the second study oral labeta lo l 
does lower d ia s to l ic  blood pressure without any resu ltan t decrease 
in  p la te le t  ac t iva t ion  or thrombin generation. This suggests 
tha t once the suggested vicious c i r c le  of hypertension, in t r a ­
vascular coagulation and de te r io ra ting  renal function (Page, 1972; 
Gavras, O live r, Aitchison et a l . ,  1975) has been tr iggered , 
blockage of one event (hypertension) has no e f fe c t  on the progress 
of other events. Until more is  known about the underlying mechanisms 
in  pre-eclampsia drug therapy must be c lose ly monitored to measure as 
many factors with regard to a l l  the systems concerned. In the second 
study labe ta lo l adm inistra tion also resulted in s ig n i f ic a n t ly  higher 
levels of plasma FPA a f te r  de live ry  and fu r th e r  studies are 
suggested to c la r i f y  th is  s i tu a t io n .
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CHAPTER 7
CHANGES JN PLASMA FIBRINOPEPTIDE A, BETATHROMBOGLOBULIN 
AND B 015-42 IN VENOUS THROMBOSIS AND IN PATIENTS WITH 
A HIGH RISK OF DEVELOPING DVT. WITH STUDIES ON 
ENHANCEMENT OF ENDOGENOUS FIBRINOLYSIS.
In th is  chapter studies were undertaken to determine 
whether plasma leve ls of f ib r inopep tide  A (FPA), betathrombo­
g lobu lin  (BTG) and B^15-42 were abnormal in a va r ie ty  of 
medical conditions associated with a high r is k  o f venous 
thrombosis as well as in  patients with a high r is k  o f post­
operative deep vein thrombosis (DVT). Venous thrombi are 
composed p r im a r i ly  of f i b r in  in which are enmeshed red blood 
c e l ls ,  white c e l ls  and p la te le ts .  Such in travascu lar f i b r in  
deposition may th e o re t ic a l ly  be the resu lt of decreased 
f ib r in o ly s is  as well as increased f i b r in  formation (Fearnley, 
1965) and abnormal p la te le t  release. In the f i r s t  study 
described in th is  chapter (7.1) I have compared patients with 
longstanding re t in a l vein occlusion with control subjects.
In the next study (7.2) plasma BTG levels were measured in  
patients w ith the nephrotic syndrome, who have a high r is k  of 
DVT, and compared to control subjects. The th i r d  study (7.3) 
analysed plasma 8^15-42 leve ls in a group of volunteers who 
received the anabolic s tero id  stanozolo l, an agent proven to  
a l te r  many haemostatic parameters. The fourth  study (7.4) 
evaluated the re la t ionsh ip  o f BTG, FPA and 8^15-42 to  
post-operative DVT and examined the ro le of malignancy and 
stanozolol treatment. In the f in a l  study (7.5) plasma BTG
2 2 4
levels were measured in 'acute' i l lnesses such as malignancy 
and in fe c t io n  and compared to control pa tients , with the 
ro le  of age and obesity also being considered. A summary 
of these resu lts  is  given in 7.6.
Z-1- Plasma FPA and BTG in Longstanding Retinal Vein Occlusion 
Introduction
Retinal vein occlusion has several well recognised c l in ic a l  
associations, including hypertension, hyperlipidaemia, diabetes, 
polycythaemia and hypergammaglobulinaemia (McGrath, Wechsler, 
Hunyor et a l . ,  1978). The la t t e r  two disorders cause increased 
blood v is c o s i ty ,  which slows re t ina l blood flow (Hume and Begg, 
1969). Increased blood v iscos ity  resu lts  in  a higher 
haematocrit and resu ltan t higher fibrinogen concentration 
which in  association with reduced re t in a l blood flow might 
resu lt in f i b r in  deposition and the formation of thrombi w ith in  
the re t in a l area. Two previous studies reported increases in 
haematocrit, v is c o s i ty ,  fibrinogen and immunoglobulins in acute 
venous occlusion (Ring, Pearson, Sanders et a l . ,  1976; McGrath, 
Wechsler, Hunyor et a l . ,  1978). No studies have evaluated 
longstanding re t in a l vein occlusion. I t  is  possible, 
the re fo re , th a t the increase in v iscos ity  might be the resu lt 
of an acute vascular event as the plasma fibrinogen level is  
known to increase in  a va r ie ty  of acute i l lnesses (Lowe, 1981). 
In add it ion , in  both studies patients with re t in a l vein 
occlusion, h a l f  of whom had hypertension were compared with 
control subjects without hypertension. Since there is  now 
good evidence tha t increased levels of blood v is c o s ity ,  
haematocrit and f ibr inogen are found in subjects with 
hypertension (Letcher, Chien, Pickering et a l . ,  1981), the
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increased blood v iscos ity  reported and hence the increased 
f ibr inogen in both studies might be the resu lt  of the 
hypertension ra ther than the re t ina l vein occlusion. The 
increased f ibr inogen concentrations in re t in a l vein occlusion 
suggests tha t abnormal coagulation, p la te le t  and f ib r in o ly t i c  
a c t iv i t y  might play a ro le  in re t in a l vein occlusion or i t s  
ischaemic complications, especia lly  i f  thrombosis contributes 
to vascular occlusion. The measurement of plasma BTG, FPA 
and fibr inogen should provide d irec t evidence of p la te le t  
ac t iva tion  and thrombin generation in re t in a l vein occlusion.
Design o f study 
Forty two unselected patients with re t ina l vein occlusion 
who were attending ophthalmology departments in  Glasgow 
hospitals were studied a f te r  informed consent. A ll were in 
the chronic phase (three months to three years) since onset 
of symptoms. A ll  underwent f u l l  Ophthalmological and medical 
assessment, inc lud ing fluorescein angiography and screening fo r  
hypertension and diabetes, which were treated appropria te ly.
T h ir ty  three control subjects were selected from patients 
attending hypertension c l in ic s  and patients admitted fo r  
e lective  surgery. This group was matched fo r  age, sex, 
smoking hab it, diabetes, hypertension, and treatment of 
hypertension with the re t in a l vein occlusion group. A ll 
subjects were ambulant and none had any acute i l ln e s s .  The 
patients were subdivided in to  those who had c a p i l la ry  non 
perfusion and/or neovascularisation at fluoresce in  angiography. 
Group 1 (20 patients) and those who did not. Group 2 (22 pa tien ts ).
226
Methods
Serum immunoglobulins were measured by automated immuno­
p ré c ip ita t io n .  Blood was collected in to  trisodium c i t r a te ,
0.129M, 9:1 V.V. fo r  the measurement of fibr inogen as previously 
described (Lowe, McArdle, Stromberg et a l . ,  1982). Plasma BTG 
was measured using the Amersham radioimmunoassay k i t  as 
described in  Chapter 5.3.2. Plasma FPA was measured using the 
IMCO radioimmunoassay with ethanol p re c ip ita t io n  to  remove the 
cross-reacting fibrinogen and charcoal separation to remove 
free  ^ ^ I  FPA as described in Chapter 5.4.2 (/\) and 5.4.2 (B). 
S ta t is t ic a l  analysis
S ta t is t ic a l  s ign if icance of d ifference in means was performed 
using Wilcoxon's rank sum te s t .
Results
C lin ica l Variables and Immunoglobulins
As shown in Table 7.1. 20 subjects with re t in a l vein 
occlusion had c a p i l la ry  non perfusion and/or neovascularisation 
at f luorescein angiography (Group 1) and 22 did not (Group 2).
52% of patients had hypertension and 52% had increased levels 
of at least one class of immunoglobulin in the fo llow ing order 
o f frequency: IgM, IgG, IgA. No patient with raised immuno­
g lobu lin  had a d e f in i te  haemoproliterative or connective t issue 
d isorder. Table 7.1. shows tha t there were no s ig n if ic a n t  
differences in c l in ic a l  factors or immunoglobulin abnormalities 
between Groups 1 and 2.
PIasma fibr inogen
A s ig n i f ic a n t ly  higher fibrinogen concentration was found 
in  group 1 ( c a p i l la ry  non perfusion and/or new vessels) when 
compared to group 2 or the control group (see Figure 7 .1 ).
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TABLE 7.1
CLINICAL FEATURES AND IMMUNOGLOBULINS IN PATIENT GROUPS
RETINAL VEIN OCCLUSION CONTROLS
GROUP 1 
(C ap il la ry  non-perfusion 
and/or neovascularisation)
GROUP 2 
(No non-perfusion 
or neovascularisation)
Number 20 22 33
Age (years) 67.6 (SEM 2.1) 6 6 . 6  (2.4) 66.7
Males 13 8 17
Smokers 2 8 9
Hypertension 13 9 17
Diabetes 1 2 2
S ite : Central 10 14
Branch 8 8
Both . 2 0
Abnormal Immunoglobulins 7/12
SEM: Standard e rro r  o f mean in parentheses
7/16
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4 -
3 -
Group 1 Groupa TotalControls
Retinal vein 
occiusion
RVO
Figure 7.1
Plasma fibrinogen levels in each of the 
groups studied. Group 1 denotes patients 
with capillary non perfusion and/or new 
vessels. Group 2 denotes patients without 
capillary non perfusion. RVO denotes 
retinal vein occlusion.
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Plasma betathrombogiobulin
Subjects in group 1 had s ta t is t i c a l l y  higher levels of 
BTG 43 ± 6 ng/ml (p <0.05) when compared to group 2,
32 ± 4 ng/ml, and the control group, 27 ± 2 ng/ml. BTG levels 
in  the to ta l re t in a l vein occlusion group, 37 ± 4 ng/ml (p <0.05) 
were also s ig n i f ic a n t ly  higher than group 1 and the control 
group (see Figure 7 .2 ).
Plasma FPA
Plasma FPA leve ls were s ig n i f ic a n t ly  higher in  group 1,
7.2 ± 2.8 ng/ml (p <0.05) when compared to group 2, 1.3 ±
0.2 ng/ml, the to ta l re t in a l vein occlusion group, 4.1 ± 1.4 
ng/ml and the control group, 1.0 ± 0.3 (see Figure 7 .3 ).
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100-
4 0 -
20-
Q ro u p l G roup2 TotalControls
Retinal vein 
occlusion
RVO
Figure 7.2
Plasma betathrombogiobulin levels in each of the 
groups studied.
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Figure 7.3
Plasma FPA levels in each of the groups studied.
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Discussion
This study has shown tha t patients with longstanding 
re t in a l vein occlusion who have c a p i l la ry  non perfusion and/or 
new vessel formation (group 1 ) have increased fibrinogen 
le ve ls , FPA and BTG leve ls . In patients with re t in a l vein 
occlusion but without ischaemic complication (group 2 ) no 
abnormalities were found in fib r inogen, FPA or BTG leve ls in 
comparison to  those in the control group. The increase in 
fibr inogen and immunoglobulin levels in group 1 is  s im ila r  to  
previous reports (Ring et a l . ,  1976; McGrath et a l . ,  1978).
The present f ind ing o f a re la tionsh ip  o f increased fibrinogen 
leve ls with c a p i l la ry  non perfusion d i f fe rs  from a previous 
report (Ring et a l . ,  1976). I t  may be that since the previous 
study examined patients in the acute phase of re t in a l vein 
occlusion (Ring et a l . ,  1976), acute phase increases may have 
obscured a re la t ionsh ip  with c a p i l la ry  non perfusion.
Uncertainty surrounds the question o f whether or not increased 
fibr inogen levels favour the formation o f a thrombus (Lowe, 1981) 
but patients in group 1 had increased levels o f FPA suggesting 
tha t thrombin generation is  present in some subjects w ith c a p i l la ry  
non perfusion.
P la te le t ac t iva t ion  and consumption in d iabe tic  retinopathy 
has been suggested by a lowered p la te le t  count (F u l le r ,  Keen,
Ja rre t et a l . ,  1979) and increased plasma BTG leve ls (Scheimthaner, 
Sinzinger, Silberbaur et a l . ,  1981). The observed increased 
plasma BTG leve ls in group 1 suggest tha t p la te le t  ac t iva t ion  is  
a feature o f ischaem ic /p ro life ra tive  retinopathy a f te r  re t in a l 
vein occlusion and may be involved in re t ina l vein occlusion and 
i t s  complications.
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Z * l*  Plasma BTG Levels 1n the Nephrotic Syndrome 
Z 'Z ‘i *  In troduction
Patients with the nephrotic syndrome (NS) present a 
group of patients with an increased r is k  of venous thrombosis, 
including renal and deep vein thrombosis (Chugh, Ma l i c k ,
Uberoi et a l . ,  1981). The p o s s ib i l i ty  of increased a r te r ia l  
disease is  somewhat controversial (M ailick  and S ho ir t ,  1981;
Wass and Cameron, 1981). Selective urinary loss o f low 
molecular weight proteins resu lts  in plasma protein 
abnormalities cha rac te r is t ic  o f NS. A resu ltan t increased 
hepatic synthesis o f both low and high molecular weight prote ins, 
include proteins tha t p a rt ic ip a te  in coagulation and f ib r in o ly s is  
(Thomson, Forbes, Prentice et a l . ,  1974). C lo tt ing  fac to rs , 
including plasma fibrinogen and fa c to r  V I I I  (Thomson et a l . ,
1974; Kanfer, Kleinknecht, Broyer et a l . ,  1971; Kendall, 
Lohmannand and Dosseter, 1971) and f ib r in o ly t i c  factors 
such as plasminogen and a ^^macroglobulin (Thomson et a l . ,1974) 
are increased. Urinary loss may re su lt  in decreased 
concentrations o f other low molecular weight in h ib i to rs  such 
as ATIII (Kauffmann, Veltkamp, von Tilberg et a l . ,  1978) and 
a 2 -antip lasmin (Taberner, Ralston and A c k r i l l ,  1981). Some 
of these disturbances (increased fibrinogen and fa c to r  V I I I ;  
decreased A T III)  may be relevant to  the increased r is k  of 
thrombosis in NS as may the r ise  in p la te le t  count (Kanfer
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et a l . ,  1971; Walter, Deppermann, Andrassy et a l . ,  1981), 
increased p la te le t adhesiveness and aggregation (Walter et 
a l . ,  1981) and increased p la te le t  release as shown by 
increased plasma leve ls of BTG (Adler, Lundin, Feinroth et a l . ,  1980; 
Tomura, Ida, Kuriyama et a l . ,  1982). Plasma BTG leve ls were 
measured in patients with NS and matched con tro ls . Controls 
were matched fo r  renal function (as measured by serum 
c re a t in in e ) ,  since several haemostatic variables are abnormal 
in  renal fa i lu re  as previously discussed.
Z-Z'Z* Design o f study
Twenty one consecutive patients with the nephrotic 
syndrome were studied. A ll had prote inuria  greater than 
3 g/24 hours and serum albumin less than 35 g / l i t r e  at the 
time of study. Most were taking d iu re t ic  drugs. Twenty one 
controls were selected from hospital s ta f f  or non-nephrotic 
renal un it pa tients . They were matched fo r  age, sex, smoking 
habit and serum c rea tin ine  with the nephrotic subjects. No 
subjects were taking anticoagulants or anti p la te le t  drugs at 
the time of study.
Z*Z'Z* Method
Plasma BTG was measured using the radioimmunoassay k i t  
(Amersham) as previously described. No PGEj was added to the 
blood sampling tubes. In nephrotic subjects, serum albumin, 
g lobu lin  and crea tin ine  were measured by Technicon Auto-analyser 
w ith crea tin ine  clearance and quan tita t ive  pro te inuria  being 
measured as previously described (Thomson et a l . ,  1974).
S ta t is t ic a l  analysis
S ta t is t ic a l  s ign if icance of differences in means was performed 
using Wilcoxon's rank sum te s t ,  and corre la tions determined by the 
least squares method.
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TABLE 7.2
C lin ica l and routine biochemical d e ta i ls  (mean ± SEN) 
o f nephrotic patients studied
Number 21
Mai es 17
Smokers 6
Age 39.4 ± 3.6
Serum albumin (g/1) 25 ± 1.1 (normal 35-55)
Serum g lobu lin  (g/1 ) 27.9 ± 0.9 (normal 22-33)
Serum cholesterol (mmol/1) 9.3 ± 0.8 (normal 4.1-7.4)
Serum crea tin ine  ( mol/1) 252 ± 41 (normal 40-130)
Urine prote in (g/24 hr) 13.0 ± 1.6 (normal <0 . 2 )
Creatinine clearance (ml/min) 56 ± 9 (normal 90-1.30)
Type o f h is to log ica l disease 
Membranous glomerulonephritis 
Minimal change glomerulonephritis 
P ro l i fe ra t iv e  glomerulonephritis 
Focal glomerulonephritis 
SLE
Amyloid
Cryoglobuli naemia
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Figure 7.4.
Plasma betathromboglobulin levels 
in patients with the nephrotic 
syndrome and controls.
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Results
C lin ica l de ta i ls  of the nephrotic patients are given in 
Table 7,2. No patient had active thrombosis at the time of 
study, but seven had a past h is to ry  of venous or a r te r ia l  
thrombosis. A s t a t is t i c a l l y  s ig n if ic a n t  increase in  plasma 
BTG was found in  the NS patients when compared to the control 
group as shown in  Figure 7.4. In the NS patients there was no 
co rre la t io n  between BTG and serum albumin, g lo bu lin ,  cho les te ro l, 
c re a t in in e , urine protein or creatin ine  clearance.
No variable was s ig n i f ic a n t ly  d i f fe re n t  in the patients 
with a h is to ry  of thrombosis compared to those without such h is to ry .  
2 'Z 'Z '  Discussion
A s ig n i f ic a n t  increase in  plasma BTG levels was shown in 
patients with nephrotic syndrome, confirming previous reports 
of increased plasma BTG levels in  NS (Adler et a l . ,  1980;
Tomura, Ida, Kuriyama et a l . ,  1982). These resu lts  may 
re f le c t  p la te le t  ac t iva t ion  in  v ivo. In a fourth  
study, no s ig n if ic a n t  increase in  BTG was observed (Walter et a l . ,  
1981). A ll four studies used the Amersham BTG k i t .
Recently low albumin leve ls have been suggested to in te r fe re  
w ith the BTG assay (Dr C Ludlam, personal communication).
Plasma leve ls o f BTG were not correlated with serum albumin 
levels in th is  present study.
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Z * l*  Plasma B|jl5-42 in £  Volunteer Study of Stanozolol Treatment 
Z * l * i *  In troduction
Decreased f ib r in o ly s is  w ith inapproprite deposition of 
in travascu lar f i b r i n ,  may play a ro le  in several vascular 
diseases (Aimer, Pandolfi and Nilsson, 1975; Walker and Davidson 1978; 
Burnand, Whimster, Naiddo et a l . ,  1982). Blood f i b r in o ly t i c  a c t iv i t y  
has been shown to be increased a f te r  the oral adm inistra tion 
of anabolic s te ro ids , such as stanozolol (Stromba, S te r l ing  
Research Laboratories, England)to normal subjects (Davidson,
Lockhead, McDonald et a l . ,  1978; Preston, Burakowski,
Porters et a l . ,  1981) and in patients with vascular diseases 
(Burnand, Clemenson, Norland et a l . ,  1980; Ja rre t ,  Norland 
and Browse, 1978). A fte r  a single intramuscular in je c t io n  of 
50 mg stanozolol in  healthy volunteers we have shown a 
s ig n if ic a n t  stimulated r ise  in  plasma f ib r in o ly t i c  a c t iv i t y  
(plasminogen ac t iva to r)  as well as plasma plasminogen le ve ls ,  
w ith in  24-48 hours (Small, McArdle, Lowe et a l . ,  1982).
However th is  increased level of plasminogen a c t iva to r  ind icates 
only a potentia l fo r  s tim ula tion of plasmin-mediated f ib r in o ly s is  
and therefore a p o s s ib i l i ty  fo r  treatment of thrombotic disorders. 
Systemic f ib r in o ly s is  with raised FDP's does not occur with 
stanozolol but is  observed a f te r  streptokinase and urokinase 
therapy.
With the recent in troduction  of the radioimmunoassay fo r  
fragment B|S15-42 which is  released during the e a r l ie s t  stage 
of plasmin p ro teo lys is , (Kudryk, Robinson, Netre et a l . ,  1982), 
a new marker may now be available fo r  the measurement of f i b r in o ly t i c  
a c t iv i t y .
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Design o f Study
Plasma levels o f B ^ 15-42 and fibrinogen were measured in nine 
healthy male subjects, age 19-35 years, before, during and a f te r  
a 14 day course of treatment with stanozolol (Stromba, S ter l ing  
Research Laboratories, England 10 mg o ra l ly /d a y ).
Z * l * l *  Methods
Plasma B ^ 15-42 leve ls were measured as described in 
Chapter 5 .5 .1 . Plasma fibrinogen levels were measured on the 
Dade fibrometer. S ta t is t ic a l  s ign if icance o f d iffe rence in 
means was performed using Wilcoxon's rank sum te s t .
2 .2 -4 . Results 
Plasma B^15-42
The plasma B ^ 15-42 leve ls  obtained are shown in  Table 7.3.
BySl5-42 leve ls  increased from 0.84 ± 0.15 (p <0.01) at 7 days, 
remained e le va te d  at 1.18 ± 0.13 (p <0.05) on day 14 and 
returned to baseline values o f 0.9 ± 0.19, 14 days a f te r  cessation 
o f therapy.
Plasma fibrinogen
The plasma fibr inogen leve ls observed are shown in Table 7.3. 
Plasma fibrinogen leve ls decreased from 2.32 ± 0.12 g/1 
(mean ± SEM) to  1.57 ± 0.1 (p <0.01) at seven days, remained 
decreased at 1.71 ± 0.09 (p <0.01) on day 14 and returned to 
baseline values 2.44 ± 0.20, 14 days a f te r  cessation o f treatment.
TABLE 7.3.
PLASMA B ^ 15-42 LEVELS IN VOLUNTEERS
(MEAN ± SEM, **£  <0.01, *£ < 0 .^ )
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DAYS 14 28
Bygl5-42
pmol/ml
0.84 
± 0.10
1.54** 
± 0.15
1.18* 
± 0.13
0.9 
± 0.19
Fibrinogen
g/1
2.32 
± 0.12
1.57** 
± 0.10
1.71** 
± 0.09
2.44
0.20
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Discussion
The find ings of th is  study are consistent w ith an increase
in  plasmin-mediated ly s is  of f ib r in (o g e n ) . A well recognised
decrease in  f ib r inogen levels with stanozolol was also observed 
(Walker and Davidson, 1978; Preston et a l . ,  1981).
This decrease in  f ibr inogen levels may be due to altered 
synthesis (Preston et a l . ,  1981) or may in part be explained by 
plasmin a c t iva t io n . Plasma levels of 8^15-42 may therefore be 
used as a marker of plasmin-induced f ib r in o ly s is .  These volunteer 
obvservations were then extended to a study in  high r is k  post­
operative patients treated with stanozolol in  an attempt to 
prevent DVT.
2 .4 . Relationship o f BTG, FPA and B^ 15-42  to  post-operative
DVT, Maiignancy and Stanozolol Treatment
Z - l * l -  In troduction
The occurrence o f venous thrombosis remains an important, 
cause of post-operative morbidity and m o rta l i ty .  Venous 
thrombi cannot be diagnosed on c l in ic a l  grounds alone with 
s u f f ic ie n t  precision fo r  s c ie n t i f ic  studies. Venography enables 
venous thrombi above a certa in  size to be id e n t i f ie d  accurately 
in the deep veins of the leg, with venous thrombi ( in  the c a l f  only) 
being id e n t i f ie d  by ^ ^ I - la b e l le d  fibrinogen scanning. Pulmonary 
thromboemboli can be diagnosed safe ly but imprecisely using isotope 
lung scans, o r precise ly but with greater hazard (and therefore 
greater patient se lection) using pulmonary arteriography.
Changes occurring in  blood coagulation tha t i n i t i a t e  the 
development of post-operative deep vein thrombosis (DVT) may allow 
a more precise id e n t i f ic a t io n  of venous thrombosis. However such
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changes in blood coagulation remain the subject of speculation.
A previous study reported tha t the prediction of DVT in post 
gynaecological surgery patients was improved by including • 
laboratory var iab les, and found s ig n if ic a n t  p red ic tive  value fo r  
pre-operative values of eug lobu lin - lys is  time, f ib r in - re la te d  
antigen, f ib r inogen , and fa c to r  V I I I  in patients in  whom DVT 
developed (Clayton, Anderson and McNicol, 1976). An increase 
in  pre-operative blood v iscos ity  has also been associated with 
post-operative DVT (Dormandy 1975). In our recent study, which 
examined the incidence of deep vein thrombosis of the leg a f te r  
major gas tro in tes t ina l surgery without prophylaxis, a comprehensive 
evaluation of pre-operative c l in ic a l  and laboratory variables 
including BTG, showed no re la t io n  between DVT a f te r  surgery and 
haemostatic variables (Lowe, Osborne, McArdle et a l . ,  1982).
This f ind ing is  in agreement with most previous studies which 
observed no re la t ion sh ip  between DVT a fte r  surgery and pre­
operative haemostatic variables (F lu te , Kakkar, Renney et a l . ,
1972; Gal lus , Hirsh and Gent, 1973; Mansfield 1972; Gordon- 
Smith, Hickman, Lequesne 1974; MacIntyre, Webber, Crispin et a l . ,  
1976) or pre-operative blood v iscos ity  (Humphreys, Walker and 
Charlesworth, 1976; Lowe, Campbell, Meek et a l . ,  1978). The 
study o f Lowe et a l . ,  1982a, observed s ig n if ic a n t  elevations 
in  plasma and blood v is c o s ity ,  f ib r inogen, fa c to r  V I I I  
and f ib r in - re la te d  antigen in  patients with malignancy, 
in fe c t io n  or hyperbilirubinaemia before surgery. Since over h a lf  
the patients had malignancy, in fe c t ion  or hyperbilirubinaemia 
before surgery, the fa i lu re  of laboratory tests to predict DVT 
may be explained by the re la t io n  between the tes ts  and the i l ln e s s  
i t s e l f ,  whereas i l ln e s s  is  not c losely related to venous thrombosis.
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Pre-operative i l ln e s s  may mask any re la tions between
laboratory variables and DVT which may be more apparent
in less sick pa tien ts , such as e lec tive  surgery in gynaecological
patients (Clayton et a l . ,  1976). The above study
of Lowe et a l . ,  1982, reported tha t a simple index of age and
per cent overweight allowed pred ic tion of a h igh -r isk  group
(incidence o f DVT >51%) and a low r is k  group (incidence o f
DVT <10%). The f ind ing of no re la t ion  between DVT a f te r  surgery
and pre-operative haemostatic variables may have been due in part
to  a lack of adequate methodology with which ac tiva t ion  of
coagulation in vivo can be monitored. With the advent of
radioimmunoassays fo r  the detection of peptide fragments of f i b r in
(ogen) released by the major proteases of the coagulation system
and f ib r in o ly t i c  systems ie . thrombin and plasmin new markers
may now be ava ilab le to assess the development of thrombotic disease
in  re la t io n  to thrombin and plasmin a c t iv i t y  as well as with regard
to p la te le t  release.
I t  has been shown by many workers tha t fo llow ing major 
e lective surgery there is  a decrease or 'shut-down' of blood 
f i b r in o ly t i c  a c t iv i t y  (plasminogen ac t iva to r a c t iv i t y )  which is  
maximum on the f i r s t  day a f te r  surgery. Since the m a jo r ity  of 
postoperative DVT form at th is  time (Negus, P into, LeQuesne et a l . ,  
1968), i t  is  possible tha t a decrease in plasmin a c t iv i t y  at th is  
point would resu lt  in an imbalance in the thrombin : plasmin 
ra t io  with thrombin action predominating and hence thrombosis as 
suggested by Nossel (1981) see Figure 2.1. Some studies have 
reported a greater degree of f i b r in o ly t i c  shut down in  patients who 
develop DVT (Mansfield 1972; Gordon-Smith et a l . ,  1974) while others 
have not (Gal lus et a l . ,  1973; MacIntyre et a l . ,  1976). Such
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c o n f l ic t in g  resu lts  may be due p a rt ly  to the e ffe c t of other parameters 
on blood f i b r in o ly t i c  a c t iv i t y ,  such as malignant disease (Browse, Gray 
and Norland, 1977) or methodology (R e i l ly ,  Burden and Fossand, 1980).
Blood f i b r in o ly t i c  a c t iv i t y  has been shown to be increased by 
drug treatment w ith anabolic steroids such as stanozolol (Stromba, 
S te r l ing  Research Laboratories, England) when administered o ra l ly  
(Davidson et a l . ,  1972; Preston et a l . ,  1981). A recent study in 
healthy volunteers has shown tha t a single intramuscular in je c t io n  o f 
50 mg stanozolol stimulated s ig n if ic a n t  rises in plasma f ib r in o ly t i c  
a c t iv i t y  (plasminogen ac tiva to r)  as well as plasma plasminogen leve ls 
w ith in  24-28 hours (Small et a l . ,  1982). A fo llow-up study 
as described in  7.3. has shown d irec t evidence of an increase 
in  plasmin a c t iv i t y  a f te r  stanozolol treatment by the measurement 
of plasma 15-42 fragment which was s ig n i f ic a n t ly  elevated fo r  at 
least seven days a f te r  treatment. The aim of the present study 
was to measure plasma levels o f BTG, FPA and B ^ 15-42, indices of 
p la te le t  release, thrombin generation and plasmin a c t iv i t y  
re spec t ive ly , in  re la t io n  to postoperative DVT, malignancy and 
stanozolol treatment.
Design o f study
T h ir ty  two patients undergoing major e lec tive  surgery were 
studied. Seventeen patients underwent surgery fo r  ea rly  malignancy 
of the stomach, duodenum, ga ll bladder, colon or rectum. Each 
patient was a high r is k  o f postoperative DVT according to the age 
and obesity index of Lowe et a l . ,  1982 (age in  years plus 1.3 X 
per cent mean weight of a population of same age, sex and he ight, 
greater than 170). Informed consent was obtained from patients .
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A fte r  overnight fa s t in g ,  blood was taken between 8 and 10 am with 
minimal s tas is  as described in  Chapter 5.4.2. All patients were 
sampled on the day p r io r  to surgery, on the morning of surgery 
and on the f i r s t  and seventh day a f te r  surgery (postoperative days 
-1 , 0, 1 and 7 in  Figures 7.5, 7.6 and 7 .7 ). Seventeen control 
patients received no spec if ic  prophylactic drugs. The other 
15 patients received an intramuscular in je c t io n  of s tanozolo l,
50 mg in  1 ml, fo llow ing the day -1 sample.
Z'£*Z* Methods
Plasma BTG leve ls were measured as described in  Chapter 5.3.2. 
FPA leve ls were determined using the bentonite extraction  method 
fo r  the removal of cross-reacting fibrinogen and double antibody
1 2 .5 ’separation o f bound and free I FPA as described in  Chapter 5 .4 .3 . 
Plasma 15-42 was measured as described in  Chapter 5 .5 .1. 
S ta t is t ic a l  Analysis
S ta t is t ic a l  s ign if icance of differences of means was performed 
using Wilcoxon's rank sum te s t .
2 .1 .1 . Results
In order to determine the re la tionsh ip  of BTG, FPA and B ^  15-42 
to  postoperative DVT, malignancy and stanozolol treatment the 
overa ll patient population was studied under the three separate 
parameters. Group 1 divided the patient group in to  those patients 
who received no prophylactic treatment and those who received 
s tanozolo l. Group 2 divided the patient group in to  those patients 
who developed no DVT a f te r  surgery and those patients who did 
develop DVT postoperatively. Group 3 divided the patient group in to  
those patients who did not undergo surgery fo r  malignancy and those 
who did have surgery fo r  early  malignancy.
246
C lin ica l Petal 1 s 
Group 2
Seventeen patients received no prophylaxis. This group 
consisted of nine males and eight females. Nine patients 
developed a DVT postoperatively and eight had malignancy pre- 
opera tive ly . F ifteen patients (e ight males, seven females) 
received stanozolol treatment pre-operative ly. Five patients 
developed a DVT and nine had malignancy.
Group 2
Eighteen patients (ten male, e ight females) did not develop 
a DVT postoperative ly. Ten patients received stanozolol treatment 
and eight had malignancy. Fourteen patients (seven males, seven 
females) developed a DVT postoperatively. Five received stanozolol 
treatment and nine had malignancy.
Group _3
F ifteen patients (s ix  males, nine females) had no malignancy 
pre-operative ly . Six patients had stanozolol treatment and f ive  
developed a DVT postoperatively. Seventeen patients (11 males,
6 females) had early  malignancy. Nine received stanozolol
treatment and nine developed DVT post-operative ly.
Betathrombogiobul1n 
Group 2  (C ontro l: s tanozo lo l)
Plasma BTG in  the control group increased on day 1 (see 
Figure 7.5 (a ) ) ,  with a s ig n if ic a n t  increase being observed on 
day 7 (p <0.02) when compared to  day -1. In the stanozolol 
group s ig n if ic a n t  increases were observed on day 1 (p <0 . 0 1 ) 
and day 7 (p <0.002) when compared to  pre-operative day 0.
No s ig n if ic a n t  differences were obtained between the two groups.
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Figure 7.5
Plasma BTG levels in each of the groups studied.
Group 1 
Group 2 
Group 3
p <0.02
no prophylaxis: stanozolol.
no DVT postoperatively: DVT postoperatively
no malignancy preoperatively: 
malignancy preoperatively.
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Group Z (No DVT:DVT) - Figure
Plasma BTG in the control group increased on day 1 with a
s ig n if ic a n t  increase being observed on day 7 (p <0.02) when 
compared to day -1 . In the group who developed a DVT post­
opera tive ly , plasma BTG leve ls were greatly  elevated on day 1 
(p <0.02) and day 7 (p <0.02) when compared to day -1 . The
diffe rence between the two groups on day 1 was s ig n if ic a n t  (p <0.05).
Group _3 mal ignancy :mal ignancy) - Figure
Plasma BTG in the control group increased on days 1 and 7 
with the increase on day 7 being s ig n if ic a n t  (p <0.05) when 
compared to day -1 . In the group with malignancy increased levels 
in  day 1 were observed on days 1 and 7. The leve ls in day 1 
were s ig n if ic a n t  (p <0.05) when compared to day -1 . No s ig n if ic a n t 
differences were found on any o f the days between each group.
Plasma Fibrinopeptide A 
Group 1 -  Figure 7_.§_ ( a^ )
In the control group plasma FPA levels were s ig n i f ic a n t ly  
elevated on day 1 (p <0.005) and day 7 (p < 0.001) when compared 
to  day -1 . In the group receiving stanozolol treatment 
s ig n i f ic a n t ly  elevated FPA levels were found on day 1 (p <0.02) 
when compared to day -1 with less elevated levels on day 7.
There were no s ig n if ic a n t  d ifferences between the two groups.
Group Z -  Figure J_»6 (_b)
In the control group plasma FPA leve ls , were s ig n i f ic a n t ly  
elevated on day 1 (p <0.005) and day 7 (p <0.02) when compared to 
day -1 . In the group who developed a DVT, s ig n i f ic a n t ly  elevated
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Figure 7.6
Plasma FPA levels in each of the groups studied. 
* p<0.05
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values were found on day 1 (p <0.005) and day 7 (p <0.02) when
compared to day -1. The FPA level on day 7 in the DVT group
was s t a t is t i c a l l y  increased (p <0.05) compared to  the level in 
the control group on day 7.
Group Z - Figure 2'É(Ç.)
S ig n if ic a n t ly  elevated FPA levels were found on day 0
(p <0.005), day 1 (p <0.02) and day 7 (p < 0.005) in  the control
group when compared to  day -1 . In the group with malignancy 
s ig n i f ic a n t ly  elevated values were found on day 1 (p <0 . 0 1 ) and 
day 7 (p <0.05) when compared to day -1. A s ig n if ic a n t  
d iffe rence was observed in FPA levels in day -1 in the group with
malignancy (p <0.05) when compared to day -1 in the control group.
6^15-42
Group I  - Figure 7_.2 ( l )
In the control group a s ig n if ic a n t  d ifference in 15-42 
levels was found in day 7 (p <0.05) when compared to day -1.
In the Group receiving stanozolol treatment an elevated 15-42
level was observed which was s ig n if ic a n t  on day 7 (p <0.005 when
compared to  day -1. A s ig n if ic a n t  increase in Bygl5-42 levels 
was observed on day 7 between the stanozolol group (p <0.05) 
and the control group.
Group _2 - Figure _7.7  { b )
A s ig n if ic a n t  increase in B^15-42 levels was found in the 
control group on day 7 when compared to day - 1 . Although the 
value on day 7 in the DVT group was elevated, the d ifference 
when compared to day -1 was not elevated. However the Byô 15-42 
level on day 0 in  the DVT group was s ig n i f ic a n t ly  higher (p <0.05) 
than tha t of the control group.
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Figure 7.7
Plasma B ^  15-42 levels in each of the groups 
studied.
*  p <0.05
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Group 2  - Figure 2*Z (£)
In the control group there were no s ig n if ic a n t  differences 
in  the plasma 15-42 leve ls on any of the days measured. In 
the group who had malignancy a s ig n if ic a n t  d iffe rence was found on 
day 7 (p <0.001) in  8^15-42 leve ls when compared to day -1. 
s ig n i f ic a n t ly  elevated 8^15-42 leve ls  were found in  the malignancy 
group in day 7 (p <0.05} when compared to the control group.
Discussion
1. The prevalence of malignancy and the incidence of DVT were 
s im ila r  in  the two treatment groups. Thus stanozolol does 
not prevent the occurrence of DVT.
2. A ll groups of patients (see Figure 7.5) had a postoperative 
r ise  in  plasma 8 TG levels on day 1 and day 7 as reported 
previously (de Boer et a l . ,  1981; Lane et a l . ,  1982a).
3. A s t a t i s t i c a l l y  s ig n if ic a n t  increase in  plasma BTG leve ls was 
found on postoperative day 1 in  the group who developed a DVT 
when compared to the group who did not. This find ing  has not 
been reported previously although an increase in  BTG leve ls , 
which occurred a f te r  the postoperative day 1 increase, was 
reported ju s t  before the development o f DVT a f te r  surgery
(de Boer et a l . ,  1981).
4. A ll groups of patients ( see Figure 7.6) had a postoperative 
r ise  in  plasma FPA levels on day 1 as reported previously 
(Torngren et a l . ,  1979; Davies et a l . ,  1980; Lane et a l . ,  1982a; 
Owen et a l . ,  1983).
5. A s ig n i f ic a n t  increase in  plasma FPA levels was found on 
postoperative day 7 in the group who developed a DVT when
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compared to the group who did not. This find ing  contrasts 
with a previous report which found no s ig n if ic a n t  d iffe rence 
in  the FPA leve ls in the groups with and w ithout DVT on 
postoperative day 7 (Lane et a l . ,  1982a). This d iffe rence 
may be due to d ifferences in the occurrence of actual thrombosis,
6 . In patients undergoing surgery fo r  ea rly  malignancy, a
pre-operative increase in FPA levels was observed when compared
to patients without malignancy. This is  in  agreement with a 
previous f ind ing (Torngren et a l . ,1979).
7. An increase in plasma 8^15-42 leve ls on postoperative day 1 was
observed in  a l l  groups (see Figure 7 .7 ).
8 . A s ig n if ic a n t  increase in plasma levels of 8^15-42 was observed 
on postoperative day 7 in  the group who received stanozolol when 
compared to the group who received no prophylaxis. This re su lt  
is  in agreement with the increase in  levels of B/&15-42 a f te r  
administration of stanozolol in volunteers as reported in 7.3.
The increase in  B ^ 15-42 a f te r  stanozolol treatment in major surgery 
is  in  agreement with the prevention of f i b r in o ly t i c  'shut-down' 
a f te r  major surgery, however th is  f ib r in o ly t i c  'shut-down' 
occurs on postoperative day 1, whereas an increase in  B ^  15-42 
was observed in a l l  groups in th is  study. This suggests that 
ra ther than there being decreased f ib r in o ly t i c  a c t iv i t y  there 
is  an enhanced expression of p lasmin-like a c t iv i t y  in the 
c irc u la t io n .  Although there may be decreased f i b r in o ly t i c  
a c t iv a to r  i t  could be postulated that there is  s t i l l  s u f f ic ie n t  
present to produce an increased expression o f f i b r in o ly t i c  a c t iv i t y .
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7.S .BetathrombogIobulin and P la te le t Counts - E ffect o f Maiignancy. 
In fe c t io n , Age and Obesity 
In troduction
In th is  chapter a study was undertaken to determine the e ffec t 
of age, obesity and 'acute' i l ln e ss  such as malignancy and in fe c t io n  
on plasma levels of BTG and p la te le t  counts. One of the problems 
associated with the detection o f markers fo r  the detection of a 
thrombotic state is  tha t such markers might be non-specific and 
might re la te  to non-thrombotic il lnesses such as malignancy, 
in fe c t io n  and jaundice. P la te le ts , coagulation and f ib r in o ly s is  
are sensitive to common stresses such as emotional s tress, pain, 
in ju ry  and surgery, as well as many commonly used drugs. Few 
published studies report a 's ic k '  control group as well as a 
'healthy* control group yet subjects w ith eg. resp ira to ry  in fe c t ion  
or malignancy may well share the abnormality with the thrombotic 
group (Lowe et a l . ,  1979d). P la te le ts  may also be 
involved in inflammation or neoplasia and may be activated and 
deposited outside large blood vessels as well as ins ide . Hence 
the presence of increased c irc u la t in g  p la te le ts  or p la te le t  
release products may re f le c t  p a rt ic ip a t io n  in non-thrombotic 
pathology or extravascular events, ra ther than in travascu la r 
thrombosis. Furthermore, most 'hea lthy ' control groups usually 
consist of hospital or laboratory s ta f f  in the 20-45 year age group 
whereas the m ajority  of pa tient groups are in  the 40-70 age group 
and hence o lder 'hea lthy ' control groups should be considered.
Elevated plasma levels of BTG have been observed in patients 
with malignant disease (B idet, F e rr ie r ,  Besse et a l . ,  1980;
F a r re l l ,  Duffy, Moriarty et a l . ,  1980). Many patients in these 
studies have disseminated malignancy. The guestion arose as to
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whether BTG levels would be elevated in early  malignancy, in older 
subjects and in acute i l ln e s s .  The aims of the present study 
therefore were (a) to  establish whether or not BTG leve ls were 
elevated in early  operable cancer and (b) to establish whether or 
not BTG leve ls were elevated in a group of patients with acute 
non-vascular i l ln e s s  eg. in fe c t io n .
Z 'Z '2 *  Design o f study
Four groups of subjects were studied. Group 1: comprised
40 healthy volunteers (mean age 27 ± 1.1 (SEM) years; th is  
included 22  females not taking oral contraceptives, 18 males).
Group 2: 29 patient controls (mean age 61.2 ± 2.1 years,
11 males, 18 females) admitted to hospital fo r  major e lec tive  
surgery fo r  non-malignant disease, with no evidence o f in fe c t io n .
Group 3: 19 patients (mean age 60.3 ± 2.2 years, 10 males,
9 females) admitted to hospital fo r  proven operable gas tro in tes tina l 
carcinoma. In a l l  patients diagnosis was subsequently confirmed at 
operation - 10 patients had colorecta l carcinoma, 7 had gastr ic  
adenocarcinoma and 2 had pancreatic carcinoma. Group 4: Nine
patients (mean age 60 ± 3.5 years, three males, s ix  females) 
admitted to hospital w ith acute bacteria l in fe c t ion  but no malignant 
disease. Five had pneumonia and four had intra-abdominal sepsis 
(appendix abscess in one and ch o le cys t i t is  in 3). No pa rtic ipan t 
was taking any a n t i -p la te le t  therapy.
Z 'Z 'Z '  Methods
Obesity was measured as per cent mean weight fo r  height, age and 
sex, compared to  adults in the Build and Blood Pressure Study (1962).
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Plasma BTG was measured using the Amersham radioimmunoassay k i t  as 
described in chapter 5.3 .2. No PGE, was added to the anticoagulant 
tubes.
P la te le t counts were performed using a Coulter automatic 
p la te le t  counter.
Serum crea tin ine  leve ls were performed by Technicon autoanalyser.
S ta t is t ic a l  analysis
A ll  data are presented as the mean ± standard e rro r o f the mean. 
The s ign if icance of d ifferences between groups was assessed by 
Wilcoxon's rank sum te s t .  Correlations were determined by the 
method of least squares.
Results
Patient contro ls (Group 2) had s ig n if ic a n t ly  higher BTG levels 
(p <0 . 0 1 ) and s ig n i f ic a n t ly  lower p la te le t  counts (p <0 . 0 1 ) than 
normal contro ls (Group 1) (See Table 7 A ) .  In the combined group 
o f 69 control subjects there was a s ig n if ic a n t  pos it ive  corre la t ion  
between BTG and age ( r  = 0.33, P <0.01) and a s ig n if ic a n t  negative 
co rre la t io n  between BTG and per cent overweight fo r  age, sex and 
height ( r  = -0.47, p <0.01). This co rre la t ion  with obesity was 
found in Group 2 ( r  = -0.58, p <0.001) but not in Group 1 - 
possibly as a re su lt  o f the re la t iv e ly  small scatter o f obesity 
in  th is  group of young healthy subjects. A s ig n if ic a n t  negative 
co rre la t ion  was found between p la te le t  count and age ( r  = - 0 . 5 5 , 
p <0.001). There was no co rre la t ion  between levels o f BTG and 
sex or smoking habits. Patients with malignancy (Group 3) and 
in fe c t io n  (Group 4) were o f s im ila r  mean age to patient contro ls 
(Group 2) and had s im ila r  levels of serum crea tin ine  and obesity. 
Patients with malignancy (Group 3) had s im ila r  levels of BTG and 
p la te le t  count compared to  Group 2. Patients with in fec t ion  
(Group 4) had s ig n i f ic a n t ly  higher levels of both BTG (p <0.05 
and p la te le t  count (p <0.02) compared to patient controls rRrmm 9 ^
TABLE 7.4
Age, BTG, p la te le t  count, -serum creatin ine and obesity 
(mean ± SEM) in groups studied (*  £  <£.05, * *  £  <0.02 
* * *  £  < £.01^ compared to  Group £ ,  patient co n tro ls )
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No
GROUP 1 
Normal 
Control 
40
GROUP 2 
Patient 
Controls 
29
GROUP 3 GROUP 4
Malignancy In fection  
19 9
Age
(years)
27.0*** 
± 1.1
61.2 
± 2.1
60.3 
± 2 . 2
60 
± 3.5
BTG
(ng/ml )
26 * * *  
± 2
43 
± 4
4
± 5
68 *  
± 14
P la te le t count 324 * * *  221
XIO^/L ± 1 6  ±16
227 
± 19
294 * 
± 19
Serum crea tin ine  79 
(umol/L) ± 4
76
± 3
76 
± 3
65 
± 10
Obesity 92 
± 2
90 
± 3
95 
± 5
97 
± 6
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Z*Z*Z* Discussion
The s ig n if ic a n t  increase in  plasma BTG levels found in the 
older patient contro ls  (Group 2) when compared to the younger 
control group (Group 1) is  not due to renal re tention since a l l  
groups had s im i la r  serum creatin ine leve ls . This increase is  
probably due to the s ig n if ic a n t  r ise  in BTG with age which has 
been previously reported (Ludlam, 1979; Dewar, Marshall,
Weightman et a l . ,  1979; Zahavi, Jones, Leyton et a l . ,  1980).
The observed decrease in p la te le t  count with age is  supported by 
the resu lts  of a large epidemiological study (Meade and North,
1977). This may re f le c t  a decrease in p la te le t  surv iva l with 
age (Abrahamsen, 1968). This increase in BTG levels w ith age 
may be a fu r th e r  re f le c t io n  of p la te le t  ac t iva t ion  in  v ivo , 
possibly secondary to the increase in atherosclerosis with age.
In control subjects BTG was correlated to sex and smoking 
hab it,  but a h ighly s ig n if ic a n t  negative association with obesity 
was observed and th is  has not been previously reported.
The f ind ing of s im ila r  BTG concentrations in patients with 
early  malignancy confirms a previous report (F arre ll et a l . ,
1980) which only observed s ig n i f ic a n t ly  elevated BTG 
levels in  the advanced stages o f malignancy. This re s u lt  
suggests, the re fo re , tha t in the early  stages of malignancy a 
small loca lised tumour does not re su lt  in  measurable p la te le t  
release. In the advanced stages of malignant disease, the 
observed increased p la te le t  release is  presumably due to a greater 
vascular involvement.
Our f ind ing of s ig n i f ic a n t ly  increased BTG levels in patients 
with in fe c t ion  suggests tha t p la te le t  ac t iva tion  occurs in  acute 
"non-vascular i l ln e s s " .  This is  supported by increasing evidence
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of p la te le t  ac t iva tion  in  acute "non-vascular" illnesses,such as 
in fections and with associated "acute-phase" changes in plasma 
proteins such as f ibrinogen levels (O'Brien, Etherington and 
Adams, 1980; Lowe et a l . ,  1979d).
In conclusion, th is  study has shown tha t elevated BTG 
levels are not spe c if ic  fo r  "vascular" i l lnesses such as a r te r ia l  
occlusion or venous thrombosis. Studies of "vascular" i l lnesses 
should, the re fo re , contain a "con tro l"  group of patients with 
"non-vascular" i l ln e s s ,  such as in fe c t io n ,  and an "o lder" pa tient 
control group.
2 '£ .  Summary
In the studies on venous thrombosis reported in th is  chapter 
several in te re s t in g  f ind ings have been observed.
1. Increased p la te le t  ac t iva t ion  and thrombin generation, as 
observed by increased BTS and FPA leve ls , were shown in  
patients with longstanding re t ina l vein occlusion who had 
c a p i l la ry  non perfusion and/or neovascular when compared to 
patients with re t ina l vein occlusion without ischaemic 
complications and con tro ls .
2. An increased plasma level of BTG was found in  patients with 
nephrotic syndrome suggesting ongoing in vivo ac tiva t ion  is  
occurring in  th is  syndrome.
3. A d ire c t measurement of in  vivo plasmin a c t iv i t y  was observed 
in  volunteers a f te r  the administration of stanozolol by the 
find ing  of increased levels of B ^ 15-42 seven days a f te r  
treatment.
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The administration of the anabolic s te ro id , s tanozolo l, 
before major abdominal surgery does not prevent the 
occurrence o f DVT postoperatively. Plasma levels o f BTG 
appear to be an index o f developing DVT, i f  measured on the 
f i r s t  day a f te r  surgery, ind ica ting  ongoing in  vivo p la te le t  
release before the development o f the thrombosis. An 
increase in FPA leve ls in early  malignancy suyggests tha t in vivo 
thrombin generation occurs in early  malignancy but such in  vivo 
thrombin generation does not predispose towards thrombosis.
The observed increase in plasma FPA levels immediately a f te r  
surgery suggests an increase in thrombin generation due to 
t issue damage and th is  cannot be regarded as predisposing 
fa c to r  towards thrombosis as th is  increase was observed in 
patients not developing a DVT. At postoperative day 7 
increased leve ls of FPA appear to ind icate an ongoing thrombotic 
process. The observed increase in plasma leve ls  o f By2l5-42 
immediately a f te r  surgery suggests ongoing i_n vivo plasmin 
a c t iv i t y  in response to f i b r in  formation as a re su lt  o f t issue 
damage, such ijT_ vivo plasmin a c t iv i t y  does not prevent the 
development o f thrombosis. In patients receiving stanozolol 
a greater increase in in vivo plasmin a c t iv i t y  was observed 
on day 7 postoperatively.
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CHAPTER 8
PLASMA FIBRINOPEPTIDE A, BETATHROMBOGLOBULIN AND 
B^15-42 IN ARTERIAL THROMBOSIS
8 .1 . In troduction
The c l in ic a l  diagnosis of a r te r ia l  thrombosis is  usually made 
as a resu lt  o f ischaemic damage to the tissue supplied by the 
vessel. This however does not give adequate precision fo r  
s c ie n t i f ic  studies. Indeed the diagnosis o f a r te r ia l  thrombosis 
is  more d i f f i c u l t  than venous thrombosis (M itch e l l ,  1978) as 
artériographie 'occlusions' may be due to a r te fa c ts , a r te r ia l  
spasm, a therosc lero tic  plaques, thrombi, emboli or combinations 
o f the phenomena. Acute occlusion o f the limb a r te r ie s  may be 
due to emboli from the heart or proximal vessels as well as 
thrombosis in s i tu :  secondary thrombosis renders diagnosis
d i f f i c u l t  even at operation. I t  is now possible to  d i f fe re n t ia te  
cerebral in fa rc t io n  from cerebral haematoma by computerised axial 
tomography, but again CT scans cannot d i f fe re n t ia te  between thrombosis 
and embolism as the cause o f the in fa rc t io n .  Myocardial in fa rc t io n  
is  almost always associated with a fresh occlusive thrombus. Most 
investigators  believe tha t the thrombus antedates and causes the 
in fa rc t  (Chandler, Chapman, Erhardt et a l . ,  1974; Fulton, 1978).
The rediscovery tha t p la te le ts  play an in i t ia t in g  ro le  in a r te r ia l  
thrombosis with ac t iva t ion  of the coagulation system and deposition 
o f f i b r in  due to  a decreased f ib r in o ly s is  suggests the measurement 
o f plasma BTG, FPA and B^15-42 as possible markers o f p la te le t  
release, thrombin and plasmin generation in a r te r ia l  thrombosis.
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The f i r s t  study described in th is  chapter (8.2) examines the 
levels of plasma FPA and BTG in patients with acute chest pain and 
normal subjects. The second study (8.3) measured plasma levels of
BTG, FPA and B ^  15-42 in patients with coronary a r te ry  disease in  
order to determine i f  plasma levels of these proteins were related 
to the extent of coronary a r te ry  disease. The th i r d  study (8.4) 
examines plasma levels of BTG and FPA in  patients with type I I  and 
IV hyperlipoproteinaemia and normal subjects to determine whether 
p la te le t  release and f ibr inogen ac tiva t ion  were involved in the 
pathogenesis of the atherosclerosis in th is  condition . The fourth  
study (8.5) measured plasma levels of BTG and FPA in  patients with 
diabetes m e ll i tus  and normal subjects in order to determine i f  there 
was a re la t ionsh ip  between BTG and FPA levels and the occurrence of 
p ro l i fe ra t iv e  retinopathy in diabetes m e ll i tus  when compared to  
normal subjects. The f i f t h  study (8 . 6 ) measured plasma levels of
BTG and FPA in patients with trans ien t cerebral ischaemic attacks 
and in  both a group of 'e ld e r ly '  and young controls to determine 
whether p la te le t  release and f i b r in  formation were involved in  the 
development of such attacks. The second part of th is  study 
assesses BTG and FPA levels as pred ic tive  indices of fu r th e r  vascular 
events. The la s t  section of th is  chapter (8.7) summarises the 
resu lts  found in  th is  chapter.
8 .£. Plasma Fibrinopeptide ^  and Betathromboglobulin in 
Patients With Acute Chest Pain 
Introduction
A ctiva t ion  of p la te le ts  and thrombin generation have been 
suggested as precursors of fresh occluding thrombus in  the coronary 
a r te r ies  supplying an area of in farcted muscle (Turpie, de Boer and 
Genton, 1982). Further evidence in  support of p la te le t  ac t iva t ion
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and thrombin generation is  obtained from the f ind ings of elevated 
levels of BTG (Rasi et a l . ,  1980; Denham et a l . ,  1977) 
and FPA (Johnsson et a l . ,  1979). However these studies 
were obtained from a group of h igh ly  selected patients and 
were not representative of unselected patients with acute 
chest pain. The present study was therefore undertaken to 
determine whether increased plasma levels of BTG and FPA were 
s p e c if ic a l ly  associated with myocardial in fa rc t io n  in  an unselected 
group of patients admitted to hospital with acute chest pain.
B . Z . Z .  Design o f study
Forty e ight consecutive patients (31 males, 17 females, age 
41-82 years) were studied w ith in  1-3 days a f te r  admission to  
hospital fo r  acute chest pain in  one general medical u n i t .
Twenty one patients (14 males, 7 females mean age 65 ± 2 (SEM) 
years) had a d e f in i te  or probable myocardial in fa rc t io n  (MI) as 
defined by Rowley and Hampton (1981) ie a convincing h is to ry  of 
ischaemic type chest pain plus both ECG changes and a r ise  in 
serum levels of cardiac enzymes to more than twice the upper l im i t  
of normal (d e f in i te  MI), or e ith e r ECG changes or enzyme r ise  
(probable MI). F ifteen patients (10 males, 5 females, mean age 
60.4 ± 3.4 years) had unstable angina, defined as a convincing 
h is to ry  of ischaemic type chest pain without such ECG and enzyme 
evidence of in fa rc t io n .  Twelve patients (7 males, 5 females, 
mean age 59.7 ± 3.1 years) had chest pain due to non-cardiac 
causes ( 8  chest in fe c t io n ,  2 pneumothorax and 2 cause unknown).
The control group consisted o f 23 hospital patients (14 males,
9 females, mean age 55.8 ± 2.5 years) without evidence o f heart 
disease, chest disease, inflammation or neoplasia.
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Figure 8.1.
Plasma betathromboglubulin levels in 
the groups studied.
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Methods
Plasma BTG leve ls were measured as described in  Chapter 5.3.2.
No PGEy was added to the anticoagulant mixture. FPA leve ls  
were determined using the ethanol extraction method to remove 
cross-reacting fibr inogen as described in  Chapter (5 .4.2 (g) and 
the charcoal separation technique to separate bound and free I 
as described in  Chapter 5.4.2(B)*
S ta t is t ic a l  analysis of d ifference in  means was performed 
using Wilcoxon's rank sum te s t .
8 .£ .4 . Results 
Betathromboglobul i n
The levels obtained fo r  plasma BTG in  each group are shown in 
Figure 8.1. No s ig n if ic a n t  difference was found between any of 
the four groups.
Fibrinopeptide A
The levels obtained fo r  plasma FPA in  each group are shown in 
Figure 8.2. S ig n if ic a n t ly  elevated mean FPA leve ls were found in  
patients with myocardial in fa rc t io n ,  unstable angina, and non­
cardiac chest pain, when compared to normal subjects (p <0 . 0 1 ). 
Despite higher levels being obtained in  patients with myocardial 
in fa rc t io n  or non-cardiac chest pain compared to patients with 
unstable angina, these differences were not s ta t is t i c a l l y  
s ig n i f ic a n t .  No s ig n if ic a n t  co rre la t ion  was found between BTG 
levels and FPA levels in any group of patients.
8 .£ .£ . Discussion
1. S ign if ica n t increases in plasma levels of FPA were shown in 
patients with myocardial in fa rc t io n ,  in agreement with a previous 
report (Johnsson et a l . ,  1979).
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2. A s ig n if ic a n t  increase was also shown in FPA levels in 
patients with unstable angina. The raised FPA leve ls therefore 
are not associated with myocardial necrosis.
3. No previous study compared patients with acute myocardial 
in fa rc t io n  or unstable angina to patients with other causes 
of acute chest pain. The present study, the re fo re , found 
s im i la r ly  elevated levels of FPA in  patients with non-cardiac 
chest pain (mostly chest in fe c t io n ) .  This re su lt  suggests 
th a t raised FPA leve ls are not spec if ic  fo r  acute coronary 
insu ff ic ie n cy  as suggested previously (Serneri et a l . ,  1981).
4. No co rre la t io n  was found between FPA levels and plasma 
fibrinogen leve ls  (Dade fibrometer) in the present study, in  
agreement w ith a previous report (Harenberg, Haas and Zimmerman,
1981), hence the increase in  FPA does not merely re f le c t  the 
increased fibrinogen levels in patients with acute i l ln e s s .
5. The mechanisms by which FPA levels r ise  in some patients with 
acute chest pain there fore , remain obscure.
6 . No s ig n if ic a n t  elevation in mean BTG levels was found in  
patients with myocardial in fa rc t io n  or unstable angina when 
compared to con tro ls , although a few patients had elevated 
values. This resu lt  is in  contrast to previous reports
(Rasi et a l . ,  1980; Denham et a l . ,  1977; Hughes, Daunt, Vass et al 
1979). However, a non-s ign if ican t elevation of PF^  ^ was reported in 
myocardial in fa rc t io n  when compared to contro ls  (O'Brien, 
Etherington, Shuttlesworth et a l . ,  1980). C on fl ic t ing  evidence is  
ava ilab le fo r  increased p la te le t  release in myocardial
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in fa rc t io n ,  e ith e r  in  vivo (raised BTG or ) or in v i t ro  
(H e p t in s ta l l , Mulley, Taylor et a l . ,  1980).
7. Measurements of BTG and FPA are therefore of no value in 
separating patients presenting with chest pain in to  those 
w ith  and without myocardial in fa rc t io n .
£ .£ . PIasma Fibrinopeptide A, Betathromboglobulin and 
B^15-42 in  Coronary Artery Disease 
In troduction
The possible involvement of haemostatic factors in atherosclerosis 
has been suggested in  an e d ito r ia l  in the Lancet (1980). Recent 
c l in ic a l  and experimental evidence suggests tha t p la te le t  ac t iva t ion  
and release may play an important ro le  in the pathogenesis of 
coronary atherosclerosis (Ross, Glomset, Kariya et a l . ,  1974; 
Rutherford and Ross, 1976) and in the complications of ischaemic 
heart disease (Haerum 1972; de Wood, Spores, Notske et a l . ,  1980). 
F ib r in  formation has also been implicated in the development of 
coronary atheroma (Smith, Staples, Dietz et a l . ,  1979; Meade, 
Chakrabarti, S t i r l in g  et a l . ,  1980). However d ire c t evidence 
of in  vivo p la te le t  ac t iva t ion  and f ib r in  formation has been 
d i f f i c u l t  to obtain in  patients with coronary a r te ry  disease, since 
sensitive  techniques of in vivo p la te le t  ac t iva t ion  and f ib r in  
formation have not been available to date.
With the development of radioimmunoassays fo r  BTG, FPA and 
B |315-42, in  vivo markers of p la te le t  release, f i b r in  formation 
and f ib r in o ly s is  respective ly , i t  should now be possible to 
measure these parameters in vivo in coronary a r te ry  disease.
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Elevated FPA levels have been previously reported in patients 
with coronary heart disease (Serneri et a l . ,  1981).
The present study was undertaken to determine whether 
p la te le t release, thrombin generation and f ib r in o ly s is  are 
re lated to the extent of coronary artery  disease.
£ .£ .£ .  Design of study
One hundred men aged 33-65 years were studied a f te r  they had 
been admitted to Glasgow Royal In f irm ary. They were a l l  studied 
before they underwent se lective coronary arteriography fo r  
assessment of chest pain: patients excluded were those with a 
h is to ry  of myocardial in fa rc t io n  in  the previous three months, those 
receiving treatment with d iu re t ics  (which causes haemoconcentration) 
or c lo f ib ra te  (which lowers fibrinogen concentration and v iscos ity ) 
and those with overt heart fa i lu re .  The extent of angiographic 
coronary occlusion was graded according to the number of major 
vessels ( r ig h t ,  l e f t  an te r io r descending, and l e f t  c ircumflex 
coronary a r te r ie s ) in  which the lumen was occluded by 50% or more; 
patients were thus c la s s i f ie d  as having one, two or three vessel 
disease (Lowe, Drummond, Lorimer et a l . ,  1980). Twenty one 
patients had one vessel disease, 24 had two vessel and 52 had 
three vessel disease.
£ .£ .£ .  Methods
Plasma BTG levels were measured as described in Chapter 5.3.2. 
FPA leve ls were determined using the bentonite method to remove 
cross-reacting f ibrinogen as described in Chapter 5 .4 .2 . The 
double antibody technique was used to separate bound and free
I FPA. Plasma BySl5-42 was measured as described in  
Chapter 5.5.1.
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Figure 8.3
Plasma betathromboglobulln levels in patients 
with coronary artery disease. 1, 2 and 3 
denotes patients having one, two or three 
vessel disease. x denotes those patients 
who had a previous myocardial infarction.
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Plasma FPA levels in each of the groups with 
coronary artery disease, ie 1, 2 or 3 vessel 
disease. (x) denotes patients with a previous 
myocardial infarction.
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vessel disease. (x) denotes those patients 
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S ta t is t ic a l  analysis
The s ign if icance of d ifference among groups was measured 
by the unpaired students' ' t ' te s t .
Results
Plasma levels of BTG, FPA 8^15-42 obtained fo r  each group 
are shown in  f igu res  8.3, 8.4 and 8.5. The leve ls of BTG, FPA, 
and B ^ 15-42 were not s ig n i f ic a n t ly  d i f fe re n t  among the three 
patient groups.
Discussion
In the present study, plasma levels of BTG, FPA and 8^15-42 
were not elevated in patients with coronary a r te ry  disease. 
Furthermore, leve ls of BTG, FPA and B^15-42 were unrelated to 
the severity  of the coronary a r te ry  disease assessed by the 
number of a r te r ies  with s ig n if ic a n t  stenotic lesions or to the 
occurrence of a previous myocardial in fa rc t io n .  A previous 
study observed s im ila r  FPA resu lts  but observed elevated BTG 
and P F^leve ls  in  patients who had previously experienced 
myocardial in fa rc t io n .  This observed p la te le t  release appeared 
to be unrelated to the extent of coronary a r te ry  disease but 
was suggested to be related to the presence of a previous 
myocardial in fa rc t io n  (Nicols et a l . ,  1982). Such d i f fe re n t  
f ind ings in  the two studies may be the resu lt of d i f fe re n t  
patient populations or d if fe re n t  assay methods.
The observations in our study suggest tha t an ongoing state 
of increased p la te le t  release and f i b r in  formation with abnormal 
f ib r in o ly s is  is  not detectable in  the peripheral blood of patients 
with coronary a r te ry  disease.
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8 Plasma F ib r i nopeptide ^  and Betathrombogl obulin in
Type I I  Hyperlipoproteinaemia 
Introduction
Type I I  hyperlipoproteinaemia (HLP) is  characterised by a 
primary increase in plasma low -dens ity - l ipop ro te in  (LDL) cho lestero l. 
The increased r is k  of premature occlusive a r te r ia l  disease in  HLP 
is  normally a t t r ib u te d  to i n f i l t r a t i o n  of the a r te r ia l  wall by 
LDL, in  proportion to i t s  plasma concentration, and i t s  concentration 
in developing a r te r ia l  lesions. While evidence has been accumulating 
fo r  the possible involvement of p la te le ts  in atherosclerosis less 
evidence exists fo r  the involvement of the coagulation system in the 
pathogenesis of atherosclerosis. An increase in plasma fibrinogen 
in  HLP (Lowe, Drummond, Third et a l . ,  1979) and evidence suggesting 
the presence of increased in travascu lar coagulation in  patients 
with hyperlipidaemia have been reported (Carvallo, Lees, Vaillancourt 
et a l . ,  1979). This study was undertaken to determine plasma levels 
o f FPA and BTG in  patients with type I I  hyperlipoproteinaemia 
(a and b) patients with type IV hyperlipoproteinaemia and a group of 
normal subjects.
B A . 2 .  Design o f study
Twenty one patients with primary type I I  HLP who were attending 
a l ip id  c l i n i c  were studied. Thirteen were male and eight were 
female: th e i r  mean age was 46 years (range 20-60). Fourteen were
current c iga re tte  smokers; none was d iabe tic ; nine had a h is to ry  of 
a r te r ia l  disease (cardiac in fa rc t io n  or angina). Plasma cholesterol 
ranged from 6.5 to 15.3 mmol/1.
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Plasma betathromboglobulln levels in patients 
with hyperlipoproteinaemia (HLP) and controls
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Eight patients with type IV HLP were also studied, six were male, 
two were female (age range 29-52 years), s ix  were current smokers; 
none was d iabe t ic .  None had a h is to ry  of a r te r ia l  disease. Plasma 
cholesterol ranged from 5.6-16.5 mmol/1.
Twenty one con tro ls , matched fo r  sex, age and smoking hab it, 
were selected from among hospital s ta f f  or patients admitted fo r  
e lec tive  minor surgery; a l l  had normal to ta l and LDL cholesterol 
concentrations.
Methods
Plasma BTG and FPA were measured as described in  8 .2 .3 .
S ta t is t ic a l  analysis was performed by the use of the Wilcoxon 
rank sum te s t .
^ .4 .^ .  Results
The plasma levels of BTG and FPA obtained in  th is  study are 
shown in  Figures 8 . 6  and 8.7 respective ly. The leve ls o f BTG and 
FPA were not s ig n i f ic a n t ly  d i f fe re n t  among the three patient groups. 
^ .4 .^ .  Discussion
In th is  study plasma levels of BTG and FPA were not elevated 
in patients with type I I  or type IV HLP. Our f ind ings are in  
agreement w ith a previous report which found no e levation of plasma 
FPA in  patients with Type I I  HLP (Nossel et a l . ,  1979). The resu lts  o f 
both studies are inconsistent with the previous reported study 
Carvalho et a l . ,  1979) which found evidence of in travascu la r 
coagulation in  type I I  and IV hyperlipoproteinaemia. The patients in 
the former two studies were asymptomatic and may have had less 
extensive atherosclerosis than those studied by Carvalho et a l . ,  1979.
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Another explanation as suggested by Nossel et a l . ,  1976, is  tha t i t  
is  by no means certa in  th a t FPA levels and abnormal f ib r inogen 
behaviour on agarose columns are equivalent measures of thrombin 
proteolysis of f ib r inogen. Our f ind ing  of normal BTG leve ls in  
type I I  and IV HLP is  inconsistent with the find ings of a shortened 
p la te le t  l i fe -span  in patients with a r te r ia l  disease (Marker and 
S l ic h te r ,  1972) and p la te le t  hyper-responsiveness in patients with 
HLP (Carvalho et a l . ,  1974). This discrepancy may again 
be due to d i f fe re n t  populations or a l te rn a t iv e ly ,  since BTG is  a 
marker of in vivo p la te le t  ac t iva t ion  i t  is  a more sens it ive  method 
of p la te le t  a c t iva t io n .  The observations found in the study 
reported in th is  section suggests tha t ongoing ac tiva t ion  of p la te le ts  
and thrombin generation does not appear to  be occurring in patients 
with type I I  and type IV hyperlipidaemia. This f ind ing  does not 
im plicate the ac t iva t ion  of p la te le ts  or thrombin generation in the 
pathogenesis of atherosclerosis.
^._5. Plasma Fibrinopeptide A and Betathrombogiobul 1 n in  Diabetes M e ll i tus  
Introduction
Patients w ith diabetes m e ll i tu s  are known to have a high 
incidence of a r te r ia l  disease. Haemostatic studies in  diabetes 
have shown the presence of blood changes favouring thrombosis.
A recent study reported tha t diabetics had higher p la te le t  
adhesiveness, f ib r inogen . Factor V I l ie  and A T II I ,  and a lower 
f ib r in o ly t i c  a c t iv i t y  and p la te le t  count than control subjects 
(F u l le r ,  Keen, Ja rre t et a l . ,  1979). Furthermore in th is  study values 
were higher in d iabetics with microvascular disease (defined as 
retinopathy or p ro te inuria ) than in diabetics without disease.
Activa tion  of blood p la te le ts  in diabetes m e ll i tu s  has been 
demonstrated by the f ind ing  of elevated plasma BTG leve ls in
2%
diabetic  pa tien ts , both with and without complications such as 
retinopathy (Burrows et a l . ,  1978; Preston et a l . ,  1978;
Borsey, Dawes, Fraser et a l . ,  1980). One study reported 
no s ig n if ic a n t  d ifference between d iabetic  patients with 
complications and controls (Campbell et a l . ,  1977).
However, th is  la t t e r  study is  subject to s ta t is t ic a l  
c r i t ic is m .  A recent study found elevated FPA leve ls in diabetics 
although the patient population was small and i t  was not evident 
what complications were present in th is  group. Increased Pf^ 
leve ls were also reported (Ek, Thunell and Blomback, 1982).
The aim of the present study was to determine whether abnormal 
levels of BTG, an index of p la te le t  release, and FPA, an index of 
thrombin generation, were abnormal in  patients with diabetes m e ll i tu s  
and i f  there was a re la t ionsh ip  between BTG and FPA leve ls and the 
presence of p ro l i fe ra t iv e  retinopathy when compared to control subjects, 
^.^._2. Design o f study
Seventeen patients with diabetes m e ll i tu s  and p ro l i fe ra t iv e  
retinopathy as diagnosed with fluorescein angiography were studied, 
ten were male and six female: th e i r  mean age was 54.6 ± 3 .7  years
(range 29-73) 16 d iabetic  patients without p ro l i fe ra t iv e  retinopathy 
were also studied. Ten were male and six were female; t h e i r  
mean age was 57.1 ± 3.0 years (range 18-76). Twenty one control 
subjects matched fo r  sex, age and smoking habit were selected from 
among hospital s ta f f  or patients admitted fo r  e lec tive  minor surgery.
Methods
Plasma BTG and FPA were measured as described in  8 .2 .3 .
S ta t is t ic a l  analysis
Analysis of the differences in  mean values was performed 
by the use of the Wilcoxon rank sum te s t .
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Plasma FPA levels in each of the groups studied.
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.^_5._4. Results
The plasma leve ls of BTG and FPA obtained in th is  study are 
shown in  Figures 8 . 8  and 8.9 respective ly. Elevated mean leve ls 
of BTG were found in d iabetic  patients with and without p ro l i fe ra t iv e  
retinopathy when compared to con tro ls . Only in the d iabetic  group 
with p ro l i fe ra t iv e  retinopathy was the d iffe rence s ig n if ic a n t .
Elevated mean levels of plasma FPA were found in both d iabetic  
groups when compared to control subjects. These differences 
were s ig n i f ic a n t .  Highly elevated mean levels o f FPA were found 
in  d iabetic  patients with p ro l i fe ra t iv e  re tinopathy, the mean levels 
being s ig n if ic a n t  when compared to the diabetic group without 
p ro l i fe ra t iv e  retinopathy and the control group.
8.5._5. Pi scussion
In th is  study elevated levels of BTG were observed in 
d iabetic patients with retinopathy, the mean level in  diabetes 
w ith p ro l i fe ra t iv e  retinopathy being s ig n if ic a n t  when compared 
to the control group. This re su lt  is  in agreement with previous 
reports (Burrows et a l . ,  1978; Preston et a l . ,  1978; Borsey et a l . ,
1980). The elevated plasma BTG levels suggest in vivo ac tiva t ion  o f 
p la te le ts  is  occurring in  diabetes. Elevated mean FPA levels were 
found in  both d iabetic  groups when compared to normal con tro ls . Highly 
elevated mean FPA levels were observed in the d iabetic  group with 
p ro l i fe ra t iv e  retinopathy which were s ig n if ic a n t  when compared to 
normal con tro ls . A s ig n if ic a n t  d ifference was found in  mean FPA 
levels in the two d iabetic  groups. These resu lts  suggest tha t 
ongoing thrombin generation is  taking place in diabetes and is 
more evident in the group with p ro l i fe ra t iv e  re tinopathy.
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Plasma F ib r i nopeptide A and Betathrombogi obul i n in 
Transient Cerebral Ischaemic Attacks.
8.^.1_. In troduction
Ischaemic stroke is  a major cause of morbid ity and m o rta l i ty  in 
a r te r ia l  thrombosis. Transient ischaemic attacks (TIA) appear to be 
the resu lt of emboli (p la te le t ,  f i b r in  or atheromatous) a r is ing  
from atheromatous lesions in the major a r te r ies  to the brain 
(F isher, 1959; Gunning, P ickering, Robb-Smith et a l . ,  1964;
Ehrenfeld, Hoyt and Wylie, 1966). TIA appear to be the most 
Important warning symptoms of an impending stroke, with the greatest 
r is k  being in the f i r s t  few months fo llowing the onset o f TIA 
(M il l ika n  and McDowell, 1978).
BTG and FPA have been reported to be increased in  cerebro­
vascular disease (Matsuda et a l . ,  1979; Hoogendijk et a l . ,  1979;
Lane, Gawel, Wolff et a l . ,  1981). Since almost 74,000 people die 
annually in  England and Wales from cerebrovascular disease (HMSO 1980), 
there is  a need fo r  p red ic tive  indices of major vascular events in TIA 
patients in  order tha t t r i a l s  of therapy can be directed at those 
most at r is k .
The aim of the present study, there fore , was to compare levels 
of BTG, an index of p la te le t  release, and FPA, an index of f i b r in  
formation by thrombin, in  patients with trans ien t cerebral ischaemic 
attacks with levels in  a group o f 'e ld e r ly '  and young contro ls  
and then to  see i f  e i th e r BTG or FPA had a p red ic tive  value fo r  
vascular events in the fo llow ing year.
2 84
1 *1 ' I *  Design of study
Plasma BTG and FPA levels were determined in 27 patients 
(20 female, 7 male), age range 49-70 years, who gave a recent 
h is to ry  of TIA as defined by unequivocal focal neurological 
symptoms or signs las t ing  less than 24 hours. Patients with 
episodes of dizziness without focal signs, or with 'drop attacks' 
were not included. BTG and FPA leve ls were also determined 
in  a group of 43 age-matched 'e ld e r ly  con tro ls ' (27 females,
16 males) age range 42-91 years, who were attending an old 
people's luncheon club, residents o f old people's home and 
from hospital s ta f f .  None had any acute i l lnesses , had no 
c l in ic a l  evidence of cerebrovascular disease and were not taking 
a n t i -p la te le t  therapy. Levels were also determined in a group 
o f 32 healthy 'young con tro ls ' (28 females, 3 males) age range 
18-28 years who were members o f hospital s ta f f .
S.6_.3 . Methods
Plasma BTG and FPA were measured as described in 8 .3 .3 . 
S ta t is t ic a l  analysis
The s ta t is t ic a l  s ign if icance o f d ifference in means was 
assessed by the Wilcoxon rank sum te s t .
Results
The values obtained fo r  BTG are shown in Figure 8.10.
Plasma BTG leve ls increased s ig n i f ic a n t ly  with age (p <0.01), 
as shown, but were higher in the TIA group compared to  age-matched 
controls (p <0.01). FPA levels obtained in each group are shown 
in  Figure 8.11. FPA levels also increased s ig n i f ic a n t ly  with age 
(p <0.05), but no s ig n if ic a n t  d iffe rence was found in FPA levels 
in  the TIA patients when compared to age-matched con tro ls . No 
sex d iffe rence in BTG or FPA levels was found.
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In the TIA group, the time since the la s t  TIA varied from 
two hours to 227 days (mean 45.5 days). In 14 o f the, patients the
TIA was th e i r  f i r s t ,  in s ix  m u lt ip le  TIA had started in the previous
year and in seven TIA had commenced in the previous 1-4 years.
Nine o f the patients were on asp ir in  therapy alone, three were on 
dipyridamole, and s ix  were on both drugs. No co rre la t io n  was 
found between the leve ls o f BTG and FPA and the time since the la s t  
TIA, ne ither was there any co rre la t io n  between BTG and FPA and 
asp ir in  or dipyridamole therapy in the TIA patients.
A pred ic tive  study was then carried out. A ll patients with 
TIA were followed fo r  one year, and subsequent m o r ta l i ty  or 
morbidity from vascular disease (completed stroke, myocardial 
in fa rc t io n  or continued TIA) was noted. At one year, repeat
BTG samples were taken from as many patients as possible; 16
samples were obtained and two patients had died. Repeat samples 
were also obtained, at one year, from s ix  o f the e ld e r ly  control 
patients with high BTG values, s ix  with intermediate BTG values 
and six with low values. FPA estimations were not repeated 
since as shown in Figure 8.11 FPA was not of p red ic tive  value in 
TIA patients .
Twelve o f the TIA patients suffered fu r th e r vascular events 
in  the subsequent year - nine had fu r th e r  TIA, one acute l e f t  
ve n tr icu la r  fa i lu re  (LVF), one fa ta l myocardial in fa rc t io n  (MI) 
and one fa ta l cerebrovascular accident (CVA). The mean BTG 
level of patients who had fu r th e r  vascular events, 56.7 ± 6.3 
(SEM) ng/ml was s ig n if ic a n t ly  higher than the mean BTG level of 
those patients who did not have a fu r the r event, 39.1 ± 4.7 
(p <0.05). The group who had fu r th e r  vascular events had a 
s im ila r  mean age, 72.8 years, to tha t o f the group who had no
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fu r th e r  events, 73.9 years. There was no co rre la t io n  between 
FPA levels and the occurrence o f vascular events in the year 
subsequent to sampling, however in  two patients who had a fu r th e r  
TIA and fa ta l  MI respective ly , no FPA resu lt was obtained.
A n t ip la te le t  therapy was administered in  a l l  but two of the 
patients who suffered fu r th e r  vascular events.
Discussion
1. S ig n if ica n t increases in plasma levels of BTG were shown 
in  TIA patients when compared to age-matched e ld e r ly  
con tro ls , in  agreement with previous reports (Matsuda et a l . ,  
1979; Hoogendijk et a l . ,1979). More importantly BTG was 
p red ic tive  of fu r th e r  vascular events.
2. The mean plasma BTG le v e l,  21.8 ng/ml, in the 73 contro ls  
of a l l  ages is  consistent with previous reports (Zahavi,
Celia , Dubiel et a l . ,  1978; Celia et a l . ,  1979).
3. A s ig n if ic a n t  r ise  in BTG with age was shown as has been
reported previously (Lane et a l . ,  1981; Dewar et a l . ,  1979; 
Zahavi et 1 . ,  1979; Ludlam, 1979).
4. The lack of sex d ifference in  BTG levels is  consistent with the 
report of Ludlam, 1979, but d i f fe rs  from other reports which 
found higher leve ls in old females compared to males (Zahavi, 
e t a l . ,  1979; Dewar et a l . ,  1980) and lower levels in
in females of a l l  ages (Dewar et a l . ,  1979).
5. Raised BTG leve ls in TIA have been reported by other workers
(Matsudu et a l . ,  1979; Hoogendijk et a l . ,  1979). Elevated
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leve ls have also been reported in acute cerebral in fa rc t io n
(Matsuda et a l . ,  1979; chronic cerebral in fa rc t io n  (Lane et a l . ,
1981) and in  myocardial in fa rc t io n  (Matsuda et a l . ,  1979;
Denham et a l . ,  1977). Increased BTG levels in  the 
above diseases ind ica te  enhanced p la te le t  release and may 
ind ica te  in  vivo ac tiva tion  of the haemostatic mechanism,
although i t  is  not known i f  such ac tiva tion  is  the resu lt  of
abnormalities of p la te le t  behaviour, of coagulation or of 
the vessel w a l l .  The f ind ing of no co rre la t ion  between the 
time of the la s t  TIA and BTG leve ls , suggests tha t raised 
levels are not simply acute changes associated w ith a TIA episode.
6 . The mean FPA value in the young controls was 1.2 ng/ml 
which is  consistent with previously reported values 
(Nossel et a l . ,  1974, Hofmann and Straub, 1977).
7. A s ig n i f ic a n t  r ise  in  FPA levels with age was shown, in  
agreement with a previous report (Lane et a l . ,  1981).
8 . FPA leve ls in the TIA patients were not s ig n i f ic a n t ly  
higher than the e ld e r ly  control group.
9. P la te le t ac t iva t ion  ra ther than f ib r in  formation is  
cha rac te r is t ic  o f TIA.
10. No co rre la t io n  was found between BTG and FPA leve ls and the 
taking of a n t i -p la te le t  drugs, in agreement with previous 
reports of no e ffe c t with asp ir in  and dipyridamole on BTG 
leve ls in  healthy volunteers (Hoogendijk, ten Cate, Ludlam 
et a l . ,  1980; Lensing, Sturk and ten Cate, 1981), or in the 
case of a s p ir in ,  in patients with cerebrovascular accident. 
Sulphinpyrozone, another a n t i -p la te le t ,  does not reduce FPA 
levels in patients with stroke (Lane et a l . ,  1981).
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11. The pred ic tive  study suggests tha t raised BTG leve ls , but
not FPA leve ls ,  appear to have a prognostic value in ind ica ting 
TIA patients at r isk  of fu r th e r  vascular events. An a rb it ra ry  
separation in to  two groups o f TIA patients may be made, those 
with BTG leve ls above 50 ng/ml, a high r isk  group, and those 
with leve ls below 50 ng/ml, a low r isk  group.
12. The resu lts  shown in Figure 8.12 suggest tha t a state of 
increased p la te le t  ac t iva tion  may be sustained fo r  a 
considerable time in the high r is k  TIA patients , however the 
f a l l  in BTG levels at the end of the year a f te r  i n i t i a l  sampling 
indicates tha t i t  is  not maintained in d e f in i te ly .  This
might suggest a diminishing r is k  of fu r th e r vascular events, 
fo r  example, healing of ulcerated plaques in cranial a r te r ie s . 
However, the fac t tha t BTG values in th is  group tended to 
remain in the upper part o f the normal range may ind icate 
ongoing p la te le t  ac t iva t ion . S im ilar BTG leve ls in the 
low r is k  group over the year a f te r  i n i t i a l  sampling 
suggests no ongoing p la te le t  ac tiva tion  is occurring in 
th is  group.
^._7. Summary
This chapter has described the measurement o f plasma 
levels of FPA, BTG and ByS15-42 as indices of p la te le t  
a c t iva t io n ,  thrombin generation and hence f i b r in  formation, 
and plasmin a c t iv i t y  respective ly in several studies related 
to  a r te r ia l  thrombosis. On the basis of the work reported 
in  th is  chapter the fo llowing conclusions are made:
1. No evidence of p la te le t  release was found in patients 
with acute chest pain as shown by s im ila r  plasma levels
2 9 2
of BTG in patients with myocardial in fa rc t io n ,  
unstable angina, non-cardiac chest pain and control 
patients. S im ila r ly  elevated levels of FPA were 
found in patients with myocardial in fa rc t io n ,  unstable 
angina and non-cardiac chest pain when compared to 
control patients. Measurements of BTG and FPA are 
therefore of no value in separating patients presenting 
with chest pain in to  those with and without myocardial 
in fa rc t io n .
2. Mean plasma levels of BTG, FPA and B^ ô 15-42 were not
elevated in patients with coronary a r te ry  disease and 
were also unrelated to the extent of the coronary 
a r te ry  disease. However, a few patients did have 
elevated FPA levels and hence f ib r in  formation may 
occur in a small number of patients with coronary 
a r te ry  disease.
3. No evidence of p la te le t  ac t iva tion  or thrombin 
generation was observed in patients with type I I  or 
type IV hyperlipoproteinaemia.
4. Ongoing p la te le t  a c t iva t io n ,  as shown by elevated BTG 
leve ls , is  suggested in d iabetic  patients with 
p ro l i fe ra t iv e  retinopathy. Increased thrombin 
generation and hence f i b r in  I formation is  suggested in 
d iabetic patients as a resu lt of increased FPA levels 
but such thrombin generation appears to be greater in 
d iabetic patients with p ro l i fe ra t iv e  retinopathy than 
in  those w ithout.
5. P la te le t ac t iva tion  rather than f ib r in  formation appears
to be cha rac te r is t ic  o f TIA patients as shown by increased 
plasma levels of BTG but not FPA in  TIA patients having
an increased r isk  of fu r th e r  vascular events.
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CHAPTER 9
BETATHROMBOGLOBULIN _IN IN VITRO STUDIES OF 
BLOOD- MATERIAL INTERACTIONS '
2 ' I  In troduction
This chapter reports on a study undertaken to assess the 
s u i t a b i l i t y  o f BTG as a marker of i j i  v i t r o  blood co m p a t ib i l i ty .
The term 'blood c o m p a t ib i l i ty '  as defined by Bruck (1980) denotes 
the absence of adverse e ffec ts  of materials on whole blood, while 
the materials perform a given function alone or as parts o f a 
device. Within the la s t  decade the development o f l i f e  support 
systems and devices to support fa i l in g  organs has led to a demand 
fo r  the production o f synthetic materia ls tha t are blood compatible 
and may be l e f t  in the body fo r  prolonged periods o f time without 
stim ulating a tissue reaction.
So fa r  no ideal material has yet been produced tha t meets the 
demands o f co m p a t ib i l i ty ,  strength and d u ra b i l i ty  and few meet 
the c r i t e r ia  la id  down by Salzman (1971). The main areas of
c l in ic a l  in te res t are in vascular g ra f ts ,  d ia lys is  membranes,
cardiopulmonary oxygenators and vascular catheters. However 
despite such problems of thrombogenicity many such devices may 
serve th e i r  function by the use o f anticoagulants in association 
with a n t i -p la te le t  agents.
An invariab le  e ffe c t o f exposure of foreign surfaces to 
native blood appears tobe adhesion and aggregation o f p la te le ts  
as described previously (Mason, Mohammad, Chuang et a l . ,  1976).
A precondition to such adhesion and aggregation is  the formation
o f a monolayer of proteins on the surface (vide in f ra )  to  which
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Figure 9.1
Scanning EM - magnified X3000 (courtesy of 
Dr R Wilkinson, Dept of Bioengineering, 
University of Strathclyde) of platelet 
adhesion to a foreign surface with pseudopodia 
thrown out in the direction of blood flow.
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to which p la te le ts  then adhere. Such adherent p la te le ts  
undergo viscous metamorphosis and th is  results  in induction 
of p la te le t  aggregation onto the surface (Baumgartner, Muggli, 
Tschopp et a l . ,  1976). Analysis of the formation of c e l lu la r  
deposits show tha t previously deposited p la te le ts  throw out 
pseudopodia which o r ien ta te  themselves in the d ire c t ion  of 
f low  and these enhance fu r th e r  p la te le t  deposition (see 
Figure 9 .1 ). This in turn accelerates the formation of a network 
of f i b r in  which traps red and white ce l ls  (see Figure 9 .2 ). 
Thrombus formation may then spread over the surface impairing 
func tion , or the adherent f i b r in - p la te let mixture may be 
washed o f f  by the flowing blood and produce emboli in the 
pa tien t. Studies of p la te le t  deposition on a r t i f i c i a l  surfaces 
suggest tha t stagnation of flow accelerates p la te le t  aggregation 
and i t  has been proposed tha t the preconditions responsible fo r  
th is  are the differences between a r te r ia l  and venous blood, the 
varying blood flow patterns and the design and mechanical 
function ing of a medical device (Bruck, 1981). The resu lts  
obtained in a recent study suggest tha t PGI% even at high 
concentrations does not prevent the formation of a monocellular 
p la te le t  layer on collagen f i b r i l s  or a r t i f i c i a l  surfaces, but i t  
does in h ib i t  clumping of fu r th e r  p la te le ts  to th is  layer and 
prevents subsequent p la te le t  thrombus formation (Fesus, H ars fa lv i,  
Kovacs et a l . ,  1981). In recent c l in ic a l  t r i a l s  conducted during 
cardioplumonary bypass surgery in animals (Longmore, Bennett, 
Gueirrara et a l . ,  1979), and in human patients (Walker, Davidson, 
Faichney et a l . ,  1981; Radegran, Aren and Teger-Nilsson, 1982)
2 9 6
Figure 9.2
Scanning EM - magnified X3000 of red cell and 
white cell aggregates form on a protein monolayer 
of a foreign surface.
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the administration of PGI% resulted in p la te le t  pro tect ion , 
decreased formation o f micro-aggregates and an improved 
haemostatic function a f te r  the appropriate procedure.
A wide spectrum of in v i t ro  tests have been devised fo r  the 
assessment of blood co m p a tib i l i ty .  Most depend on the measurement 
of ac t iva t ion  of components of the coagulation system (see Figure 
9 .3 ). I t  is  however, c lear tha t the information gained from 
in  v i t ro  tes t in g  cannot be applied d ire c t ly  to the c l in ic a l  
s itu a t io n  and material assessment and development would therefore 
benefit from more re l ia b le  methods of evaluation. The ava ilab le 
tes ts  have been extensively reviewed (Salzman, 1972; Bruck, 1974;
Forbes and Prentice, 1978) and a selection is  set out in  Table 9.1.
Since the release of granular material from w ith in  the 
p la te le ts  is  accompanied by the formation of protrusions of the 
p la te le t  plasma membrane and as morpholgical studies of adhesions 
to surfaces show that p la te le ts  extrude th e i r  granules in to  
pseudopodia, i t  would seem tha t the adhesion of p la te le ts  to a 
foreign surface is  accompanied by the release of p la te le t  contents 
such as BTG. To date, no in v i t ro  studies have been reported 
on the monitoring of changes in  BTG leve ls when p la te le t  adhesion 
and aggregation occur on synthetic materia ls. The aim of the 
present study reported in th is  chapter was to measure BTG leve ls 
under te s t  conditions and with the use of d i f fe re n t  polymer materia ls. 
9^.2. Design of study - Methods
Values of BTG obtained in  non-anticoagulated, c i t ra te d  and 
heparinised blood were measured in normal ind iv idua ls  to 
standardise the method. Samples were obtained from young healthy 
members of hospital s ta f f .
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Figure 9.3
Blood-artificial surface interactions.
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BTG release from blood in the syringe:
Venous blood was collected in to  a 30 ml syringe with c i t r a te  
and heparin as anticoagulant and at various time in te rva ls  a f te r  
the beginning of the venepuncture 2.7 ml a liquots were transferred 
in to  BTG sample tubes. The ro le of BTG in in v i t r o  thrombus 
formation was studied by taking samples of non-anticoagulated 
blood at one minute in te rva ls ,  and s i la s t ic  tubes f i l l e d  with blood, 
closed loops formed (Chandler, 1958) and the tubes ro ta ted. Blood 
was removed at d i f fe re n t  time in te rva ls  fo r  assay of BTG leve ls .
The e f fe c t  of o s c i l la t io n  on the p la te le t  release reaction was 
measured by taking samples at specified times a f te r  o s c i l la t io n  
had commenced.
Material assessment
Four materials were evaluated: s i l icon ised  glass tubes
(Becton Dickinson L td ) , ;  polypropylene tubes ( S te r i l in  L td . ) ;  
p las t ic ised  polyvinyl ch loride sheet (Avon Medical Ltd) and 
s i l icone  rubber sheet (Dow Corning Inc).
Tubes
10 cm s il icon ised  glass tubes, 10 cm X 1.5 cm, had a 
s il icon ise d  natural rubber stopper and the 10  cm polypropylene 
tubes, 10 cm X 1.5 cm had a polypropylene stopper. Ten ml of 
whole blood without anticoagulant was placed in to  each of the 
tubes and mixed on a r o l le r  mixer fo r  six minutes. 2.7 ml of 
blood was transferred in to  two BTG sampling tubes and BTG assays 
carried out.
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FI at sheets
A te s t  ce l l  w ith two sheets of polyvinyl ch loride or 
s i l icone  rubber mounted w ith in  i t  was attached to an o s c i l la t in g  
r ig ,  f i l l e d  with 10 ml whole blood without anticoagulant and 
o sc i l la te d  at 150 rev/min fo r  s ix  minutes. BTG assays were 
then carried out.
Measurement o f BTG
Plasma BTG was measured as described in  Chapter 5.32. 
Measurement o f FPA
P la te le t aggregation and release of p la te le t  contents can be 
induced by a number of agents including thrombin. Therefore, i f  
BTG release is  measured with any degree of c e r ta in ty ,  some estimate 
of the levels of thrombin must be obtained. Therefore, FPA 
levels were measured in  order to demonstrate tha t BTG release from 
p la te le ts  could be a tt r ib u te d  to in te rac tion  of p la te le ts  with the 
polymer ra ther than the presence of thrombin.
Results
Normal values: Figure914 shows the normal values of BTG in
non-anticoagulated, c i t ra te d  and heparinised blood. The mean 
values obtained were:
(1) non-anticoagulated blood, 36.9 ± 3.9 ng/ml (range 15-73)
(2) c itra ted  blood, mean value, 69.0 ± 10.3 ng/ml (range 28-142)
(3) heparinised blood, mean value, 48.7 ± 8.2 ng/ml (range 26-76).
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Figure 9.4
Concentrations of BTG in whole blood 
with and without anticoagulants, 
Individual values, and mean + S.D.
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BTG release from the syringe
As shown in  Figure 9.5, in  c itra te d  blood there is  a gradual 
Increase in  BTG levels t i l l  about e ight minutes a f te r  which there 
is  a steep r ise  in  BTG leve ls . For comparison, the resu lts  of 
Ludlam and Cash (1976) who used no anticoagulant are also shown.
They found a s im i la r  sharp increase in  the levels of BTG a f te r  
about nine minutes. With heparin, however, large rises were seen 
a f te r  20 minutes. The resu lts  are the average of three experiments. 
BTG; in v i t r o  thrombus formation
Figure 9.6 shows the rapid increase of BTG le ve ls ,  reaching the 
maximum measurable by the radioimmunoassay used, w ith in  1 0 - 1 2  
minutes in  the three experiments that were carried out. The 
thrombus was v is ib le  in the tube about a minute before the maximum 
level of BTG is  achieved.
BTG during o s c i l1ation o f blood
The resu lts  obtained with the o s c i l la t io n  of blood are shown 
in  Figure 9.7. No d e f in i te  pattern of release was observed and 
there are d i f fe re n t  patterns of release in  the three experiments. 
Comparison o f FPA level and BTG release
The release of FPA in  a syringe with whole blood without 
anticoagulant is  shown in  Figure 9.8. Figure 9.9 shows the 
re la t ionsh ip  between BTG release and FPA level in  the same 
sample of blood. There is  a gradual increase in the BTG level 
(as in  the syringe. Figure 9.4) followed by a rapid increase.
There is  a corresponding increase in the FPA level a f te r  s ix  
minutes. Therefore, i f  BTG levels are measured fo r  blood-polymer 
in te rac tions , the blood-polymer contact time in the absence of an 
anticoagulant should be less than 6 - 8  minutes.
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Fifflire 9.5
BTG release from blood in the syringe 
using citrate and heparin. Results 
are compared with BTG levels in whole 
blood without anticoagulant, obtained 
by Ludlam and Gash (1976).
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Figure 9.6
BTG release In in vitro thrombus formation; 
a typical curve.
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Figure 9.7
BTG release from citrated blood during 
oscillation; results of three test runs.
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Figure 9.8
A typical curve of FPA levels in normal 
whole blood without anticoagulant.
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Figure 9.10
BTG release from whole blood in siliconised 
glass and polypropylene tubes.
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Material assessment 
Tubes
S ilicon ised glass tubes (Figure 9.10) caused greater release 
of BTG compared with the polypropylene tubes and, the re fo re , 
polypropylene in i t ia t e s  less thrombus formation than s il icon ised  
glass. However there was no s ig n if ic a n t  d ifference between the 
tubes when the experiment was repeated with c i t ra te d  blood.
F lat sheets
Polyvinyl ch loride sheets gave mean BTG values of 
120 ± 21 ng/ml over seven experiments. The mean BTG level fo r
s i l ico n e  rubber was 105 ± 18 ng/ml. The s i l icone  rubbers appear, 
therefore to be less thrombogenic than polyvinyl ch lo r ide .
Discussion
Adler et al (1979) compared the e ffec ts  of haemodialysis on 
plasma BTG levels with patients on e ith e r Cuprophan (Travenol) or 
regenerated ce llu lose  (Cordis Dow) a r t i f i c i a l  kidneys. They 
found tha t there was an acute r ise  in the BTG leve ls in the f i r s t  
hour of d ia ly s is  which then remained constant throughout the 
remainder of the treatment when using the Travenol hollow f ib re  
kidney; however, th is  e ffec t was not observed with the Cordis Dow 
kidney, and the d ifference in the observations was re la ted to the 
blood com pa tib i l i ty  of the two types of hollow f ib re s .  These 
experiments studied the overall performance of the device, and 
are not necessarily ind ica t ive  of the blood com pa tib i l i ty  of the 
materials of the kidneys as the effec ts  of extracorporeal c i rc u la t io n ,  
pumps etc con tr ibu te towards the measured BTG leve ls .  By measuring 
BTG leve ls in  patients with chronic renal fa i lu re  on d i f fe re n t
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dia lyse rs , Akizawa et al (1981) also concluded tha t BTG is  an 
excellent marker fo r  the blood com pa tib i l i ty  of a r t i f i c i a l  kidneys. 
However, l ik e  the resu lts  of Adler et al (1980) th is  study did not 
d i f fe re n t ia te  between the blood co m p a tib i l i ty  of the material from 
the overall performance of the device and extracorporeal tub ing.
The studies carr ied out in th is  chapter measured the potentia l 
use of BTG as a marker of blood co m p a tib i l i ty .  The acute r ise  in 
BTG from blood in  the syringe is  in agreement with the resu lts  of 
Adler et al (1980). The observation tha t o s c i l la t io n  of blood 
causes increased release of BTG, suggests tha t blood has to be mixed 
in  d i f fe re n t  ways i f  BTG release is  to be used as a marker fo r  
blood-material in te rac t io ns . When the release o f FPA was measured, 
abnormal values were obtained a f te r  6 - 8  minutes ind ica ting  the 
presence of thrombin. Thus i f  BTG levels are to be measured fo r  
blood-material in te rc t io n s  in the absence of thrombin, the time 
blood-material contact occurs should be less than 6 - 8  minutes.
In v i t r o  tes t ing  of d i f fe re n t  materials showed that 
polypropylene in i t ia t e s  less thrombus formation than s i l icon ise d  glass. 
S ilicone rubber was less thrombogenic than polyvinyl ch lo ride .
_9.^. Summary
This chapter has described the development of new haematological 
tes ts  fo r  blood com pa tib i l i ty  assessment. BTG and FPA were regarded 
as f u l f i l l i n g  the necessary requirements of s e n s i t iv i t y  and 
re p ro d u c ib i l i ty .  However, as the measurement o f FPA required a 
large volume of blood, i t  was considered impracticable to include 
th is  te s t  each time blood is  exposed to materia ls . S ilicon ised 
glass tubes were more thrombogenic than polypropylene tubes.
Polyvinyl ch loride was more thrombogenic than s i l ico n e  rubber.
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In v i t r o  blood com pa tib i l i ty  assessment based on the release 
o f BTG does provide relevant information on blood-polymer in te raction, 
The studies in th is  chapter demonstrated s ig n if ic a n t  d ifferences in 
the release o f BTG fo r  d i f fe re n t  polymers and these find ings 
suggest fu r th e r  assessment of other polymers is  appropriate.
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CHAPTER 10 
CONCLUSIONS AND DISCUSSION
i£ * l *  In troduction
In th is  thesis the ro le played by p la te le ts ,  f i b r in  
deposition and f ib r in o ly s is  in normal haemostasis has been discussed 
in  p a r t ic u la r  de ta il (Chapter 1). Abnormalities of the above 
processes as possible mechanisms in thrombosis were consequently 
discussed in  Chapter 2. To obtain a measurement of p la te le t  
a c t iva t io n ,  the radioimmunoassay of betathromboglobulin (BTG) 
was set up (as described in Chapter 3). The radioimmunoassays 
of f ib r in op ep tid e  A (FPA) and BjS 15-42 as indices of f i b r in  
formation and plasmin a c t iv i t y  were also set up (as described in 
Chapter 4). The methodology and measurement of these parameters 
and th e i r  assay in normal subjects was studied (Chapter 5).
Samples from normal pregnant women and pregnant women with 
hypertension of pregnancy or pre-eclampsia as well as the e ffec t of 
an anti-hypertensive drug on patients with pre-eclampsia were studied 
(Chapter 6 ). Measurements of BTG, FPA and B^15-42 were studied in 
patients with deep venous thrombosis, chronic re t in a l vein occlusion, 
the nephrotic syndrome and compared to control subjects. A 
double b lind  t r i a l  of the administration of s tanozo lo l, a 
f i b r in o ly t i c  enhancing drug, was evaluated in the prevention 
o f venous thrombosis a f te r  major gastro in tesina l surgery.
The administra tion of th is  drug to healthy volunteers was also 
studied. The e ffe c t of age, obesity and 'acute i l ln e s s '  on plasma 
BTG and p la te le t  counts were also studied. These studies are 
described in  Chapter 7.
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Plasma levels of BTG, FPA and B/215-42 were also measured in 
c l in ic a l  conditions associated with a r te r ia l  thrombosis such as 
myocardial in fa rc t io n  and compared to patients with non-ischaemic 
chest pain and control pa tients . The extent of coronary a r te ry  
disease on these measurements was also studied. BTG and FPA 
measurements were also studied in  patients with type I I  and type 
IV hyperlipoproteinaemia, in  patients with diabetes m e ll i tu s  with or 
without p ro l i fe ra t iv e  retinopathy and compared to normal con tro ls . 
Plasma BTG and FPA measurements were studied in patients with 
trans ien t ischaemic attacks and compared to control groups. These 
patients were studied one year la te r .  A ll these studies on a r te r ia l  
thrombosis are discussed in  Chapter 8 .
The measurement of BTG and FPA was evaluated in studies of 
d i f fe re n t  a r t i f i c i a l  surfaces and various parameters a ffec t ing  the 
te s t  conditions were evaluated (as described in Chapter 9).
1£*1* M  Assessment o f Plasma BTG, FPA and B^  15-42 as 
Markers fo r  Thrombosis 
The fo llow ing  questions have to be answered:
(1) What conclusions can be drawn from the various measurements 
obtained using the assays of plasma BTG, FPA and B|gl5-42?
How do these measurements re la te  to each other?
(2) What practical problems are associated with these techniques 
and what modifications could be introduced to improve these 
techniques ?
(3) Are these techniques l i k e ly  to be useful as markers fo r  
thrombosis and the management of patients or do they so le ly  
have a ro le at the research level ? .
These questions w i l l  be discussed in  turn beginning w ith a 
summary of re su lts .
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J G Summary of the resu lts  in th is  thesis
. Normal non pregnant women (Group Chapter 6_.Z)
Normal values o f BTG, an index o f p la te le t  release and 
a c t iv i t y ,  and FPA, an index of f i b r in  formation, were observed 
in  th is  group (see Figures 6.1. and 6 ,2 ). Hence there is no 
evidence of in travascu lar coagulation in th is  group.
1* Normal non pregnant women taking oral contraceptive therapy 
(Group 4, Chapter 6.2)
Normal values o f BTG and FPA were obtained in th is  group 
(see Figures 6.1 and 6 .2 ).
_3. Normal pregnant women (Group _3, Chapter 6^.^)
Increased BTG leve ls  were observed in the 2nd and 3rd tr im ester 
o f pregnancy suggesting increased p la te le t  ac t iva t ion  is  occurring. 
However there is  l i t t l e  evidence o f f i b r in  deposition in  th is  group 
as normal FPA levels were obtained (see Figures 6.1 and 6 .2 ).
_4. Essential hypertension in pregnancy ( Group 2 ,  Chapter 6 , 2 )
Evidence of an increase in p la te le t  a c t iv i t y  as observed by an 
increase in BTG leve ls and f i b r in  formation, as suggested by increased 
FPA levels (see Figures 6,1 and 6.2) indicates in travascu lar 
coagulation is  occurring in th is  group.
In tra  uterine growth re tardation (Group 2» ^*3.)
Normal BTG leve ls were observed in th is  group (see Figure 6 .3 ).
An increase in  f i b r in  formation as shown by an increase in FPA levels
was observed (see Figure 6 .4 ), This may re f le c t  an increase in 
f i b r in  in the placental bed in I.U.G.R.
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§_• Mild to  moderate pre-eelampsia (Group Chapter _6 «2)
No evidence of p la te le t  release (see Figure 6.3) but an increase 
in  f i b r in  formation as shown by an increase in FPA levels 
(see Figure 6.4) was observed in th is  group. A n t i -p la te le t  therapy, 
did not prevent th is  f i b r in  formation.
Z* Severe pre-eclampsia (Group I ,  Chapter j6 -Z)
Evidence of p la te le t  release, an increase in  BTG levels 
(see Figure 6.1) and an increase in  f ib r in  formation, as observed by 
an increase in  FPA levels (see Figure 6.2) suggests some degree of 
activated coagulation with f ib r in  deposition in the placental bed 
is  occurring in  these patients.
The measurements of both BTG and FPA were not able to d is t ingu ish  
the severe pre-eelamptic patients from the essential hypertension group, 
S,  Chronic re t in a l vein occlusion ( Chapter 2*1)
An increase in plasma fibrinogen levels (see F igure7.1) 
an increase in  plasma BTG levels (see Figure 7.2) and an increase in 
FPA leve ls  (see Figure 7.3) were observed in patients with c a p i l la ry  
perfusion and/or neovascularisation. Measurements of f ib r inogen,
BTG and FPA did not d is tingu ish  between patients with and without RVO, 
or RVO patients with and without complications. I t  is  possible tha t 
the observed ac tiva t ion  of coagulation may be the re su lt  of activated 
coagulation in  other vessels in the vasculature.
_9. The nephrotic syndrome ( Chapter 2*2)
Evidence of an increase in  p la te le t  release was observed in 
these patients when compared to control patients (see Figure 7 .4 ). 
Unfortunately the FPA assay was not available when th is  study was 
carried out, thus evidence of f i b r in  formation is  not ava ilab le .
Plasma BTG leve ls  did not d is t ingu ish  between e ith e r group.
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10. Admi ni s t ra t i  on o f stanozolol to heal thy volunteers 
( Chapter ] _, 3)
An increase in plasma B^15-42 leve ls in normal volunteers 
a f te r  the adm inistra tion of stanozolo l, suggests d ire c t  evidence 
o f in vivo plasmin a c t iv i t y  is  occurring fo r  at least seven days 
a f te r  adm in istra tion of the drug.
11. High r is k  DVT ( Chapter 2*1)
Plasma BTG leve ls
An increase in BTG leve ls (see Figure 7.S) was observed one 
day post-operative ly in each of the three sub groups o f patients 
i . e .  (a) those not receiving or those receiving stanozolol treatment, 
(b) those patients who did not and who did develop a post-operative 
DVT, (c) those patients with and without early operable malignancy.
This observed increase in BTG is  probably the resu lt  o f tissue 
damage and trauma during surgery. However in patients who then 
developed a DVT th is  increase was s ig n if ic a n t suggesting tha t in these 
patients the surgical procedure tr iggered a greater p la te le t  ac tiva tion  
before the onset o f thrombosis. However the increased values did not 
d is t ingu ish  those with and without thrombosis.
PIasma FPA leve ls
An increase in FPA levels was observed post-opera tive ly in a l l
three sub groups. A s ig n if ic a n t  r ise  in FPA leve ls was observed on
post-operative day 7 in  those patients who had developed a DVT,
ind ica ting  an increased f ib r in  formation had occurred. However,
these increased values did not d is t ingu ish  those with and without
DVT. A s ig n if ic a n t  increase in FPA levels in patients with early
operable cancer was observed pre-operatively suggesting ongoing f ib r in
formation is  occurring in these patients . I t  is  in te res ting  to  note
tha t in each of the control groups of the three sub groups an increase 
in  FPA leve ls was observed on the morning before surgery, presumably
due to  overnight s tress.
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PIasma B/jl5-42 1evels
A r ise  in plasma B^15-42 leve ls ,  ind ica ting an increase in 
plasmin a c t iv i t y ,  was observed in a l l  three sub groups post- 
opera tive ly . This would suggest tha t an increase in plasmin 
a c t iv i t y  occurs a f te r  surgery despite previous reports o f a 
f ib r in o ly t i c  shut-down a f te r  surgery. A s ig n if ic a n t  increase in 
plasma B^15-42 leve ls  was observed on the seventh post-operative 
day in the group who received stanozolo l, thus stanozolol has 
increased plasmin a c t iv i t y  in vivo a f te r  surgery. A s ig n if ic a n t  
r ise  in Bygl5-42 leve ls was observed on the morning of surgery 
in  those patients who then developed a DVT suggesting an increase 
in  i^asmin a c t iv i t y  is  already ongoing in the patients before 
surgery. While some o f these patients did receive stanozolol th is  
increase was also shown in  patients who did not receive stanozolol. 
However post-opera tive ly a greater increase, although not s ig n if ic a n t 
was observed between post-operative days 1-7 in patients who did 
not develop a DVT and those who d id , suggesting a decrease in plasmin
a c t iv i t y  in patients developing a DVT. In patients with malignancy
lower pre-operative values o f B ^ 15-42 were observed suggesting a 
reduced plasmin a c t iv i t y  is  present in these pa tients , however, 
post-opera tive ly a s ig n if ic a n t  increase in B^15-42 leve ls was 
observed in the seventh post-operative day. This may be the
re su lt  of a steeper r ise  in FPA leve ls with resu lt ing  f i b r in
formation in th is  sub group on the f i r s t  day post-opera tive ly.
Overall the resu lts  obtained in th is  study suggest tha t BTG 
leve ls  on the f i r s t  day post-operative ly are an index o f developing 
DVT. As the prevalence o f malignancy and DVT is  s im ila r  in the 
two treatment groups, malignancy does not predispose towards 
thrombosis. Stanozolol despite increasing in vivo plasmin a c t iv i t y  
does not prevent a DVT. In early malignancy an increase in f ib r in  
formation was observed.
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12. Early malignancy and in fe c t ion  ( Chapter
As v e r if ie d  in the previous study no increase in BTG levels 
was observed in patients with early malignancy. An increase in 
plasma BTG leve ls was observed in patients with "non-vascular 
i l ln e s s "  chest in fec t ion  when compared to control pa tients . This 
re su lt  suggests tha t elevated BTG levels are not spe c if ic  to 
thrombosis and occur in non-thrombotic i l lnesses.
13. Acute chest pain ( Chapter 8 ._2)
No increase in BTG leve ls  was observed in patients with 
myocardial in fa rc t io n ,  unstable angina and non-cardiac chest pain 
when compared to normal subjects (see Figure 8 ,1 ) .  Increased FPA 
le ve ls , suggesting f i b r in  formation, were shown in patients with myo­
cardia l in fa rc t io n ,  unstable angina and non-cardiac chest pain (see 
Figure 8 .2 ) .  Hence raised FPA leve ls are not spec if ic  fo r  acute 
coronary in su ff ic ie n cy . Neither are raised FPA leve ls  spec if ic  fo r  
thrombosis.BTG and FPA leve ls  are, there fore , o f no value in 
separating patients with acute chest pain in to  those with and without 
myocardial in fa rc t io n .
14. Coronary a r te ry  disease ( Chapter 8.2)
S im ilar values o f BTG, FPA and B^)15-42 were found in patients 
with 1, 2 or 3 vessel disease of the coronary a r te r ie s .  However 
some patients with 2 and 3 vessel disease had s l ig h t ly  higher BTG 
and FPA leve ls (see Figures 8.3 and 8 .4 ) ,  perhaps suggesting that 
s l ig h t  ac t iva t ion  o f coagulation is  occurring in these patients.
15. Type I I  and type IV hyperlipoproteinaemia ( Chapter 8 .£)
Plasma leve ls of BTG and FPA were not elevated in patients
with type I I  and type IV hyperlipoproteinaemia. This resu lt
suggests tha t p la te le t  release and f ib r in  formation are not 
implicated in  the development o f atherosclerosis.
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16. Diabetes me11itu s  ( Chapter 2*2)
No increase in BTG levels in diabetes m e ll i tus  was observed 
in  patients with diabetes m e ll i tus  and retinopathy e ith e r 
p ro l i fe ra t iv e  or n o n -p ro l i te ra t ive ,  suggesting no p la te le t  ac tiva tion  
is  occurring in these patients . A s ig n if ic a n t increase in plasma 
FPA leve ls was found in d iabetic  patients with p ro l i fe ra t iv e  or 
no n -p ro l i te ra t ive  retinopathy (see Figure 8 .9 ). This suggests 
f i b r in  formation is  ongoing in diabetes m e ll i tus  and appears to be 
higher in patients with p ro l i fe ra t iv e  retinopathy. This f ind ing may 
re f le c t  the severity  o f the disease and may be due to  other 
abnormalities of th is  disease.
17. Transient ischaemic attacks ( Chapter 8.2)
A s ig n if ic a n t  increase in plasma BTG leve ls , ie p la te le t  a c t iva t io n , 
was observed in patients with TIA when compared to e ld e r ly  controls 
(see Figure 8.10). While an increase in FPA leve ls  was observed 
in  the TIA group, th is  was not s ig n if ic a n t  when compared to  e ld e r ly  
con tro ls . Elevated plasma BTG leve ls were found to predict patients 
who developed fu r th e r  vascular events.
A r t i f i c i a l  surfaces (Chapter 2)
Studies on d i f fe re n t  a r t i f i c i a l  surfaces showed tha t plasma BTG 
leve ls  (see Figure 9.10) are an index of the thrombogenicity of 
these m ateria ls . Unfortunately FPA measurements were not applicable 
as the increases observed were not due to the material i t s e l f  but to 
the thrombin release reaction (see Figure 9 .9 ).
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_10-2. Probiems Associated with the Radioimmunoassay Techniques
These problems have been discussed in previous chapters. The 
recommended protocols must be adhered to  s t r i c t l y .  A perfect 
venepuncture must always be carried out. Preparation of plasma
samples must be carried out immediately. This implies tha t the
same person should be present or perform the venepunctures and 
th is  is  not always practicab le . With regard to  the BTG assay, 
i f  these conditions are adhered to correct values should be 
obtained. One o f the problems with the use o f the Amersham 
radioimmunoassay k i t  is  tha t the optimum value measured is  around 
210 ng/ml. While th is  would be adequate in most c l in ic a l  samples, 
in  assays carried out in the a r t i f i c i a l  surfaces studies, a greatly  
increased optimum value would be preferred.
The main problem associated with the FPA and Bygl5-42 assays is  
the removal of cross reacting fibrinogen from plasma samples before 
assay. While most of the studies in th is  thesis used the bentonite 
extraction  method, th is  may not be adequate as the bentonite has a 
l im ited  number of binding s ites  and a 75% extraction by ethanol 
has been recently  recommended (personal communication H L Nossel).
While th is  may suggest that some of the highly elevated c l in ic a l  samples 
are erroneously high, a double bentonite extraction method was used 
and thus most assays should be the correct value. The use of the 
double antibody separation technique fo r  the removal of bound 
antigen is  preferred and should become standard practice .
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10.4. C lin ica l Implications o f the Measurement o f Plasma BTG,
FPA and B ^15-42 
While the assay of BTG can be performed w ith in  four hours, a 
time delay o f 30 hours in obtaining the resu lts  of the FPA and 
B^15-42 assays l im i ts  th e i r  use in the diagnosis and management of 
thrombotic diseases.
The resu lts  in th is  thesis do suggest a ro le fo r  
plasma BTG in  the development of venous thrombosis and possibly 
a r te r ia l  thrombosis. An overall view of the resu lts  in th is
thesis suggest tha t i t  is  not possible to  use these assays as
c l in ic a l  markers fo r  thrombosis. However, as a research tool 
they have a very important ro le as suggested at the beginning 
o f th is  thes is . One of the main problems in developing tests fo r  
the detection o f thrombosis is  tha t the i n i t i a l  events in thrombosis 
are s im ila r  to  those occurring in normal haemostasis and acute 
i l lnesses , as the resu lts  in th is  thesis have shown. Consequently 
patients with acute il lnesses should be excluded from control groups. 
The resu lts  in th is  thesis also suggest the use of a "non-vascular 
i l ln e s s "  control group in a l l  studies in order to be certa in  tha t 
abnormalities measured are spec if ic  to  thrombosis.
With regard to the underlying mechanisms in thrombosis, the 
studies carried out in th is  thesis suggest tha t in venous thrombosis, 
p la te le t  ac t iva t ion  is  occurring as an i n i t i a l  event, therefore BTG 
may be a marker o f a pre-thrombotic sta te . F ib r in  deposition occurs 
at a la te r  event. Since no co rre la t ion  was found in most studies 
between BTG and FPA, thrombin does not appear to  be responsible fo r
th is  p la te le t  a c t iva t io n . I t  is in te res ting  to note tha t in some
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c l in ic a l  conditions such as longstanding re t ina l vein occlusion, 
ongoing f ib r in  deposition and p la te le t  release is  s t i l l  occurring 
months a f te r  the thrombotic episode occurs and may, there fore , 
ind icate a continuous pre-thrombotic state in these pa tients .
The resu lts  obtained in the DVT study support the e a r l ie r  find ings 
o f McNicol and Douglas, 1976, tha t there is l i t t l e  evidence of a 
disturbance in the equilibrium  between c lo t t in g  and ly s is  in the 
development of DVT, however an examination of Figure 7.7 shows that 
in  patients who developed a DVT a f te r  the f i r s t  postoperative day 
the value o f B 15-42 was not greater than the FPA value and 
perhaps some evidence does ex is t fo r  the theory postulated by 
Nossel (1981) tha t i t  is  the rate of proteolysis o f the B ^  chain 
o f f ibr inogen which determines the development of thrombosis.
In a r te r ia l  thrombosis, a greater increase in p la te le t  
ac t iva t ion  would haVÔbeen expected in c l in ic a l  conditions associated 
with a r te r ia l  thrombosis. The resu lts  obtained in th is  thesis do 
not support th is  hypothesis. The measurement o f BTG was o f no 
c l in ic a l  value in  the management of coronary a rtery  disease.
However in patients with cerebral a r te r ia l  disease BTG measurements 
do have important implications in the management and detection of 
th is  disease. I t  is  possible tha t differences observed in the 
BTG measurements obtained between the coronary a r te ry  and TIA study 
re f le c t  d ifferences in the d i f fe re n t  vascular compartments with 
obvious differences in blood flow and hence ac tiva tion  s ites  of 
thrombosis. Such differences may also apply to the d iabetic  
retinopathy study, however in th is  study f ib r in  formation and not 
p la te le t  ac t iva tion  appeared to be predominant.
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The underlying mechanism in  both a r te r ia l  and venous thrombosis 
s t i l l  appears unsolved and as suggested at the beginning of th is  
thes is , the processes of p la te le t  ac t iva t ion , c lo t t in g  and 
f ib r in o ly s is  are c lose ly  in te r l in ke d  in the thrombotic mechanism.
10.-Z* Final Comments and Aspects fo r  Future In v e s t igation
Thrombosis involves the complicated in te ractions o f many 
fac to rs . The complexity of these in te ractions suggests 
the need fo r  new inves tiga tive  too ls in the search fo r  an 
understanding of such a complicated event as thrombosis. Many 
of the studies in th is  thesis have validated previous research 
and other studies have shown new findings and consequently raised 
questions on the detection of thrombosis. Since the use of the 
B ^ 1 5 -4 2  assay was only carried out in three of the studies 
reported, a reappraisal of the other studies with the inc lusion of 
th is  assay is  recommended to determine i f  a decrease in  plasmin 
a c t iv i t y  may be associated with thrombosis.
Recently new assays fo r  FPB, des-Arg FPB, fragments D and E, 
have been available and hence th e i r  measurement is  suggested in 
c l in ic a l  conditions associated w ith thrombosis. With the 
development of new peptide fragments and epitopes of f ib r inogen 
(see review by Plow and Edgington, 1982), other possible markers may 
soon be ava ilab le . I t  may be tha t seria l studies on the development 
of thrombosis w i l l  reveal more information of the DVT studies 
reported in  th is  thes is . Daily blood samples might have revealed 
more information. The use of the BTG, FPA and B ^15-42 assays may 
have potentia l in the development of in v i t ro  and in  vivo studies 
on the development of thrombosis especia lly in animal models.
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The resu lts  in  the a r t i f i c i a l  surfaces study have great potentia l 
with regard to a r t i f i c i a l  organ studies in animals and man, 
especia lly  with the development of the a r t i f i c i a l  heart.
S ixty years ago Bordet wrote:
"Coagulation has been studied fo r  years and years 
by many inves tiga to rs , none of them can presume 
tha t the problem is  yet solved, every one of them 
merely indulges in  the hope of gathering more 
complementary data, a l i t t l e  more in fo rm ation".
I hope in  th is  thesis I have gathered a l i t t l e  more information 
and complementary data.
326
REFERENCES
Abildgaard, U (1968)
Highly pu r if ied  anti-thrombin I I I  with heparin cofactor a c t iv i t y  
prepared by disc electrophoresis.
Scandinavian Journal o f Cl i nical and Laboratory Investi ga tion , 21, 89-91.
Abrahamsen, A F (1968)
A m odifica tion  of the technique fo r  C r- la be ll ing  of blood 
p la te le ts  giving increased c irc u la t in g  p la te le t  ra d io a c t iv i ty
Scandinavian Journal o f Haematology, 2> 53-63.
Adler, A J , Lundin, A P, Friedman, E A and Berlyne, G M (1979)
Effect of haemodialysis on plasma beta thromboglobulin leve ls .
Transactions of the American Society o f A r t i f i c i a l  Internal Organs,
25, 347-350.
Adler, A J ,  Lundin, A P, Feinroth, M V, Friedman, E A and Berlyne G M
(1980)
Beta-thromboglobulin levels in the nephrotic syndrome
American Journal o f Medicine, 69: 4, 551- 554.
Alexander, B and Landwehr, G (1949)
Evolution of prothrombin conversion accelerator in  stored human 
plasma and prothrombin f ra c t ions .
American Journal o f Physiology, 159, 332-331.
A lk ja e rs ig , N, F letcher A P and Sherry, S (1959)
The mechanism of c lo t  d isso lu tion  by plasmin
Journal of C lin ica l Inve s t ig a t io n , 38, 1086- 1095.
A lk ja e rs ig , N, F le tcher, A and Burste in, R (1975)
Association between oral contraceptive use and thromboemolism:
A new approach to i t s  investiga tion  based on plasma fibrinogen 
chromatography.
American Journal o f Obstetrics and Gynecology, 122, 199-211.
A lk ja e rs ig , N and F le tcher, A P (1982)
Catabolism and excretion of fib r inopeptide-A .
Blood, 60, 148-156
A lk jaers ig  N, Laursen, B and Fletcher A (1972)
The response of the blood coagulation system a f te r  acute 
thrombic stroke.
Journal o f C l in ica l Inves tiga tions , 51, 2a-3a.
327
Aimer, L 0, Pandolfi, M and Nilsson, I M (1974)
Diabetic retinopathy and the f ib r in o ly t i c  system.
Diabetes, 24, 529-534
Ambrus C M and Markus G (1960)
Plasmin-antiplasmin complex as a reservo ir of f i b r in o ly t i c  enzyme.
American Journal of Physiology, 199, 491-494.
Anderton, J L, Fananapazir, L and Dawes, J (1980)
Urinary beta-thromboglobulin in essential hypertension.
B r i t is h  Journal of Haematology, 44, 307-311.
D'Angelo V, V i l la  S, Mysliwiec, M, Donati, M B and de Gaetano, G (1978) 
Defective f ib r in o ly t i c  and p ros ta cyc l in - l ike  a c t iv i t y  in human 
atheromatous plaques.
Thrombosis and Haemostasis, 39, 535-536.
Anitschkow, N and Chalatow, S (1913)
Uber experimentelle cholesterine ste-atose und ihre bedeutung 
fu r  der entstehung einger patholog ischer prozesse
Z e n tra lb la t t  fu r  A11gemeine Pathologie und Pathologische Anatomie, 24, !_
Anning, S T (1957)
The h is to r ic a l  aspects of venous thrombosis.
Medical H is tory , 1, 28-37.
Aoki, N and Moroi, M (1974)
D is t in c t io n  of serum in h ib i to r  of activator-induced c lo t  lys is  
from OL, - a n t i t ry p s in .
Proceedings o f the Society fo r  Experimental Biology and Medicine, 
1467567-570.
Astedt, B, Isacson, S and Nilsson, I M (1970)
F ib r in o ly t ic  o f veins during pregnancy.
Acta Obstetrica et Gynacologica Scandinavica, 49, 171-173
Astrup, T (1956)
F ib r in o lys is  in the organism.
Blood, 11, 781-
Astrup, T (1965)
Assay and content of tissue thromboplastin in  d i f fe re n t  organs. 
Thrombosis et Diathesis Haemorrhagica, 14, 401.
Austen, D E (1974)
Factor V I I I  of small molecular weight and i t s  aggregation. 
B r i t is h  Journal o f Haematology, 27, 89-100.
328
Aranda, M, Saez, M, A b r i l ,  V, Carrarach, J, Caste lls , E and 
Castellano S J M (1979)
Beta-thromboglobulin levels and oral contraception, 
( le t te r )  Lancet 2 (8137), 308-9.
Baele, G, Bogaerts H, Clement D L, Pannier, R and Barbier, F (1981) 
P la te le t ac t iva t ion  during treadm ill exercise in  patients with 
chronic peripheral a r te r ia l  disease.
Thrombosis Research, 23, 215-223.
Baker, W H, Fareed, J, Messmore, H L, K n i f f in ,  J , S q u i l la c i ,  G and 
Foldes, M (1981)
Effect of exercise on p la te le t  function in patients with 
in te rm it te n t c laud ica tion .
(Abstract) Thrombosis and Haemostasis, 46, Abstract No 1405.
Baldauf, W, Wurzinger, L J and Kinder, J (1978)
The ro le of stagnation point flow in the formation of p la te le t  
thrombi on glass surfaces in tubes with various geometry.
Pathology, Research and P ractice , 163, 9-33.
Bang, N U and Chang, M L (1974)
Soluble f i b r in  complexes.
Seminars in Thrombosis and Hemostasis, _1, 91-128.
Barlow, G H, Holleman, W H and Lorand, L (1970)
The action of Arvin on f ib r in  s ta b i l iz in g  fa c to r  ( fa c to r  X I I I )  
Research Communications in Chemical Pathology and Pharmacology 
(Westbury NY), 1, 39-42.
Barlow, G H, Rueter, A and Tribby, I (1975)
Production of plasminogen a c t iva to r  by tissue cu ltu re  techniques.
In Proteases and B io log ica l Control
'ëïï. Reich, E, R ifk in  D B and Shaw, E. Cold Spring Harbour Conferences 
on Cell P ro l i fe ra t io n ,  2, 321-325.
Barnes, A J , Locke, P, Scudder, P R, Dormandy, T L, Dormandy, J A 
and Slack, J (1977)
Is hyperviscosity a trea tab le  component of d iabetic  m icroc ircu la tory  
disease?
Lancet 2 ,  789-791.
Barnhart, M I and Chen, S T (1978)
Vessel wall models fo r  studying in te rac tion  c a p a b i l i t ie s  with blood 
p la te le ts .
Seminars in Thrombosis and Hemostasis, 5, 112-155.
329
B arrow c li f fe , T W, Johnson, E A and Thomas, D (1978) 
Anti thrombin I I I  and heparin.
B r i t is h  Medical B u l le t in ,  34, 143-150.
B as t l, C P, Musial, J , Kloczewiak, Guzzo, J, Berman, I and 
Niewiarowski, S (1981)
Role of kidney in the catabolic clearance of human p la te le t  
antiheparin proteins from ra t c irc u la t io n .
Blood, 57, 233-238.
Baumgartner, H R, Muggli, R, Tschopp, T B and T u r i t to ,  V T (1976) 
P la te le t adhesion, release and aggregation in flowing blood: 
Effects of surface properties and p la te le t  function . 
Thrombosis and Haemostasis, 35, 124-138.
Bayley, T, Clements, J A and Osbahr, A J (1967)
Pulmonary and c irc u la to ry  e ffec ts  of f ib r inopep tides . 
C ircu la t ion  Research, 21, 469-485.
Beatt ie , A, Ogston, D, Bennett, B and Douglas, A S (1976) 
In h ib ito rs  of plasminogen activa t ion  in human blood. 
B r i t is h  Journal o f Haematology, 32, 135- 143.
Beck, E A, Charache, P and Jackson, D P (1965)
A new inherited  coagulation disorder caused by an abnormal 
fib r inogen ("Fibrinogen Baltimore")
Nature, 208, 143-145.
Begent, N and Born, G V (1970)
Growth rate in  vivo of p la te le t  thrombi, produced by 
iontophoresis o f ADP, as a function o f mean blood flow v iscos ity . 
Nature ( London) , 227, 926-930.
Begg, G S, Pepper, 0 S, Chesterman, C N and Morgan, F J (1978) 
Complete covalent s tructure of human B-thromboglobulin. 
B iochemistry, 17, 1739-1744.
B e lle r, F K (1969)
The ro le  of endotoxin in disseminated in travascu lar coagulation. 
Thrombosis et Diathesis Haemorrhagica, Suppl 36, 125- 150.
330
Bend itt, E P and Benditt J M (1973)
Evidence fo r  a monoclonal o r ig in  of human a therosc le ro tic  plaques.
Proceedings o f the National Academy of Sciences, USA, 70, 1753- 1756.
B en iv ien i, A (1928)
Quoted by Long, E R.
A H istory o f Pathology, Baltimore. Williams and W ilk in s , 291.
Bennett, N B (1967)
A method fo r  the quan tita t ive  assay of in h ib i to r  of plasminogen 
a c tiva t ion  in human serum.
Thrombosis et Diathesis Haemorrhagica, 17, 12-22.
Bennett, N B, Ogston, C M and Ogston, D (1968)
The e ffec t of prolonged exercise on the components of the blood 
f i b r in o ly t i c  enzyme system.
Journal o f Physiology, 198, 479-485.
Bennett, B, Forman, W B and Ratnoff, 0 D (1973)
Studies on the nature of antihemophilic fac to r  ( fa c to r  V I I I ) .  
Further evidence re la t in g  the AHF-like antigens in normal and 
hemophilic plasmas.
Journal o f C lin ica l In ve s t ig a t io n , 52, 2191-2197.
Bernik, M B and Kwaan, H C (1969)
Plasminogen a c t iva to r  a c t iv i t y  in cultures from human tissues.
An immunological and histochemical study.
Journal of C lin ica l Inve s t ig a t io n , 48, 1740-1753.
Bessis, M (1977)
Blood smears re in te rp re ted .
Translated by Brecher, G. Springer In te rn a t io n a l, B e r l in .
Bertina, R M, Broekmans, A W, van der Linden, I K and Mertens, K (1982) 
Protein C defic iency in  a Dutch fam ily  with thrombotic disease.
Thrombosis and haemostasis, 48, 1-5.
Bettelheim, F R and Bailey, K (1952)
The products of the action of thrombin on f ib r inogen. 
Biochimica et Biophysioca Acta, £ ,  578- 579.
331
Bettelheim, F R (1956)
The c lo t t in g  of f ib r inogen. I I .  Fractionation of peptide material 
1 ite ra ted .
Biochimica et Biophysica Acta, 19, 121-130.
B idet, J M, Fe rr ie re , J P, Besse, G, Choi l e t ,  P, G a il la rd , G and
Plagne, R (1980)
Evaluation of B-thromboglobulin levels in cancer patients :
Effects of antitumour chemotherapy.
Thrombosis Research, 19, 429-433.
Biggs, R, Macfarlane, R G and P i l l in g ,  J (1947)
Observations on f ib r in o ly s is :  Experimental a c t iv i t y  produced by
exercise or adrenaline.
Lancet, 402-405.
B ile z ik ia n , S B, Nossel, H L, B u tle r, V P, Canfield, R E (1975) 
Radioimmunoassay of human fib r inopep tide  B and k ine tics  of 
f ib r inopep tide  cleavage by d i f fe re n t  enzymes.
Journal o f C lin ica l Inve s t iga t ion , 56, 438-445.
B i l l s ,  T K, Smith, J B and S i lv e r ,  M J (1976)
Metabolism of C arachidonic acid by human p la te le ts
Biochimica et Biophysica Acta, 424, 303-314.
Bizzozero, J (1881)
Ueber einen neuen formbestandtheil des blutes und dessen ro l le  bei 
der thrombose und der blutgerinnung.
Virchows Archiv fu r  Pathologische, Anatomie und Physio logie, 90, 261-332
B le y l , U (1977)
Morphologic diagnosis of disseminated in travascu lar coagulation: 
H is to log ica l,  histochemical and electron microscopic studies. 
Seminars in Thrombosis and Haemostasis, 3^ , 247-267.
Blomback, B and Blomback, M (1956)
P u r i f ic a t io n  of human and bovine fibrinogen
Arkiv Kemi, 10, 415- 443.
Blomback, B (1958)
Studies on the action of thrombic enzymes on bovine fibrinogen 
as measured by N-terminal analysis.
Arkiv Kemi, 12, 321-335.
332
Blomback, B and Laurent, T C (1958)
N-terminal and l ig h t  scattering studies on fibrinogen and i t s  
transformation to f i b r in .
Arkiv Kemi, 12, 137-146.
Blomback, B and Vestermark, A (1958)
Iso la t ion  of f ib r ino -pep tides  by chromatography. 
A rk iv Kemi, 12, 173-182.
Blomback, B and Blomback, M (1966)
P u r if ica t io n  of human and bovine fibr inogen 
Arkiv Kemi, 10, 415-443.
Blomback, B, Blomback, M and Edman, P (1966)
Human f ib r inopeptides is o la t io n :  Characterization and structure .
Biochimica et Biophysica Acta, 115, 371-396
Blomback, B (1967)
Fibrinogen to f i b r in  transformation.
In Blood C lo tt ing  Enzymology
ed. SeegersjW H. New York: Academic Press, 143-215 .
Blomback, M, Blomback, B, Mammen, E F, and Prasad, A S (1968) 
Fibrinogen D e tro it  - A molecular defect in the N-terminal 
disulphide knot of human fibrinogen?
Nature, 218, 134-137.
Blomback, B, Blomback, M Olsson, P, Svendsen, L and Aberg, G (1969) 
Synthetic peptides with anticoagulant and vasodilating a c t iv i t y .  
Scandinavian Journal o f C lin ica l and Laboratory Inves tiga tion , Suppl 
107, 59-64.----------------------------------------------------  ^
Blomback, B, Hogg, D H, Gardlund, B, Hessel, B and Kudryk, B (1976)
Fibrinogen and f i b r in  formation.
Thrombosis Research, B ( Suppl 2) ,  329-346.
Blomback, B, Hessel, B, Hogg, D and Therkildsen, L (1978)
A two step f ib r in o g e n - f ib r in  t ra n s i t io n  in blood coagulation. 
Nature, 275, 501-505.
Bloom, A L, Giddings, J C and Wilks, C J (1973)
Factory V I I I  on the vascular intima: Possible importance in  
haemostasis and thrombosis.
Nature ( New B iology) , 241, 217- 219.
333
Bloom, A L (1975)
In travascular coagulation and the l iv e r .  
B r i t i  sh Journal o f Haematology, 30, V-]_.
de Boer, A C, Han, P, Turpie, A G G, Butt, R, Z ie lin sky , A and 
Genton, E (1981)
Plasma and urine Beta-thromboglobulin concentration in patients 
with deep vein thrombosis 
Blood, 58, 693-698.
de Boer, A C, Turpie A G G, Butt, R and Genton E (1981)
Thromboxane B^, and betathromboglobulin in symptomatic coronary 
arte ry  disease.
Thrombosis and Haemostasis, 46. Abstract No 0844.
de Boer, A C, Turpie, A G, Butt, R, Duke, R J, Bloch, R F and 
Genton E (1982)
Plasma betathromboglobulin and serum fragment E in  acute 
pa rt ia l stroke.
B r i t i  sh Journal o f Haematology, 50, 327-334.
Bolton, A E, Ludlam, C A, Moore, S, Pepper, D S and Cash, J D (1976) 
Three approaches to the radioimmunoassay of human B-thromboglobulin 
B r i t i  sh Journal o f Haematology, 33, 233-238
Bolton, A E, Cooke, E D, Lekhwani, C P and Bowcock, S A (1980)
Urinary B-thromboglobulin levels as a diagnostic marker fo r  
postoperative deep vein thrombosis 
Thrombosis Research, 19, 249-255.
Boneu, B, Bierme, R, Fournie, A and Pontonnier, G (1977)
Factor V I I I  complex fe ta l growth re tardation and toxaemia.
Lancet %, 263.
Bonnar, J , McNicol, G P and Douglas, A S (1971)
Coagulation and f ib r in o ly t i c  systems in pre-eclampsia and eclampsia 
B r i t is h  Medical Journal 2, 12-16.
Bordet, J.
The theories of blood coagulation. 
B u l le t in  John Hopkins H osp ita l, 32, 213-218.
334
Born, G V R (1962)
Aggregation of blood p la te le ts  by adenosine diphosphate and 
and i t s  reversa l.
Nature, 194, 927-929.
Borsey, D Q, Dawes, J , Fraser, D M, Prowse, C V, E lton, R A
and Clarke, B F (1980)
Plasma beta-thromboglobulin in diabetes m e ll i tu s
D iabetologica, 18, 353- 357.
B o t t i ,  R E and Ratnoff, 0 D (1964)
The clot-promoting e ffe c t of soaps of long-chain saturated 
fa t ty  acids.
Journal o f C lin ica l Inve s t ig a t io n , 42, 1569-1577.
Boughton B J, A l l in g to n , M J and King, A (1978)
P la te le t and plasma B-thromboglobulin in m ye lopro life ra tive  
syndromes and secondary thrombocytosis.
B r i t is h  Journal o f Haematology, 40, 125- 132.
Brash, J L, Brophy, J M and Feuerstein, I A (1976)
Adhesion of p la te le ts  to a r t i f i c i a l  surfaces: E ffect of red ce lls
Journal o f Biomedical Materials Research, 10, 429-443.
Breen, F A J r  and T u l l is  J L (1968)
Ethanol ge la tion : A rapid screening te s t  fo r  in travascu la r
coagulation.
Annals o f Internal Medicine, 69, 1197-1206.
Brown, D L (1975)
Complement and coagulation.
B r i t i  sh Journal o f Haematology, 30, 377- 382.
Brown, C H, Leverett, L B, Lewis, C W, A lfre y , C P Jr and Heliums, J D 
(1975)
Morphological, biochemical and functional changes in human 
p la te le ts  subjected to shear stress.
Journal o f Laboratory and C lin ica l Medicine, 86, 462-471.
Browse, N L, Gray, L and Mori and, M (1977)
Changes in the blood f ib r in o ly t i c  a c t iv i t y  a f te r  surgery.
(The e f fe c t  of deep vein thrombosis and malignant disease).
B r i t is h  Journal o f Surgery, 64, 23-27.
Brozovic, M (1981)
Acquired disorders of blood coagulation.
In Haemostasis and Thrombosis
eds. Bloom, A L and Thomas, D P. Churchill Liv ingstone, 198-224.
335
Bruck, S D (1974)
Polymeric materia ls : Current status of b iocom pa tib i l i ty .
Biomaterial and Medical Devices and A r t i f i c i a l  Organs, _1, 79-98.
Bruck, S D (1980)
Problems and arte facts  in the evaluation of polymeric materials 
fo r medical uses.
Biomateria ls, 1, 103-107.
Brucke, V E (1857)
Ueber die ursache der gerinnung des blutes.
Archie fu r  Pathologische Anatomie und Physiologie und fu r  K1inische 
Medicin, 12, 81.
Budzynski, A Z and Marder, V J (1973)
Solid phase synthesis of human f ib r inopeptides A and B.
In Protides o f the B io log ica l f l u id s .
êôf. Peeters, H. Oxford: Pergamon, 287-293.
Budzynski, A Z, Marder, V J and Sherry S (1975)
Reaction of plasmic degradation products of f ibr inogen in the 
radioimmunoassay of human fib r inopeptide  A.
Blood, 45, 757-768.
Buluk, K and Malofiejew, M (1969)
The pharmacological properties of fibrinogen degradation products, 
B r i t is h  Journal of Pharmacology, 35, 79-89.
Burnand, K, Clemenson, G, Norland, M, J a r re t t ,  P E M and Browse, N L 
(1980)
Venous lipodermatoscle ro s is : Treatment by f ib r in o ly t i c  
enhancement and e la s t ic  compression.
B r i t is h  Medical Journa l, 280, 7-12.
Burnand, K G, Whimster, I ,  Naiddo, A and Browse, N L (1982)
P e r ica p i l la ry  f i b r in  in  the ulcer-bearing skin of the leg:
The cause o f venous lipodermatosclerosis and venous u lce ra tion . 
B r i t is h  Medical Journa l, 285, 1071-1072
Burrows, A W, Chavin, S I and Hockaday, T D R (1978)
Plasma-thromboglobulin concentrations in  diabetes m e llitus , 
Lancet 1, 235-237.
Burrows, A W (1981)
Beta-thromboglobulin in diabetes: Relationship with blood
glucose and f ib r inopep tide  A.
In Pathogenetic Concepts o f Diabetic Microangiopathy.
eds. P fe i f fe r ,  E F, R a il ,  J E. S tu ttga rt - New York: Georg
Thieme Verlag. 22-25.
336
Cazenave, J P, Dejana, E, Kinlough-Rathbone, R L, Packham, M A and
Mustard, J F (1979)
P la te le t in te ractions with the endothelium and the subendothelium: 
the ro le  of thrombin and prostacyc lin .
Haemostasis, 8, 183-192.
Celia , G, Zahavi, J , d e  Haas, H A and Kakkar, V V (1979)
B-thromboglobulin, p la te le t  production time and p la te le t  
function in  vascular disease.
B r i t is h  Journal of Haematology, 43, 127- 136.
Chakrabarti, R, B irks, P M and Fearnley, G R (1963)
Origin of blood f i b r in o ly t i c  a c t iv i t y  from veins and i t s  bearing 
on the fa te  of venous thrombi.
Lancet %, 1288- 1290.
Chandler, A B (1958)
In v i t r o  thrombotic coagulation of the blood: A method fo r
producing a thrombus.
Laboratory In ve s t ig a t io n , 7_j 110-114.
Chandler, A B, Chapman, I ,  Erhardt, L R, Roberts, W C, Schwartz, C J,
Sinapius, D, Spain, D M, Sherry, S, Ness, P M and Simon, T L (1974) 
Coronary thrombosis in  myocardial in fa rc t io n :  Report of a
workshop on the ro le of coronary thrombosis in the pathogenesis of 
acute myocardial in fa rc t io n .
American Journal o f Cardiology, 34, 823:833.
Chang, M L and Bang, N U (1977)
B iologica l behaviour of higher molecular weight products of 
f ib r in o ly s i  s.
Journal o f Laboratory and C lin ica l Medici ne, 90, 216-226.
Chesley, L C (1978)
Eclampsia: The remote prognosis.
Seminars in perina to logy, _2, 99-111.
Chesney, C M, P i fe r ,  D D and Colman, R W (1978)
Factor V coagulant a c t iv i t y  of human p la te le ts  generated by collagen.
C ircu la t ion  58 (Suppl. I I ) 209
337
Chesterman, C N, A l l in g to n , M J and Sharp, A A (1972)
Relationships of plasminogen ac t iva to r to f i b r in .
Nature ( New Biology) , 238, 15-17.
Christman, 0 K, Acs, G, S i la g i ,  S and S ilve rs te in ,  S C (1975)
In Proteases and Biologica l Contro l.
eïïs. Reich E, R i fk in ,  D B and Shaw, E.
Cold Spring Harbor Conferences on Cell P ro l i fe ra t io n .  2, 827.
Chugh, K S, Malick, N, Uberoi, H S, Gupta, V K, Aggarwal, M L,
Singhal, P C, Suri S and Jain S K (1981)
Renal vein thrombosis in nephrotic syndrome - A prospective 
study and review.
Postgraduate Medical Journa l, 57 (671) ,  566-570
Clark, A J (1938)
The normal anti-thrombin of the blood and i t s  re la t io n  to heparin.
American Journal o f Physiology, 123, 712
Clauss, A (1957)
Gerinnungsphysiologische Schnell methode zur bestimmung des fibrinogens
Rapid physiological coagulations method in determination of fib r inogen
Acta Haematologica, 17, 237-246.
Clayton, J K, Anderson, J A and McNicol, G P (1976)
Preoperative pred ic tion of post-operative deep vein thrombosis.
B r i t is h  Medical Journa l, 2, 910-912.
C line, M J , Melmon, K L, Davis, W C and Williams, H E (1968)
Mechanism of endotoxin in te rac tion  with human leucocytes.
B r i t is h  Journal o f Haematology, 15, 539-547.
Coccherij^S, Mannucci, P M, P a la re t i ,  G, Gervasoni, W, Poggi, M 
and Vigano, S (1982)
S ignificance of plasma fib r inopeptide  A and high molecular weight 
f ibr inogen in patients with l i v e r  c ir rh o s is .
B r i t is h  Journal o f Haematology, 52, 503-509.
338
Cochrane, C G, Revak, S D and Wuepper, K D (1973)
Activa tion  of Hageman fac to r  in  so lid  and f lu id  phases. 
A c r i t i c a l  ro le  of k a l l ik re in .
Journal o f Experimental Medici ne, 138, 1564-1583.
Collen, D and de Maeyer, L (1975)
Molecular biology of human plasminogen.I. Physio-chemical 
properties and microheterogeneity.
Thrombosis et Diathesis Haemorrhagica, 34, 396- 402.
Collen, D, Ong, E B and Johnson , A J (1975)
Human plasminogen: In v i t r o  and in vivo evidence fo r  the 
b io log ica l in te g r i t y  o f NH2  -terminal glutamic acid plasminogen
Thrombosis Research, %, 515-529.
Colman, R W, M a tt le r ,  L and Sherry, S (1969)
Studies on the p re -k a i l ik re in  (k a ll ik re in o g e n )-K a l l ik re in  enzyme 
system of human plasma,11. Evidence re la t in g  the kao lin -act iva ted  
argin ine esterase to  plasma k a l l ik re in .
Journal o f C lin ica l Inve s t ig a t io n , 48, 23-32.
Condie, R G (1976)
Plasma f ib r in o ly t i c  a c t iv i t y  in pregnancy with p a r t ic u la r  
reference to pre-eclampsia.
Austra lian and New Zealand Journal o f Obstetrics and Gynaecology,
16, 18-23.
Cooper, H A, Bowie, E J W and Owen, C A (1974)
Evaluation of patients with increased f ib r in o ly t i c  s p l i t  products 
(ESP) in  th e i r  serum.
Mayo C lin ic  Proceedings, 49, 654- 657.
Cossu, M M, Tantalo, V, Paracchini, N L, Mondonico, P, Rossi, E,
C la r is -App ian i, A, Tento r i, F and Edefonti, A (1981)
Pattern of plasma beta-thromboglobulin, p la te le t  fa c to r  IV 
and fa c to r  V I I I  complexing in monitoring haemolytic uremic 
syndrome in ch ildren
Thrombosis and Haemostasis, 46, Abstract No 0080.
Cuatrecasas, P. (1970)
Agarose derivatives fo r  p u r i f ic a t io n  of prote in by a f f in i t y  
chromatography.
Nature, 228, 1327-1328.
339
Damus, P S, Hicks, M and Rosenberg, R D (1973)
Anticoagulant action of heparin.
Nature, 246, 355-357.
Dastre, A (1893)
F ibrinolyse dans le sang.
Arch Physiol Norm Pathol. 661- 663.
Davidson, J F, McNicol, G P, Frank, G L, Anderson, T J and Douglas, A S
(1969)
Plasminogen-activator-producing tumour.
B r i t is h  Medical Journal I ,  88-91.
Davidson, J F, Lockhead, M, McDonald, G A and McNicol, G P (1978) 
F ib r in o ly t ic  enhancement by stanozolo l: A double b lind  t r i a l  
B r i t is h  Journal o f Haematology, 22, 543-559.
Davey, M G and Luscher, E F (1968)
Release reactions of human p la te le ts  induced by thrombin and 
and other agents.
Biochimica et Biophysica Acta, 165, 490-506.
Davie, E W and Fujikawa, K (1975)
Basic mechanisms in blood coagulation.
Annual Reviews o f Biochemistr.y, 44, 799- 829.
Davies, G C, Sobel , M and Salzman, E N (1980) 
Elevated plasma f i b r  
during cardiopulmona 
C ircu la t ion , 61, 808-814.
r inopep tide  A and thromboxane B leve ls 
l onary bypass.
Dawes, J, Smith, R C and Pepper, D S (1978)
The release, d is t r ib u t io n  and clearance of human B-thromboglobulin 
and p la te le t  fa c to r  4.
Thrombosis Research, 12, 851-861.
Dawes, J, Smith, R C, Borsey, D and Aronstam, D (1979)
The value of urinary B-thromboglobulin measurements in 
c l in ic a l  s itua t ions .
Thrombosis ana Haemostasis, 42, Abstract No 0346.
340
Day, W C and Barton, P G (1971)
Studies on the s ta b i l i t y  of bovine plasma Factor V.
Biochimica et Biophysica Acta, 261, 457-468.
Dembinska-Kiec, A, Gryglewska, T, Zmuda, A and Gryglewski, R J (1977) 
The generation of prostacyclin by a rte r ies  and by the coronary 
vascular bed is  reduced in experimental atherosclerosis in rabbits,
Prostaglandins, 14, 1025- 1034.
Denham, M J , Fisher, M, James, G and Hassan, M (1977)
B-thromboglobulin and heparin-neutra lis ing a c t iv i t y  te s t in  
c l in ic a l  conditions.
Lancet I ,  1154.
Denis, P S (1838)
Essai sur l 'a p p l ic a t io n  de^la chemie A 1 'etude physiologique 
du sang de l'homme et a 1 'e tu d e .^
Physio-Pathologique, Hygienéque et Thérapeutique des Maladies de 
Cette Humeur.
Denson, K W E (1977)
In Human B1ood Coagulation, Haemostasis and Thrombosis, 2nd e d i t io n , 
ed. Biggs, R. Oxford: S c ie n t i f ic  Press, 602.
Derechin, M^(1955^
Caractères genereaux de la paracoagulation f ib r in o ly t iq u e .
Revue d 'Hématologie, 10, 35-40.
Dewar, H A, Marshall, T, Weightman, D, Prakash, V and Boon, P J (1979) 
B-thromboglobulin in antecubital vein blood - the influence of 
age, sex, and blood group.
Thrombosis and Haemostasis, 42, 1159- 1163.
Dintenfass, L (1971)
V iscosity  factors in blood flow , ischaemia and thrombosis.
In Blood Microrheology.
London: Butterworth, 267.
Documenta Geigy, S c ie n t i f ic  Tables, 6th ed it ion  (1962)
K. Diem. Geigy, Manchester, 263.
341
Donati, M B, Verhaeghe, R, Culasso, D E and Vermylen, 0 (1976)
Molecular size d is t r ib u t io n  of f ibrinogen deriva tives formed 
in  v i t r o  and in vivo: A chromatographic study.
Thrombosis and Haemostasis, 36, 14-26.
D o o l i t t le ,  R F (1977)
Structure and function of fibrinogen
Horizons in Biochemistry and Biophysics, _3, 164-191
D o o l i t t le ,  R F (1981)
Fibrinogen and f i b r in .
In Haemostasis and Thrombosis.
eds. Bloom, A L and Thomas, D P. Churchill L ivingstone, 198-224.
Dormandy, J A, Hoare, E, Colley, J, Arrowsmith, D E, Dormandy, T L (1973) 
C l in ic a l ,  haemodynamic, rheological and biochemical find ings in 
126 patients with in te rm it te n t c laudication.
B r i t is h  Medical Journa l, 4^ 576-581.
Dormandy, J A (1975)
Hyperviscosity angina.
Lancet _1, 679- 680.
Dougherty, J H, Levy, D E and Weksler, B B (1977)
P la te le t ac t iva t ion  in acute cerebral ischaemia. Serial 
measurements of p la te le t  function in cerebrovascular disease.
Lancet 1, 821-824.
Douglas, J T, Lowe, GDC,  Forbes, C D and Prentice C R M  (1982)
Beta-thromboglobulin and p la te le t  counts - e ffe c t of malignancy, 
in fe c t io n ,  age and obesity.
Thrombosis Research, 25, 459- 464.
Douglas, J T, Shah, M, Lowe, G D 0, Belch, J J F, Forbes, C D and
Prentice, CRM  (1982)
Plasma f ib r inopep tide  A and beta-thromboglobulin in pre-eclampsia 
and pregnancy hypertension.
Thrombosis and Haemostasis, 47, 54-55.
342
Douglas, J T, Lowe, G D 0, Forbes, C D and Prentice, CRM (1983) 
Plasma f ib r inopep tide  A and beta-thromboglobulin in patients 
w ith chest pain.
Thrombosis and Haemostasis, 50, 541-542.
Duguid, J B (1976)
The dynamics of atherosclerosis.
Aberdeen U nivers ity  Press
Duncan, A (1979)
B-thromboglobulin levels and oral contraception.
Lancet I I , 631.
Edgington, T N and Plow, E (1979)
D if fe re n t ia t io n  between fibrinogen and f ib r in  cleavage fragments 
based on immunochemical corre lates of s tructure  and c l in ic a l  
app lica tions.
In Haemostasis and Thrombosis.
id's. Neri-Serneri, G, Prentice, CRM.  London: Academic Press, 27-43
E d ito r ia l (1975)
Hypertension in pregnancy
Lancet I ,  487-489.
E d ito r ia l (1979)
P la te le ts  beta-thromboglobulin and diabetes m e ll i tu s .  
Lancet 1, 250-251.
E d ito r ia l (1980)
L ip ids , p la te le ts  and atherosclerosis. 
Lancet 1, 464-465.
Egeberg, 0 (1965)
Inherited antithrombin defic iency causing thrombophilia 
Thrombosis et Diathesis Haemorrhgica, 13, 516- :530.
343
Ehrenfeld, W K, Hoyt, W F and W yllie  E J (1966)
Embolization and trans ien t blindness from caro tid  
atheroma. Surgical considerations.
Archives o f Surgery (Chicago) , 787- 794.
Ek, I ,  Thunell, S and Blomback, M (1982)
Enhanced in vivo p la te le t  ac tiva tion  in diabetes m e ll i tu s .  
Scandi navi an Journal o f Haematology, 29, 185- 191.
Ekert, H, Friedlander, I and Hardisty, R M (1970)
The ro le of p la te le ts  in f ib r in o ly s is .  Studies on the 
plasminogen ac t iva to r and antiplasmin a c t iv i t y  of p la te le ts .
B r i t is h  Journal o f Haematology, 18, 575-584.
Enos, W F, Beyer, J C and Holmes, R H (1955)
Pathogenesis of coronary heart disease in American sold iers 
k i l le d  in  Korea.
Journal o f the American Medical Association, 158, 912-914.
Enticknap, J B, Gooding, P G, Lansley, T S (1969)
P la te le t size and function in ischaemic heart disease 
Journal o f Atherosclerosis Research, 10, 41-49.
Erickson, B W and M e r r i f ie ld ,  R B (1976)
Solid phase peptide synthesis.
In The Prote ins.
eds Neurath, H, H i l l ,  R L. New York: Academic Press, 2, 255-527.
Esmon, C T and Owen, W G (1981)
Id e n t i f ic a t io n  of an endothelial ce ll cofactor fo r  thrombin- 
catalyzed ac tiva tion  of protein C.
Proceedings o f the National Academy o f Sciences o f the United States 
o f America, 78, 2249-2252.
Esnouf, M P and Tunnah, G W (1967)
The is o la t io n  and properties of the throm bin-like a c t iv i t y  from 
ancistrodon rhodustoma venom.
B r i t is h  Journal o f Haematology, 13, 581-590.
Evensen, S A and H jo r t ,  P F (1970)
Pathogenesis of disseminated in travascular coagulation. 
Haematologie und B1uttransfusion; Sonderbaende zu B lut (München) 
9, 109-120.
344
Ewart, M R, Hatton, M W, Basford, J M and Dodson, K S (1970) 
The p ro teo ly t ic  action of arvin on human fib r inogen . 
Biochemical Journa l, 118, 603-609.
Fabris, F, Casonato, A, Randi, M L and Giroi ami, A (1980)
Plasma and p la te le t  beta-thromboglobulin  levels in patients 
with May-Hegglin anomaly.
Haemostasis, 9, 126-130.
F a r re l l ,  R J , Duffy, M J and Duffy G J and Mori a r ty ,  M J (1979)
Elevated betathromboglobulin in patients with malignancy.
Thrombosis and Haemostasis, 42, Abstract No. 0334.
F a r re l l ,  R J, Duffy, M J , .  Mori a r ty ,  M J and Duffy, G J (1980)
Plasma concentrations of the p la te le t-s p e c if ic  beta­
thrombogl obul in in malignant disease.
B r i t is h  Journal o f Cancer, 41, 989-991.
Fearnley, G R (1964)
Physiology and pharmacology of f ib r in o ly s is .
B r i t is h  Medical B u l le t in , 20, 185- 188.
Fernlund, P and S ten flo , J (1979)
Amino acid sequence of bovine protein C.
In Vitamin J< Metabolism and Vitamin J< Dependant P ro te ins.
ed. S u tt ie ,  J W. Baltimore: Univers ity  Park Press, 84-88.
Fesus, L, H a rs fa lv i,  J, Kovacs, E, Muszbek, L and S tad ler, I (1981)
Effect of prostaglandin I, on p la te le t  adhesion.
B iom ateria ls , 2,  53-54.
F iles , J C, Mai pass, T W, Yee, E K, R itch ie , J L, Harker, L A (1981) 
Studies of human p la te le t  a-granule release in v ivo.
Blood, 607-618.
Fisher, C M (1959)
Cerebrovascular diseases: pathophysiology, diagnosis and treatment
Journal o f chronic diseases, 8 ,  419-447.
F le tcher, A P, A lk ja e rs ig , N, O'Brien, J and Tulevsk, V G (1970)
Blood hypercoagulability  and thrombosis.
Transactions o f the Association of American Physicians, 83, 159-167.
345
Fletcher, A P and A l ja e rs ig ,  N (1973)
Laboratory diagnosis of in travascu lar coagulation.
In Recent Advances in Thrombosis.
ed P o lle r ,  L. Churchill Livingstone, 87-111.
F lu te , P T, Kakkar, V V, Renney, J T F and Nicolaides, A N (1972)
The blood and venous thromboembolism.
In Thromboembolism. Diagnosis and Treatment
eds Kakkar, V V, Jouhar, A J. Edinburgh: Churchill Livingstone, 2-12
Forbes, C D, Pensky, J and Ratnoff, 0 D (1970)
In h ib i t io n  of activated hageman fac to r and activated plasma 
thromboplastin antecedent by pu r if ied  serum C$ in a c t iva to r .
Journal of Laboratory and C lin ica l Medicine, 76, 809-815.
Forbes, C D and Ratnoff, 0 D (1972)
Studies on plasma thromboplastin antecedent (Factor X I) ,  PTA 
defic iency and in h ib i t io n  of PTA by plasma; pharmacologic 
in h ib i to rs  and spec if ic  anti serum
Journal o f Laboratory and C lin ica l Medicine, 79, 113-127.
Forbes, C D, Lowe, G D 0 and Prentice, CRM (1978)
Thrombolytic therapy - ind ica tions , advantages and disadvantages,
Angiology, 29, 783-790.
Forbes, C D and Prentice, CRM  (1978)
Thrombus formation and a r t i f i c ia l  surfaces.
B r i t is h  Medical B u l le t in ,  34, 201-207.
Fournie, A, Monrozies, M, Pontonnier, G, Boneu, B and Bierme, R (1981) 
Factor V I I I  complex in normal pregnancy, pre-eclampsia and 
fe ta l growth retardation..
B r i t is h  Journal of Obstetrics and Gynaecology, 88, 250-254.
Friedman, L I ,  Liem, H, Grabowski, E F, Leonard, E F and McCord, C W
(1970)
Inconsequentia lity  of surface properties fo r  i n i t i a l  
p la te le t adhesion.
Transactions - American Society fo r  A r t i f i c i a l  Internal Organs, 
(Washington) , 16, 63-73.
Fuchs, G, Egbring, R and Havemann, K (1977)
Fibrinogen marburg: a new genetic variant of f ib r inogen .
B lu t, 34, 107-118.
346
Fujikawa, K, Legaz, M E and Davie, E W (1972)
Bovine factors X, and X ^ (Stuart Factor). Iso la t ion  and
characte risa tion .
Biochemistry, 11, 4882-4891.
Fukami, M H, Niewiarowski, S, Rucinski, B, Salganicoff, L (1979)
Subcellu lar lo c a liz a t io n  of human p la te le t antiheparin proteins 
Thrombosis Research, 14, 433-443.
F u l le r ,  J H, Keen, H, Ja rre t,  R J, Omer, T, Meads, T W,
Chakrabarti, R, North W R S and S t i r l in g ,  Y (1979)
Haemostatic variables associated with diabetes and 
i t s  complications.
B r i t is h  Medical Journa l, _2, 964- 966.
Fulton, W F (1978)
Coronary thrombotic occlusion in myocardial in fa rc t io n  and 
thrombosis in the pathogenesis of atherosclerosis.
In In ternationa l Conference on Atherosclerosis.
ed. Carlson, L A, P a o le t t i ,  R and Weber, 6. New York:
Raven Press, 75-89.
Furlan, M, Kemp, G and Beck, E A (1975)
Plasmic degradation of human fibrinogen I I I .  Molecular 
model of the plasmin-resistant d is u lf id e  knot in monomeric 
Fragment D.
Biochimica et Biophysica Acta, 400, 95-111.
Fuster, V D and Bowie E J W (1978)
In te rac tion  of p la te le ts  with the endothelium in normal and 
von Willebrand pigs.
In Thrombosis, Animal and C lin ica l Models. Advances in Experimental
Medicine, Biology Series Vol 102
eds Day H J, Molony, B A, Nishizan, E E and Rynbrandt.
New York: Plenum Press, 187-196.
Fuster, V D, Bowie, E J W, Lewis, J C, Fass, D N, Owen, C A and 
Brown, A L (1978)
Resistance to a r te r io sc le ro s is  in pigs with von Willebrand's 
disease: Spontaneous and high cholesterol diet-induced
a r te r io sc le ro s is .
Journal o f C lin ica l In ve s t ig a t io n , 61, 722-730.
347
Gaffney, P J and Dobos, P (1971)
A s truc tu ra l aspect of human fibrinogen suggested by i t s  
plasmin degradation.
FEBS Letters 15, 13-16
Gaffney, P J and Brasher, M (1973)
Subunit s tructure  of the plasmin-induced degradation products 
of cross linked f ib r in .
Biochimica et Byophysica Acta, 295, 308-313.
Gaffney, P J , Lane, D A, Kakkar, V V and Brasher, M (1975)
Characterisation of a soluble D dimer-E complex in cross- 
linked f i b r in  digests.
Thrombosis Research, 7, 89-99.
Gaffney, P J (1977)
Structure of fibrinogen and degradation products of 
fib r inogen and f i b r in .
B r i t is h  Medical B u l le t in ,  33, 245-251.
Gaffney, P J (1981)
The f ib r in o ly t i c  system.
In Haemostasis and Thrombosis.
eds. Bloom, A L and Thomas D P. Churchill L ivingstone, 198-224.
Gal lus, A S, Hirch, J and Gent, K (1973)
Relevance of preoperative and postoperative blood tests  to 
postoperative leg-vein thrombosis.
Lancet 2, 805-809.
Gavras, H, O live r ,  N, A itch ison, J. Begg, C, Briggs, J D, Brown, J J,
Horton, P N, Lee, F, Lever, A F, Prentice, C, Robertson, J I S (1975) 
Abnormalities of coagulation and the development of malignant 
phase hypertension.
Kidney In ternationa l (Suppl) ,  S252-261.
Gensini, G F, Abbate, R, F a v i l la ,  S and Neri Serneri, G G (1979) 
Changes of p la te le t  function and blood c lo t t in g  in 
diabetes m e !l itus .
Thrombosis and Haemostasis, 42, 983-993.
G err its , W B J, F l ie r ,  0 T N, van der Meer J (1974)
Fibrinopeptide A immunoreactivity in human plasma. 
Thrombosis Research, 5, 197-212.
348
G iro lam i, A (1975)
In Prothrombin and re lated coagulation fa c to rs .
eds. Hemker, H C and Veltkamp, J J. Boerhave Series No 10, .
Leiden Univers ity  Press, 230-242.
Glavind J , Hartmann, J, Clemmensen, J, Jessen, K E, Dam, H (1952)
Studies on ro le of lipoperoxides in human pathology; presence 
of peroxidized l ip id s  in a therosc lero tic  arota.
Acta Pathologica et M icrob io log ica, Scandinavia, 30,
Godal, H C, Madsen, K and Nissen-Meyer, R N (1962)
Thrombo-embolism in  patients with to ta l proconvertin 
(Factor V II)  defic iency. A report on two cases.
Acta Medica Scandinavica, 171, 325-327.
Godal, H C and Abildgaard, V (1966)
Gelation of soluble f ib r in  in plasma by ethanol.
Scandinavian Journal of Haematology, 2 y 342- 350
Goldsmith, H L (1971)
Deformation of human red ce lls  in tube flow.
Biorheology, %, 235- 242.
Goodfriend, T L and B a l l ,  D L (1969)
Radioimmunoassay of bradykinin chemical m odification to enable 
use of radioactive iodine.
Journal o f Laboratory and C lin ica l Medicine, 73, 501-511.
Gorman, R R, Bunting, S and M i l le r ,  0 V (1977)
Modulation of human p la te le t  adenylate cyclase by prostacyclin (PGX)
Prostaglandins, 13, 377-388.
Gordon, Y B, Martin, M J , Landon, J and Chard T (1975)
The development of radioimmunoassays fo r  fib r inogen degradation 
products: Fragments D and E.
B r i t is h  Journal o f Haematology, 29, 109- 119.
Gordon, Y B, Ratky, S M, Sola, C M, Lewis, J, Baker, L R I and
Chard, T (1975)
C ircu la ting  leve ls of f ib r in / f ib r in o g e n  degradation fragment E 
in normal pregnancy and in association with in tra u te r in e  growth 
re tardation  and perinatal asphyxia.
B r i t i  sh Journal o f Obstetrics and Gynaecology, 82, 958-963.
Gordon, Y B, Cooke, E D, Bowcock, S A, Ratky, S M, P ilcher, M F and
Chard, T (1977)
Non-invasive screening fo r  venous thromboembolic disease.
B r i t is h  Journal o f Haematology, 35, 505-510.
349
Gordon-Smith, I C, Hickman, J A and Le Quesne, L P (1974)
Postoperative f ib r in o ly t i c  a c t iv i t y  and deep vein thrombosis.
B r i t is h  Journal o f Surgery, 61, 213-218.
Gotze, 0, and Mul ler-Eberard, H J (1971)
The C3-activator system: An a lte rna tive  pathway of complement
a c t iva t io n . .
Journal o f Experimental Medicine, 134, Suppl: 90S-108S.
Grabowski, E F, Friedman, L I and Leonard E F (1972)
Effects of shear rate on p la te le t  d i f fu s io n  and adhesion to 
a foreign surface.
Indian Engineering and Chemical Fund, 11, 224- 232.
Gralnick, H R and A b re ll,  E (1973)
Studies of the procoagulant and f ib r in o ly t i c  a c t iv i t y  of 
promyelocytes in acute promyelocytic leukaemia.
B r i t is h  Journal o f Haematology, 24, 89-99.
Grette, K (1962)
Studies on the mechanism of thrombin-catalyzed hemostatic 
reactions in  blood p la te le ts .
Acta Physiologica Scandinavica ( Stockholm) (Suppl) £ ,  1-93.
G r i f f in ,  J H (1978)
The ro le of surface in surface-dependant ac tiva tion  of Hageman 
Factor (blood coagulation Factor X I I ) .
Proceedings o f the National Academy o f Sciences o f the United States of
America (WasïïTngton), 75 1998-2002.
G r i f f in ,  J H, Evatt, B, Zimmerman, T S, K le iss, A J and Wideman, C (1981) 
Deficiency of protein C in congenital thrombotic disease.
Journal o f C lin ica l Inve s t iga t ion , 68, 1370-1373.
Gryglewski, R J , Korbut, R and Ocetkiewicz, A C (1978)
Generation of prostacyclin by lungs in vivo and i t s  release in to  
the a r te r ia l  c i rc u la t io n .
Nature, 273, 765-767.
Gunning, A J , P ickering, G W, Robb-Smith, A H and Russell, R R (1964) 
Mural thrombosis of the in terna l caro tid  a r te ry  and subsequent 
emboli sm.
Quarterly Journal o f Medicine, 33, 155-195.
350
Gurewich, V and Hutchinson, E (1971)
Detection of in travascu lar coagulation by a seria l d i lu t io n  
protamine su lfa te  te s t .
Annals of Internal Medicine, 75, 895-902.
Gurewich, V (1973)
Ethanol ge lation and protamine su lfa te . Comparison and c r i t iq u e
Thrombosis et Diathesis Haemorrhagica, 29, 733- 734.
Gurewich, V, Hume, M and P atr ick , M (1973)
The laboratory diagnosis o f venous thromboembolic disease by 
measurement of f ib r in o g e n / f ib r in  degradation products and 
f i b r in  monomer.
Chest, 64, 585-590. '
Gurewich, V and L ip insk i B (1976)
Semiquantitative determination of soluble f i b r in  monomer 
complexes by chromatography and s e r ia l -d i lu t io n  protamine 
sulphate te s ts .
American Journal o f C lin ica l Pathology, 65, 397-401.
Haerem, J W (1972)
P la te le t aggregates in intramyocardial vessels of patients 
dying suddenly and unexpectedly of coronary a r te ry  disease. 
A therosclerosis, 15, 199-213.
Hales, C N and Randle, P J (1963)
Immunoassay of in su lin  with insu lin -an tibody p re c ip ita te . 
Biochemical Journa l, 88, 137-146.
H a ll,  C E and S layter H S (1959)
The fibrinogen molecule: i t s  s ize, shape and mode of
polymerization.
Journal o f Biophysical and Biochemical Cytology, 5^ , 11-16.
Hamberg, M, Svensson, J and Samuelsson, B (1975)
Thromboxanes: A new group of b io lo g ic a l ly  active compounds
derived from prostaglandin endoperoxides.
Proceedings o f the National Academy o f Sciences, USA. 72, 2994-2998.
351
Hampton, J R and M itc h e l l ,  J R A (1974)
P la te le t e lectrophoresis: The present pos it ion .
Thrombosis et Diathesis Haemorrhagica, 31, 204- 244.
Han, P, Turpie, A G G and Genton, E (1979)
Plasma B-thromboglobulin: d i f fe re n t ia t io n  between in travascu lar
and extravascular p la te le t  destruction.
Blood, 54, 1192-1196.
Han, P, Butt, R W, Turpie, A G, Walker, W H C and Genton, E (1980)
B-thromboglobulin radioimmunoassay, a laboratory characterization 
and evaluation.
Journal o f immunoassay, %, 211- 227.
Handin, R I ,  McDonough, M and Lesch, M (1978)
. Elevation of p la te le t  fac to r  4 in acute myocardial in fa rc t io n :  
Measurement of radioimmunoassay.
Journal o f Laboratory and C lin ica l Medicine, 91, 340-349.
Harenberg, J, Hopp, G and Schmidt-Gayk, H (1979)
Fibrinopeptide A in human plasma-evaluation of a new rad io ­
immunoassay technique on m ic ro l i te r -p la te s .
Thrombosis Research, 15, 513-522.
Harenberg, J , Haas, R and Zimmerman, R (1981)
Measurement of f ib r inopep tide  A in patients treated with 
Phenoprocoumon.
Thrombosis and Haemostasis, 45, 282-284.
Harker, L A and S l ic h te r ,  S J (1974)
A r te r ia l  and venous thromboembolism: K inetic  characterisation
and evaluation of therapy.
Thrombosis et Diathesis Haemorrhagica, 31, 188 -203.
Harker, L A, Ross, R, S l ich te r ,  S J and Scott, C R (1976)
Homocystine-induced atherosclerosis. The ro le  of endothelial 
ce l l  in ju ry  and p la te le t  response in i t s  genesis.
Journal o f  C lin ica l Inve s t iga t ion , 58, 731-741.
Harker, L A (1978)
P la te le t mechanisms in the genesis and prevention of g ra f t -  
re lated vascular in ju ry  reactions and thromboembolism.
In Vascular Grafts
eds. Sawyer, P N, K a p l i t t ,  M J. New York: Appleton-Century-Crofts.
352
Harrison, H E, Reece, A H and Johnson, M (1978)
Decreased vascular prostacyclin in experimental diabetes.
L ife  Sciences, 23, 351-356.
Hathaway, W E, Belhasen, L P and Hathaway, H S (1965)
Evidence fo r  a new plasma thromboplastin fa c to r .  1. Case report 
on coagulation studies and physio-chemical properties.
Blood, 26, 521-532.
Hathaway, W E and A1sever, J (1970)
The re la t io n  of 'F le tcher Factor' to factors  XI and X II .
B r i t is h  Journal o f Haematology, 18, 161-169.
Heck, L W and Kaplan, A D (1974)
Substrates of human Hageman fa c to r .  1. Iso la t io n  and 
characterisation of human fac to r  XI (PTA) and i t s  in h ib i t io n  
of the activated enzyme by alpha 1 -a n t i t ryp s in .
Journal o f Experimental Medici ne, 140, 1615- 1630.
Hedner, U and Nilsson, I M (1971)
Anti thrombin I I I  in a c l in ic a l  m ateria l.
In ternational Society on Thrombosis and Haemostasis, Washington, 398.
Hedner, V (1973)
Studies on an in h ib i to r  of plasminogen ac tiva t ion  in human serum. 
Thrombosis et Diathesis Haemorrhagica, 30, 414-424.
Hemker, H C and Kahn, M J (1967)
Reaction sequence of blood coagulation.
Nature, 215, 1201-1202.
Hemker, H C, Veltkamp, J J, Hensen, A and Loe liger, E A (1963)
Nature of prothrombin biosynthesis: Pre:prothrombinaemia in
vitamin-K de fic iency.
Nature, 200, 589-590.
H e p t in s ta l l ,  S, Mulley, C P, Taylor, P M and M itc h e l l ,  J R A (1980) 
P la te le t release reaction in myocardial in fa rc t io n .
B r i t is h  Medical Journal, 280, 80-81.
Herbert, V, Lau, K S, G o tt l ieb , C W and B leicher, S J (1965) 
Coated charcoal immunoassay of in su lin .
Journal o f C lin ica l Endocrinology and Metabolism, 25, 1375- 1384,
Hewson, W (1772)
The works o f William Hewson, FRS
ed. G u ll ive r G. London: The Sydenham Society, 1846, 40.
353
Higgins, D L, Penner, J A and Shafer, J A (1981a)
Fibrinogen Petoskey: Id e n t i f ic a t io n  of a new dyfibrinogenemia
characterized by altered release of f ib r inopep tide  A.
Thrombosis Research, 23, 491-504.
Higgins, D L and Shafer J A (1981b)
Fibrinogen Petoskey, a dysfibrinogenaemia characterized by 
replacement of Arg-A Alpha 16 by a h is t id y l  residue. Evidence 
fo r  thrombin-catalized hydrolysis at a h is t id y l  residue.
Journal o f B io log ica l Chemistry, 256, 12013-12017.
Higgs, E A, Higgs, G A, Moncada, S and Vane, J R (1978)
Prostacyclin (PGI2) in h ib i ts  the formation of p la te le t  thrombi in 
a r te r io le s  and venules of the hamster cheek pouch.
B r i t is h  Journal o f Pharmacology, 63, 535-539
Hippocrates (5th Century, B.C). Cited by McEwan, H.P. in  M.D thesis 3366
Prote inuria  in Pregnancy
Univers ity  of Glasgow, 1970.
Hofman, V and Straub, P W (1977)
A radioimmunoassay technique fo r  the radio measurement of 
human f ib r in op ep tid e  A.
Thrombosis Research, 11, 171-181.
Hogg, D H and Blomback, B (1978)
The mechanism of the fibrinogen-thrombin reaction.
Thrombosis Research, 12, 953- 964.
Holland, E (1909)
Recent work on the e tio logy of eclampsia.
Journal o f Obstetrics and Gynaecology of the B r i t is h  Empire, 16, 255- 273
H olt, J C and Niewiarowski, S (1979)
On the re la t ionsh ip  between low a f f in i t y  PF, and beta- 
thromboglobulin.
Thrombosis and Haemostasis, 42, Abstract 0640.
Hoogendijk, E M G, Jenkins, C S P, van Wijk, E H, Vos, J and
ten Cate, J W (1979)
Spontaneous p la te le t  aggregation in cerebrovascular disease.
I I .  Further characterisation of the p la te le t  defect.
Thrombosis and Haemostasis, 41, 512-522.
354
Hoogendijk, E M G, ten Cate, J, Ludlam, C A and Bruin, T (1980)
No e ffec t of asp ir in  on B-thromboglobulin plasma levels in 
healthy volunteers.
Thrombosis Research, 19, 257- 262.
Hope, W, Martin, T J, Chesterman, C.N and Morgan, F J (1979)
Human betathromboglobulin in h ib i ts  PGI^ production and binds to 
a spec if ic  s i te  in bovine a o rt ic  endothelial c e l ls .
Nature, 282, 210-212.
Hornstra, G (1978)
The f i l t ra gom e te r in thrombosis research.
P Ia te le t Function Testing
eds. Day, H J, Holmsen, H and Zucker, M. Washington U.S.
Dhew Publication No (NIH) 78-1087 416-427
Horowitz, H I and Fugimoto, M M (1965)
Association of factors  XI and XII with blood p la te le ts .  
Proceedings of the Society fo r  Experimental Biology and Medicine 
119, 487-492.
Howard, M A, Montgomery, D C and Hardi s ty , R M (1974) 
Factor V I I I  re lated antigen in p la te le ts .  
Thrombosis Research, 4, 617-624.
Howie, P W, Prentice, CRM  and McNicol, G P (1971)
Coagulation, f ib r in o ly s is  and p la te le t  function in pre-eclampsia, 
essential hypertension and placental in su ff ic ie n cy .
Journal o f Obstetrics and Gynaecology of the B r i t is h  Commonwealth,
78, 992-1003.
Hoyer, L W and Breckenridge, R I (1970)
Immunologic studies of antihemophilic fa c to r  (AHF Factor V I I I ) .  
I I .  Properties of cross reacting materia l.
Blood, 809-820.
Hudry-Clergeon, G, P atu ra l, L and Suscil lon, M (1974)
Id e n t i f ic a t io n  d'un complexe (D-D) E dans les produits de 
degradation de la f ib r in e  bovine s ta b il isé e  par le fc to r  X I I I .  
Pathologie et B io lo g ie , 22 (Suppl) 47.
Hughes, A, Daunt, S, Vass, G and Wickes, J (1979)
B-thromboglobulin and myocardial in fa rc t io n .
Thrombosi s and Haemostasis, 42, 357. Abstract No 0850.
van H u ls te i jn ,  H, B r ie t ,  E, Koch, C. Hermans, J and Bertina, R (1982a) 
Diagnostic value of f ib r inopeptide  A and beta-thromboglobulin 
in acute deep vein thrombosis and pulmonary embolism. 
Acta-Medica Scandinavica (StockhoIm) 211, 323-330
355
van H u ls te i jn ,  H, Fibbe, W, Bertina, R and B rie t E (1982b)
Plasma f ib r inopep tide  A and beta-thromboglobulin in major 
bacteria l in fe c t ions .
Thrombosis and Haemostasis, 48, 247-249.
van H u ls te i jn ,  H, K o l f f ,  J , B r iè t ,  E, van der Laarse, A and 
Bertina, R (1982c)
Fibrinopeptide A and beta-thromboglobulin in patients with 
angina pectoris and acute myocardial in fa rc t io n .
Thesis, Leiden.
Hume, R and Begg, I S (1969)
The re la t ionsh ip  of blood volume and blood v iscos ity  to re t ina l 
size and c irc u la t io n  time in polycythaemia.
The Wi111am McKenzie Centenary Symposiurn on the Occular C ircu la tion  
in Health and Disease.
London: Kimpton, 158-169.
Humphreys, N V, Walker, A and Charlesworth, D (1976)
Altered v iscos ity  and y ie ld  stress in patients with abnormal 
malignancy: Relationship to deep vein thrombosis.
B r i t is h  Journal o f Surgery, 63, 559-561.
Hunter, J A (1817)
A t r e a t i se on the blood, inflammation, and gun-shot wounds. 
London: Cox.
Hunter, W M and Greenwood, F C (1962)
Preparation of iodine-131 labelled human growth hormone of 
high spec if ic  a c t iv i t y .
Nature, 194, 495-496.
Huth, K, Schoenborn, W and Knorpp, K (1967)
Experimental le  verbrauchskoagul opathie liach in travenoser 
zufuhr von f e t t  und endotoxin.
Thrombosis et Diathesis Haemorrhagica, 17, 129- 243.
la t r id i s ,  P G and Ferguson, J H (1965)
The plasmatic atmosphere of blood p la te le ts .  Evidence that only 
f ib r inogen AcG and activated Hageman fac to r  are present on the 
surface of p la te le ts .
Thrombosis et Diathesis Haemorrhagica, 13, 114- 125.
356
Ire land , H, Lane, D A, Wolff, S and Foadi, M (1982)
In VIVO p la te le t release in m ye lopro life ra tive  disorders. 
Thrombosis and Haemostasis, 48, 41-45.
Irey, N S, Manion, W C and Taylor H B (1970)
Vascular lesions in women taking oral contraceptives. 
Archives o f Pathology, 89, 1-8.
Isacson, S and Nilsson, I M (1972)
Defective f ib r in o ly s is  in blood and vein walls in recurrent 
' id io p a th ic '  venous thrombosis.
Acta Chirurgica Scandinavica, 138, 313-319.
Jackson, C M and Hanahan, D J (1968)
Studies on bovine fac to r  X. 1. Large scale p u r i f ic a t io n  of the 
bovine plasma protein possessing fac to r  X a c t iv i t y .
Biochemistry, _7» 4492- 4505.
Janka, H U, Standi, E and Mehnert H (1981)
Increased p la te le t  adenylate cyclase a c t iv i t y  in d iabetic 
patients with microangiography.
Hormone Metabol1c Research (Suppl) 11, 26-29.
J a r re t t ,  P E M, Norland, N and Browse, N L (1978)
Treatment of Raynaud's phenomenon by f ib r in o ly t i c  enhancement.
B r i t is h  Medical Journa l, _2, 523- 525.
Jelen, I ,  Fananapazir, L and Crawford, T B (1979)
The possible re la t io n  between la te  pregnancy hypertension and 
5-hydroxytryptamine levels in maternal blood.
B r i t is h  Journal o f Obstetrics and Gynaecology, 86, 468-471.
Jerushalmy, Z and Zucker, M B (1966)
Some e ffec ts  of f ibr inogen degradation products (FDP) on blood 
p la te le ts .
Thrombosis et Diathesis Haemorrhagica, 15, 413-419.
Jesty, J and Esnouf, P (1973)
The preparation of activated fac to r  X and i t s  action on 
prothrombin.
Biochemical Journa l, 137, 791-799.
Johnson, B J and May, W P (1969)
Rapid peptide synthesis: Synthesis of human fib r inopep tide  A.
Journal o f Pharmacological Science, 58, 1568.
357
Kanaide, H and Shainoff, J R (1975)
Cross-link ing of f ibr inogen and f i b r in  by f ib r in - s ta b i l i z in g  
fa c to r  (Factor X I I I  A).
Journal o f Laboratory and C lin ica l Medicine, 85, 574- 597.
Kanfer, A, Kleinknecht, D, Broyer, MandJosso, F (1970)
Coagulation studies in 45 cases of nephrotic syndrome without 
uremi a.
Thrombosis et Diathesis Haemorrhagica, 24, 562- 571.
Kaplan, A P and Austen, K F (1972)
The f i b r in o ly t i c  pathway of human plasma. Iso la t ion  and 
characterization of the plasminogen proactiva to r.
Journal o f Experimental Medicine, 136, 1378-1393.
Kaplan, K L, Nossel, H L, D r i l l in g s ,  M, Lesznik, G (1978)
Radioimmunoassay of p la te le t  fac to r  4 and beta-thromboglobulin: 
development and app lica tion  to studies o f p la te le t  release in  
re la t io n  to f ib r inopep tide  A generation.
B r i t is h  Journal o f Haematology, 39, 129-146.
Kaplan, K L, Broekman, M J, Chernoff, A, Lesznik, G R and D r i l l in g s ,  M
(1979)
P la te le t «granule prote ins: Studies on release and sub -ce llu la r
lo c a l iz a t io n .
Blood, 604-618.
Kaplan, K L (1980)
Beta-thromboglobul i n
In Progress in Hemostasis and Thrombosis
ed. Spaet, T H. Grune and S tra tton , 5, 153-179.
Kaplan, K L , D r i l l in g s ,  M and Lesznik, G (1981)
Fibrinopeptide A cleavage and p la te le t  release in  whole blood in 
v i t r o .  Effects of s t im u l i ,  in h ib i to rs ,  and a g ita t io n .
Journal o f C l in ica l Inve s t ig a t io n , 67, 1561-1568.
Karpatkin, S (1978)
P la te le t volume d is t r ib u t io n .
In P la te le t Function Testing
eds. Day, H J, Holmsen, H and Zucker, M. Washington U.S. Dhew 
Publication (NIH) 78-1087, 334-354.
358
Kass, L, Ratnoff, 0 D and Leon, M A (1969)
Studies on the p u r i f ic a t io n  of antihemophilic fa c to r  (Factor V I I I )  
Separation of p a r t ia l ly  p u r if ied  antihemophilic fa c to r  by gel 
f i l t r a t i o n  of plasma
Journal o f C lin ica l In ve s t ig a t io n , 48, 351
Kauffmann, R H, Veltkamp, J J , van T ilbe rg , N H and van Es, L A (1978) 
Acquired antithrombin I I I  de fic iency and thrombosis in the 
nephrotic syndrome.
American Journal o f Medicine, 65, 607-613.
Kazama, M and Abe, T (1976)
Change of the molecular mass of f ibrinogen in  c irc u la t in g  blood, 
as an index of the hypercoagulable s ta te s .
Thrombosis Research, (Suppl) 133-142.
Kendall, A G, Lohmann, R C and Dossetor, J B (1971)
Nephrotic syndrome. A hypercoagulable s ta te .
Archives o f Internal Medicine, 127, 1021-1027.
K ie ru l f ,  P and Godal, HJ C (1971)
Fibrinemia in medical patients screened by the Ethanol te s t .  
Acta Medica Scandinavica, 190, 185-190.
K i l ln e r ,  M S and Lees, R S (1981)
High molecular weight f ibr inogen derivatives in hyperlipidemia, 
Thrombosis Research, 22, 329- 344.
K is ie l ,  W, Ericsson, L H and Davie, E W (1976)
P ro teo ly t ic  ac t iva tion  of prote in C from bovine plasma. 
B iochemistry, 15, 4893-4900.
K is ie l ,  W, Canfie ld, W M, Ericsson, L H and Davie, E W (1977)
Anticoagulant properties of bovine plasma protein C fo llow ing 
a c t iva t ion  by thrombin.
Biochemistry, 16, 5824-5831.
359
K is ie l ,  W (1979)
Human plasma protein C: Iso la t io n , cha rac te r isa tion , and
mechanism of ac t iva t ion  by Alpha-thrombin.
Journal o f Cl in ic a l In ve s t ig a t io n , 64, 761-769.
K lobusitzky, D and Konig, P (1936)
Biochemische studien uber die g i f te  der schlangen gattung 
bothrops. IV m itte ifung : Die wirkung der gerinnungs
fordernden substanz in vivo.
ArchiV fu r  Experimentale Pathologie und Pharmakologie, 182, 577-583.
K lu f t ,  C (1978)
Blood f ib r in o ly s is :  preactivators and activa tors  in human plasma
Thesis, Leiden U n ive rs ity .
Kockum, C (1976)
Radioimmunoassay of f ib r inopeptide  A: C lin ica l app lications.
Thrombosis Research, B,  225-236.
Kockum, C and Frebelius, S (1980)
Rapid radioimmunoassay of human fib r inopep tide  A - removal of 
cross-reacting fibrinogen with bentonite.
Thrombosis Research, 19, 589-598.
Kopec, M, Budzynski, A, Stachurska, J, Wegrzyadwicz, Z and Kowalski, E 
(1966)
Studies on the mechanism of interference by fibrinogen 
degradation products (FDP) with the p la te le t  function . Role of 
fib r inogen in the p la te le t  atmosphere.
Thrombosis et Diathesis Haemorrhagica, 15, 476- 490.
Kopec, M, Teisseyre, E, Dudek-Wejciechowska, 6, Kloczewiak, M, 
Pankiewicz, A and L a ta l lo ,  Z S (1973)
Studies on the "Double D" fragment from s ta b il ise d  bovine f ib r in .  
Thrombosis Research, 2,  283-292.
Koppel, G (1970)
The s tructure  of f ibr inogen.
Thrombosis et Diathesis Haemorrhagica ( Suppl ) 39, 71-73.
360
Johnson, M, Harrison, H E, Raftery, A T and Elder, J B (1979)
Vascular prostacyclin may be reduced in diabetes in man.
Lancet, _1, 325-326.
Johnsson, H, O rin ius, E and Paul, C (1979)
Fibrinopeptide A (FPA) in patients with acute myocardial in fa rc t io n .
Thrombosis Research, 16, 255-260.
Johnston, R V, de Boer, A and Turpie, A G G (1981)
Unpublished observations.
J o is t ,  J H, Niewiarowski, S, Nath, N and Mustard, J F (1976)
P la te le t antiplasmin: I ts  extrusion during the release reaction ,
subce llu la r lo c a l iz a t io n ,  characte riza tion , and re la t ionsh ip  to 
antiheparin in p ig  p la te le ts .
Journal o f Laboratory and C lin ica l Medicine, 87, 659-669.
J o is t ,  J H, Baker, R K and Smith, M (1978)
P la te le t function in diabetes m e ll i tu s .
In P Ia te le t Function Testing.
ed. Day, H J, Holmsen, H and Zucker. Washington U S Dhew Publication,
No (NIH) 78-1087, 662-669.
J o is t ,  J H, Baker, R K and Schoenfield, G (1979)
Increased in vivo and in v i t ro  p la te le t  function in Type I I  and 
Type IV hyperlipoproteinemia.
Thrombosis Research, 15, 9.5-108.
Jonker, J J C and den Ottolander, G J H (1979)
P la te le t function studies in normal volunteers and patients 
w ith angina pectoris .
Thrombosis and Haemostasis, 42. Abstract No 0338.
Jorgensen, L and Borchgrevink, C F (1964)
The haemostatic mechanism in patients with haemorrhagic diseases.
A h is to log ica l study of wounds made fo r  primary and secondary 
bleeding time te s ts .
Acta Pathologica M icrob io log ica, Scandinavica, 60, 55-82.
Kakkar, V J (1978)
Advances in  Thrombolytic therapy.
In F ib r in o ly s is : Current Fundamental and C lin ica l Concepts.
eds. Gaffney, P J and Balkuv-U lutin, S. London: Academic Press, 191-200
Kalousek, F, Koningsberg, W and Nemerson, Y (1975)
A ctiva tion  of fac to r  IX by activated fac to r  X: A l in k  between 
the e x tr in s ic  and in t r in s ic  coagulation systems.
FEBS Le tte rs , 50, 382-385.
361
Kowalska-Loth, B, Garlund, B, Egberg, N and Blomback, B (1973)
Plasmic degradation products of human fibrinogen chemical and 
immunological reaction between fragment E and N-DSK. 
Thrombosis Research, 2, 423-450.
Kowalski, E, Kopec, M and Wegrzynowicz, Z (1964)
Influence of f ibr inogen degradation products (FDP) on p la te le t  
aggregation, adhesiveness and viscous metamorphosis.
Thrombosis et Diathesis Haemorrhagica, 10, 406-423.
Kudryk, B, Robinson, D, Netre, C, Hessel, B, Blomback, M and Blomback,
(1982)
Measurement in human blood of f ib r in o g e n / f ib r in  fragments 
containing the B 15-42 sequence.
Thrombosis Research, 25, 277-291.
Kwaan, H C and Hatem, A A (1978)
The ly s is  of early f i b r in  by eosinphils.
In Progress in Chemical F ib r ino lys is  and Thrombolysis 
New York: Raven Press, 3, 413-415.
Laake, K and Osterud, B (1974)
A ctiva tion  of pu r if ied  plasma Factor V II by human plasmin, 
plasma k a l l i k r e in ,  and activated components of the human 
in t r in s ic  blood coagulation system.
Thrombosis Research, 5, 759-772.
La Gamma, K S and Nossel, H L (1978)
The s t a b i l i t y  of f ib r inopep tide  B immunoreactivity in blood 
Thrombosis Research, 12, 447-454.
Lagarde, M and Dechavanne, M (1977)
Increase of p la te le t  prostaglandin cyc lic  endoperoxides in 
thrombosi s.
Lancet, 1, 88.
Lamming, G D, Broughton-Pipkin, F, B and Symonds, E M (1980) 
Comparison of the alpha and beta blocking drug, la b e ta lo l ,  
and Methyl Dopa in  the treatment of moderate and severe 
pregnancy-induced hypertension.
C lin ica l and Experimental Hypertension, 865-895.
362
Lane, D A, van Ross, M, Kakkar, V V, Bottomley, J, Dhir, K, Holt, L P J 
and Maclver, J E. (1980)
An abnormal fibr inogen w ith delayed f ib r inopep tide  A release. 
B r i t is h  Journal of Haematology, 46, 89-98.
Lane, D A, Gawel, M J ,  Wolff S, Ire land, H and Rose, F C (1981)
The e ffec ts  of age and thrombotic stroke upon plasma concentrations 
of fibr inogen derivatives and p la te le t  release.
Thrombosis and Haemostasis, 46. Abstract No 1404.
Lane, D A, Ire land , H, Wolff, S, Grant, R, Jennings, S, Allen-Mersh, T
(1982a)
Plasma concentrations of f ib r inopeptide  A, fib r inogen fragment 
Bjg 1-42 and beta-thromboglobulin fo llowing to ta l  hip replacement. 
Thrombosis Research, 26, 111-118.
Lane, D A, Warwick, J and Thomson, E (1982b)
D if fe re n t renal handling of f ib r inopeptide  A (FPA) and 
f ibrinogen fragment6615-42: Evidence th a t6 À l5 -4 2  is
catabolised by the kidney.
Annual General Meeting of the B r i t is h  Society fo r  Thrombosis and 
Haemostasis, September, C a rd if f .
Lane, D A, Southan, C, Ire land , H, Thompson, E, Kehl, M and Henschen, A
(1983)
Delayed release of an abnormal f ib r inopeptide  A from fibr inogen 
Manchester: E ffect of the A Alpha 16 Arg leads to  His
sub s t itu t io n  upon f ib r in  monomer polymerization and the 
immunological cross re a c t iv i ty  of the peptide.
B r i t is h  Journal o f Haematology, 53, 587-597.
Lane, D A, W olff, S, Ire land, H, Gawel, M and Foadi, M (1983)
A ctiva tion  of coagulation and f ib r in o ly t i c  systems fo llow ing stroke 
B r i t is h  Journal of Haematology, 53, 655-658.
L a ta l lo ,  Z S, Budzynski, A Z, L ip in s k i ,  B and Kowalski, E (1964) 
In h ib i t io n  of thrombin and of f i b r in  polymerisation, two 
a c t iv i t ie s  derived from plasmin digested f ib r inogen.
Nature. 203, 1184-1185.
363
L a ta l lo ,  Z S, Teisseyre, E, A rde lt,  W, Wegrzynowicz, Z and Kopec, M
(1978)
F ib r ino-(geno) lys is  by enzymes other than plasmin.
In F ib r in o ly s is : Current Fundamental and C lin ica l Concepts.
London: Academic Press. 129-136.
Lauritsen, 0 S (1968)
Urokinase in h ib i to r  in  human plasma.
Scandinavian Journal o f C lin ica l and Laboratory Inves tiga tion .
22, 314-321.
Legaz, M E, Schmer, G, Counts, R B and Davie E W (1973)
Iso la t ion  and characterisation of human fa c to r  V I I I  (a n t i -  
haemophilic fa c to r ) .
Journal o f B io log ica l Chemistry, 248, 3946- 3955.
Legrand, Y, Pignaud, G, Caen, J P, Robert B and Robert, L (1975)
Separation of human blood p la te le t  elastase and proelastase by 
a f f in i t y  chromatography.
Biochemical and Biophysical Research Communications, 63, 224-231.
Lensing, A W A, Sturk, A and ten Cate, J W (1981)
No e ffe c t of persantin on p la te le t  aggregation and plasma BTG 
leve ls in  healthy volunteers.
Thrombosis and Haemostasis, 46. Abstract No 1284.
Letcher, R L, Chien, S, P ickering, T G, Sealey, J E, Laragh, J H (1981) 
D irect re la t ionsh ip  between blood pressure and blood v iscos ity  in 
normal and hypertensive subjects. Role of fibr inogen and 
concentration.
American Journal o f Medicine, 70, 1195-1202.
Lever, J C W (1843)
Cases with puerperal convulsions with remarks.
Guy's Hospital Reports, 8, 495-517.
Levine, S P and Krentz, L S (1977)
Development of a radioimmunoassay fo r  human p la te le t  fa c to r  4. 
Thrombosis Research, 11, 673-686.
Levine, S P, Lindenfeld, J, E l l i s ,  J B, Raymond, N M and Krentz, L S 
(1981)
Increased plasma concentrations of p la te le t  fa c to r  4 in coronary 
a r te ry  disease - a measure of in vivo p la te le t  ac t iva t ion  and 
secretion.
C ircu la t ion , 64, 626-632
364
Lewis, P (1982)
The ro le of prostacyclin  in pre-eclampsia.
B r i t i  sh Journal of Hospital Medici ne, 393-395.
Lewy, R I ,  Smith, J B, S i lve r ,  M J , Saia, J, Walinsky, P and Weiner, L
(1979)
Detection of"thromboxane B^ in peripheral blood of patients 
with Prinz Metal's angina.
Prostaglandins in  Medicine, 243-248.
Lieberman, G E, Lewis, G P and Peters, T J (1977)
A membrane-bound enzyme in rabbit aorta capable of in h ib i t in g  
adenosine-diphosphate-induced p la te le t aggregation.
Lancet, 2, 330-332
L ip in s k i ,  B, Wegrzynowicz, Z, Budzynski, A, Kopec, M, L a ta l lo ,  Z S
and Kowalski, E (1967)
Soluble unclo ttab le  complexes formed in the presence of 
fibr inogen degradation products (FDP's) during the f ib r inogen- 
f i b r i n  conversion and th e i r  potentia l s ign if icance in pathology.
Thrombosis et Diathesis Haemorrhagica, 17, 65-77.
L ip in s k i ,  B and Worowski, K. (1968)
Detection of soluble f ib r in  monomer complexes in blood by means 
of protamine sulphate te s t .
Thrombosis et Diathesis Haemorrhagica, 20, 44-49.
L is te r ,  J (1863)
On the coagulation of blood.
Proceedings o f the Royal Society, London, 12, 580-611.
Liu, C Y, Nossel, H L and Kaplan, K I (1979)
The binding of thrombin by f i b r in .
Journal o f B io log ica l Chemistry, 254, 10421-10425.
Longmore, D B, Bennett, G, Gueirrara, D, Smith, M, Bunting, S, 
Moncada, S, Reed, P, Read, M G and Vane, J R (1979)
Prostacyclin: a solution to some problems of extracorporeal
c i rc u la t io n .  Experiments in greyhounds.
Lancet 1, 1002-1005.
Lopas, H, B irndorf, N I ,  B e l l ,  C R, Robboy, S J and Colman, R W (1973) 
Experimental immune hemolytic transfusion reactions in monkeys: 
A c tiva tion  of the k a l l ik re in  system.
American Journal o f Physiology, 225, 372-379.
Lorand, L and Jacobsen, A (1958)
Studies on the polymerisation of f i b r in :  The ro le of the
globulin: fibrin stabilising factor.
Journal of Biological Chemistry, 230, 421-434. •
365
Lorand, L (1972)
F ib r ino ligase : The f ib r in - s ta b i l i z in g  fa c to r  system of
blood plasma.
Annals o f the New York Academy o f Sciences, 202, 6-30.
Lowe, G D Oi Campbell, A F, Meek, D R, Forbes, C D, Prentice, CRM  
and Cummings, S W (1978)
Subcutaneous ancrod in prevention of deep vein thrombosis a f te r  
operation fo r  fractured neck of femur.
Lancet, I I , 698-700.
Lowe, GOO,  Drummond, M M, Th ird, J L, Bremner, W F, Forbes, C D, 
Prentice, C R M  and Lawrie, T D V (1979a)
Increased plasma fibrinogen and p la te le t  aggregates in type I I  
hyperli poproteinaemia.
Thrombosis and Haemostasis, 42, 1503-1507.
Lowe, G D, Johnston, R V, Drummond, M M, Forbes, C D and Prentice, CRM,  
(1979b)
Induction of c irc u la t in g  p la te le t  aggregates in healthy subjects 
by a saturated fa t  meal.
Thrombosis Research, 16, 565-568.
Lowe, G D,0, Morrice, J J, Forbes, C D, Prentice, C R, Fulton, A J and 
Barbenel, J C (1979c)
Subcutaneous ancrod therapy in peripheral a r te r ia l  disease: 
improvement in blood v iscos ity  and n u tr i t io n a l blood flow.
Angiology, 30, 594-599.
Lowe, G D, Reavey, M M, Johnston, R V, Forbes, C D and Prentice, CRM 
(1979d)
Increased p la te le t  aggregates in vascular and non-vascular 
i l ln e s s :  co rre la t io n  with plasma fibrinogen and e ffe c t  of ancrod.
Thrombosis Research, 14, 377-386.
Lowe, G D 0, Drummond, M M, Lorimer, A R, Hutton, I ,  Forbes, C D, 
Prentice, C R M  and Barbanel, J C (1980)
Relation between extent of coronary artery disease and 
blood v isco s ity .
B r i t is h  Medical Journa l, 280, 673-674.
Lowe, G D 0, Drummond, M M, Forbes, C D and Barbenel, J C (1981)
Occlusive a r te r ia l  disease and blood rheology.
In C lin ica l aspects o f blood v iscos ity  and cel 1 d e fo rm a b il i ty , 
eds Lowe, G D 0, Barbanel, J C and Forbes, C D.
New York; Springer-Verlag, 133-148.
366
Lowe, G D (1981)
Laboratory evaluation of hypercoagulability . 
C lin ics  in Haematology, 10, 407- 442.
Lowe, G D 0, Drummond, MM, Forbes, C D and Barbanel, J C (1981) 
Occlusive a r te r ia l  disease and blood rheology.
In C lin ica l Aspects o f B1ood V iscos ity  and Cel 1 D e fo rm ab il i ty , 
eïïs. Lowe, G D 0, BarFanel, J C and Forbes, C D.
Springer-Verlag, New York, 219.
Lowe, G D 0, Osborne, D H, McArdle, B M, Smith, A, Carter, D C, 
Forbes, C D, McLaren, D and Prentice, CRM (1982a)
Prediction and selective prophylaxis of venous thrombosis 
in  e lec t ive  gastro in tes tina l surgery.
Lancet, I ,  409-412.
Lowe, G D, McArdle, B M, Stromberg, P, Lorimer, A R, Forbes, C D 
and Prentice, CRM  (1982b)
Increased blood v iscos ity  and f ib r in o ly t i c  in h ib i to r  in 
Type I I  hyperlipoproteinaemia.
Lancet, 1, 472-475.
Ludlam, C A, Moore, S, Bolton, A E, Pepper, D S and Cash, J D (1975a) 
The release of a human p la te le t  spec if ic  protein measured by a 
radioimmunoassay.
Thrombosis Research, 543-548.
Ludlam, C A, Bolton, A E, Moore, S and Cash, J D (1975b)
New rapid method fo r  diagnosis o f deep venous thrombosis.
Lancet, I I , 259-260.
Ludlam, C A and Cash, J D (1976)
Studies on the l ib e ra t io n  of beta-thromboglobulin from human 
p la te le ts  in  v i t r o .
B r i t is h  Journal o f Haematology, 33, 239-247.
Ludlam, C A (1979)
Evidence fo r  the p la te le t  s p e c i f ic i ty  of beta-thromboglobulin 
and study on on i t s  plasma concentration in  healthy ind iv idua ls
B r i t is h  Journal o f Haematology, 41, 271-278.
Lunell (1982)
Unpublished observation - personal communication.
367
Macfarlane, R G (1964)
An enzyme cascade in the blood c lo t t in g  mechanism, and i t s  
function as a biochemical am p lif ie r .
Nature, 202, 498-499.
M acGillivray, I (1961)
Hypertension in pregnancy and i t s  consequences.
Journal o f Obstetrics and Gynaecology of the B r i t is h  Commonwealth, 
68, 557-569.
M acGillivray, I (1981)
Aetiology of pre-eclampsia.
B r i t is h  Journal o f Hospital Medicine, 28, 110- 119.
McGrath, M A, Wechsler, F, Hunyor, A B L and Penny R (1978)
Systemic factors con tr ibu ting  to re t ina l vein occlusion.
Archives o f Internal Medicine, 138, 216-220.
MacIntyre, D E, Pearson, J D, and Gordon, J L (1978)
Localisation and stim ula tion of prostacyclin production in 
vascular cel 1 s.
Nature, 271, 549-551
Macintyre, I M C, Webber, R G, Crisp in , J R, Jones, O R B ,  Wood, J K,
A llan , N C, Prescott, R J and Ruckley, C V (1976)
Plasma f ib r in o ly s is  and postoperative deep vein thrombosis.
B r i t i  sh Journal o f Surgery, 63, 694-697.
McKay, D G and Muller-Berghaus, G (1967)
Therapeutic implications of disseminated in travascu la r coagulation.
American Journal o f Cardiology, 20, 392- 410.
McKay, D G (1970)
Progress in  disseminated in travascu lar coagulation.
C a lifo rn ia  Medicine, 111, 186- 198.
McKay, D G (1972)
P a rt ic ip a t io n  of components of the blood coagulation system 
in  the inflammatory response.
American Journal o f Pathology, 67, 181-210.
McKee, P A, Mattock, P and H i l l ,  R L (1970)
Subunit s truc ture  of human fibr inogen, soluble f i b r in  and 
cross-linked inso luble f i b r in .
Proceedings o f the National Academy o f Sciences (USA) , 66, 738-744.
MacKie, M J, Bennet, B, Ogston, D and Douglas, A S. (1978)
Familial thrombosis: inherited defic iency of anti thrombin I I I .
The British Medical Journal. 1, 136-138.
368
MacKie, M, Booth, N and Bennett, B (1979)
Comparison of the human activa tors  of plasminogen. 
Thrombosis and Haemostasis, 42, Abstract No 0864.
McKillop, C, Edgar, W, Forbes, C D and Prentice, CRM.  (1975)
In vivo production of soluble complexes containing fibrinogen- 
f i b r in  re lated antigen during ancrod therapy.
Thrombosis Research, 7, 361-372.
McKillop, C Howie, P W and Forbes, C D and Prentice, CRM (1976) 
Soluble f ib r in o g e n / f ib r in  complexes in pre-eclampsia.
Lancet I ,  56-58.
McMillan, C R, Saito, H, Ratnoff, 0 D and Walton, A C (1974)
The secondary s tructure  of human Hageman fa c to r  ( fa c to r  X II) 
Journal o f C lin ica l In ve s t ig a t io n , 54, 1312-1322.
McMillan, D E (1976)
Plasma prote in  changes, blood v iscos ity  and d iabetic  
microangiopathy.
Diabetes, 25 (2 Suppl) ,  858-864.
McNicol, G P, Gale, S B and Douglas, A S (1963)
In v i t r o  and in vivo studies of a preparation of urokinase. 
B r i t is h  Medical Journa l, 1, 909-915.
McNicol, G P and Douglas, A S (1976)
The f i b r in o ly t i c  enzyme system 
In Human Blood Coagulation, Haemostasis and Thrombosis. 
ecT. Biggs, R. Oxford: Blackwell. 2nd E d it ion , 399-435.
Magnusson, S, Peterson, J E, Settrup-Jenson, L and Claeys, H (1975) 
Complete primary s truc ture  of prothrombin: is o la t io n ,  s tructure
and re a c t iv i ty  of ten carboxylated glutamic acid residues and 
regulation of prothrombin ac tiva tion  by thrombin.
In Proteases and B iolog ica l Control
êÏÏs Reich, E, R i fk in ,  D B and Shaw, E. Cold Spring Harbor 
Conferences on Cell P ro l i fe ra t io n ,  213-249.
369
Mal l i c k ,  N P and S ho ir t ,  C D (1981)
The nephrotic syndrome and ischaemic heart disease.
Nephron, 27, 54-57.
Malmsten, C, Hamberg, M, Svensson, J and Samuelsson, B (1975) 
Physiological ro le  of an endoperoxide in human p la te le ts :  
Hemostatic defect due to p la te le t  cyclooxygenase defic iency. 
Proceedings o f the National Academy o f Sciences, USA. 72, 1446- 1450.
Malofiejew, M (1971)
The b io log ica l and pharmacological properties of some fibrinogen 
degradation products.
Scandinavian Journal o f Haematology, 13, 303-310.
Malpighi, M (1686)
De polypo cordis d is s e r ta t io .  
In Opera Omnia. London, R. S cott. 
XCited by Murano, 6 . 1974j
Mammen, E F, Prasad, A, Barnhardt, M I and Au. C C (1969)
Congenital dysfibrinogenemia: Fibrinogen D e tro it .
Journal o f C lin ica l In ve s t ig a t io n , 48, 235-249.
Mammen, E F, Thomas, W R and Seegers, W H. (1960)
Activa tion  of pu r if ied  prothrombin to autoprothrombin I or 
autoprothrombin I I  (p la te le t  cofactor I I )  or autothrombin I I -A .
Thrombosis et Diathesis Haemorrhagica, 5^ , 218-249.
Mansfield, A 0 (1972)
A lte ra t io n  in f ib r in o ly s is  associated with surgery and venous 
thrombosis.
B r i t is h  Journal o f Surgery, 59, 754-757.
Marder, V J, Shulman, N R and C a rro l l ,  W R (1969)
High molecular weight derivatives of human fibrinogen produced by 
plasmin 1. Physiochemical and immunological characte risa tion .
Journal o f B io log ica l Chemistry, 244, 2111-2119.
Marder, V J and Budzynski, A Z (1975)
Data fo r  defin ing fibrinogen and i t s  plasmic degradation products,
Thrombosis et Diathesis Haemorrhagica, 33, 199-207.
370
Margaretten, N, Zunker, H 0, and McKay D G (1964)
Production of the generalized Schwartzman reaction in  pregnant 
ra ts  by intravenous in fusion of thrombin.
Laboratory Inve s t iga t ion . 13, 552- 559.
Markus, G, Evers, J L and Hobika, G H (1976)
Activa to r a c t iv i t ie s  of the trans ien t forms of human plasminogen- 
streptokinase complex during i t s  p ro teo ly t ic  conversion to the 
stable a c t iva to r  complex.
Journal o f B io log ica l Chemi s t r y , 251, 6495-6504.
Markwardt, F (1978)
N atu ra lly  Occurring In h ib ito rs  of F ib r in o ly s is .
In F ib r in o ly t ic s  and A n t i -F ib r in o ly t ic s .
ed. Markwardt, F. B erl in : Springer-Verlag. 487 - 509.
Marlar, R A, K le iss , A and G r i f f in ,  J H. (1981)
Human prote in C: Inac tiva t ion  of factors V and V I I I  in  plasma
by the activated molecule.
Annals o f the New York Academy o f Sciences, 370, 303-310.
Marsh, N A and Gaffney, P (1980)
Some observations on the release of e x tr in s ic  and in t r in s ic  
plasminogen activa to rs  during exercise in man.
Haemostasis, £ ,  238-247.
Mason, R G, Mohammad, S F, Chuang, H Y K, Richardson, P D (1976)
The adhesion of p la te le ts  to subendothelium, collagen, and 
a r t i f i c i a l  surfaces.
Seminars in Thrombosis and Haemostasis, 3 ,  98-116.
Matsuda, T, Seki, T, Ogawara, M, Miura, R, Yokouchi, M and Murakami, M
(1979)
Comparison between plasma levels of B-thromboglobulin and p la te le t  
fa c to r  4 in various diseases.
Thrombosis and Haemostasis, 42, Abstract No 0678.
Matthews, J H, O'Connor, J F, Hearnshaw, J R and Wood, J K (1979)
Beta-thromboglobulin and glycosylated haemoglobin in diabetes
m e ll i tu s .
Scandinavian Journal o f Haematology, 23, 421-426.
Matthias, F R, Reinicke, R and Heene, D L (1977)
A f f in i t y  chromatography and quantita tion  of soluble f i b r in  
from plasma.
Thrombosis Research, 10, 365-384.
371
Meade, T W and North W R S (1977)
Population-based d is tr ib u t io n s  of haemostatic variables.
B r i t is h  Medical B u i le t in , 33, 283- 288.
Meade, T W, Chakrabarti, R, S t i r l in g ,  Y, Haines, A P, North W R S
and Thomson, S J (1980)
Haemostatic function and cardiac death: early  resu lts  of a
prospective study.
Lancet 1050.
Meden-Britth, G and Radegran K (1980)
Fibrinopeptide A as a measure of coagulation a c t iv i t y  induced by 
surgery. An experimental study in dogs.
Thrombosis Research, 18, 333-341.
Michael, C A (1979)
Use of labe ta lo l in the treatment of severe hypertension during 
pregnancy.
B r i t is h  Journal o f Cl in ic a l  Pharmacology, £  (Suppl ) 2^ , 211S-215S.
Michael, C A (1980)
Early fe ta l lung maturation associated with labe ta lo l therapy,
Singapore Journal of Obstretr ics and Gynaecology, 11.
M ile t ic h ,  J P, Jackson, C M and Majerus, P W (1977)
In teraction  of coagulation fac to r  Xa with human p la te le ts .
Proceedings o f the National Academy o f Sciences, USA. 74, 4033-4036.
M i l le r ,  0 V and Gorman, R R (1976)
Modulation of p la te le t  cyc l ic  nucleotide content by PGE and 
the prostaglandin endoperoxide PGG^
Journal o f Cyclic Nucleotide Research, Z ,  79-87.
M il l ik a n ,  C H and McDowell, F H (1978)
Treatment of t rans ien t ischemic attacks.
Stroke, 9, 299-308.
Minna, J D, Robboy, J S, and Colman, R W (1974)
In Disseminated Intravascular Coagulation in Man
S p r in g f ie ld , I I l i n o i s l  Charles Thomas, 93.
M itc h e l l , J R A (1978)
C lin ica l events resu lt ing  from thrombosis formation.
B r i t i  sh Medical B u l le t in , 34, 103-106.
Mombelli, G, Roux, A, Haeberli, A and Straub, P W (1982)
Comparison of - f ib r inogen k ine tics  and f ib r in o p e p tid e  A 
in  patients with disseminated neoplasias.
Blood, 60, 381-388.
372
Moncada, S, Gryglewski, R, Bunting, S and Vane, J R (1976)
An enzyme iso la ted from a rte r ies  transforms prostaglandin 
endoperoxides to an unstable substance tha t in h ib i ts  
p la te le t  aggregation.
Nature, 263, 663-665.
Moncada, S, Neman, A G, Higgs, E A and Vane, J R (1977)
D if fe re n t ia l  formation of prostacyclin (PGX or PGI% ) by 
layers of the a r te r ia l  w a l l .  An explanation fo r  the anti 
thrombotic properties o f vascular endothelium.
Thrombosis Research, 11, 323-344.
Moncada, S and Vane, J R (1977)
The discovery of prostacyclin  - A fresh ins igh t in to  arachidonic 
acid metabolism.
In Biochemical Aspects of Prostaglandins and Thromboxanes.
eïïs. Kharasch, N and Fried, J.
New York: Academic Press. 155-177.
Moncada, S, Korbut, R, Bunting, S and Vane, J R (1978)
Prostacyclin is  a c irc u la t in g  hormone.
Nature, 273, 767-768.
Moncada, S and Vane, J R (1978)
Pharmacology and endogenous roles of prostaglanding endoperoxides, 
thromboxane A% and prostacyc lin .
Pharmacological Reviews, 30, 293-331.
Moncada, S and Vane, J R (1979)
Arachidonic acid metabolites and the in te rac tions  between 
p la te le ts  and blood vessel walls .
New England Journal o f Medicine, 300, 1142-1147.
Moncada, S and Vane, J R (1981)
Prostacyclin : Homeostatic regulator or b io log ica l cu r io s ity?
C lin ica l Science, 61, 369-372.
Al-Mondhiry, H, B ilezekian, S B and Nossel, H L (1975)
Fibrinogen "New York" an abnormal f ibrinogen associated with 
thromboembolism: functional evaluation.
Blood, 45, 607-619.
373
Moore, S, Pepper, D S and Cash J D (1975a)
The iso la t io n  and characterisation of a p la te le t  sp e c if ic  
B-globulin (B thromboglobulin) and the detection of a n t i-  
urokinanase and anti-plasmin released from thrombin-aggregated 
washed human p la te le ts .
Biochimica et Biophysica Acta, 379, 360- 369.
Moore, S, Pepper, D S and Cash, J D (1975b)
The iso la t io n  and characterisation of p la te le t  fa c to r  4 
released from thrombin-aggregrated washed human p la te le ts  and 
i t s  d issocia tion in to  subunits and the iso la t io n  of membrane- 
bound anti heparin a c t iv i t y .
Biochimica et Biophysica Acta, 379, 370- 384.
Moore, S, Friedman, R J , Singal, D P, Gaul d ie , J, Blajchman, M A and 
Roberts R S (1976)
In h ib i t io n  of injury-induced thromboatherosclerotic lesions by 
a n t i -p la te le t  serum in rabb its .
Thrombosis and Haemostasis, 35, 70-81.
Moore, S and Pepper, D S (1976)
Id e n t i f ic a t io n  of a p la te le t  spec if ic  release product 
B thromboglobulin.
In P la te le t Physiology,
eïï. Gordon, J L .  North Holland; E lsevier, Biomedica Press, 
Amsterdam, 293-311.
Morawitz, P (1905)
Die chemie der b lutgerinning
Ergebnisse der Physiologie (biologischen Chemie und experimentellen
PharmakoTogie) 4_, 307-422.
Morrison, D C and Cochrane, C G (1974)
Direct evidence fo r  Hageman fa c to r  (Factor X II)  ac t iva t ion  by 
bacteria l l ipolysaccharides (endotoxins)
Journal o f Experimental Medicine, 140, 797-811.
Moroz, L A and Gilmore, N J (1976)
F ib r ino lys is  in normal plasma and blood: Evidence fo r
s ig n if ic a n t  mechanisms independent of the plasminogen-plasmin 
system.
Blood, 531-545.
M orta l i ty  S ta t is t ic s  fo r  England and Wales 1978.
London. HMSO 1980.
374
Mosher, D F (1975) •
C ross-linking of co ld-inso lub le  g lobulin  by f ib r in - s ta b i l i z in g  
fac to r.
Journal o f B io log ica l Chemistry, 250, 6614- 6621.
Mosseson, M W, Finlayson, J S and Galanakis, D (1973) . ,
The essential covalent s tructure of human fibr inogen evinced 
by analysis of derivatives formed during plasmic hydro lys is.
Journal o f B io log ica l Chemistry, 248, 7913-7929.
Muller-Berghaus, G (1977)
Pathophysiology of generalized in travascular coagulation.
Seminars in Thrombosis and Haemostasis, _3, 209- 246.
Murakoshi, T, Takei, H, Seya, T, Oguma, Y, Yamauchi, M, Nagata, H
and Hasegana, H. (1981)
Plasma fib r inopep tide  A and B-thromboglobulin in pre-eclampsia.
Lancet I I , 248.
Murano, G (1974)
The molecular s tructure of f ibr inogen.
Seminars in Thrombosis and Haemostasis, 1, 1-31.
Murphy, E A and Mustard, J F (1962)
Coagulation tes ts  and p la te le t economy in a therosc le ro tic  and 
control subjects.
C irc u la t io n , 25, 114-125.
Murphy, E A, Francis, M E and Mustard, J F (1972)
The estimation of blood p la te le t  su rv iva l.  IV Characteris tics
of the residual errors from regression .
Thrombosis et Diathesis Haemorrhagica, 28, 447- 456.
Murtaugh, P A and Gladner, J A (1974)
A modified procedure fo r  the rapid iso la t io n  of f ib r ino-pep tides, 
Archives o f Biochemistry and Biophysics, 163, 784-786.
Mustard, J F, Murphy, E A, Rowsell, H C and Downie, H G (1962)
Factors in fluencing thrombus formation in  vivo.
American Journal o f Medicine, 33, 621-647.
Mustard, J F, Kinlough-Rathbone, R L, and Packham, M A (1974)
Recent studies of research in the pathogenesis of thrombosis. 
Thrombosis et Diathesis Haemorrhagica, 59 ,(Suppl) 157.
375
Mustard, J F, Packham, M A and Kinlough-Rathbone, R L (1978)
P la te le t su rv iva l.
In P la te le t Function Testing.
"êïïs Day, H J, Holmsen, H and Zocker, M B. Washington, Dhew. 545-560.
Myers, T J, R ickies, F R, Barb, C and Cronlund, M (1981)
Fibrinopeptide A in  acute leukemia: Relationship of ac tiva tion
of blood coagulation to disease a c t iv i t y .
Blood, 57, 518-525.
Nachman, R L, Weksler, B and F e rr is ,  B (1972)
Characterization of human p la te le t  vascular permeability-enhancing 
a c t iv i t y .
Journal o f C lin ica l Inve s t iga t ion , 51, 549-556.
Needleman, P, Moncada, S and Bunting S, Vane, J R, Hamberg, M and
Samuelsson, B (1976)
Id e n t i f ic a t io n  of an enzyme in p la te le t  microsomes which 
generates thromboxane A from prostaglandin endoperoxides.
Nature, 261, 558-560.
Negus, D, P into, D J, Lequesne, L P, Brown, N and Chapman M (1968)
'^“^ I labelled fibrinogen in the diagnosis of deep vein thrombosis 
and i t s  co rre la t ion  with phlebography.
B r i t is h  Journal o f Surgery, 55, 835-839.
Nenci, G G, B e r re t t in i ,  M, Todisco, T and Pari se, P (1981)
Enhanced plasma beta-thromboglobulin in hypoxemia: E ffect
o f dipyridamole.
(L e tte r)  New England Journal of Medicine, 304, 1044.
Nicholas, T E (1978)
Maternal administration of salbutamol and lab e la lo l increases 
the amount of a lveolar surfactant in the day 27 fe ta l ra b b it .
Proceedings o f the Austra lian Physiological and Pharmacological Society
9, 146P.
376
Nichols, A B, Owen, J , Kaplan, K L, Sciacca, R R, Cannon, P J
and Nossel, H L (1982)
Fibrinopeptide A, p la te le t  Factor 4, and beta thromboglobulin 
levels in coronary heart disease.
Blood 60, 650-654.
Niewiarowski, S and Gurewich, V (1971)
Laboratory inves tiga tion  of in travascu lar coagulation. The 
seria l d i lu t io n  protamine sulphate tes t fo r  the detection of 
f i b r in  monomer and f ib r in  degradation products.
Journal o f Laboratory and C lin ica l Medicine, 77, 665-676.
Niewiarowski, S (1977)
Proteins secreted by the p la te le t .
Thrombosis and Haemostasis, 38, 924-938.
Niewiarowski, S, Walz, D A, James, P, Rucinski, B and Kueppers, F (1980) 
Id e n t i f ic a t io n  and separation of secreted p la te le t  proteins by 
is o e le c tr ic  focusing. Evidence that low a f f in i t y  p la te le t  
Factor 4 is  converted t o B  thromboglobulin by l im ited  pro teo lys is .
Blood, 55, 453-456.
Nolf, P (1908) /  /
Preparation e t propriétés coagulantes de la thrombozyine.
Archives Internationales de phys io log ie , 6. 1 .
Nordoy, A and Rodset, J M (1971)
P la te le t phospholipids and th e i r  function in patients with 
ischaemic heart disease.
Acta Medica Scaninavica, 188, 133-137.
Nossel, H L, Rubin, H, D r i l l in g s ,  M and Hsieh, R (1968)
In h ib i t io n  of Hageman fac to r  ac t iva t io n .
Journal o f C lin ica l Inve s t iga t ion , 47, 1172-1180.
Nossel, H L, Younger, L R, Wilner, G D (1971)
Radioimmunoassay of human f ib r inopep tide  A.
Proceedings o f the National Academy of Sciences, USA, 6 8 , 2350-2353.
377
Nossel, H L, Yudelman, I ,  Canfield, R E, B u tle r, V P, Spanondis, K,
Wilner, G D and Qureshiu, G D (1974)
Measurement of f ib r inopeptide  A in  human blood.
Journal of C lin ica l Inve s t iga t ion , 54, 43-53.
Nossel , H L (1976a)
Radioimmunoassay of f i b r i nopeptides in re la t io n  to in travascu lar 
coagulation and thrombosis.
New England Journal o f Medicine, 295, 428-432.
Nossel, H L, T i , M, Kaplan, K L, Spanondis, K, Sol and, T and B utle r, V P
(1976b)
The generation of f ib r inopeptide  A in  c l in ic a l  blood samples. 
Evidence fo r  thrombin a c t iv i t y .
Journal o f C lin ica l Inve s t iga t ion , 58, 1136-1144.
Nossel, H L, B u tle r , V P, Wilner, G D, Canfield, R E and Harfen is t, E J . 
(1976c)
S p e c if ic i ty  of antisera to human fib r inopeptide  A used in 
c l in ic a l  f ib r in op ep tid e  A assays.
Thrombosis and Haemostasis, 35, 101-109.
Nossel, H L, Smith, F R, Seplowitz, A H, D e ll,  R B, Sciacca, R R, 
Merskey, C and Goodman, D S (1979a)
Normal levels of f ib r inopep tide  A in patients with primary 
hyperli p idemi a.
C ircu la tion  Research, 45, 347-350.
Nossel, H L, Wasser, J , Kaplan, K L, LaGamma, K S, Yudelman, I and 
Canfield, R E (1979b)
Sequence of f ibr inogen proteo lysis and p la te le t  release a f te r  
in tra u te r in e  in fusion of hypertonic sa line.
Journal o f Cl in ica l Inve s t ig a t io n , 64, 1371-1378.
Nossel, H L (1981)
Relative proteo lys is  of the fibrinogen B beta chain by thrombin 
and plasmin as a determinant of thrombosis.
Nature, 291, 165-167.
Nussenzweig, V, Seligmann, M, Pelmont, J and Grabar, P (1961)
Les produts de degradationjdu fibrinogene humain par la plasmine 
I :  Separation et propriétés physicochimiques.
Annal es de L ' In s t i tu e  Pasteur, 100, 377-387.
378
O'Brien, J R, Etherington, M, Jamloeson, S, Klaber, M R, L incoln, S V 
(1974)
P la te le t function long a f te r  a r te r ia l  and venous thrombosis. 
Thrombosis et Diathesis Haemorrhagica, 31, 279-290.
O'Brien, J R, Etherington, M D, Jamieson, S, Lawford, P, L incoln, S V 
and A1kjaersig,N J (1975)
Blood changes in atherosclerosis and long a f te r  myocardial 
in fa rc t io n  and venous thrombosis.
Thrombosis et Diathesis Haemorrhagica, 34, 483-497.
O'Brien, J R,. Etherington, M D, and Shuttleworth, R (1977)
thromboglobulin and heparin-neutra lis ing a c t iv i t y  te s t  in 
c l in ic a l  conditions.
Lancet, 1 ( l e t t e r ) , 1153-1154.
O'Brien, J R (1977)
The prethrombotic state.
In Recent Advances in Blood Coaquiation 2,
ed. P o l le r ,  L. Edinburgh, Churchill Livingstone, 241-266.
O'Brien, J R, Etherington, M 0 and Adams, C M (1980a)
The e ffe c t of minor i l ln e s s  on the heparin thrombin c lo t t in g  time, 
Thrombosis Research, 19, 55-61.
O'Brien, J R, Etherington, M D, Shuttleworth, R D and Calwell, W H 
(1980b)
P la te le t function in  acute myocardial in fa rc t io n .  Patients 
compared with con tro ls .
Thrombosis and Haemostasis, 44, 96-99.
Odegard, 0 R, Lie, M and Abildgaard, U (1975)
Heparin co -fac to r a c t iv i t y  measured with an amidolytic method. 
Thrombosis Research, 287-294.
Ogston, D, Bennet, B and Mackie, M (1976)
Properties of a p a r t ia l ly  p u r if ie d  preparation of a c irc u la t in g  
plasminogen a c t iva to r .
Thrombosis Research, 8 , 276-284.
Ogston, D and Bennet B (1977)
Surface-mediated reactions in the formation of thrombin, plasmin 
and k a l l ik re in .
B r i t is h  Medical B u l le t in ,  34, 107-112.
379
Olsson, P I and Johnsson, H (1972)
Interference of acetyl sali c yc l ic  acid, heparin and fibrinogen 
degradation products in haemostasis of reptilase-defibrinogenated 
dogs.
Thrombosis Research, _1, 135-146.
van Oost, B A (1981)
Detection of p la te le t  ac t iva t ion  in thrombosis. Thesis, Utrecht,
Osbahr, A J (1975)
S tru c tu re -a c t iv i ty  re la tionsh ips of the vasopressor a c t iv i t y  of 
canine peptide A from fib r inogen.
Biochimica et Biophysica Acta, 386, 373-381.
Osterud, B, Berre, A, Otnaess, A B, B jo rk l id ,  E and Prydz, H (1972) 
A ctiva tion  of the coagulation Factor VII by tissue thromboplastin 
and calcium.
Biochemistry, 11, 1853-2857.
Osterud, B, Miller-Anderson, M, Abildgaard, U and Prydz, H (1976) 
The e f fe c t  of anti thrombin I I I  on the a c t iv i t y  of the 
coagulation fac to rs , V I I ,  IX and X.
Thrombosis and Haemostasis, 35, 295-304.
Owen, J , Kvam, D, Nossel, H L, Kaplan, K L and Kernoff, P B A (1983) 
Thrombin and plasmin a c t iv i t y  and p la te le t  ac t iva t ion  in  the 
development of venous thrombosis.
Blood, 61, 476-482.
Owren, P A (1947)
The coagulation of blood; investigations on new d o t in g  factor. 
Acta Medica Scandinavica (Suppl) 194, 1-327.
Page, E W (1972)
On the pathogenesis of pre-eclampsia and eclampsia.
Journal of Obstetrics and Gynaecology o f the B r i t is h  Commonwealth, 
7'9, 883-M41
Pal ester-Chlebowczyk, M, Stryzewska, E, Sitkowski, W (1971)
Preliminary resu lts  of the protamine sulphate te s t  in plasma of 
various pa tien ts .
Scandinavian Journal of Haematology, ( Suppl) 13, 183-188.
Pandolfi, M, Nilsson, I H, Robertson, B and Isacson, S (1967) 
F ib r in o ly t ic  a c t iv i t y  of human veins.
Lancet I I ,  127-128.
380
Pandolfi, M, Isacson, S and Nilsson, I M (1969)
Low f ib r in o ly t i c  a c t iv i t y  in the walls o f veins in patients 
with thrombosis.
Acta Medica Scandinavica, 186, _l-_5.
P are ti,  F I ,  Dawes, J, Franchi, F, Mannucci, D M and Pepper, D S (1979) 
Content and release of B-thromboglobulin and p la te le t  fa c to r  4 
in  patients w ith q u a l i ta t iv e  p la te le t  defects.
Thrombosis Research, 16, 537-542.
Paton, R C and Douglas, A S (1978)
Mechanisms of thrombotic disease.
In Pathobiology Annual
ed. loachim, H L. Raven, New York, 59.
Pearson, T C and Wetherley-Mein, G (1978)
Vascular occlusive episodes and venous haematocrit in  primary 
p ro l i fe ra t iv e  polycythaemia.
Lancet U_, 1219-1222.
P e t i t ,  J L (1731)
D isserta tion  sur la manniere d*arrester le sang dans les 
hemorrhagies.
Member o f Academy of Royal Sciences, _1, 85-102.
P e tra l i to ,  A, Fiore, C E, Mangiafico, R A and Malatino, L S (1982) 
Beta-thromboglobulin plasma levels in d i f fe re n t  stages of 
a r te r ia l  hypertension.
Thrombosis and Haemostasis, 48, 241.
Peuscher, F W, van Aken, W G, F l ie r ,  0 T N, Stoepman-van Dalen, E A,
Cremer-Goote, T M and van Mourik, J A (1980a)
Effect of anticoagulant treatment measured by f ib r in op ep t id e  A
(FpA) in  patients with venous thromboembolism.
Thrombosis Research, 18, 33-43.
Peuscher, F W, Cleton, F J ,  Armstrong, L, Stoepman-van Dalen, E A,
van Mourik, J A and van Aken, W G (1980b)
S ignificance of plasma fib r inopeptide  A (FpA) in  patients with 
malignancy.
Journal o f Laboratory and C lin ica l Medicine, 96, 5-14*
P fue lle r ,  S L and Luscher, E F (1972)
The e ffe c t of immune complexes on blood and th e i r  re la tionsh ips
to complement ac t iva t io n .
Immunochemistry, 9^ , 1151-1165.
Piper, P J and Vane, J R (1969)
Release of additional factors in anaphylaxis and i t s  antagonism 
by anti-inflammatory drugs.
Nature, 223, 29-35.
381
Pizzo, S V, Schartz, M L, H i l l ,  R L and McKee, P A (1972)
Mechanism of ancrod anticoagulation, A d ire c t p ro te o ly t ic  
e ffec t on f i b r in .
Journal o f C lin ica l In ve s t ig a t io n , 51, 2841-2850.
Pizzo, S V, Schwartz, M L, H i l l ,  R L, and McKee, P A (1973)
The e ffec t of plasmin on the subunit s tructure of human fibrinogen, 
Journal o f B io log ica l Chemistry, 247, 636-645.
Plato (1892)
Tima eus 
In The Dialogues o f Plato
ëïï. Jewet, B. New York: Macmillan, 3rd ed. 3, 339-543.
Plow, E F and Edgington, T S (1975)
An a lte rna t ive  pathway fo r  f ib r in o ly s is .  I The cleavage of 
fib r inogen by leucocyte proteases at Physiological pH.
Journal o f C lin ica l Inve s t iga t ion , 56, 30-38.
Poggi, A, Niewiarowski, S, Holt, J C, D a l i 'O l io ,  A, Stewart, G J, 
and Smith, J V (1981)
Human p la te le t-secre ted proteins (LA-PF^,BT6 ) do not modify 
prostacyclin  (PGI% ) production by bovine ao rt ic  endothelial c e l ls  
Thrombosis and Haemostasis, 46, Abstract No 0105.
Poole, J C F and French, J E (1961)
Thrombosis
Journal o f Atherosclerosis Research, 1, 251-282.
Praga, C and Pog lian i, E (1971)
Effect of nimergoline ( F I .6714) on human p la te le t  aggregation 
in v i t ro .
Acta Medica Scandinavica ( Suppl) ,  525, 263-266.
Prazich, J A, Rapaport, S I ,  Samples, J R and Engler, R (1977) 
P la te le t aggregate ra tios - standardisation of technique and 
tes t resu lts  in patients with myocardial ischemia and cerebro­
vascular disease.
Thrombosis and Haemostasis, 38, 597-605.
Prentice, CRM,  Turpie, A G G, Hassanein, A A, McNicol, C P and 
Douglas, A S (1969)
Changes in p la te le t  behaviour during arvin therapy.
Lancet, 1 645-647. '
382
Preston, F E, Ward, J 0, Marcola, B H, Porter, N R, Timperley, W R, 
O'Malley, B C (1978)
Elevated B-thromboglobulin  levels and c ircu la t in g  p la te le t  
aggregartes in d ibe tic  microangiopathy.
Lancet, 1, 238-240.
Preston, F E, Burakowski, B K, Porters, N R and Mali a, R G (1981) 
The f ib r in o ly t i c  response to stanozolol in normal subjects. 
Thrombosis Research, 22, 543-551.
Pritchard , J A, Weisman, R, Ratnoff, 0 0 and Vosburgh, G J (1954) 
Intravascular hemolysis, thrombocytopenia and other hematologic 
abnormalities associated with severe toxemia of pregnancy.
New Engl and Journal o f Medicine, 250, 89-98.
Prowse, C V, Mattock, P, Esnouf, M P and Russell, A M (1976)
A variant of prothrombin induced in c a t t le  by prolonged 
adm inistra tion of warfarin .
Biochimica et Biophysica Acta, 434, 265- 279.
Prowse, C V, Vigano, S, Borsey, D Q and Dawes, J (1980)
The release of beta-thromboglobulin from p la te le ts  during the 
c lo t t in g  of whole blood.
Thrombosis Research, 17, 433-442.
Prowse, C V, Dawes, J, Lane, D A, Ire land, H and Knight I (1982) 
Proteolysis of f ibrinogen in healthy volunteers fo llow ing 
Major and minor in vivo plasminogen ac t iva t io n .
Thrombosis Research, 27, 91-97.
Pumphrey, C W, Pepper, D S and Dawes, J (1979)
Heparin-PFi^ pulsing as a measure of p la te le t-endo the lia l 
c e l l  reaction in vivo.
Thrombosis and Haemostasis, 42, Abstract No 0090.
Pumphrey, C W and Dawes, J (1981)
Elevation of plasma B-thromboglobulin in patients with 
prosthetic  cardiac valves.
Thrombosis Research, 22, 147- 155.
Quick, A J (1943)
On the co n s t itu t io n  of prothrombin. 
American Journal of Physiology, 140, 212-220.
383
R adc lif fe , R and Nemerson, Y (1975)
Activation and control o f Factor VII by activated Factor X 
and thombin. Iso la tion  and characterization of a single 
chain form of fa c to r  V II.
Journal o f B io log ica l Chemistry, 250, 388-395.
Radegran, K, Aren, C and Teger-Nilsson, A C (1982)
Prostacyclin in fusion during extracorporeal c irc u la t io n  fo r  
coronary bypass.
Journal o f Thoracic and Cardiovascular Surgery, 205-211.
Rakoczi, I ,  T a l l ia n ,  F, Bagdany, S and Gati, I (1979)
P la te le t l i fe -span  in  normal pregnancy and pre-eclampsia 
as determined by a non-radioisotope techniaue.
Thrombosis Research, 15, 553-556.
Rapaport, S I ,  Schiffman, S, Patch, M J, Ames, S B (1963)
The importance of ac t iva t ion  of antihaemophilic g lobulin  and 
proaccelerin by traces of thrombin in the generation of in t r in s ic  
prothrombin a c t iv i t y .
Blood, 21, 221-236.
Rasi, V, T o rs t i la ,  I and Ikkala , E (1980)
yS-thromboglobulin in  acute myocardial in fa rc t io n .
Acta Medica Scandinavica ( Suppl ) 642, 85-91.
Ratnoff, 0 D and Rosenblum, J H (1959)
Role of Hageman Factor in the in i t ia t io n  of c lo t t in g  by glass. 
Evidence tha t glass frees Hageman fac to r from in h ib i t io n .
American Journal o f Medicine, 25, 160-168.
Ratnoff, 0 D, Busse, R J and Sheon, R P (1968)
The demise of John Hageman.
New Engl and Journal o f Medicine, 279, 760-761.
Ratnoff, 0 D, Kass, L and Lang, P D (1969)
Studies on the p u r i f ic a t io n  of antihemophilic fa c to r  (Factor V I I I ) .  
I I .  Separation of p a r t ia l ly  pu r if ied  antihemophilic fac to r by 
gel f i l t r a t i o n  of plasma.
Journal o f C lin ica l Investiga tion 48, 957-962.
Ratnoff, 0, D (19077)
The haemostatic defects of l i v e r  disease.
Haemostasis: Biochemistry, Physiology and Pathology
eds. Ogston, D and Bennet, B. London: John Wiley and Sons, 446-465.
384
Redman, C W G, A l l in g to n , M J , Bolton, F G and S t i r r a t ,  G M (1977)
Plasma B-thromboglobulinin pre-eclampsia.
Lancet I I , 248.
Reekers, P P M,  Lindhout, M J , Kop-Klaason, B H M and Hemker, H C (1973) 
Démonstration of three anomalous plasma proteins induced by a 
vitamin K agonist.
Biochimica et Biophysica Acta, 317, 559-562.
R e i l ly ,  D T, Burden, A C and Fossard, D P (1980)
F ib r ino lys is  and the prediction of deep vein thrombosis.
B r i t is h  Journal o f Surgery, 67, 6 6 - 6 8 .
Remuzzi, G, Cavenaghi, A E, Mecca, G, Donati, M B and de Gaetano, G (1977) 
Prostacyclin (PGI% ) and bleeding time in uremic patients
Thrombosis Research, 11, 919-920.
Revak, S D, Cochrane, C G, Johnston, A R and Hugli, T E (1974)
Structura l changes accompanying enzymatic ac t iva t ion  of human 
Hageman fac to r .
Journal o f C lin ica l Inve s t iga t ion , 54, 619-627.
Rezvan, H and Howell, R M (1977)
Protein-magnetic-resonance studies of the in te rac t io n  of 
thromboplastin apoprotein with l ip id s .
Biochemical Society Transactions, _5, 1549-1551.
Richardson, B W (1858)
The cause of the coagulation of the blood
C hurch il l ,  London.
Rick, M E and Hoyer, L W (1973)
Immunologic studies of antihemophilic fa c to r  (AHF Factor V I I I ) .
V. Immunologic properties of AHF subunits produced by s a l t  
di ssoci a tion.
Blood, 42, 737-747.
385
Riddle, J M and Barnhardt, M I (1964)
U ltras truc tu ra l study of f i b r in  d isso lu tion via emigrated 
polymorphonuclear neutrophils.
American Journal o f Pathology, 45, 805-823.
Rijken, D C, Wijngaards, G, Zaal-de-Jong, M and Welbergen, J (1979)
P u r if ica t io n  and pa rt ia l characterisation of plasminogen ac t iva to r  
from human uterine t issue.
Biochimica et Biophysica Acta, 580, 140-153.
Ring, C P, Pearson, T C, Sanders, M D and Weatherley-Mein, G (1976) 
V iscosity  and re t in a l vein thrombosis.
B r i t is h  Journal o f Ophthalmology, 60, 397-410.
Robbins, K C, Summaria, L, Hsiew, B and Shah, R J (1967)
The peptide chains of human plasmin. Mechaniism of ac tiva tion  
of human plasminogen to plasmin.
Journal o f B io log ica l Chemistry, 242, 2333-2342.
Robbins, J C, Summaria, L and Barlow, G H (1975)
Activa tion  of plasminogen.
In Proteases and Biologica l Contro l.
ecT. Reich, E. Cold Spring Harbour. Conferences on Cell P ro l i fe ra t io n .
2, 305-310.
Robb-Smith, A H T (1967)
Why the p la te le ts  were discovered. 
B r i t is h  Journal of Haematology, 13, 618-637.
Roddie, I C, Shepherd, J T and Whelan, R F (1955)
Action of 5-hydroxytryptamine on the blood vessels of the 
human hand and forearm.
B r i t is h  Journal o f Pharmacology, 10, 445-450.
386
Rosenberg, J S, McKenna, P W and Rosenberg, R D (1975)
In h ib it io n  of human fac to r  IXA by human antithrombin.
Journal o f B io log ica l Chemistry, 250, 8883-8888.
Ross, R, Glomset, J , Kariya, B and Marker, L (1974)
A platelet-dependent serum fa c to r  tha t stimulates the 
p ro l i fe ra t io n  of a r te r ia l  smooth muscle ce l ls  in v i t r o .
Proceedings o f the National Academy o f Science ( USA) , _71, 1207-1210.
Ross, R and Glomset,- J A (1976)
The pathogenesis of atherosclerosis.
New Engl and Journal o f Medicine, 295, 369-377; 420-425.
Ross, R, Glomset, J and Marker, L (1977)
Response to in ju ry  and atherogenesis.
American Journal o f Pathology, 8 6 , 675-684.
Rowley, J M and Hampton, J R (1981)
Diagnostic c r i t e r ia  fo r  myocardial in fa rc t io n .
B r i t is h  Journal o f Hospital Medicine, 26, 253- 258.
van Royen, E A, T re ffe rs , D E and ten Cate, J W (1974)
Hypertonic saline induced abortion as pathophysiologic model 
o f low grade in travascu lar coagulation.
Scandinavian Journal o f Haematology, 13, 166-174.
Rucinski, B, Niewiarowski, S, James, P, Walz, D A and Budzynski, A Z, 
(1979)
Antiherparin  proteins secreted by human p la te le ts .
P u r i f ic a t io n ,  characterisation and radioimmunoassay.
Blood, 53, 47-62.
Rutherford, R B and Ross, R (1976)
P la te le t factors stimulate f ib ro b la s ts  and smooth muscle 
ce lls  quiescent in  plasma serum to  p ro l i fe ra te .
Journal o f Cel 1 B io logy, 69, 196- 203.
387
Ryo, R, P r o f f i t t ,  R T and Devel, T F (1980)
Human p la te le t  fa c to r  4: Subcellu lar lo c a liz a t io n  and
cha rac te r is t ics  of release from in ta c t p la te le ts .  
Thrombosis Research, 17, 629-644.
Saito, H, Ratnoff, 0 D, Marshall, J S, Pensky, J (1973)
Partia l p u r i f ic a t io n  of plasma thromboplastin antecedent 
(Factor XI) and i t s  ac tiva tion  by tryp s in .
Journal o f C lin ica l Inve s t iga t ion , 52, 850-861.
Saito, H, Ratnoff, 0 D, Waldman, R and Abraham, J P (1975)
Fitzgera ld T ra i t :  Deficiency of a h ithe rto  unrecognised agent,
F itzgera ld  Factor, pa rt ic ipa t ing  in surface-mediated reactions 
of c lo t t in g ,  f in r in o ly s is ,  generation of k in ins and the property 
o f d ilu ted  plasma enhancing vascular permeability (PF/DIL)
Journal o f C lin ica l Inve s t iga t ion , 55, 1082-1089.
Salmon, J and Bonameaux, Y (1958)
Etudes des anti genes piaquettaires e t ,  en p a r t ic u l ie r ,  
du f i b r i nogene.
Thrombosis et Diathesis Haemorrhagica, _2, 93-110.
Salzman, E W and Levine, L (1971)
Cyclic 3 ' ,  5' -  Adenosine monophosphate in human blood p la te le ts  
I I  E ffect o f N - 2 '0-Dibutryl cyc l ic  3 ' ,5 * -Adenosine monophosphate 
on p la te le t  function .
Journal o f C lin ica l Inve s tiga tion , 50, 131-141.
Salzman, E W (1971)
Non-thrombogenic surfaces: C r i t ic a l review.
Blood, 509-523.
Salzman, E W (1972a)
Cyclic AMP and p la te le t  function.
New Engl and Journal o f Medicine, 286, 358-363.
Salzman, E W (1972b)
Surface e ffec ts  in haemostasis and thrombosis.
In The Chemistry o f Biosurfaces.
eds. Hair, M L. New York: Marcel Dekker Inc. 2, 489.
388
Sandbjerg-Hansen, M and Clemmensen, I (1980)
Partia l p u r i f ic a t io n  and characterisation of a new fas t-ac t in g  
plasmin in h ib i to r  from human p la te le ts .  Evidence fo r  non- 
id e n t i ty  with the known plasma proteinase in h ib i to rs .  
Biochemical Journa l, 187, 173-180.
Sasaki, T, Page, I H and Shainoff, J R (1966) 
Stable complex of f ibr inogen and f ib r in .  
Science, 152, 1069-1071.
Schernthaner, G, Sinzinger, H, Silberbauer, K, Frey ler, H,
Muhlhauser, I and Kaliman, J (1981)
Vascular prostacyc lin , p la te le t  s e n s i t iv i ty  to prostaglandings 
and p la te le t  spec if ic  proteins in diabetes m e ll i tu s .
In Pathogenetic Concepts o f Diabetic Microangiopathy.
eïïs. P fe i f fe r ,  E F, R a il ,  J E. S tu ttg a rt ,  New York: Georg Thieme
Verlag, 33-42.
Schiffman, S and Lee, P (1974)
Preparation, characterisation and ac tiva t ion  of a h ighly 
pu r if ied  fa c to r  XI: Evidence that a higherto unrecognised
plasma a c t iv i t y  pa rt ic ipa tes in the in te rac tion  of factors 
XI and X II .
B r i t is h  Journal o f Haematology, 27, 101-114.
Schwartz, M L, Pizzo, S V, H i l l ,  R L and McKee, P A (1973)
Human Factor X I I I  from plasma and p la te le ts .  Molecular weights 
Subunit s truc tures, p ro teo ly t ic  a c t iva t io n ,  and c ross-l ink ing  of 
fib r inogen and f ib r in .
Journal o f B io logica l Chemistry, 248, 1395-1407.
Schwartz, R,Greston, W and K le iner, G J (1972)
D efib r ina tion  in saline abortion.
Obstetrics and Gynaecology, 40, 728-737.
Schwartz, M B, Hawiger, J, Timmons, S and Fries inger, G C (1980) 
P la te le t aggregates in  ischemic heart disease.
Thrombosis and Haemostasis, 43, 185-188.
Schoenmakers, J C G, Matze, R, Haanen, C and Z i l l i k e n ,  F (1965)
Hageman fa c to r ,  a novel s ia log lycoprote in with esterase a c t iv i ty ,  
Biochemica et Biophysica Acta, 101, 166-176.
389
Seamen, A J (1970)
The recognition of in travascu lar c lo t t in g .  The plasma 
protamine paracoagulation te s t .
Archives o f Internal Medicine, 125, 1016-1021.
Seegers, W F, N ie ft ,  M L and Vanderbelt, J M (1945)
Decomposition products of fibrinogen and f i b r in .
Archives o f Biochemistry, 76, 15-19.
Seegers, W H, Cole, E R, Harmison, C R and Monkhouse, F C (1964)
Neutra lization of autoprothrombin C a c t iv i t y  with antithrombin.
Canadian Journal o f Biochemistry, 42, 359-364.
Seegers, W H, Novoa, E, Henry, R L, Hassouna, H I (1976)
Relationship of 'new' vitamin K - dependant prote in C and 'o ld ' 
autoprothrombin I l - a .
Thrombosis Research, 543-552.
Seegers, W H, Marlar, R A and Walz, D A (1978)
Anticoagulant e ffec ts  of autoprothrombin I I-A  and 
prothrombin fragment I .
Thrombosis Research, 13, 233-243.
Semar, M, Skoza, L and Johnson, A J (1969)
Partia l p u r i f ic a t io n  and properties of a plasminogen ac tiva to r 
from human erythrocytes.
Journal o f C lin ica l Inve s t ig a t io n , 48, 1777-1785.
Serneri, G G N, Gensini, G F, Abbate, R,. Mugnaini, C, F a v i l la ,  S,
B ru n e i l i ,  C, Chierchia, S and Parodi, 0 (1981)
Increased f ib r in op ep tid e  A formation and thromboxane A 
production in patients with ischemic heart disease:
Relationships to coronary pathoanatomy, r is k  fa c to rs , and 
c l in ic a l  manifestations.
American Heart Journa l. 101, 185-194.
S e v it t ,  S and Gallagher, N (1961)
Venous thrombosis and pulmonary embolism. A c l in ico -pa tho log ica l 
study in  in ju red and burned patients.
B r i t is h  Journal o f Surgery, 48, 475-489.
Shainoff, J R and Page, I M (1960)
Cofibrins and f i b r in  intermediates as ind ica tors  of thrombin 
a c t iv i t y  in vivo.
C ircu la tion  Research, 1013-1022.
Shainoff, J R and Page, I H (1962)
S ignificance of c ryo p ro fib r in  in f ib r in o g e n - f ib r in  conversion.
Journal o f Experimental Medicine, 116, 687-707.
390
Shapiro, S S, Martinez, J and Holburn, R R (1969)
Congenital dysprothrombinemia: An inherited  s truc tu ra l
disorder of human prothrombin.
Journal o f C lin ica l Inve s t iga t ion , 48, 2251- 2259.
Sharp, A A (1977)
Diagnosis and management of disseminated in travascu lar coagulation
B r i t is h  Medical B u l le t in , 33, 265-272.
Shimamoto, T, Kobayashi, M, Takahashi, T, Takashima, Y, Sakamoto, M
and Morooka, S (1978)
An observation of thromboxane A% in a r te r ia l  blood a f te r  
cholesterol feeding in rabb its .
Japanese Heart Journa l, 19, 748-753.
Sherman, L A (1982)
F ib r in o g e n /f ib r in  fragments in uremia.
Thrombosis Research, 27, 625-626.
Shulman, S (1959)
The size and shape of bovine fibrinogen studies of sedimentation, 
d if fu s ion  and v iscos ity .
Journal o f the American Chemical Society, 75, 5846-5852.
Sixma, J J (1978)
Techniques fo r  diagnosing prethrombotic states: A review.
Thrombosis and Haemostasis, 40, 252-259.
S la te r , T F (1972)
Free Radical Mechanisms in  Tissue In ju ry , 
London: Academic Press.
Small, M, Jack, A S, Lowe, GDC,  Mutch, A F, Forbes, C D and 
Prentice, C R M  (1983a)
Coronary artery  disease in  severe haemophilia.
B r i t is h  Heart Journa l, 49, 604-607.
Small, M, Douglas, J T, Lowe, G D 0 and Forbes, C D (1983b)
Increased plasmin a c t iv i t y  during stanozolol administration 
Lancet 1_, 1114 ( L e t te r )
391
Small, M, McArdle, B M, Lowe, G D 0, Brodie, M J , Forbes, C D
and Prentice, CRM (1983b)
Oral stanozolol: E ffects on plasma and saliva f ib r in o ly s is
and plasma v iscos ity  in  normal males.
Thrombosi s Research ( i n Press)
Smith, R C, Duncanson, J, Ruckley, C V, Webber, R G, A llan , N C,
Dawes, J, Bolton, A E, Hunter, W M, Pepper, D S, Cash, 0 D (1978) 
B-Thromboglobulin and deep vein thrombosis.
Thrombosis and Haemostasis, 39, 338-345.
Smith, E B, Staples, E M, D ietz, H and Smith, R H (1979)
Role of endothelium in sequestration of l ipop ro te in  and fibr inogen 
in  ao rt ic  lesions, thrombi and g ra f t  pseudo-intimas.
Lancet I I , 812.
Smitherman, T C, Milam, M, Woo, J, W illerson, J T and Frenkel, E P (1981)
Elevated betathromboglobulin in peripheral venous blood of
patients with acute myocardial ischemia: D irect evidence fo r
enhanced p la te le t  re a c t iv i ty  in vivo.
American Journal o f Cardiology, 48, 395-402.
Sobel, G W, Mohler, S R, Jones, N W, Dowdy, A B and Guest, M M (1952)
Urokinase: An a c t iva to r  of plasma p ro f ib r in o ly s in  extracted
from urine.
American Journal o f Physiology, 171, 768-769.
Soria, J, Soria, C and Caen, J P (1983)
A new type of congenital dysfibrinogenaemia with defective
f i b r in  ly s is  -  Dusard syndrome: possible re la t io n  to thrombosis.
B r i t i  sh Journal o f Haematology, 53, 575-586.
Spragg, J, Kaplan, A P and Austen, K F (1973)
The use of is o -e le c t r ic  focusing to study components of the 
human kin in-form ing system.
Annals o f  the New York Academy of Sciences, 209, 372-386.
Stachurska, J , L a ta l lo ,  Z S and Kopec, M (1970)
In h ib i t io n  of p la te le t  aggregation by d ia lysable fibrinogen 
degradation products (FDP)
Thrombosis et Diathesis Haemorrhagica, 23, 91-98.
Stander, R W, Flessa, H C, Glueck, H I and Kischer, C T (1971)
Changes in  maternal coagulation factors a f te r  in t ra  amniotic 
in je c t io n  of hypertonic sa line .
Obstetrics Gynecology, 37, 660-666.
39 2
Stead, N, Kaplan, A P and Rosenberg, R D (1976)
In h ib it io n  of activated fa c to r  XII by antithrombin-heparin cofactor.
Journal o f B io log ica l Chemi s t r y , 251, 6481-6488.
Steele, P P, Weily, H S and Genton, E (1973)
P la te le t survival and adhesiveness in recurrent venous thrombosis.
New England Journal o f Medicine, 288, 1148-152.
Steele, P P, Weily, H S, Davies, H and Genton, E (1974)
P la te le t surviva l in patients with rheumatic heart disease.
New England Journal o f Medicine, 290, 537-539.
Steele, P, Battock, D and Genton, E (1975)
Effects of c lo f ib ra te  and sulfinpyrazone on p la te le t  survival 
time in coronary a r te ry  disease.
C irc u la t io n , 52, 473-476.
Stemerman, M B (1974)
Vascular intimai components: precursors of thrombosis.
In Progress in Hemostasis and Thrombosis.
ed. Spaet, T H. New York: Grune and S tra tton , 2, 1.
Stewart, G J (1971)
An electron microscope study o f the polymerization of fibrinogen 
and i t s  de r iva t ives .
In Fibrinogen Degradation Products.
eds. Verstraete, M, Vermylen, J , Donati, M. Copenhagen, Munksgaard, 165.
Stewart, M E, Douglas, J T, Lowe, G D 0, Prentice, C R M  and
Forbes, C D (1983)
Prognostic value of beta-thromboglobulin in patients with trans ien t 
cerebral ischaemia.
Lancet I I , 479-482.
S tuart, M J , Murphy, S and Oski, F A (1975)
A simple non radioisotope technic fo r  the determination of p la te le t  
l i  fespan.
New England Journal o f Medicine, 292, 1310-1313.
Svendsen, L, Blomback, B, Blomback, M and Olsson, P (1972)
Synthetic chromogenic substrates fo r  determination of t ryp s in , 
thrombin, and throm bin-like  enzymes.
Thrombosis Research, _1, 267-278.
Svensson, J, Hamberg, K and Samuelsson, B (1975)
Prostaglandin endoperoxides ,IX. Characterization of rabbit 
aorta contracting substance (RCS) from guinea pig lung and 
human p la te le ts .
Acta Physiologica Scandinavica, 94, 222-228.
393
Szczeklik, A, Gryglewski, R J, Musial, J, Grodzinska, L, Serwonzka, M, 
and Marcinkiewicz, E (1978)
Thromboxane generation and p la te le t  aggregation in  surviva ls 
of myocardial in fa rc t io n .
Thrombosis and Haemostasis, 40, 66-74.
Taberner, D A, Ralston, J and A c k r i l l ,  P (1981)
Acquired alphaz -antip lasmin defic iency in glomerular prote inuria  
B r i t is h  Medical Journa l, 282, 1121.
Takaki, A, Yamaguchi, T and Oshato, K (1974)
K in in-1 ike a c t iv i t ie s  of the synthetic low molecular weight 
fragment of fib r inogen degradation products.
Thrombosis et Diathesis Haemorrhagica, 32, 350-355.
Tateson, J E, Moncada, A S and Vane, T R (1971)
Effects of prostacyclin  (PGX) on cyc l ic  AMP concentrations in  
human p la te le ts .
Prostaglandins 13, 389-397.
Teger-Nilsson, A C and Grondahl, N J (1974)
A search fo r  f ib r inopeptides in urine during experimental 
in travascu lar coagulation in dogs.
Thrombosis Research, 4, 131-136.
Thackrah, C T (1819)
An enquiry in to  the nature and properties of the blood as 
existant in health and disease.
Cox, London.
Thomas, D J, Du Boulay, G H, Marshall, J , Pearson, T C, Russell, R W, 
Symon, L, Wetherley-Mein, G and Z ilkha, E (1977)
Effect of haematocrit on cerebral blood flow in man.
Lancet, I I ,  941-943.
Thomas, A M, Hytten, F E, and B i l l ie w ic z ,  W Z (1967)
The epidemiology of oedema during pregnancy.
Journal of Obstetrics and Gynaecology o f the B r i t is h  Commonwealth 
74, 1-10.
394
Thomson, C, Forbes, C D, Prentice, C R M and Kennedy, A C (1974) 
Changes in blood coagulation and f ib r in o ly s is  in the 
nephrotic syndrome.
Quarterly Journal of Medicine, 43, 399- 407.
Thorsen, S (1975)
Differences in the binding to f ib r in  of native plasminogen and 
plasminogen modified by p ro teo ly t ic  degradation. Influence of 
omega-aminocarboxylic acids.
Biochimica et Biophysica Acta, 393, 55-65.
Thornton, C A and Bonnar, J (1978)
Factor V l l l - re la te d  antigen and fac to r V I I I  coagulant a c t iv i t y  
in normal pregnancy, pre-eclampsia and abruptio placentae.
In Pregnancy Hypertension
ed. Bonnar, J , M acGillivray. I ,  Symond, S E M. Lancaster, England:
MTP Press Limited, 419-425.
T i ta n i ,  K, Hermodson, M A, Fujikawa, K, Ericsson, L H, Walsh, K A, 
Neurath, H and Davie, E W (1972)
Bovine fac to r  X la (activated Stuart fac to r) evidence of 
homology with mammalian serine proteases.
Biochemi s t r y , 11, 4899-4903.
Tocantins, L M (1949)
H is to r ica l notes on blood p la te le ts .
Geore ^  Mi not Symposiurn of Haematology
eds. Dameshek, W, Taylor, F A L. New York: Grune and S tra tton .
988, 533-562.
Todd, A S (1959)
The h is to log ica l lo ca lisa t io n  of f ib r in o ly s in  a c t iva to r .
Journal of Pathology and Bacterio logy, 78, 281- 283.
Tomura, S, Ida, T, Kuriyama, R, Chida, Y, Takeuchi, J , Motomiya, T
and Yamazaki, H (1982)
Activa tion  of p la te le ts  in patients with chronic p ro l i fe ra t iv e  
glomerulonephritis and the nephrotic syndrome.
C lin ica l Nephrology, 17, 24-30.
Torngren, S, Noren, I nd Savidge, G (1979)
The e ffec t of low-dose heparin on fib r inopep tide  A, p la te le ts ,  
fibr inogen degradation products and other haemostatic parameters 
measured in connection with in te s t in a l surgery.
Thrombosis Research, 14, 871-879.
395
Tremoli, E, Maderna, P, S i r t o r i ,  M and S i r t o r i ,  C R (1979)
Malondialdehyde formation in type I la hypercholesterolemia patients
Haemostasis, S,  47-53.
Trope, G E, Lowe, G D 0, McArdle, B M, Douglas, J T, Forbes, C D,
Prentice, C M and Foulds, W S (1983)
Abnormal blood v iscos ity  and haemostasis in long-standing re t ina l 
vein occlusion.
B r i t is h  Journal o f Ophthalmology, 67, 137-142.
Tschopp, T B and Baumgartner, H R (1976)
Enzymatic removal of ADP from plasma: unaltered p la te le t  adhesion
but reduced aggregation on subendothelium and collagen f i b r i l s .
Thrombosis and Haemostasis, 35, 334-341.
T u r r i t to ,  V T and Baumgartner, H R (1975)
P la te le t in te rac t io n  with subendothelium in  a perfusion system; 
Physical ro le  of red blood c e l ls .
Microvascular Research, £ , 335- 344.
T u r i t to ,  V T, Muggli, R and Baumgartner, H R (1977)
Physical factors influencing p la te le t  deposition on 
subendothelium: importance of blood shear ra te .
Annals o f the New York Academy o f Sciences, 283, 283-292.
Turpie, A G G, de Boer, A C, Genton, E, Butt, R, Han, P and
Gunstensen, T (1981)
P la te le t survival time and betathromboglobulin in cardiac 
valve replacement.
American Journal o f Cardiology, 47, 498.
Turpie, AG G, de Boer, A C and Genton, E (1982)
P la te le t consumption in  cardiovascular disease.
Seminars in Thrombosis and Hemostasis, B,  161-185.
Varandeus, J (1619)
Haemostatic changes associated with pre-eclampsia and hormone 
therapy.
Cited by Howie, P. W j j i  ^  Thesis 4063, Univers ity  o f Glasgow, 1974.
Vermylen, J , Donati, M B and Verstraete, M (1971)
The id e n t i f ic a t io n  of fibrinogen derivatives in plasma and 
serum by agarose gel f i l t r a t i o n .
Scandinavian Journal o f Haematology, (Suppl) 13, 219-223.
V ic ic ,  W J, Lages, B and Weiss, H J (1980)
Release of human p la te le t  Factor V a c t iv i t y  is  induced by both 
collagen and ADP and is  inh ib ited  by asp ir in .
Blood, 448-455.
396
Virchow, R L (1863)
C e llu la r pathology as based upon physiological and pathological
h is to logy .
2nd ed it ion  (Trans) by Chance, F. Philadelphia, J B L ipp inco tt.
Voisin, P, Rouselle, D, Guimont, C, Drouin, P and S to l tz ,  J F (1981) 
Evolution of BTG level in d iabetic patients undergoing 
a r t i f i c i a l  pancreas treatment.
Thrombosis and Haemostasis, 46, Abstract No 1414.
Wagner, R H, Cooper, H A and Owen, W G (1973)
Dissociation of antihaemophilic fac to r and separation of a small
active fragment
Thrombosis et Diathesis Haemorrhagica, (Suppl) 54, 185.
Walker, I D and Davidson, J F (1978)
Longterm f ib r in o ly t i c  enhancement with anabolic steroid therapy:
A f iv e  year study.
Progress in Chemical F ib r in o lys is  and Thrombolysis
eds Davidson, J F, Rowan, R M, Samama, M M, Des Noyers, P C.
New York: Raven Press, Vol. 3, 491-499.
Walker, I D, Davidson J F, Faichney, A, Wheatley, D J and Davidson, K G
(1981)
A double-blind t r i a l  of prostacyclin in pulmonary bypass surgery.
B r i t is h  Journal o f Haematology, 49, 415-423.
Wallen, P and Wiman, B (1970)
Characterisation of human plasminogen,IJDn the re la tionsh ip  
between d i f fe re n t  molecular forms of plasminogen demonstrated 
in  plasma and found in pu r if ied  preparations.
Biochimica et Biophysica Acta, 221, 20-30.
Walsh, P N (1972a)
The role of p la te le ts  in the contact phase of blood coagulation.
B r i t is h  Journal o f Haematology, 22, 237-254.
Walsh, P N (1972b)
The e ffec ts  of collagen and kaolin on in t r in s ic  coagulation 
a c t iv i t y  of p la te le ts . Evidence fo r an a lte rna t ive  pathway in  
in t r in s ic  coagulation not requiring fac to r X I I .
B r i t is h  Journal o f Haematology, 22, 393-405.
Walsh, P N (1973)
P la te le t coagulant a c t iv i t ie s :  Evidence fo r  m u lt ip le  d if fe re n t
functions of p la te le ts  in in t r in s ic  coagulation.
Series Haematol ogica, §_, 579-592.
397
Walsh, P N (1974)
P la te le t coagulant a c t iv i t ie s  and thrombosis: A hypothesis
Blood, 43, 597-605.
Walsh, P N, P a re ti,  F I and Corbett, J J (1976)
P la te le t coagulant a c t iv i t ie s  and serum l ip id s  in tra ns ien t 
cerebral ischaemia.
New Engl and Journal of Medicine, 295, 854-858.
Walsh, P N, Rogers, P H, Marder, V J, Gagnate lli, G, Escovitz, E S 
and Sherry, S (1976)
The re la t ionsh ip  of p la te le t  coagulant a c t iv i t ie s  to venous 
thrombosis fo llowing hip surgery.
B r i t is h  Journal o f Haematology, 32, 421-437.
Walsh, P N, Goldberg, R E, Tay, R L and Magargal, L E (1977)
P la te le t coagulant a c t iv i t ie s  and re t ina l vein thrombosis. 
Thrombosis and Haemostasis, 38, 399-406.
Walter, E, Deppermann, D, Andrassy, K and Koderisch, J (1981)
P la te le t hyperaggregability as a consequence of the nephrotic 
syndrome.
Thrombosis Research, 23, 473-479.
Wass, V and Cameron, J S (1981)
Cardiovascular disease and the nephrotic syndrome: the other
side of the coin.
Nephron, 27, 58-61.
Weily, H S, Steele, P P, Davies, H, Pappas, G and Genton E (1974)
P la te le t surviva l time in patients with substitu te  heart valves 
New England Journal of Medicine, 290, 534-537.
Weisel, J W, P h i l l ip s ,  G N and Cohen, C (1981)
A model from electron microscopy fo r  the molecular s tructure  of 
fibr inogen and f i b r in .
Nature, 289, 263-267.
398
Weiss, A E, Easterling, W E, Odoni, M H, McMillan, C W, Johnson, A M 
and Ta lbert, L M (1972)
D efib r ina tion  syndrome a f te r  in tra-am nio tic  in fusion of hypertonic 
s a l ine.
American Journal o f Obstetrics and Gynaecology, 113, 868-874.
Weiss, H J, Baumgartner, H R, Tschopp, T B, T u r i t to ,  V T and 
Cohen, D (1978)
Correction by fac to r  V I I I  of the impaired p la te le t  adhesion 
to sub-endothelium in von Willebrand disease.
Blood, 51, 267-279.
Weiss, H J, W itte, L D, Kaplan, K L, Lages, B A, Chernoff, A, 
Nossel, H L, Goodman, D S and Baumgartner, H R (1979)
Studies on granule-bound substances in 18 patients including 
variants de fic ien t in  a-granules, p la te le t  fa c to r  4 , beta­
thromboglobulin and p la te le t  derived growth fa c to r .
Blood, 54, 1296-1319.
Wessler, S and Yin, E (1968)
Experimental hypercoagulable state induced by fa c to r  X. 
Comparison of the non activated and activated forms. 
Journal of Laboratory and C lin ica l Medicine, 72, 256-260.
Whigham, K, Howie, P W, Drummond, A H and Prentice, CRM (1978) 
Abnormal p la te le t  function in pre-eclampsia.
B r i t is h  Journal of Obstetrics and Gynaecology, 85, 28-32.
White, A M and H e p t in s ta l l ,  S (1978)
Contribution of p la te le ts  to thrombus formation. 
B r i t i  sh Medical B u l le t in ,  34, 123-128.
White, G C and Marouf, A A (1981)
P la te le t fa c to r  4 levels in patients with coronary a rte ry  disease, 
Journal o f Laboratory and C lin ica l Medicine, 97, 369-378.
Wilner, G D, Nossel, H L and Leroy, E C (1968)
Activa tion  o f Hageman fac to r by collagen.
Journal o f C lin ica l Inve s t iga t ion , 47, 2608-2615.
Wilner, G D and Birken, S (1975)
Synthesis and radioimmunoassay of canine f ib r inopep tide  A 
Thrombosis Research, 7, 753-763.
399
Wilner, G D, Nossel, H L, Canfield, R E and B u tle r , V P (1976)
Immunochemical studies of human f ib r inopep tide  A using synthetic 
peptide homologues.
Biochemistry, 15, 1209-1213.
Wilner, G D (1980)
Molecular basis fo r  measurement of c irc u la t in g  fibrinogen 
de riva tives .
In Progress in Hemostasis and Thrombosis 
ed Sppaet, T H. Grune and S tra tton , 4, 211-248.
Wiseman, R (1686)
Several Chirurgical Treatises, 
eds. Norton, R and Macock, J. London, 1,64.
W itte , L D, Kaplan, K L, Nossel, H L, Lages, B A, Weiss, H J and 
Goodman, 0 S (1978)
Studies of the release from human p la te le ts  of the growth 
fac to r  fo r  cultured human a r te r ia l  smooth muscle c e l ls .  
C ircu la tion  Research, 42, 402-409.
de Wood, M A, Spores, J, Notske, R, Mouser, L T, Burroughs, R, 
Golden, M S and Lang, H T (1980)
Prevalence of to ta l coronary occlusion during the early hours 
of transmural myocardial in fa rc t io n .
New England Journal o f Meicine, 303, 897-902.
Woolf, N (1978)
Thrombosis and atherosclerosis. 
B r i t is h  Medical B u l le t in ,  34, 137-142.
Wu, K K and Hoak, J C (1974)
A new method fo r  the quantita t ive  detection of p la te le t  
aggregates in patients with a r te r ia l  in s u ff ic ie n c y . 
Lancet I I ,  924-926.
Wu, K K, Armstrong, M L, Hoak, J C and Megan, M B (1975)
P la te le t aggregates in hypercholesterolemic rhesus monkeys. 
Thrombosis Research, 7, 917-924.
Wuepper, K 0 (1972)
Inflammation, Mechanisms and Contro l.
eds. Lepow, I W and Ward, P A. New York: Academic Press, 93.
400
Yalow, R S and Berson, S A (1960)
Immunoassay of endogenous plasma insu lin  in man.
Journal o f C lin ica l Inve s t iga t ion , 39, 1157-1175
Yoda, Y and Abe, T (1981)
Fibrinopeptide A (FPA) level and fibrinogen k ine tics  in patients 
with malignant disease.
Thrombosis and Haemostasis, 46, 706-709.
Yudelman, I ,  Spanondis, K and Nossel, H L (1974)
Comparative behaviour of *^®I-fibrinogen and '"^^ I- f ib r in  in 
so lu tion.
Thrombosis Research, 5,  495-509.
Yudelman, I ,  Nossel, H L, Kaplan, K L and Hirsh, J (1978)
Plasma f ib r inopeptide  A in  symptomatic venous thromboembolism. 
Blood, 1189-1195.
Yudelman, I and Greenberg, J (1982)
Factors a ffec t ing  f ib r inopeptide  A levels in patients with venous 
thromboembolism during anticoagulant therapy.
Blood, 59, 787-792.
Zahavi, J, Celia, G, Dubiel, M and Kakkar, V V (1978)
The v a r ia b i l i t y  of plasma beta-thromboglobulin in  healthy 
i nd ividuals.
Thrombosis and Haemostasis, 40, 565-567.
Zahavi, J , Jones, NA G,  Betteridge, D J, Leyton, J , Galton, D J, 
Clark, S E and Kakkar, V V (1979)
P la te le t Factor 4, B-thromboglobulin. Malondialdehyde 
formation, and blood l ip id s  in patients with diabetes m e ll i tu s . 
Thrombosis and Haemostasis, 42, Abstract No 0794.
Zahavi, J, Hamilton, WAP,  O 'R e il ly , M J G, Clark, S E, Cotton, L T 
and Kakkar, V V (1979)
Abnormal p la te le t  function in Raynaud's phenomenon.
Thrombosis and Haemostasis, 42, Abstract No 0344.
Zahavi, J , Jones, N A G,  Leyton, J, Dubiel, K and Kakkar, V V (1980) 
Enhanced in vivo p la te le t  "release reaction" in old healthy 
i nd iv iduals.
Thrombosis Research, 17, 329-336.
401
i
Zahavi, J, Price, A J and Kakkar, V V (1980)
Enhanced p la te le t release associated with general anaesthesia. 
Lancet I ,  1132-1133.
Ziel insky. A, Hirsh, J, Straumanis, G, Carter, C J , Gent, M,
Sackett, D L, H u ll,  R, Kelton, J G, Powers, P and Turpie, A G (1982) 
The diagnostic value of the f ib r in o g e n / f ib r in  fragment E antigen 
assay in c l in i c a l l y  suspected deep vein thrombosis.
Blood, 59, 346-350.
Zimmerman, T S, Ratnoff, 0 0 and Powell, A E (1971)
Immunologic d i f fe re n t ia t io n  of c lassic hemophilia ( fa c to r  V I I I  
defic iency) and von Willebrand's disease.
Journal o f C lin ica l Inves tiga tion , 50, 244-254.
, Zola-Sleczek, E and Szczepaniec, M (1974)
Rozpuszczalne kompleksy monomerow f ib ryny  w chorobie nadcis 
niewiowej.
Pol ski T.ygodnik Lekarski, 29, 213-216.
THROMBOSIS RESEARCH 25; 459-464, 1982 
0049-3848/82/060459“06$03.00/0 Printed in the USA. 
Copyright (c) 1982 Pergamon Press Ltd. All rights reserved
-THROMBOGLOBULIN AND PLATELET COUNTS - EFFECT OF 
MALIGNANCY, INFECTION, AGE AND OBESITY
Jessie T. Douglas, G.D.O, Lowe, C.D. Forbes and
C.R.M. Prentice
University Department of Medicine, Royal Infirmary, 
Glasgow, United Kingdom.
(Received 32.11.1981; in revised form 11.1.1982.
Accepted by Editor D. Ogston)
ABSTRACT
Plasma levels of beta-thromboglobulin (BTG) and 
platelet count were studied in 69 control subjects, 19 
patients with operable abdominal malignancy, and 9 pat­
ients with acute bacterial infection. In control sub­
jects there was a significant rise in BTG and fall in 
platelet count with age, and a negative correlation of 
BTG with obesity. BTG and platelet count were normal 
in patients with operable malignancy, but significantly 
increased in patients with acute bacterial infection. 
These effects must be considered in studies of BTG and 
thrombosis.
If
INTRODUCTION
Increased levels of plasma ^-thromboglobulin (BTG), a mark­
er of platelet release, have been reported in vascular disorders 
such as deep vein thrombosis (1,2), pre-eclampsia (3), acute 
myocardial infarction (4-6), glomerulonephritis (7), diabetes 
mellitus (8) and in the nephrotic syndrome (9), Elevated levels 
of plasma BTG have also been reported in patients with malignant 
disease (10,11). In these studies many patients had dissemin­
ated malignancy. The aims of this study were (a) to establish
whether or not BTG levels were elevated in early, operable can­
cer and (b) to establish whether or not BTG levels were elevat-
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ed in a group of patients with acute non-vascular illness, i.e., 
infection.
METHODS
We studied 4 groups of subjects. Group 1: comprised 40 
healthy volunteers (mean age 2 7 + 1.1 (S.E.M.) years) 22 females 
not taking oral contraceptives, 18 males). Group 2 ; 2 9 patient 
controls (mean age 61.2 + 2 . 1  years, 11 males, 18 females) ad­
mitted to hospital for elective surgery for non-malignant dis­
ease, with no evidence of infection. Group 3; 19 patients (mean 
age 60.3 + 2.2 years, 10 males, 9 females) admitted to hospital 
for elective surgery for proven operable gastrointestinal car­
cinoma, In all patients diagnosis was subsequently confirmed 
at operation - 10 patients had colorectal carcinoma, 7 had gast­
ric adenocarcinoma and 2 had pancreatic carcinoma. Group 4 ; 9 
patients (mean age 60 + 3.5 years, 3 males, 6 females) admitted 
to hospital with acute bacterial infection but no malignant dis­
ease. Five had pneumonia and four had intra-abdominal sepsis 
(appendix abscess in one and cholecystitis in 3). Participants 
on drugs which may have had an influence on platelet function 
were excluded from this study. Obesity was measured as per cent 
mean weight for height, age and sex, compared to adults in the 
Build and Blood Pressure Study (12) . Plasma j? -thromtooglobulin 
was measured by radioimmunoassay (13). 2.5 ml of venous blood
was drawn without stasis through a 2lG Abbott butterfly and im­
mediately transferred into precooled polystyrene tube containing 
EDTA and theophylline. After 30 minutes in an ice-water slurry 
the blood was spun at 3,000 g at 4°C for 30 minutes and 0.5 ml 
of the middle layer of the platelet poor plasma was withdrawn for 
BTG determination. The concentration of BTG in platelet poor 
plasma was determined in duplicate by radioimmunoassay using a 
kit supplied by the Radiochemical Centre, Amersham. Whole Blood 
Platelet Counts were performed using a Coulter automatic platelet 
counter. Serum Creatinine Levels were performed by Technicon 
autoanalyser. Statistical Analysis; All data are presented as 
the mean standard error of the mean. The significance of dif­
ferences between groups was assessed by Wilcoxon's rank sum test. 
Correlations were determined by the method of least squares.
RESULTS
Patient controls had significantly higher BTG levels (p< O.Ol) 
and significantly lower platelet counts (p < 0.01) than normal 
controls. in the combined group of 69 control subjects there was 
a significant positive correlation between BTG and age ( r  = 0,33, 
p < O.Ol) and a significant negative correlation between BTG and 
percent overweight for age, sex and height ( r  =-0.47, p< 0.01). 
This correlation with obesity was found in Group 2 (r = -0.58, 
p< 0.001), but not in Group 1 - possibly due to the relatively 
small scatter of obesity in this group of young healthy subjects.
À
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A significant negative correlation was found between platelet 
count and age (r = -0.5 5, p< 0.001). There was no correlation 
between levels of BTG and sex or smoking habits.
TABLE 1.
Age, fî -thromboglobulin, platelet count, serum creatinine 
and obesity (mean + S.E.M.) in groups studied (*p< 0.05, 
**p ^  0.02, ***p<0.01 compared to Group 2, patient controls)
GROUP 1 GROUP 2 GROUP 3 GROUP 4
Normal Patient
Controls Controls Malignancy Infection
No. 40 29 19 9
***
Age 27.0 61.2 60.3 60.0
(years) ±  1.1 + 2.1 + 2.2 + 3.5
BTG 26*** 43 42 68*
(ng/ml) ±  2 + 4 + 5 + 14
Platelet Count 324*** 221 227 2 94**
X lO^/L ± 16 + 16 + 19 + 19
Serum Creatinine 79 76 76 65
( fA mol/L) + 4 + 3 ±  3 + 10
Obesity 92 90 95 97
{% mean weight) ±  2 ±  3 ±  5 ± 6
Patients in group 3 (malignancy) and group 4 (infection) were 
of similar mean age to group 2 (patient controls) and had simi­
lar levels of serum creatinine and obesity. Patients with mal­
ignancy (group 3) had similar levels of BTG and platelet count 
compared to group 2. Patients with infection (group 4) had 
significantly higher levels of both BTG (p< 0.05) and platelet 
count (p<0.02) compared to group 2.
DISCUSSION
Since all groups had similar mean serum creatinine levels 
differences in BTG levels cannot be ascribed to renal retention. 
We found the older patient controls (group 2) had higher levels 
of BTG than the younger normal controls (group 1) probably due 
to the significant rise in BTG with age which has been previous­
ly reported (14-16). We also found a decrease in platelet 
count with age, a finding supported by the results of a large 
epidemiological study (17). This may reflect a decrease in 
platelet survival with age (18). The increase in BTG levels 
with age may be a further reflection of platelet activation in 
vivo, possibly secondary to the increase in atherosclerosis with
462 BTG AND PLATELET COUNTS Vol.25, No.6
age.
In control subjects BTG was unrelated to sex and smoking 
habit, but we found a highly significant negative association 
with obesity which has not been previously reported. The rea­
sons for this are not known and this association requires fur­
ther study.
Our finding of similar BTG concentrations in patients with 
early malignancy compared to control patients confirms the 
report of Farrell ^t (11) who only found significantly ele­
vated BTG levels in the advanced stages of malignancy. It appears 
therefore that in the early stages of malignancy a small local­
ised tumour does not cause measurable platelet release. In the 
advanced stages of malignant disease the demonstration of in­
creased platelet release is presumably due to a greater vascular 
involvement.
There is increasing evidence that platelets are activated in 
acute"non-vascular" illnesses, such as infections,with associ­
ated "acute-phase" changes in plasma proteins such as elevated 
fibrinogen levels (19-20). Our finding of significantly incre­
ased BTG levels in patients with infection suggests that plate­
let activation occurs in acute "non-vascular" illness. It 
appears that, as with other tests of platelet behaviour, elevat­
ions of plasma BTG are not specific for "vascular" illnesses 
such as arterial occlusion or venous thrombosis.
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